RAPPORT
ANNUEL
2015
LES ANNEXES
RÉ
VO
LU
TION(S)
sommaire
03 équipes de recherche de Gustave Roussy
05 Publications à impact factor supérieur à 20
(228 publications)
26 Publications à impact factor compris entre 10 et 20
(73 publications)
33 Publications à impact factor compris entre 5 et 10
(458 publications)
3
/ équipes de recherche DE GUSTAVE ROUSSY
• TLS Polymérases et Cancer
Responsable : Patricia Kannouche
CNRS UMR 8200 - Stabilité génétique et oncogenèse,
Patricia Kannouche
• Organisation nucléaire et modèles pathologiques
Responsables : Yegor Vassetzky / Marc Lipinski
CNRS UMR 8126 - Signalisation, Noyaux et Innovations en
oncologie, Joëlle Wiels / Marc Lipinski
• Les voies de signalisation FANC/BRCA
et Cancers
Responsable : Filippo ROSSELLI
CNRS UMR 8200 - Stabilité génétique et oncogenèse,
Patricia Kannouche
• Oncogenèses et résistance à l’apoptose
dans les lymphomes B
Responsable : Joëlle Wiels
CNRS UMR 8126 - Signalisation, Noyaux et Innovations en
oncologie, Joëlle Wiels / Marc Lipinski
• Recombination / Réparation et Cancer
Responsable : Bernard Lopez
CNRS UMR 8200 - Stabilité génétique et oncogenèse,
Patricia Kannouche
• Intégrité du génome et microscopie moléculaire
Responsable : Éric Le Cam
CNRS UMR 8126 - Signalisation, Noyaux et Innovations en
oncologie, Joëlle Wiels / Marc Lipinski
• Réparation de l’ADN
Responsable : Murat Saparbaev
CNRS UMR 8200 - Stabilité génétique et oncogenèse,
Patricia Kannouche
• Microenvironnement tumoral, exosomes
et microARN dans les tumeurs solides
Responsable : Pierre Busson
CNRS UMR 8126 - Signalisation, Noyaux et Innovations en
oncologie, Joëlle Wiels / Marc Lipinski
• Division cellulaire et stabilité génomique
Responsable : Olivier Gavet
CNRS UMR 8200 - Stabilité génétique et oncogenèse,
Patricia Kannouche
• Vectorologie des Acides Nucléiques
et des Médicaments Anticancéreux
Responsables : Lluis Mir / K. Benihoud
CNRS UMR 8203 - Laboratoire de Vectorologie et
Thérapeutiques anticancéreuses, Lluis Mir et K. Benihoud
• Nouvelles Thérapies Anticancéreuses
Responsable : Liliane Massade
CNRS UMR 8203 - Laboratoire de Vectorologie et
Thérapeutiques anticancéreuses, Lluis Mir et K. Benihoud
• Physiologie et Pathologie Moléculaires
des Rétrovirus Endogènes et Infectieux
Responsable : Thierry Heidmann
CNRS UMR 9196
• Trafic intracellulaire, complexes
macromoléculaires et cancer
Responsable : Svetlana Dokudovskaya
CNRS UMR 8126 - Signalisation, Noyaux et Innovations en
oncologie, Joëlle Wiels / Marc Lipinski
• Imagerie multimodale en cancérologie
Responsable : Nathalie Lassau
CNRS UMR 8081 - Imagerie par Résonance Magnétique Médicale
et Multi-Modalités (IR4M), Luc Darrasse et Nathalie Lassau
• Stades précoces de la transformation
hématopoïétique
Responsables : Olivier Bernard / Virginie Penardlacronique
Inserm UMR 1170 - Hématopoïèse normale et pathologique,
Olivier Bernard
• Des cellules souches hématopoïétiques
aux mégacoryocytes
Responsable : Hana Raslova
Inserm UMR 1170 - Hématopoïèse normale et pathologique,
Olivier Bernard
• Génétique et modélisation des tumeurs malignes
pédiatriques
Responsable : Thomas Mercher
Inserm UMR 1170 - Hématopoïèse normale et pathologique,
Olivier Bernard
4
• Des cellules souches hématopoïétiques aux monocytes
Responsables : Eric Solary / Françoise Porteu
Inserm UMR 1170 - Hématopoïèse normale et
pathologique, Olivier Bernard
• Biomarqueurs prédictifs
et nouvelles stratégies thérapeutiques en oncologie
Responsable : Fabrice André
Inserm UMR 981
• Stress réplicatif, instabilité génomique et mitose
Responsable : Valéria Naim - Équipe ERC Starting
CNRS UMR 8200 - Stabilité génétique et oncogenèse,
Patricia Kannouche
• Immunologie des tumeurs et immunothérapie
Responsable : Laurence Zitvogel
Inserm UMR 1015
• Méthodologie et épidémiologie clinique pour l’oncologie
moléculaire (équipe 2)
Responsable : Stephan Michiels
Centre de recherche en épidémiologie et en santé des
populations, Bruno Falissard
• Radiothérapie moléculaire
Responsables : Eric Deutsch et Jean-Luc Perfettini
Inserm UMR 1030
• Immunologie intégrative des tumeurs
Responsable : Fathia Mami-Chouaib / Salem CHOUAIB
Inserm UMR 1186
• Réparation des cassures double brin
et intégrité du génome
Responsable : Gérard Mazon - Equipe ATIP-AVENIR
CNRS UMR 8200 - Stabilité génétique et oncogenèse,
Patricia Kannouche
• Invasion collective et morphogenèse épithéliale
Responsable : Fanny Jaulin - Equipe ATIP-AVENIR
CNRS UMR 8126 - Signalisation, Noyaux et Innovation en
oncologie, Joëlle Wiels
• Endocytose, cytosquelette et migration cellulaire
Responsable : Guillaume Montagnac - Equipe ATIPAVENIR
Inserm UMR 1170 - Hématopoïèse normale et
pathologique, Olivier Bernard
• Cellules souches hématopoïétiques normales et
cancéreuses : contrôles génétique et épigénétique
Responsable : Camille Lobry - Equipe ATIP-AVENIR
Inserm UMR 1170 - Hématopoïèse normale
pathologique, Olivier Bernard
• Rôle de la traduction d’ARNm dans la présentation
antigénique
Responsable : Sébastien Apcher - Equipe ATIP-AVENIR
Inserm UMR 1015 - Immunologie des tumeurs et
immunothérapie, Laurence Zitvogel
et
• Oncogenèse et progression tumorale du mélanome
Responsable : Medhi Khaled - Equipe ATIP-AVENIR
Inserm UMR 1186 - Immunologie intégrative des tumeurs,
Fathia Mami-Chouaib
• Epidémiologie des radiations, épidémiologie clinique
des cancers et survie (équipe 3)
Responsable : Florent de Vathaire
Centre de recherche en épidémiologie et en santé des
populations, Bruno Falissard
• Mode de vie, génétique et santé : études intégratives
et trans-générationnelles (équipe 9)
Responsable Marie-Christine Boutron-Ruault
Centre de recherche en épidémiologie et en santé des
populations, Bruno Falissard
• Management des organisations de santé
Responsable : Etienne Minvielle
EHESP - EA 7348
• Apoptose, cancer et immunité
Responsable : Guido Kroemer
Inserm / CNRS UMRS1138 Université Paris-Descartes Centre de Recherche des Cordeliers, Pascale Ferre /
Guido Kroemer
5
/ Publications internationales
Gustave Roussy en 2015
À impact factor supérieur à 20 (228 publications)
1. Albigès L., Xie W., Chen Y.H., Boher J.M., Valenca L.B.,
Bernard B.D., Culine S., Habibian M., Carducci M.A.,
DiPaola R.S., Liu G., Pomerantz M., Nakabayashi
M., Kantoff P.W., Fizazi K., Gravis G., and Sweeney
C. Disease burden and outcome in metastatic
hormone sensitive prostate cancer (mHSPC). [2015]
Journal of Clinical Oncology (33) 15 suppl : 5052.
Impact factor : 20,982
2. Albigès L., Fay A.P., Xie W., McDermott D.F., Heng
D.Y.C., Dariane C., De Velasco G., Lester R.E.,
Escudier B., and Choueiri T.K. Efficacy of targeted
therapies after PD1/PD-L1 inhibitors in metastatic
clear cell renal cell carcinoma (mRCC): A multiinstitution retrospective cohort. [2015] Journal of
Clinical Oncology (33) 7 suppl : 456. Impact factor :
20,982
3. Amela E., Bompas E., Le Cesne A., Tresch E., Italiano
A., Piperno-Neumann S., Collard O., Vansteene D.,
Domont J., Saada E., Isambert N., Salas S., Chevreau
C., Bertucci F., Delaine S.C., Blay J.Y., and Penel
N. A phase II trial of sorafenib (SO) in advanced
chordoma patients (pt). [2015] Journal of Clinical
Oncology (33) 15 suppl : 10520. Impact factor :
20,982
4. André F., Deluche É., and Bonnefoi H. Bevacizumab:
the phoenix of breast oncology? [2015] Lancet
Oncology (16) 6 : 600-601. Impact factor : 26,509
5. Angevin E., Isambert N., Trillet-Lenoir V.N., You B.,
Alexandre J., Zalcman G., Viehl P., Farace F., Valleix
F., Podoll T., Kuramochi Y., Miyashita I., Hosono O.,
Dang N.H., Ohnuma K., Yamada T., Kaneko Y., and
Morimoto C. First-in-human phase I administration
of YS110, a monoclonal antibody directed against
the CD26 immunostimulatory molecule in advanced
cancer patients. [2015] Journal of Clinical Oncology
(33) 15 suppl : 2519. Impact factor : 20,982
6. Arkenau H.T., Gazzah A., Plummer R., Blagden S.P.,
Mak G., Soria J.C., Greystoke A., Rizzuto I., Rogan
D., Mazumdar J., Laubscher K., Auger K.R., Swartz
L.S., Mattern M.L., Nebot N., Singh R.P., Fleming
R.A., and Yan L. A phase Ib dose-escalation study
of GSK2256098 (FAKi) plus trametinib (MEKi) in
patients with selected advanced solid tumors .
[2015] Journal of Clinical Oncology (33) 15 suppl :
2593. Impact factor : 20,982
7. Barrios C.H., Anton A., Delaloge S., Montemurro F.,
Wuerstlein R., Robb S., Button P., and Ellis P.A. Safety of
trastuzumab emtansine (T-DM1) in 373 patients 65 years
or older with HER2-positive advanced breast cancer: A
subgroup analysis of the Kamilla study. [2015] Journal of
Clinical Oncology (33) 15 suppl : 603. Impact factor : 20,982
8. Bauer T.M., Shaw A.T., Solomon B., Besse B., James
L.P., Clancy J.S., Mugundu G., Martini J.F., Abbattista
A., and Felip E. Phase I/II study of PF-06463922, an
ALK/ROS1 tyrosine kinase inhibitor, in patients with
advanced non-small-cell lung cancer harboring
specific molecular alterations. [2015] Journal of
Clinical Oncology (33) 15 suppl : TPS2620. Impact
factor : 20,982
9. Beer T.M., Armstrong A.J., Sternberg C.N., Higano
C.S., Rathkopf D.E., Loriot Y., Saad F., Joshua A.M., De
Bono J.S., Venner P.M., Carles J., Mainwaring P.N.,
Evans C.P., Parli T., Mansbach H.H., Bhattacharya S.,
Van Os S., Phung D., and Tombal B.F. Enzalutamide
(ENZA) in men with chemotherapy-Naive metastatic
castration-resistant prostate cancer (mCRPC):
Final analysis of the phase 3 PREVAIL study. [2015]
Journal of Clinical Oncology (33) 15 suppl : 5036.
Impact factor : 20,982
10. Bellmunt J., Eigl B.J., Senkus-Konefka E., Loriot
Y., Twardowski P., Castellano D.E., Blais N., Sridhar
S.S., Sternberg C.N., Retz M., Blumenstein B.A.,
Jacobs C., Stewart P.S., and Petrylak D.P. First-line
randomized phase II study of gemcitabine/cisplatin
plus apatorsen or placebo in patients with advanced
bladder cancer: The International Borealis-1 trial.
[2015] Journal of Clinical Oncology (33) 15 suppl :
4503. Impact factor : 20,982
11. Ben Arush M.W., Minard-Colin V., Mosseri V.,
Desfachelles A.S., Bergeron C., Algret N., Fassola
S., André N., Thebaud E., Corradini N., Bernier
V., Martelli H., Ranchere-Vince D., and Orbach
D. Does aggressive local treatment have an
impact on survival in children with metastatic
rhabdomyosarcoma? [2015] Journal of Clinical
Oncology (33) 15 suppl : 10540 . Impact factor :
20,982
12. Besse B., Mazieres J., Ribassin-Majed L., Barlesi
F., Bennouna J., Gervais R., Moreau L., Berard H.,
Debieuvre D., Molinier O., Moro-Sibilot D., Souquet
P.J., Pignon J.P., Amour E., Celebic A., Morin F.,
Milleron B., Zalcman G., and Soria J.C. Pazopanib
(P) or placebo in completely resected stage I NSCLC
patients: Survival results of the phase II trial IFCT0703. [2015] Journal of Clinical Oncology (33) 15
suppl : 7510. Impact factor : 20,982
13. Blanchard P., Lee A., Marguet S., Leclercq J., Ng
W.T., Ma J., Chan A.T., Huang P.Y., Benhamou E.,
Zhu G., Chua D.T., Chen Y., Mai H.Q., Kwong D.L.,
Cheah S.L., Moon J., Tung Y., Chi K.H., Fountzilas
G., Zhang L., Hui E.P., Lu T.X., Bourhis J., and
Pignon J.P. Chemotherapy and radiotherapy in
6
nasopharyngeal carcinoma: an update of the MACNPC meta-analysis. [2015] Lancet Oncology (16) 6 :
645-655. Impact factor : 26,509
14. Blay J.Y., Shen L., Kang Y.K., Rutkowski P., Qin S.,
Nosov D., Wan D., Trent J., Srimuninnimit V., Papai
Z., Le Cesne A., Novick S., Taningco L., Mo S., Green
S., Reichardt P., and Demetri G.D. Nilotinib versus
imatinib as first-line therapy for patients with
unresectable or metastatic gastrointestinal stromal
tumours (ENESTg1): a randomised phase 3 trial .
[2015] Lancet Oncology (16) 5 : 550-560. Impact
factor : 26,509
15. Blay J.Y., Molimard M., Cropet C., Domont J., Toulmonde
M., Bompas E., Cassier P.A., Ray-Coquard I.L., Rios
M., Adenis A., Italiano A., Le Cesne A., Bouche O., Mir
O., Duffaud F., Bertucci F., Isambert N., Belleville A.,
Gautier J., and Perol D. Final results of the multicenter
randomized phase II PAZOGIST trial evaluating
the efficacy of pazopanib (P) plus best supportive
care (BSC) vs BSC alone in resistant unresectable
metastatic and/or locally advanced gastrointestinal
stromal tumors (GIST). [2015] Journal of Clinical
Oncology (33) 15 suppl : 10506. Impact factor : 20,982
16. Boige V., Vincent M., Alexandre P., Stoehlmacher J.,
Tejpar S., Landolfi S., Le Malicot K., Greil R., Cuyle
P.J., Yilmaz M.K., Faroux R., Matzdorff A., Salazar
R., Sanches E., Mineur L., Lepage C., Taieb J., and
Laurent-Puig P. DYPD genotyping to predict toxicity
in patients with stage III colon cancer treated with
5-fluorouracil-based adjuvant chemotherapy in the
PETACC-8 phase III trial. [2015] Journal of Clinical
Oncology (33) 15 suppl : 3584. Impact factor : 20,982
17. Bonastre J., Marguet S., Lueza B., Michiels S.,
Delaloge S., and Saghatchian M. Reply to V.P. Retel et
al, D. Gauchan et al, and C. Rahilly-Tierney et al(CostEffectiveness of the 70-Gene Signature Versus
Adjuvant! Online and Systematic Chemotherapy for
Risk Stratification of Patients With Node-Negative
Breast Cancer: Does Accuracy Matter?). [2015]
Journal of Clinical Oncology (33) 14 : 1629-1630.
Impact factor : 20,982
18. Bonneterre J., Leary A., Campone M., Italiano A., Sablin
M.P., Floquet A., Berton-Rigaud D., Lhomme C., Lesoin
A., Chocteau-Bouju D., Fabbro M., Favier L., Gladieff
L., Ray-Coquard I., Bexon A.S., Gilles E.M., Bisaha
J., Zukiwski A., and Cottu P.H. Phase 2 clinical study
of onapristone (ONA) in patients (pts) with uterine
endometrioid adenocarcinoma (EC) expressing the
activated progesterone receptor (APR(pos)). [2015]
Journal of Clinical Oncology (33) 15 suppl : TPS5616.
Impact factor : 20,982
19. Borget I., Martelli N., Vainchtock A., and Scotte
F. Thromboembolic events in hospitalized cancer
patients: Impact on stay duration and cost for
four major cancer localizations. [2015] Journal of
Clinical Oncology (33) 15 suppl : e17784. Impact
factor : 20,982
20. Borget I., Bonastre J., Catargi B., Deandreis D.,
Zerdoud S., Rusu D., Bardet S., Leenhardt L.,
Bastie D., Schvartz C., Vera P., Morel O., Benisvy
D., Bournaud C., Bonichon F., Kelly A., Toubert
M.E., Leboulleux S., Journeau F., Benhamou E.,
and Schlumberger M. Quality of Life and CostEffectiveness Assessment of Radioiodine Ablation
Strategies in Patients With Thyroid Cancer: Results
From the Randomized Phase III ESTIMABL Trial.
[2015] Journal of Clinical Oncology (33) 26 : 28852892. Impact factor : 20,982
21. Bougeard G., Renaux-Petel M., Flaman J.M.,
Charbonnier C., Fermey P., Belotti M., GauthierVillars M., Stoppa-Lyonnet D., Consolino E.,
Brugieres L., Caron O., Benusiglio P.R., Bressac-de
Paillerets B., Bonadona V., Bonaiti-Pellie C., Tinat J.,
Baert-Desurmont S., and Frebourg T. Revisiting LiFraumeni Syndrome From TP53 Mutation Carriers.
[2015] Journal of Clinical Oncology (33) 21 : 23452352. Impact factor : 20,982
22. Brock P.R., Maibach R., Childs M., Rajput K., Neuwelt
E.A., Roebuck D., Sullivan M.J., Laithier V., Ronghe
M., Lockwood L., dall’Igna P., Hiyama E., Brichard
B., Skeen J., Mateos M.E., Fabre M., Rangaswami
A.A., Capra M., Czauderna P., and Morland B. Antitumor efficacy in SIOPEL 6: A multi-centre open
label randomised phase III trial of the efficacy of
sodium thiosulphate (STS) in reducing ototoxicity
in patients receiving cisplatin (Cis) monotherapy
for standard risk hepatoblastoma (SR-HB). [2015]
Journal of Clinical Oncology (33) 15 suppl : 10039.
Impact factor : 20,982
23. Brose M.S., Schlumberger M., Tahara M., Wirth L.J.,
Robinson B., Elisei R., Newbold K., Kiyota N., Hoff
A.O., Dutcus C., Song J., Sherman S.I., and Taylor
M.H. Effect of age and lenvatinib treatment on
overall survival for patients with I-131-refractory
differentiated thyroid cancer in SELECT . [2015]
Journal of Clinical Oncology (33) 15 suppl : 6048.
Impact factor : 20,982
24. Brose M.S., Schlumberger M., Pena C., and Kappeler
C. Sorafenib for patients with differentiated thyroid
cancer. Reply. [2015] Lancet (385) 9964 : 228-229.
Impact factor : 44,002
7
25. Cabagnols X., Cayuela J.M., and Vainchenker W.
A CALR Mutation Preceding BCR-ABL1 in an
Atypical Myeloproliferative Neoplasm. [2015] New
England Journal of Medicine (372) 7 : 688-690.
Impact factor : 59,558
26. Casali P.G., Le Cesne A., Poveda V.A., Kotasek D.,
Rutkowski P., Hohenberger P., Fumagalli E., Judson
I.R., Italiano A., Gelderblom H., Adenis A., Hartmann
J.T., Duffaud F., Goldstein D., Broto J.M., Gronchi A.,
Dei Tos A.P., Marreaud S., van der Graaf W.T., Zalcberg
J.R., Litiere S., and Blay J.Y. Time to Definitive
Failure to the First Tyrosine Kinase Inhibitor in
Localized GI Stromal Tumors Treated With Imatinib
As an Adjuvant: A European Organisation for
Research and Treatment of Cancer Soft Tissue
and Bone Sarcoma Group Intergroup Randomized
Trial in Collaboration With the Australasian GastroIntestinal Trials Group, UNICANCER, French
Sarcoma Group, Italian Sarcoma Group, and
Spanish Group for Research on Sarcomas. [20-122015] Journal of Clinical Oncology (33) 36 : 42764283. Impact factor : 20,982
27. Cassier P.A., Maki R.G., Wagner A.J., Bompas E.,
Gelderblom H., Kroep J.R., Thomas D.M., Italiano A.,
Seddon B.M., Van der Graaf W.T., Domont J., Blay
J.Y., and Stacchiotti S. Imatinib mesylate (IM) activity
in patients (pts) with locally advanced tenosynovial
giant cell tumor/pigmented villonodular synovitis
(TGCT). [2015] Journal of Clinical Oncology (33) 15
suppl : 10561. Impact factor : 20,982
28. Cavalcanti A., Robert C., Mateus C., Muret J., Lebbe
C., Dutriaux C., Maubec E., Arnault J.P., Mansard S.,
Templier C., Lacour J.P., and Lanoy E. A randomized,
open label, multicenter comparative phase II
trial of ipilimumab after isolated limb perfusion
(ILP), versus ILP alone in patients with in-transit
metastases melanoma stage IIIB and IIIC. [2015]
Journal of Clinical Oncology (33) 15 suppl : e20107.
Impact factor : 20,982
29. Chan A., Delaloge S., Holmes F.A., Moy B., Iwata
H., Harvey V.J., Robert N.J., Silovski T., Gokmen E.,
Von Minckwitz G., Ejlertsen B., Chia S.K., Mansi J.,
Barrios C.H., Gnant M., Wong A., Bryce R., Yao B., and
Martin M. Neratinib after adjuvant chemotherapy
and trastuzumab in HER2-positive early breast
cancer: Primary analysis at 2 years of a phase 3,
randomized, placebo-controlled trial (ExteNET).
[2015] Journal of Clinical Oncology (33) 15 suppl :
508. Impact factor : 20,982
30. Chawla S.P., Schoffski P., Blay J.Y., Jones R.L.,
Gelderblom H., Attia S., Chmielowski B., Van Tine
B.A., Trent J.C., Patel S., Wagner A.J., Viele J.K.,
Chugh R., Le Cesne A., Tinoco G., Sankhala K.K.,
Falcone J., Schweizer C., Weil S., and Maki R.G. A
study of the safety and efficacy of the combination
of gemcitabine and docetaxel with ontuxizumab
(MORAb-004) in metastatic soft tissue sarcoma.
[2015] Journal of Clinical Oncology (33) 15 suppl :
TPS10577. Impact factor : 20,982
31. Choueiri T., Escudier B., Powles T., Mainwaring P.,
Rini B., I, Donskov F., Hammers H., Hutson T., Lee
J.L., Peltola K., Roth B., Bjarnason G., Geczi L., Keam
B., Maroto P., Heng D., Schmidinger M., Kantoff P.,
Borgman-Hagey A., Hessel C., Scheffold C., Schwab
G., Tannir N., and Motzer R. Cabozantinib versus
Everolimus in Advanced Renal-Cell Carcinoma.
[2015] New England Journal of Medicine (373) 19 :
1814-1823. Impact factor : 59,558
32. Choueiri T.K., Fishman M.N., Escudier B., McDermott
D.F., Kluger H.M., Stadler W.M., Perez-Gracia J.L.,
McNeel D.G., Curti B.D., Harrison M.R., Plimack
E.R., Appleman L.J., Fong L., Drake C.G., Young
T.C., Chasalow S.D., Ross-Macdonald P., Simon J.S.,
Walker D., and Sznol M. Immunomodulatory activity
of nivolumab in metastatic renal cell carcinoma
(mRCC): Association of biomarkers with clinical
outcomes. [2015] Journal of Clinical Oncology (33)
15 suppl : 4500. Impact factor : 20,982
33. Christopher A., Van Akkooi J., Siegel P., Schoengen
A., Roewert-Huber J., Eggermont A.M., and Voit
C.A. Long-term results of ultrasound (US)guided fine needle aspiration cytology (FNAC) in
conjunction with sentinel node biopsy (SNB) to
support step-wise approach in melanoma. [2015]
Journal of Clinical Oncology (33) 15 suppl : 9067.
Impact factor : 20,982
34. Colomba E., Albigès L., Le Teuff G., Eisen T., Stewart
G., Fife K., Srinivasan A., Larkin J.M., Biondo A.,
Pickering L.M., Boyle H.J., Derosa L., Ralph C.,
Saldana C., Bernhard J.C., Barthelemy P., Recine F.,
and Escudier B. Metastatic chromophobe renal cell
carcinoma treated with target therapies: A Renal
Cross Chanel Group (RCCG) study. [2015] Journal
of Clinical Oncology (33) 15 suppl : 4561. Impact
factor : 20,982
35. Conteduca V., Caffo O., Fratino L., Lo Re G., Basso
U., D’Angelo A., Donini M., Verderame F., Ratta R.,
Procopio G., Campadelli E., Massari F., Gasparro D.,
Ermacora P., Messina C., Giordano M., Alesini D.,
Maines F., and De Giorgi U. Visceral disease site to
predict clinical outcome of metastatic castrationresistant prostate cancer (mCRPC) patients (pts)
8
treated with abiraterone acetate (AA): Results of the
Italian compassionate use named patient program
(NPP). [2015] Journal of Clinical Oncology (33) 15
suppl : e16045. Impact factor : 20,982
36. Cottu P.H., Italiano A., Varga A., Campone M., Leary
A., Floquet A., Berton-Rigaud D., Sablin M.P., Lesoin
A., Lhomme C., Bexon A.S., Gilles E.M., Jackson D.,
Bisaha J., Zukiwski A., Bosq J., and Bonneterre
J. Onapristone (ONA) in progesterone receptor
(PR)-expressing tumors: Efficacy and biomarker
results of a dose-escalation phase 1 study. [2015]
Journal of Clinical Oncology (33) 15 suppl : 5593.
Impact factor : 20,982
37. Creutzberg C.L., de Boer S.M., Putter H., Powell
M., Mileshkin L.R., Katsaros D., Bessette P., HaieMeder C., Ledermann J.A., Ottevanger P., Khaw
P., Colombo A., Fyles A.W., Baron M.H., Nijman
H.W., Nout R.A., Smit V.T., Verhoeven-Adema K.,
Kruitwagen R.F., and Kitchener H.C. Adjuvant
chemotherapy and radiation therapy (RT) versus
RT alone for women with high-risk endometrial
cancer: Toxicity and quality-of-life results of the
randomized PORTEC-3 trial . [2015] Journal of
Clinical Oncology (33) 15 suppl : 5501. Impact
factor : 20,982
38. Cunningham D., Zurlo A., Salazar R., Ducreux M.,
Waddell T.S., Stein A., Tournigand C., Scheithauer
W., Sobrero A.F., Van Cutsem E., and Arnold
D. IMPALA, a randomized phase III study in
patients with metastatic colorectal carcinoma:
Immunomodulatory maintenance therapy with
TLR-9 agonist MGN1703. [2015] Journal of Clinical
Oncology (33) 3 suppl : TPS791. Impact factor :
20,982
39. Daud A., Ribas A., Robert C., Hodi F., Wolchok J.D.,
Joshua A.M., Hwu W.J., Weber J.S., Gangadhar
T.C., Joseph R.W., Dronca R.S., Patnaik A., Zarour
H.M., Kefford R., Lindia J.A., Li X.N., Ebbinghaus
S., Kang S.P., and Hamid O. Long-term efficacy of
pembrolizumab (pembro; MK-3475) in a pooled
analysis of 655 patients (pts) with advanced
melanoma (MEL) enrolled in KEYNOTE-001. [2015]
Journal of Clinical Oncology (33) 15 suppl : 9005.
Impact factor : 20,982
40. De Santis M., Mulders P., Fizazi K., Gray T.E., McCoy
C., Stubbs A., and Powles T. First prospective,
open-label, phase 2 study of sipuleucel-T (sip-T)
in European men with metastatic, castrationresistant prostate cancer (mCRPC). [2015] Journal
of Clinical Oncology (33) 15 suppl : e16015. Impact
factor : 20,982
41. Delaloge S., Caron O., and Feunteun J. Effect of
PALB2 status on breast cancer precision medicine.
[2015] Lancet Oncology (16) 6 : 598-600. Impact
factor : 26,509
42. Denkert C., Von Minckwitz G., Brase J.C., Sinn
B.V., Gade S., Kronenwett R., Pfitzner B.M., Salat
C., Loi S., Schmitt W.D., Schem C., Fisch K., DarbEsfahani S., Mehta K., Sotiriou C., Wienert S., Klare
P., André F., Klauschen F., Blohmer J.U., Krappmann
K., Schmidt M., Tesch H., Kuemmel S., Sinn P.,
Jackisch C., Dietel M., Reimer T., Untch M., and Loibl
S. Tumor-Infiltrating Lymphocytes and Response
to Neoadjuvant Chemotherapy With or Without
Carboplatin in Human Epidermal Growth Factor
Receptor 2-Positive and Triple-Negative Primary
Breast Cancers. [2015] Journal of Clinical Oncology
(33) 9 : 983-991. Impact factor : 20,982
43. Doucet L.S., Derosa L., Albigès L., Massard C., Loriot
Y., Fizazi K., and Escudier B.J. Medical therapy for
renal cell cancer with pancreatic metastases:
Experience of the Gustave Roussy Institute. [2015]
Journal of Clinical Oncology (33) 7 suppl : 503.
Impact factor : 20,982
44. Duffaud F., Meeus P., Bertucci F., Delhorme J.B.,
Stoeckle E., Isambert N., Bompas E., Gagniere J.,
Bouche O., Toulmonde M., Salas S., Blay J.Y., and
Bonvalot S. Selective indications of surgery in
esophageal gastrointestinal stromal tumors: A
retrospective study of the French Sarcoma Group
(FSG). [2015] Journal of Clinical Oncology (33) 15
suppl : 10534. Impact factor : 20,982
45. Durand J.P., Hebuterne X., Raynard B., Saint Guily
J.L., and Goldwasser F. Prevalence of malnutrition in
PS 0-1 cancer patients: Results of the NutriCancer2
one-day national survey in 2,197 cancer patients.
[2015] Journal of Clinical Oncology (33) 15 suppl :
1587. Impact factor : 20,982
46. Eggermont A.M., Chiarion-Sileni V., Grob J.J.,
Dummer R., Wolchok J.D., Schmidt H., Hamid O.,
Robert C., Ascierto P.A., Richards J.M., Lebbe C.,
Ferraresi V., Smylie M., Weber J.S., Maio M., Konto
C., Hoos A., de Pril V., Gurunath R.K., de Schaetzen
G., Suciu S., and Testori A. Adjuvant ipilimumab
versus placebo after complete resection of high-risk
stage III melanoma (EORTC 18071): a randomised,
double-blind, phase 3 trial. [2015] Lancet Oncology
(16) 5 : 522-530. Impact factor : 26,509
47. Escudier B.J., Abadie-Lacourtoisie S., Blanc E.,
Guillot A., Priou F., Mahammedi H., Thiery-Vuillemin
A., Geoffrois L., Tubiana-Mathieu N., Adenis A.,
Ferlay C., and Albigès L. Efficacy of everolimus in
9
poor risk patients: Result of the POORTOR study.
[2015] Journal of Clinical Oncology (33) 7 suppl :
488. Impact factor : 20,982
48. Escudier B.J., Koscielny S., Maddala T., Svedman C.,
Verkarre V., Radulescu C., Neuzillet Y., Timsit M.O.,
Hemmerle I., Tsiatis A.C., Bonham M., Knezevic D.,
Martini J.F., Williams J.A., Lebret T., Goddard A.D.,
and Mejean A. Robustness of the 16-gene signature
for prediction of recurrence-free interval in localized
clear cell renal cell carcinoma. [2015] Journal of
Clinical Oncology (33) 7 suppl : 455. Impact factor :
20,982
49. Eveno C., Parc Y., Laurent A., Ducreux M., and Pocard
M. Body-mass index, cancer, and implications for
screening. [2015] Lancet Oncology (16) 3 : E102-E103.
Impact factor : 26,509
50. Fassnacht M., Berruti A., Baudin E., Demeure M.J.,
Gilbert J., Haak H., Kroiss M., Quinn D.I., Hesseltine
E., Ronchi C.L., Terzolo M., Choueiri T.K., Poondru
S., Fleege T., Rorig R., Chen J., Stephens A.W.,
Worden F., and Hammer G.D. Linsitinib (OSI-906)
versus placebo for patients with locally advanced or
metastatic adrenocortical carcinoma: a double-blind,
randomised, phase 3 study. [2015] Lancet Oncology
(16) 4 : 426-435. Impact factor : 26,509
51. Fay A.P., Kwiatkowski D.J., Gray K.P., Thorner A., Rini
B.I., Agarwal N., Ho T.H., Song J., Barrios P.M., Albigès
L., Van Allen E.M., Krajewski K.M., Porta C., Pal S.K.,
Bellmunt J., McDermott D.F., Heng D.Y.C., Signoretti
S., and Choueiri T.K. Activating genomic mutations in
the mTOR pathway to predict responses to everolimus
and temsirolimus in patients with metastatic renal
cell carcinoma (mRCC): Results from a large multiinstitutional cohort . [2015] Journal of Clinical
Oncology (33) 15 suppl : 4519. Impact factor : 20,982
52. Fizazi K. and Dreicer R. Reply to K. Lu. [2015] Journal
of Clinical Oncology (33) 28 : 3222-3222. Impact
factor : 20,982
53. Fizazi K., Faivre L., Lesaunier F., Delva R., Gravis
G., Rolland F., Priou F., Ferrero J.M., Houede N.,
Mourey L., Theodore C., Krakowski I., Berdah J.F.,
Baciuchka M., Laguerre B., Flechon A., Ravaud A.,
Cojean-Zelek I., Oudard S., Labourey J.L., ChinetCharrot P., Legouffe E., Lagrange J.L., Linassier C.,
Deplanque G., Beuzeboc P., Davin J.L., Martin A.L.,
Habibian M., Laplanche A., and Culine S. Androgen
deprivation therapy plus docetaxel and estramustine
versus androgen deprivation therapy alone for highrisk localised prostate cancer (GETUG 12): a phase 3
randomised controlled trial. [2015] Lancet Oncology
(16) 7 : 787-794. Impact factor : 26,509
54. Fizazi K., Shore N.D., Tammela T.L., Sarapohja T.,
Vuorela A., Kuss I., Snapir A., and Smith M.R. ARAMIS
trial: Efficacy and safety phase 3 trial of ODM-201
in men with high-risk non-metastatic castrationresistant prostate cancer (nmCRPC). [2015] Journal
of Clinical Oncology (33) 15 suppl : TPS5080. Impact
factor : 20,982
55. Fizazi K., Jones R., Oudard S., Efstathiou E., Saad F.,
de Wit R., De Bono J., Cruz F.M., Fountzilas G., Ulys
A., Carcano F., Agarwal N., Agus D., Bellmunt J.,
Petrylak D.P., Lee S.Y., Webb I.J., Tejura B., Borgstein
N., and Dreicer R. Phase III, Randomized, DoubleBlind, Multicenter Trial Comparing Orteronel (TAK700) Plus Prednisone With Placebo Plus Prednisone
in Patients With Metastatic Castration-Resistant
Prostate Cancer That Has Progressed During or
After Docetaxel-Based Therapy: ELM-PC 5. [2015]
Journal of Clinical Oncology (33) 7 : 723-731. Impact
factor : 20,982
56. Fleisher M., Danila D.C., Fizazi K., Hirmand M.,
Selby B., Phung D., De Bono J.S., and Scher
H.I. Circulating tumor cell (CTC) enumeration in
men with metastatic castration-resistant prostate
cancer (mCRPC) treated with enzalutamide postchemotherapy (phase 3 AFFIRM study) . [2015]
Journal of Clinical Oncology (33) 15 suppl : 5035.
Impact factor : 20,982
57. Fresneau B., Paulussen M., Hackshaw A., Hawkins
D.S., Anderson J.R., Judson I.R., Dirksen U., Lewis
I.J., van den Berg H., Gaspar N., Gelderblom H.,
Whelan J., Boos J., Wheatley K., Pignon J.P., Le Deley
M.C., and Le Teuff G. Investigating the heterogeneity
of alkylating agents’ efficacy between genders:
A meta-analysis of randomized trials comparing
cyclophosphamide and ifosfamide (MAIAGE study).
[2015] Journal of Clinical Oncology (33) 15 suppl :
e21500. Impact factor : 20,982
58. Galluzzi L., Buque A., Kepp O., Zitvogel L., and
Kroemer G. Immunological Effects of Conventional
Chemotherapy and Targeted Anticancer Agents .
[14-12-2015] Cancer Cell (28) 6 : 690-714. Impact
factor : 23,214
59. Gan H.K., Lickliter J., Millward M., Gu Y., Su W., Qi C.,
Mu H., Frigault M., Morgan S., Gardner H.A., Albigès
L., Pal S.K., Burris H.A., and Choueiri T.K. cMet:
Results in papillary renal cell carcinoma of a phase
I study of AZD6094/volitinib leading to a phase 2
clinical trial with AZD6094/volitinib in patients with
advanced papillary renal cell cancer (PRCC). [2015]
Journal of Clinical Oncology (33) 7 suppl : 487.
Impact factor : 20,982
10
60. Gangadhar T.C., Mehnert J., Patnaik A., Hamid O.,
Carlino M.S., Hodi F., Blank C.U., Ribas A., Robert
C., Kondic A.G., Ahamadi M., Freshwater T., de
Greef R., van Vugt M., Lubiniecki G., Ebbinghaus S.,
Kang S.P., and Daud A. Population pharmacokinetic
(popPK) model of pembrolizumab (pembro; MK3475) in patients (pts) treated in KEYNOTE-001 and
KEYNOTE-002. [2015] Journal of Clinical Oncology
(33) 15 suppl : 3058. Impact factor : 20,982
61. Garon E.B., Rizvi N.A., Hui R., Leighl N., Balmanoukian
A.S., Eder J.P., Patnaik A., Aggarwal C., Gubens M.,
Horn L., Carcereny E., Ahn M.J., Felip E., Lee J.S.,
Hellmann M.D., Hamid O., Goldman J.W., Soria
J.C., Dolled-Filhart M., Rutledge R.Z., Zhang J.,
Lunceford J.K., Rangwala R., Lubiniecki G.M., Roach
C., Emancipator K., and Gandhi L. Pembrolizumab
for the Treatment of Non-Small-Cell Lung Cancer.
[2015] New England Journal of Medicine (372) 21 :
2018-2028. Impact factor : 59,558
62. Gaspar N., Hawkins D.S., Dirksen U., Lewis I.J.,
Ferrari S., Le Deley M.C., Kovar H., Grimer R.,
Whelan J., Claude L., Delattre O., Paulussen M.,
Picci P., Sundby Hall K., van den Berg H., Ladenstein
R., Michon J., Hjorth L., Judson I., Luksch R.,
Bernstein M.L., Marec-Berard P., Brennan B.,
Craft A.W., Womer R.B., Juergens H., and Oberlin
O. Ewing Sarcoma: Current Management and
Future Approaches Through Collaboration. [2015]
Journal of Clinical Oncology (33) 27 : 3036-3046.
Impact factor : 20,982
63. Gazzah A., Boni V., Soria J.C., Holgado E., Even
C., Kaci M.O., Nazabadioko S., Xue W., and Calvo
E. Phase Ib study of afatinib plus standard-dose
cetuximab in patients (pts) with advanced solid
tumors. [2015] Journal of Clinical Oncology (33) 15
suppl : 2536. Impact factor : 20,982
64. Gentili M., Kowal J., Tkach M., Satoh T., Lahaye
X., Conrad C., Boyron M., Lombard B., Durand
S., Kroemer G., Loew D., Dalod M., Thery C., and
Manel N. Transmission of innate immune signaling
by packaging of cGAMP in viral particles. [2015]
Science (349) 6253 : 1232-1236. Impact factor :
34,661
65. Giannatempo P., Pond G.R., Sonpavde G., Albany C.,
Loriot Y., Sweeney C., Cary K.C., Salvioni R., Colecchia
M., Nicolai N., Raggi D., El Mouallem N.R., Feldman
H., Fizazi K., Einhorn L.H., and Necchi A. Treatment
and clinical outcomes of patients with teratoma with
somatic-type malignant transformation (TMT): An
international collaboration. [2015] Journal of Clinical
Oncology (33) 7 suppl : 375. Impact factor : 20,982
66. Giralt J., Tao Y., Bensadoun R.J., Lalla R.V., Ozsahin
E.M., Pajkos G., Kortmann R.D., Contreras-Martinez
J., Ceruse P., Zasadny X., de la Vega F.A., Attali P.,
Vasseur B., and Henke M. Mucoadhesive clonidine
(Clonidine Lauriad) in the prevention of severe
radiomucositis in head and neck cancer patients: A
phase II randomized trial. [2015] Journal of Clinical
Oncology (33) 15 suppl : 6058. Impact factor : 20,982
67. Girault A., Gerves-Pinquie C., and Minvielle
E. Designing a payment system to support cancer
care coordination and improve patient adherence
to oral chemotherapies: A literature review. [2015]
Journal of Clinical Oncology (33) 15 suppl : e17803.
Impact factor : 20,982
68. Gizzi M., Baciarello G., Flechon A., Beuzeboc P.,
Angelergues A., Roubaud G., Bompas E., Le Moulec
S., Latorzeff I., Delva R., Voog E., Priou F., Duclos
B., Laguerre B., Vassal C., Goupil M.G., Patrikidou
A., Fizazi K., and Loriot Y. Previous enzalutamide
therapy and response to subsequent taxane therapy
in metastatic castration-resistant prostate cancer.
[2015] Journal of Clinical Oncology (33) 7 suppl :
227. Impact factor : 20,982
69. Gougis P., Paci A., Coriat R., Urien S., and Mir
O. Nilotinib versus imatinib for GIST. [2015] Lancet
Oncology (16) 7 : E311-E311. Impact factor : 26,509
70. Graff J.N., Baciarello G., Armstrong A.J., Higano
C.S., Iversen P., Forer D., Mansbach H.H., Phung D.,
Tombal B.F., Beer T.M., and Sternberg C.N. Clinical
outcomes and safety in men >= 75 and < 75 years
with metastatic castration-resistant prostate
cancer (mCRPC) treated with enzalutamide in the
phase 3 PREVAIL trial. [2015] Journal of Clinical
Oncology (33) 7 suppl : 200. Impact factor : 20,982
71. Grassi P., Doucet L.S., Giglione P., Gruenwald V.,
Melichar B., Galli L., De Giorgi U., Guida A., Ortega C.,
Santoni M., Bamias A., Verzoni E., Necchi A., Derosa
L., Studentova H., Pacifici M., De Braud F.G., Porta C.,
Escudier B.J., and Procopio G. Pancreatic metastases
from renal cell carcinoma: Prognostic relevance and
outcome in patients treated with targeted agents .
[2015] Journal of Clinical Oncology (33) 15 suppl :
4550. Impact factor : 20,982
72. Grassi P., Doucet L.S., Gruenwald V., Melichar B., Galli
L., De Giorgi L., Guida A., Ortega C., Santoni M., Bamias
A., Verzoni E., Iacovelli R., Derosa L., Studentova H.,
Paciflci M., De Braud F.G., Escudier B.J., and Procopio
G. Prognosis and outcome of patients with pancreatic
metastases from renal cell carcinoma: When the site
matters. [2015] Journal of Clinical Oncology (33) 7
suppl : 484. Impact factor : 20,982
11
73. Grasso C.S., Tang Y., Truffaux N., Berlow N.E., Liu
L., Debily M.A., Quist M.J., Davis L.E., Huang E.C.,
Woo P.J., Ponnuswami A., Chen S., Johung T.B., Sun
W., Kogiso M., Dui Y., Qi L., Huang Y., Huett-Cabezas
M., Warrenm K.E., Le Dret L., Meltzerm P.S., Mao
H., Quezado M., van Vuurden D.G., Abraham J.,
Fouladi M., Svalina M.N., Wang N., Hawkins C.,
Nazarian J., Alonso M.M., Raabe E.H., Hulleman E.,
Spellman P.T., Li X.N., Keller C., Pal R., Grill J., and
Monje M. Functionally defined therapeutic targets
in diffuse intrinsic pontine glioma . [2015] Nature
Medicine (21) 6 : 555-559. Impact factor : 30,367
74. Gravis G., Boher J.M., Joly F., Oudard S., Albigès L.,
Priou F., Latorzeff I., Delva R., Krakowski I., Laguerre
B., Rolland F., Theodore C., Deplanque G., Ferrero
J.M., Pouessel D., Mourey L., Beuzeboc P., Habibian
M., Soulie M., and Fizazi K. Androgen deprivation
therapy (ADT) plus docetaxel (D) versus ADT alone
for hormone-naive metastatic prostate cancer
(PCa): Long-term analysis of the GETUG-AFU 15
phase III trial. [2015] Journal of Clinical Oncology
(33) 7 suppl : 140. Impact factor : 20,982
75. Grob J.J., Amonkar M.M., Karaszewska B., Schachter
J., Dummer R., Mackiewicz A., Stroyakovskiy D.,
Drucis K., Grange F., Chiarion-Sileni V., Rutkowski P.,
Lichinitser M., Levchenko E., Wolter P., Hauschild A.,
Long G.V., Nathan P., Ribas A., Flaherty K., Sun P., Legos
J.J., McDowell D.O., Mookerjee B., Schadendorf D., and
Robert C. Comparison of dabrafenib and trametinib
combination therapy with vemurafenib monotherapy
on health-related quality of life in patients with
unresectable or metastatic cutaneous BRAF Val600mutation-positive melanoma (COMBI-v): results of a
phase 3, open-label, randomised trial. [2015] Lancet
Oncology (16) 13 : 1389-1398. Impact factor : 26,509
76. Grüenewald T.G., Bernard V., Gilardi-Hebenstreit P.,
Raynal V., Surdez D., Aynaud M.M., Mirabeau O., CidreAranaz F., Tirode F., Zaidi S., Perot G., Jonker A.H.,
Lucchesi C., Le Deley M.C., Oberlin O., Marec-Bérard
P., Véron A.S., Reynaud S., Lapouble E., Boeva V., Frio
T.R., Alonso J., Bhatia S., Pierron G., Cancel-Tassin
G., Cussenot O., Cox D.G., Morton L.M., Machiela M.J.,
Chanock S.J., Charnay P., and Delattre O. Chimeric
EWSR1-FLI1 regulates the Ewing sarcoma
susceptibility gene EGR2 via a GGAA microsatellite.
[2015] Nature Genetics (47) 9 : 1073-1078. Impact
factor : 31,616
77. Guinney J., Dienstmann R., Wang X., de Reynies A.,
Schlicker A., Soneson C., Marisa L., Roepman P.,
Nyamundanda G., Angelino P., Bot B.M., Morris
J.S., Simon I.M., Gerster S., Fessler E., Melo F.D.S.,
Missiaglia E., Ramay H., Barras D., Homicsko K., Maru
D., Manyam G.C., Broom B., Boige V., Perez-Villamil
B., Laderas T., Salazar R., Gray J.W., Hanahan D.,
Tabernero J., Bernards R., Friend S.H., Laurent-Puig P.,
Medema J.P., Sadanandam A., Wessels L., Delorenzi M.,
Kopetz S., Vermeulen L., and Tejpar S. The consensus
molecular subtypes of colorectal cancer . [2015]
Nature Medicine (21) 11 : 1350-1356. Impact factor :
30,367
78. Harrington K., Temam S., Mehanna H., D’Cruz A.,
Jain M., D’Onofrio I., Manikhas G., Horvath Z., Sun Y.,
Dietzsch S., Dubinsky P., Holeckova P., El-Hariry I.,
Franklin N., Biswas-Baldwin N., Legenne P., Wissel
P., Netherway T., Farrell J., Ellis C., Wang-Silvanto J.,
Amonkar M., Ahmed N., Santillana S., and Bourhis
J. Postoperative Adjuvant Lapatinib and Concurrent
Chemoradiotherapy Followed by Maintenance
Lapatinib Monotherapy in High-Risk Patients With
Resected Squamous Cell Carcinoma of the Head
and Neck: A Phase III, Randomized, Double-Blind,
Placebo-Controlled Study. [10-12-2015] Journal of
Clinical Oncology (33) 35 : 4202-4209. Impact factor :
20,982
79. Hodi F., Postow M.A., Chesney J.A., Pavlick A.C., Robert
C., Grossmann K.F., McDermott D.F., Linette G.P.,
Meyer N., Giguere J.K., Agarwala S.S., Shaheen M.F.,
Ernstoff M.S., Minor D.R., Salama A., Taylor M.H., Ott
P.A., Horak C.E., Gagnier P., and Wolchok J.D. Clinical
response, progression-free survival (PFS), and safety
in patients (pts) with advanced melanoma (MEL)
receiving nivolumab (NIVO) combined with ipilimumab
(IPI) vs IPI monotherapy in CheckMate 069 study.
[2015] Journal of Clinical Oncology (33) 15 suppl :
9004. Impact factor : 20,982
80. Hollebecque A., Bahleda R., Thery J.C., Faivre L.,
Le Deley M.C., Paci A., Varga A., Gazzah A., Massard
C., Poinsignon V., Malekzadeh K., Ribrag V., Angevin
E., Postel-Vinay S., Gomez-Roca C.A., Gharib M.,
Dufour F., Soria J.C., and Spano J.P. Phase I study
of temsirolimus in combination with cetuximab in
patients with advanced solid tumors. [2015] Journal of
Clinical Oncology (33) 15 suppl : 2599. Impact factor :
20,982
81. Horn L., Spigel D.R., Gettinger S.N., Antonia S.J., Gordon
M.S., Herbst R.S., Sequist L.V., Chappey C., Kowanetz
M., Sandler A., and Soria J.C. Clinical activity, safety
and predictive biomarkers of the engineered antibody
MPDL3280A (anti-PDL1) in non-small cell lung cancer
(NSCLC): update from a phase Ia study. [2015] Journal
of Clinical Oncology (33) 15 suppl : 8029. Impact
factor : 20,982
12
82. Hurvitz S.A., André F., Jiang Z., Shao Z., Mano M.S.,
Neciosup S.P., Tseng L.M., Zhang Q., Shen K., Liu
D., Dreosti L.M., Burris H.A., Toi M., Buyse M.E.,
Cabaribere D., Lindsay M.A., Rao S., Pacaud L.B.,
Taran T., and Slamon D. Combination of everolimus
with trastuzumab plus paclitaxel as first-line
treatment for patients with HER2-positive advanced
breast cancer (BOLERO-1): a phase 3, randomised,
double-blind, multicentre trial . [2015] Lancet
Oncology (16) 7 : 816-829. Impact factor : 26,509
83. Hyman D.M., Puzanov I., Subbiah V., Faris J.E.,
Chau I., Blay J.Y., Wolf J., Raje N.S., Diamond E.L.,
Hollebecque A., Gervais R., Elena Elez-Fernandez M.,
Italiano A., Hofheinz R.D., Hidalgo M., Chan E., Schuler
M., Lasserre S.F., Makrutzki M., Sirzen F., Veronese
M.L., Tabernero J., and Baselga J. Vemurafenib in
Multiple Nonmelanoma Cancers with BRAF V600
Mutations. [2015] New England Journal of Medicine
(373) 8 : 726-736. Impact factor : 59,558
84. Isakoff S.J., Saleh M.N., Lugovskoy A., Mathews S.,
Czibere A.G., Shields A.F., Bahleda R., Soria J.C., and
Arnedos M. First-in-human study of MM-141: A novel
tetravalent monoclonal antibody targeting IGF-1R
and ErbB3. [2015] Journal of Clinical Oncology (33)
3 suppl : 384. Impact factor : 20,982
85. Italiano A., Bonneterre J., Varga A., Rezai K., Campone
M., Floquet A., Leary A., Berton-Rigaud D., Sablin
M.P., Lesoin A., Lokiec F.M., Lhomme C., Bexon
A.S., Gilles E.M., Bisaha J., Zukiwski A., and Cottu
P.H. Safety and pharmacokinetic (PK) results from
phase 1 of an ongoing phase 1-2 study of onapristone
(ONA) in patients (pts) with progesterone receptor
(PR)-expressing cancers. [2015] Journal of Clinical
Oncology (33) 15 suppl : e16517. Impact factor :
20,982
86. Jaenne P.A., Yang J.C.-H., Kim D.W., Planchard D.,
Ohe Y., Ramalingam S.S., Ahn M.J., Kim S.W., Su
W.C., Horn L., Haggstrom D., Felip E., Kim J.H.,
Frewer P., Cantarini M., Brown K.H., Dickinson P.A.,
Ghiorghiu S., and Ranson M. AZD9291 in EGFR
Inhibitor-Resistant Non-Small-Cell Lung Cancer.
[2015] New England Journal of Medicine (372) 18 :
1689-1699. Impact factor : 59,558
87. Jeremy Wen Q., Yang Q., Goldenson B., Malinge S.,
Lasho T., Schneider R.K., Breyfogle L.J., Schultz R.,
Gilles L., Koppikar P., Abdel-Wahab O., Pardanani A.,
Stein B., Gurbuxani S., Mullally A., Levine R.L., Tefferi
A., and Crispino J.D. Targeting megakaryocyticinduced fibrosis in myeloproliferative neoplasms by
AURKA inhibition. [2015] Nature Medicine (21) 12 :
1473-1480. Impact factor : 30,367
88. Joseph R.W., Gangadhar T.C., Puzanov I., Robert
C., Hamid O., Dummer R., Ribas A., Mehnert J.M.,
Daud A., Celentano K.A., Lindia J.A., Chatterjee M.S.,
Turner D.C., Mayawala K., Elassaiss-Schaap J., de
Alwis D.P., Li X.N., Ebbinghaus S., Kang S.P., and
Kefford R. Model-based analysis of the relationship
between pembrolizumab (MK-3475) exposure and
efficacy in patients with advanced or metastatic
melanoma. [2015] Journal of Clinical Oncology (33)
15 suppl : 3068. Impact factor : 20,982
89. Kappeler C., Healy D.P., Baumer C., Meinhardt G.,
Elisei R., Schlumberger M., and Brose M.S. Analysis
of tumor growth rate for radioiodine (RAI)refractory differentiated thyroid cancer patients
receiving placebo and/or sorafenib in the phase III
DECISION study. [2015] Journal of Clinical Oncology
(33) 15 suppl : 6015. Impact factor : 20,982
90. Kaymakcalan M.D., Xie W., Albigès L., North S.A.,
Kollmannsberger C.K., Smoragiewicz M., Kroeger
N., Wells C., Rha S.Y., Lee J.L., Fay A.P., Heng
D.Y.C., and Choueiri T.K. Risk factors and a model to
predict toxicity-related treatment discontinuation
in patients with metastatic renal cell carcinoma
treated with VEGF-targeted therapy: Results
from the International Metastatic RCC Database
Consortium. [2015] Journal of Clinical Oncology
(33) 7 suppl : 464. Impact factor : 20,982
91. Kim E., Ilagan J.O., Liang Y., Daubner G.M., Lee
S.C., Ramakrishnan A., Li Y., Chung Y.R., Micol J.B.,
Murphy M.E., Cho H., Kim M.K., Zebari A.S., Aumann
S., Park C.Y., Buonamici S., Smith P.G., Deeg H.,
Lobry C., Aifantis I., Modis Y., Allain F.H., Halene S.,
Bradley R.K., and Abdel-Wahab O. SRSF2 Mutations
Contribute to Myelodysplasia by Mutant-Specific
Effects on Exon Recognition. [2015] Cancer Cell (27)
5 : 617-630. Impact factor : 23,214
92. Kim J.W., Bellmunt J., Powles T., Loriot Y., Vogelzang
N.J., Zambrano C.C., Burris H.A., Teng S.L.M., Shen
X., Bruey J.M., Boyd Z., Hegde P.S., and Petrylak
D.P. Clinical activity, safety, and biomarkers of
MPDL3280A in metastatic urothelial bladder
cancer: Additional analysis from phase IA study.
[2015] Journal of Clinical Oncology (33) 7 suppl :
297. Impact factor : 20,982
93. Kreimer A.R., Brennan P., Kuhs K.A., Waterboer
T., Clifford G., Franceschi S., Michel A., WillhauckFleckenstein M., Riboli E., Castellsague X.,
Hildesheim A., Fortner R.T., Kaaks R., Palli D.,
Ljuslinder I., Panico S., Clavel-Chapelon F., BoutronRuault M.C., Mesrine S., Trichopoulou A., Lagiou P.,
Trichopoulos D., Peeters P.H., Cross A.J., Bueno-
13
de-Mesquita H., Vineis P., Larranaga N., Pala V.,
Sanchez M.J., Navarro C., Barricarte A., Tumino
R., Khaw K.T., Wareham N., Boeing H., Steffen A.,
Travis R.C., Ramon Quiros J., Weiderpass E., Pawlita
M., and Johansson M. Human Papillomavirus
Antibodies and Future Risk of Anogenital Cancer:
A Nested Case-Control Study in the European
Prospective Investigation Into Cancer and Nutrition
Study. [2015] Journal of Clinical Oncology (33) 8 :
877-884. Impact factor : 20,982
94. Kroemer G., Senovilla L., Galluzzi L., André F.,
and Zitvogel L. Natural and therapy-induced
immunosurveillance in breast cancer . [2015]
Nature Medicine (21) 10 : 1128-1138. Impact factor :
30,367
95. Kurzeder C., Bover I., Marme F., Rau J., Pautier P.,
Colombo N., Lorusso D., Ottevanger P., Bjurberg M.,
Marth C., Barretina-Ginesta P., Vergote I., Floquet
A., Del Campo J.M., Mahner S., Bastiere-Truchot
L., Mitchell L., Polleis S., Du Bois A., and GonzalezMartin A. Efficacy and safety of chemotherapy
(CT) +/- pertuzumab (P) for platinum-resistant
ovarian cancer (PROC): AGO-OVAR 2.20/ ENGOTov14/ PENELOPE double-blind placebo-controlled
randomized phase III trial. [2015] Journal of Clinical
Oncology (33) 15 suppl : 5504. Impact factor : 20,982
96. Le Cesne A., Blay J.Y., Domont J., Tresch-Bruneel
E., Chevreau C., Bertucci F., Delcambre C., SaadaBouzid E., Piperno-Neumann S., Bay J.O., Mir O.,
Ray-Coquard I., Ryckewaert T., Valentin T., Isambert
N., Italiano A., Clisant S., and Penel N. Interruption
versus continuation of trabectedin in patients with
soft-tissue sarcoma (T-DIS): a randomised phase
2 trial. [2015] Lancet Oncology (16) 3 : 312-319.
Impact factor : 26,509
97. Le Loarer F., Watson S., Pierron G., de Montpreville
V.T., Ballet S., Firmin N., Auguste A., Pissaloux D.,
Boyault S., Paindavoine S., Dechelotte P.J., Besse
B., Vignaud J.M., Brevet M., Fadel E., Richer W.,
Treilleux I., Masliah-Planchon J., DevouassouxShisheboran M., Zalcman G., Allory Y., Bourdeaut
F., Thivolet-Bejui F., Ranchere-Vince D., Girard N.,
Lantuejoul S., Galateau-Salle F., Coindre J.M., Leary
A., Delattre O., Blay J.Y., and Tirode F. SMARCA4
inactivation defines a group of undifferentiated
thoracic malignancies transcriptionally related to
BAF-deficient sarcomas. [2015] Nature Genetics
(47) 10 : 1200-1205. Impact factor : 31,616
98. Le Pechoux C., Dunant A., Faivre-Finn C., Thomas
P.A., Pourel N., Lerouge D., Edwards J., Van Schil
P., Rami-Porta R., Dansin E., Nestle U., Fadel E.,
and Zalcman G. Postoperative Radiotherapy for
Pathologic N2 Non-Small-Cell Lung Cancer Treated
With Adjuvant Chemotherapy: Need for Randomized
Evidence. [2015] Journal of Clinical Oncology (33)
26 : 2930-2931. Impact factor : 20,982
99. Leary A., Genestie C., Adam J., Le Formal A.,
Pautier P., Lhomme C., Chen-Min-Tao R., and
Auguste A. Genomic profile and immune infiltrate in
paired ovarian cancer (OC) samples pre- and postneoadjuvant chemotherapy (NC) . [2015] Journal
of Clinical Oncology (33) 15 suppl : 5575. Impact
factor : 20,982
100. Lemiale V., Mokart D., Resche-Rigon M., Pene F.,
Mayaux J., Faucher E., Nyunga M., Girault C., Perez
P., Guitton C., Ekpe K., Kouatchet A., Theodose I.,
Benoit D., Canet E., Barbier F., Rabbat A., Bruneel
F., Vincent F., Klouche K., Loay K., Mariotte E.,
Bouadma L., Moreau A.S., Seguin A., Meert A.P.,
Reignier J., Papazian L., Mehzari I., Cohen Y.,
Schenck M., Hamidfar R., Darmon M., Demoule A.,
Chevret S., and Azoulay E. Effect of Noninvasive
Ventilation vs Oxygen Therapy on Mortality
Among Immunocompromised Patients With Acute
Respiratory Failure: A Randomized Clinical Trial.
[27-10-2015] JAMA (314) 16 : 1711-1719. Impact
factor : 37,684
101. Lipton A., Smith M.R., Fizazi K., Stopeck A., Henry
D.H., Shore N., Saad F., Spencer A., Zhu L., and
Warner D.J. Bone turnover marker (BTM) levels and
clinical outcomes in advanced cancer patients (pts)
treated with antiresorptive bone therapies. [2015]
Journal of Clinical Oncology (33) 15 suppl : e22236.
Impact factor : 20,982
1 02. Llovet J.M., Park J.W., Torres F., Decaens T.,
Boucher E., Raoul J.L., Kudo M., Chang C., Boige
V., Assenat E., Kang Y.K., Lim H.Y., Walters I., and
Lencioni R. Objective response by mRECIST to
predict survival in hepatocellular carcinoma: A
multivariate, time-dependent analysis from the
phase III BRISK-PS study. [2015] Journal of Clinical
Oncology (33) 15 suppl : 4084. Impact factor : 20,982
103. Lode H.N., Valteau-Couanet D., Garaventa A., Gray
J., Castel V., Yaniv I., Siebert N., Jensen C., Endres S.,
Pill L., Eger C., Seidel D., Juettner M., Kietz S., Ehlert
K., Janzek E., Loibner H., Mueller I., and Ladenstein
R.L. Long-term infusion of anti-GD2 antibody
ch14.18/CHO in combination with interleukin-2 (IL2)
activity and efficacy in high-risk relapsed/refractory
neuroblastoma patients. [2015] Journal of Clinical
Oncology (33) 15 suppl : TPS10080. Impact factor :
20,982
14
104. Loibl S., Majewski I., Guarneri V., Nekljudova V.,
Holmes E.M., Bria E., Denkert C., Eidtmann H.,
Sotiriou C., Loi S., André F., Untch M., Conte P.F.,
Piccart-Gebhart M.J., Von Minckwitz G., and Baselga
J. Correlation of PIK3CA mutation with pathological
complete response in primary HER2-positive breast
cancer: Combined analysis of 967 patients from
three prospective clinical trials. [2015] Journal of
Clinical Oncology (33) 15 suppl : 511. Impact factor :
20,982
105. Long G.V., Stroyakovskiy D., Gogas H., Levchenko E.,
de Braud F., Larkin J., Garbe C., Jouary T., Hauschild
A., Grob J.J., Chiarion-Sileni V., Lebbe C., Mandala
M., Millward M., Arance A., Bondarenko I., Haanen
J.B., Hansson J., Utikal J., Ferraresi V., Kovalenko
N., Mohr P., Probachai V., Schadendorf D., Nathan P.,
Robert C., Ribas A., DeMarini D.J., Irani J.G., Swann
S., Legos J.J., Jin F., Mookerjee B., and Flaherty
K. Dabrafenib and trametinib versus dabrafenib
and placebo for Val600 BRAF-mutant melanoma:
a multicentre, double-blind, phase 3 randomised
controlled trial. [2015] Lancet (386) 9992 : 444-451.
Impact factor : 44,002
106. Lorigan P., Ascierto P.A., Dummer R., Eggermont
A.M., Flaherty K.T., Garbe C., Gogas H., Hauschild
A., Kefford R.F., Kirkwood J.M., Larkin J., Long
G.V., Maio M., McArthur G.A., Ribas A., Robert C.,
Schadendorf D., Sondak V.K., Wolchok J.D., and
Hudson A.M. Expanded access programmes: Patient
interests versus clinical trial integrity. [2015] Lancet
Oncology (16) 1 : 15-17. Impact factor : 26,509
1 07. Loriot Y., Massard C., Lefebvre C., Dogan S.,
Ileanaecaterina E., Lacroix L., Job B., Ngo-Camus
M., Fizazi K., Auger N., Richon C., Koubi-Pick V.,
Hollebecque A., De Baere T., Vielh P., Ledeley M.C.,
Vassal G., Eggermont A.M., and Soria J.C. Genomic
landscape of metastatic platin-resistant urothelial
cancer patients. [2015] Journal of Clinical Oncology
(33) 7 suppl : 316. Impact factor : 20,982
108. Loriot Y., Miller K., Sternberg C.N., Fizazi K., de
Bono J.S., Chowdhury S., Higano C.S., Noonberg
S., Holmstrom S., Mansbach H., Perabo F.G.,
Phung D., Ivanescu C., Skaltsa K., Beer T.M., and
Tombal B. Effect of enzalutamide on health-related
quality of life, pain, and skeletal-related events
in asymptomatic and minimally symptomatic,
chemotherapy-naive patients with metastatic
castration-resistant prostate cancer (PREVAIL):
results from a randomised, phase 3 trial. [2015]
Lancet Oncology (16) 5 : 509-521. Impact factor :
26,509
109. Maio M., Grob J.J., Aamdal S., Bondarenko I., Robert
C., Thomas L., Garbe C., Chiarion-Sileni V., Testori A.,
Chen T.T., Tschaika M., and Wolchok J.D. Five-Year
Survival Rates for Treatment-Naive Patients With
Advanced Melanoma Who Received Ipilimumab
Plus Dacarbazine in a Phase III Trial. [2015] Journal
of Clinical Oncology (33) 10 : 1191-1196. Impact
factor : 20,982
1 10. Malka D., Castan F., Francois E., Bouche O.,
Bennouna J., Ghiringhelli F., De La Fouchardiere
C., Borg C., Samalin E., Bachet J.B., Raoul J.L.,
Cvitkovic F., Miglianico L., Bengrine-Lefevre
L., Dahan L., Lecaille C., Aparicio T., Perrier
H., Gourgou S., and Taieb J. FOLFOX alone or
combined to rilotumumab or panitumumab as
first-line treatment in patients (pts) with advanced
gastroesophageal adenocarcinoma (AGEA): An
open-label, randomized phase II trial (PRODIGE
17 ACCORD 20 MEGA). [2015] Journal of Clinical
Oncology (33) 15 suppl. Impact factor : 20,982
1 11. Manfredi S., Leconte B., Uguen T., le Sourd S.,
Cernon C., Morcet J., Laine F., Baudin E., and Cadiot
G. Study of the therapeutic management of gastric
carcinoid tumors from data of the French national
cohort of neuroendocrine tumors: CARGAS study.
[2015] Journal of Clinical Oncology (33) 15 suppl :
4094. Impact factor : 20,982
1 12. Markt S.C., Miller R., O’Donnell E., Albigès L.,
Bernard B.D., Lago-Hernandez C., Curreri S.A.,
Wright A.A., Beard C., and Sweeney C. BMI at
diagnosis and adverse outcomes among men with
malignant testicular germ cell tumors . [2015]
Journal of Clinical Oncology (33) 7 suppl : 400.
Impact factor : 20,982
113. Martin L., Senesse P., Gioulbasanis I., Antoun S.,
Bozzetti F., Deans C., Strasser F., Thoresen L., Jagoe
R., Chasen M., Lundholm K., Bosaeus I., Fearon
K.H., and Baracos V.E. Diagnostic Criteria for the
Classification of Cancer-Associated Weight Loss.
[2015] Journal of Clinical Oncology (33) 1 : 90-99.
Impact factor : 20,982
114. Massard C., Azaro A., Le Tourneau C., Soria J.C.,
Alt M., Smith C., Ohnmacht U., Oakeley G., Patel
B., Yuen E., Benhadji K.A., and Ahnert J.R. Firstin-human study of LY3039478, a Notch signaling
inhibitor in advanced or metastatic cancer. [2015]
Journal of Clinical Oncology (33) 15 suppl : 2533.
Impact factor : 20,982
1 15. Massard C., Penttinen H., Bono P., Vjaters E.,
Lietuvietis V., Tammela T.L., Vuorela A., Nykanen
P., Pohjanjousi P., and Fizazi K. Pharmacokinetics,
15
activity, and safety of ODM-201 in chemotherapynaive patients with metastatic castration-resistant
prostate cancer: An open-label phase I trial with
long-term extension . [2015] Journal of Clinical
Oncology (33) 7 suppl. Impact factor : 20,982
1 16. Massard C., Oulhen M., Le Moulec S., Loriot Y.,
Auger N., Beuzeboc P., Albigès L., Culine S., Oudard
S., Hennequin C., Vielh P., Farace F., and Fizazi
K. Molecular characterization of heterogeneity in
circulating tumor cells (CTCs) and tumor samples
of metastatic castration-resistant prostate cancer
(mCRPC) patients: The multicenter PETRUS
program. [2015] Journal of Clinical Oncology (33) 7
suppl : 149. Impact factor : 20,982
117. Mateo J., Fizazi K., Pezaro C.J., Loriot Y., Mehra
N., Albigès L., Bianchini D., Varga A., Ryan C.J.,
Petrylak D.P., Shen L., Zhang J., Attard G., De Bono
J.S., and Massard C. Phase 1/2 trial of cabazitaxel
with abiraterone acetate in patients with metastatic
castration-resistant prostate cancer (mCRPC)
progressing after docetaxel and abiraterone acetate:
Phase 2 results. [2015] Journal of Clinical Oncology
(33) 7 suppl : 268. Impact factor : 20,982
1 18. Matias M., Deschamps F., Albigès L., Loriot Y.,
Massard C., Fizazi K., De Baere T., and Escudier
B.J. Thermal ablation for the treatment of bone
metastases (BM) in patients (pts) with metastatic
renal cell carcinoma (mRCC): Experience from IGR.
[2015] Journal of Clinical Oncology (33) 7 suppl :
437. Impact factor : 20,982
1 19. Mazieres J., Zalcman G., Crino L., Biondani P.,
Barlesi F., Filleron T., Dingemans A.M., Lena H.,
Monnet I., Rothschild S.I., Cappuzzo F., Besse B.,
Thiberville L., Rouviere D., Dziadziuszko R., Smit
E.F., Wolf J., Spirig C., Pecuchet N., Leenders F.,
Heuckmann J.M., Diebold J., Milia J.D., Thomas R.K.,
and Gautschi O. Crizotinib Therapy for Advanced
Lung Adenocarcinoma and a ROS1 Rearrangement:
Results From the EUROS1 Cohort. [2015] Journal of
Clinical Oncology (33) 9 : 992-999. Impact factor :
20,982
1 20. Mazieres J., Barlesi F., Molinier O., Monnet I.,
Audigier-Valette C., Besse B., Toffart A.C., Renault
P.A., Masson P., Mennecier B., Fraboulet S.M., Hiret S.,
Westeel V., Dumont P., Cortot A.B., Pichon E., Lebitasy
M.P., Morin F., and Zalcman G. IFCT-1003 LADIE trial:
Randomized phase II trial evaluating treatment with
EGFR-TKI versus EGFR-TKI associated with antiestrogen in women with non-squamous advanced
stage NSCLC. [2015] Journal of Clinical Oncology
(33) 15 suppl : TPS8110. Impact factor : 20,982
121. Mazieres J., Barlesi F., Filleron T., Besse B., Monnet
I., Beau-Faller M., Peters S., Dansin E., Frueh M.,
Pless M., Karachaliou N., Wislez M., Fournel P.,
Westeel V., Cappuzzo F., Cortot A.B., Moro-Sibilot D.,
Milia J., and Gautschi O. Lung cancer patients with
HER2 mutations treated with chemotherapy and
HER2 targeted drugs: Results form the EUHER2
cohort study. [2015] Journal of Clinical Oncology
(33) 15 suppl : 11076. Impact factor : 20,982
122. McNeish I.A., Oza A.M., Coleman R.L., Scott C.L.,
Konecny G.E., Tinker A., O’Malley D.M., Brenton J.,
Kristeleit R.S., Bell-McGuinn K., Oaknin A., Leary A.,
Lin K., Raponi M., Giordano H., Goble S., Rolfe L.,
Yelensky R., Allen A.R., and Swisher E.M. Results
of ARIEL2: A Phase 2 trial to prospectively identify
ovarian cancer patients likely to respond to
rucaparib using tumor genetic analysis. [2015]
Journal of Clinical Oncology (33) 15 suppl : 5508.
Impact factor : 20,982
1 23. Mendelsohn J., Lazar V., Rubin E., Pawitan Y.,
Bresson C., Soria J.C., Eggermont A., Wunder F.,
Scoazec J.Y., Hong W.K., Blay J.Y., Schilsky R.L., and
Kurzrock R. Therapeutic Interventional Mapping
System (TIMS): A novel strategy for the selection
of tri-targeted therapy combinations for non-small
cell lung cancer (NSCLC). [2015] Journal of Clinical
Oncology (33) 15 suppl : 7524. Impact factor : 20,982
124. Messai Y., Noman Z., Hasmim M., Janji B., Albigès
L., Escudier B., and Chouaib S. Role of ITPR1/HIF-2
alpha axis in protecting renal cancer cells against
natural killer cells . [2015] Journal of Clinical
Oncology (33) 7 suppl : 417. Impact factor : 20,982
125. Michailidou K., Beesley J., Lindstrom S., Canisius
S., Dennis J., Lush M.J., Maranian M.J., Bolla M.K.,
Wang Q., Shah M., Perkins B.J., Czene K., Eriksson
M., Darabi H., Brand J.S., Bojesen S.E., Nordestgaard
B.G., Flyger H., Nielsen S.F., Rahman N., Turnbull
C., Fletcher O., Peto J., Gibson L., dos-Santos-Silva
I., Chang-Claude J., Flesch-Janys D., Rudolph A.,
Eilber U., Behrens S., Nevanlinna H., Muranen T.A.,
Aittomäki K., Blomqvist C., Khan S., Aaltonen K.,
Ahsan H., Kibriya M.G., Whittemore A.S., John E.M.,
Malone K.E., Gammon M.D., Santella R.M., Ursin
G., Makalic E., Schmidt D.F., Casey G., Hunter D.J.,
Gapstur S.M., Gaudet M.M., Diver W.R., Haiman C.A.,
Schumacher F., Henderson B.E., Le Marchand L.,
Berg C.D., Chanock S.J., Figueroa J., Hoover R.N.,
Lambrechts D., Neven P., Wildiers H., Van Limbergen
E., Schmidt M.K., Broeks A., Verhoef S., Cornelissen
S., Couch F.J., Olson J.E., Hallberg E., Vachon C.,
Waisfisz Q., Meijers-Heijboer H., Adank M.A., van der
16
Luijt R.B., Li J., Liu J., Humphreys K., Kang D., Choi
J.Y., Park S.K., Yoo K.Y., Matsuo K., Ito H., Iwata H.,
Tajima K., Guénel P., Truong T., Mulot C., Sanchez
M., Burwinkel B., Marme F., Surowy H., Sohn C.,
Wu A.H., Tseng C.C., Van Den Berg D., Stram D.O.,
González-Neira A., Benitez J., Zamora M.P., Perez
J.I., Shu X.O., Lu W., Gao Y.T., Cai H., Cox A., Cross
S.S., Reed M.W., Andrulis I.L., Knight J.A., Glendon
G., Mulligan A.M., Sawyer E.J., Tomlinson I., Kerin
M.J., Miller N., Lindblom A., Margolin S., Teo S.H., Yip
C.H., Taib N.A., Tan G.H., Hooning M.J., Hollestelle
A., Martens J.W., Collée J.M., Blot W., Signorello
L.B., Cai Q., Hopper J.L., Southey M.C., Tsimiklis
H., Apicella C., Shen C.Y., Hsiung C.N., Wu P.E., Hou
M.F., Kristensen V.N., Nord S., Alnaes G.I., Giles G.G.,
Milne R.L., McLean C., Canzian F., Trichopoulos D.,
Peeters P., Lund E., Sund M., Khaw K.T., Gunter
M.J., Palli D., Mortensen L.M., Dossus L., Huerta
J.M., Meindl A., Schmutzler R.K., Sutter C., Yang
R., Muir K., Lophatananon A., Stewart-Brown S.,
Siriwanarangsan P., Hartman M., Miao H., Chia K.S.,
Chan C.W., Fasching P.A., Hein A., Beckmann M.W.,
Haeberle L., Brenner H., Dieffenbach A.K., Arndt V.,
Stegmaier C., Ashworth A., Orr N., Schoemaker M.J.,
Swerdlow A.J., Brinton L., Garcia-Closas M., Zheng
W., Halverson S.L., Shrubsole M., Long J., Goldberg
M.S., Labrèche F., Dumont M., Winqvist R., Pylkäs
K., Jukkola-Vuorinen A., Grip M., Brauch H., Hamann
U., Brüning T., Radice P., Peterlongo P., Manoukian
S., Bernard L., Bogdanova N.V., Dörk T., Mannermaa
A., Kataja V., Kosma V.M., Hartikainen J.M., Devilee
P., Tollenaar R.A., Seynaeve C., Van Asperen C.J.,
Jakubowska A., Lubinski J., Jaworska K., Huzarski T.,
Sangrajrang S., Gaborieau V., Brennan P., McKay J.,
Slager S., Toland A.E., Ambrosone C.B., Yannoukakos
D., Kabisch M., Torres D., Neuhausen S.L., AntonCulver H., Luccarini C., Baynes C., Ahmed S., Healey
C.S., Tessier D.C., Vincent D., Bacot F., Pita G., Alonso
M.R., Álvarez N., Herrero D., Simard J., Pharoah P.P.,
Kraft P., Dunning A.M., Chenevix-Trench G., Hall P.,
and Easton D.F. Genome-wide association analysis
of more than 120,000 individuals identifies 15 new
susceptibility loci for breast cancer. [2015] Nature
Genetics (47) 4 : 373-380. Impact factor : 31,616
126. Michels J., Caron O., Rey A., Dunant A., Duvillard
P., Gouy S., Leary A., Lhomme C., Morice P., and
Pautier P. Epithelial ovarian carcinoma in very
young patients. [2015] Journal of Clinical Oncology
(33) 15 suppl : e16546. Impact factor : 20,982
127. Minard-Colin V., Brugieres L., Reiter A., Cairo M.S.,
Gross T.G., Woessmann W., Burkhardt B., Sandlund
J.T., Williams D., Pillon M., Horibe K., Auperin A., Le
Deley M.C., Zimmerman M., Perkins S.L., Raphael
M., Lamant L., Klapper W., Mussolin L., Poirel
H.A., Macintyre E., Damm-Welk C., Rosolen A.,
and Patte C. Non-Hodgkin Lymphoma in Children
and Adolescents: Progress Through Effective
Collaboration, Current Knowledge, and Challenges
Ahead. [2015] Journal of Clinical Oncology (33) 27 :
2963-2974. Impact factor : 20,982
128. Minard-Colin V., Anderson J.R., Bisogno G., Schwob
D., Rodeberg D.A., Stevens M., Ferrari A., Martelli
H., Walterhouse D., De Salvo G.L., Arndt C.A., Rey A.,
Oberlin O., Meder C.H., and Hawkins D.S. Localized
vagina/uterus rhabdomyosarcoma (VU RMS):
Results of a pooled analysis from four international
cooperative groups . [2015] Journal of Clinical
Oncology (33) 15 suppl : 10063. Impact factor :
20,982
129. Mir O., Brodowicz T., Wallet J., Italiano A., Le Cesne
A., Blay J.Y., Ryckewaert T., Bertucci F., PipernoNeumann S., Ploner F., Toulmonde M., Domont J.,
Saada E., Delcambre C., Isambert N., Delaine S.C.,
Taieb S., Lindner E., Lieg-Atzwanger B., and Penel
N. Activity of regorafenib (RE) in leiomyosarcomas
(LMS) and other types of soft-tissue sarcomas (OTS):
Results of a doubleblind, randomized placebo (PL)
controlled phase II trial. [2015] Journal of Clinical
Oncology (33) 15 suppl : 10504. Impact factor :
20,982
130. Monk B.J., Poveda A., Vergote I., Raspagliesi F.,
Fujiwara K., Bae D.S., Oaknin A., Ray-Coquard
I., Provencher D.M., Karlan B.Y., Lhomme C.,
Richardson G., Rincon D.G., Coleman R.L., Brize A.,
Zhang K., Vogl F.D., Bach B.A., and Oza A.M. Impact
of trebananib plus weekly paclitaxel on overall
survival (OS) in patients (pts) with recurrent
ovarian cancer and ascites: Results from the phase
III TRINOVA-1 study . [2015] Journal of Clinical
Oncology (33) 15 suppl : 5503. Impact factor : 20,982
131. Montgomery R.B., Antonarakis E.S., Hussain M.,
Fizazi K., Joshua A.M., Attard G., Sadar M., Perabo
F., and Chi K.N. A phase 1/2 open-label study of
safety and antitumor activity of EPI-506, a novel AR
N-terminal domain inhibitor, in men with metastatic
castration-resistant prostate cancer (mCRPC) with
progression after enzalutamide or abiraterone .
[2015] Journal of Clinical Oncology (33) 15 suppl.
Impact factor : 20,982
1 32. Moraga I., Wernig G., Wilmes S., Gryshkova V.,
Richter C.P., Hong W.J., Sinha R., Guo F., Fabionar
H., Wehrman T.S., Krutzik P., Demharter S., Plo I.,
Weissman I.L., Minary P., Majeti R., Constantinescu
17
S.N., Piehler J., and Garcia K. Tuning Cytokine
Receptor Signaling by Re-orienting Dimer Geometry
with Surrogate Ligands. [2015] Cell (160) 6 : 11961208. Impact factor : 28,710
133. Moro-Sibilot D., Faivre L., Zalcman G., Perol M.,
Barlesi F., Otto J., Monnet I., Cortot A.B., Wislez
M., Lena H., Mazieres J., Durando X., Lantuejoul S.,
Rouquette I., Florin A.M., Ferretti G., Labouret N.H.,
Nowak F., Jimenez M., and Vassal G. Crizotinib in
patients with advanced ROS1-rearranged nonsmall cell lung cancer (NSCLC). Preliminary results
of the ACSe phase II trial. [2015] Journal of Clinical
Oncology (33) 15 suppl. Impact factor : 20,982
134. Morris M.J., Higano C.S., Scher H.I., Sweeney C.,
Antonarakis E.S., Shevrin D.H., Ryan C.J., Lorlot
Y., Fizazi K., Pandit-Taskar N., Garcia-Vargas J.E.,
Lyseng K., Bloma M., Aksnes A.K., and Carrasquillo
J.A. Effects of radium-223 dichloride (Ra-223) with
docetaxel (D) versus D on prostate-specific antigen
(PSA) and bone alkaline phosphatase (bALP) in
patients (pts) with castration-resistant prostate
cancer (CRPC) and bone metastases (mets): A
phase 1/2a clinical trial. [2015] Journal of Clinical
Oncology (33) 7 suppl : 202. Impact factor : 20,982
135. Morris M.J., Higano C.S., Scher H.I., Sweeney C.,
Antonarakis E.S., Shevrin D.H., Ryan C.J., Loriot
Y., Fizazi K., Pandit-Taskar N., Garcia-Vargas J.E.,
Lyseng K., Bloma M., and Carrasquillo J.A. Effects
of radium-223 dichloride (Ra-223) with docetaxel
(D) vs D on prostate-specific antigen (PSA) and bone
alkaline phosphatase (bALP) in patients (pts) with
castration-resistant prostate cancer (CRPC) and
bone metastases (mets): A phase 1/2a clinical trial.
[2015] Journal of Clinical Oncology (33) 15 suppl :
5012. Impact factor : 20,982
136. Morris M.J., Molina A., Small E.J., de Bono J.S.,
Logothetis C.J., Fizazi K., de Souza P., Kantoff P.W.,
Higano C.S., Li J., Thian K., Larson S.M., Matheny
S.L., Naini V., Burzykowski T., Griffin T.W., Scher
H.I., and Ryan C.J. Radiographic Progression-Free
Survival As a Response Biomarker in Metastatic
Castration-Resistant Prostate Cancer: COU-AA-302
Results. [2015] Journal of Clinical Oncology (33)
12 : 1356-1363. Impact factor : 20,982
137. Motzer R., Escudier B., McDermott D., George S.,
Hammers H., Srinivas S., Tykodi S.S., Sosman
J.A., Procopio G., Plimack E.R., Castellano D.,
Choueiri T.K., Gurney H., Donskov F., Bono P.,
Wagstaff J., Gauler T.C., Ueda T., Tomita Y., Schutz
F.A., Kollmannsberger C., Larkin J., Ravaud A.,
Simon J.S., Xu L.A., Waxman I.M., and Sharma P Nivolumab versus Everolimus in Advanced RenalCell Carcinoma. [2015] New England Journal of
Medicine (373) 19 : 1803-1813. Impact factor :
59,558
138. Nault J.C., Datta S., Imbeaud S., Franconi A., Mallet
M., Couchy G., Letouze E., Pilati C., Verret B., Blanc
J.F., Balabaud C., Calderaro J., Laurent A., Letexier
M., Bioulac-Sage P., Calvo F., and Zucman-Rossi
J. Recurrent AAV2-related insertional mutagenesis
in human hepatocellular carcinomas. [2015] Nature
Genetics (47) 10 : 1187-1193. Impact factor : 31,616
139. Necchi A., Miceli R., Bregni M., Oechsle K., Kanfer E.,
Massard C., Flechon A., Laszlo D., Arpaci F., Wuchter
P., Crysandt M.M., Unal A., Nagler A., Wahlin A.,
Michieli M., Pflueger K.H., Ringhoffer M., Badoglio
M., Pedrazzoli P., and Lanza F. Impact of response
to induction chemotherapy (CT) and prior paclitaxel
(TXL)-based CT on the outcome of salvage highdose chemotherapy (HDCT) for relapsed germcell tumors (GCT) in the modern era: An EBMT
Solid Tumors Working Party study. [2015] Journal
of Clinical Oncology (33) 15 suppl : 4535. Impact
factor : 20,982
140. Necchi A., Lo Vullo S., Giannatempo P., Mariani L.,
Raggi D., Schumacher K., Massard C., Kanfer E.,
Oechsle K., Laszlo D., Michieli M., Pflueger K.H.,
Ifrah N., Crysandt M.M., Wuchter P., Nagler A.,
Wahlin A., Badoglio M., Pedrazzoli P., and Lanza
F. Conventional-dose (CDCT) versus high-dose
chemotherapy (HDCT) in the salvage management
of relapsed pure seminoma: Results from an
international database. [2015] Journal of Clinical
Oncology (33) 15 suppl : e15559. Impact factor :
20,982
141. Neuzillet C., Seitz J.F., Fartoux L., Malka D., Lledo
G., Tijeras-Raballand A., De Gramont A., Ronot
M., Bouattour M., Dreyer C., Amin A., BrunisholzBourget P., Hadengue A., Roldan N., Chibaudel B.,
Raymond E., and Faivre S.J. Sunitinib as second-line
treatment in patients with advanced intrahepatic
cholangiocarcinoma (SUN-CK phase II trial): Safety,
efficacy, and updated translational results. [2015]
Journal of Clinical Oncology (33) 3 suppl : 343.
Impact factor : 20,982
142. O’Sullivan C.C., Bradbury I., Campbell C., Spielmann
M., Perez E.A., Joensuu H., Costantino J.P., Delaloge
S., Rastogi P., Zardavas D., Ballman K.V., Holmes E.,
de Azambuja E., Piccart-Gebhart M., Zujewski J.A.,
and Gelber R.D. Efficacy of Adjuvant Trastuzumab
for Patients With Human Epidermal Growth Factor
Receptor 2-Positive Early Breast Cancer and
18
Tumors <= 2 cm: A Meta-Analysis of the Randomized
Trastuzumab Trials . [2015] Journal of Clinical
Oncology (33) 24 : 2600-2U37. Impact factor : 20,982
143. Oaknin A., Floquet A., Le Tourneau C., Ray-Coquard
I.L., Joly F., Hidalgo M., Leary A., Krieter O., Lahr
A., Rossomanno S., Lechner K., Nayak T., Boetsch
C., Rasuo G., Morel A., and Vergote I. Single agent
vanucizumab (RO5520985) for platinum (Pt)resistant recurrent ovarian cancer (OC): Results
from a single arm extension phase of the phase I
FIH study. [2015] Journal of Clinical Oncology (33)
15 suppl : 5549. Impact factor : 20,982
144. Olszanski A.J., Middleton M.R., Bahleda R., Heist
R.S., Rangachari L., Zhou X., Bozon V., Kneissl M., and
Macarulla T. A phase Ib study of investigational panRAF kinase inhibitor MLN2480 plus investigational
TORC1/2 inhibitor MLN0128, investigational Aurora
A kinase inhibitor alisertib (MLN8237), or paclitaxel
in patients (pts) with advanced solid tumors. [2015]
Journal of Clinical Oncology (33) 15 suppl : TPS2609.
Impact factor : 20,982
145. Pacheco T.R., Fernandes A.C., Ali S.M., Maia-Matos
M., da Costa A.L.G.G., Abreu C., Alves A.T., Correia
L., Lara J.F., Michaelson R.A., Ferreira A.R., Matias
M., Leitzel K., Lipton A., and Costa L. Activation of
PI3K/AKT/mTOR pathway in ER plus breast cancer:
Analysis of paired primary and metastatic tumor
samples. [2015] Journal of Clinical Oncology (33)
15 suppl : 577. Impact factor : 20,982
1 46. Pautier P., Floquet A., Chevreau C., Penel N.,
Guillemet C., Delcambre C., Cupissol D., Selle F.,
Isambert N., Piperno-Neumann S., Thyss A., Bertucci
F., Bompas E., Alexandre J., Collard O., Lavau-Denes
S., Soulie P., Toulmonde M., Le Cesne A., Lacas B.,
and Duffaud F. Trabectedin in combination with
doxorubicin for first-line treatment of advanced
uterine or soft-tissue leiomyosarcoma (LMS-02): a
non-randomised, multicentre, phase 2 trial. [2015]
Lancet Oncology (16) 4 : 457-464. Impact factor :
26,509
147. Petrylak D.P., Vogelzang N.J., Budnik N., Wiechno
P.J., Sternberg C.N., Doner K., Bellmunt J., Burke
J.M., de Olza M.O., Choudhury A., Gschwend J.E.,
Kopyltsov E., Flechon A., Van As N., Houede N.,
Barton D., Fandi A., Jungnelius U., Li S., de Wit R., and
Fizazi K. Docetaxel and prednisone with or without
lenalidomide in chemotherapy-naive patients with
metastatic castration-resistant prostate cancer
(MAINSAIL): a randomised, double-blind, placebocontrolled phase 3 trial. [2015] Lancet Oncology
(16) 4 : 417-425. Impact factor : 26,509
148. Petrylak D.P., Powles T., Bellmunt J., Braiteh F.S.,
Loriot Y., Zambrano C.C., Burris H.A., Kim J.W.,
Teng S.L.M., Bruey J.M., Hegde P., Abidoye O.O.,
and Vogelzang N.J. A phase Ia study of MPDL3280A
(anti-PDL1): Updated response and survival data
in urothelial bladder cancer (UBC). [2015] Journal
of Clinical Oncology (33) 15 suppl : 4501. Impact
factor : 20,982
149. Pierga J.Y., Bidard F.C., Autret A., Petit T., André
F., Dalenc F., Levy C., Ferrero J.M., Romieu G.,
Bonneterre J., Lerebours F., Bachelot T.D., Kerbrat
P., Charafe-Jaufret E., Lemonnier J., and Viens
P. Circulating tumor cells (CTC) and pathological
complete response (pCR) as independent prognostic
factors in inflammatory breast cancer (IBC) in a
pooled analysis of two multicentre phase II trials
(BEVERLY 1 & 2) of neoadjuvant chemotherapy
combined with bevacizumab . [2015] Journal of
Clinical Oncology (33) 15 suppl : 108. Impact factor :
20,982
1 50. Pinto N.R., Applebaum M.A., Volchenboum S.L.,
Matthay K.K., London W.B., Ambros P.F., Nakagawara
A., Berthold F., Schleiermacher G., Park J.R., ValteauCouanet D., Pearson A.D.J., and Cohn S.L. Advances
in Risk Classification and Treatment Strategies for
Neuroblastoma. [2015] Journal of Clinical Oncology
(33) 27 : 3008-3017. Impact factor : 20,982
1 51. Planchard D., Groen H.J., Kim T.M., Rigas J.R.,
Souquet P.J., Baik C.S., Barlesi F., Mazieres J., Quoix
E.A., Curtis C., Mookerjee B., Bartlett-Pandite A.N.,
Tucker C., D’Amelio A., and Johnson B.E. Interim
results of a phase II study of the BRAF inhibitor
(BRAFi) dabrafenib (D) in combination with the
MEK inhibitor trametinib (T) in patients (pts) with
BRAF V600E mutated (mut) metastatic non-small
cell lung cancer (NSCLC). [2015] Journal of Clinical
Oncology (33) 15 suppl : 8006. Impact factor : 20,982
1 52. Planchard D., Shtivelband M., Shi K., Ibrahim
R., Ballas M., and Soria J.C. A phase III study
of MEDI4736 (M), an anti-PD-L1 antibody, in
monotherapy or in combination with Tremelimumab
(T), versus standard of care (SOC) in patients (pts)
with advanced non-small cell lung cancer (NSCLC)
who have received at least two prior systemic
treatment regimens (ARCTIC) . [2015] Journal
of Clinical Oncology (33) 15 suppl : 8006. Impact
factor : 20,982
153. Poortmans P., Collette S., Kirkove C., Van Limbergen
E., Budach V., Struikmans H., Collette L., Fourquet A.,
Maingon P., Valli M., De Winter K., Marnitz S., Barillot
I., Scandolaro L., Vonk E., Rodenhuis C., Marsiglia H.,
19
Weidner N., van Tienhoven G., Glanzmann C., Kuten
A., Arriagada R., Bartelink H., and van den Bogaert
W. Internal Mammary and Medial Supraclavicular
Irradiation in Breast Cancer. [2015] New England
Journal of Medicine (373) 4 : 317-327. Impact
factor : 59,558
154. Postow M.A., Chesney J., Pavlick A.C., Robert C.,
Grossmann K., McDermott D., Linette G.P., Meyer
N., Giguere J.K., Agarwala S.S., Shaheen M., Ernstoff
M.S., Minor D., Salama A.K., Taylor M., Ott P.A., Rollin
L.M., Horak C., Gagnier P., Wolchok J.D., and Hodi
F. Nivolumab and Ipilimumab versus Ipilimumab in
Untreated Melanoma. [2015] New England Journal
of Medicine (372) 21 : 2006-2017. Impact factor :
59,558
155. Pouessel D., Terrisse S.A., Mouillet G., Breitkopf K.,
Theodore C., Lobbedez F.J., Roubaud G., Flechon A.,
Tourani J.M., Massard C., Thiery-Vuillemin A., Oudard
S., Sevin E., Chevret S., and Culine S. Activity of
docetaxel (D) and new generation hormonotherapies
(NGH) in patients with metastatic castrate-resistant
prostate cancer (mCRPC) following front line
cabazitaxel (C). [2015] Journal of Clinical Oncology
(33) 15 suppl : e16094. Impact factor : 20,982
156. Pouessel D., Chevret S., Roubaud G., Aarab-Terrisse
S., Chevreau C., Vordos D., Rolland F., Boudin L.,
Joly F., Joly C., Beuzeboc P., Boyle H.J., Farneti D.,
Dauba J., Moriceau G., Alexandre I., Deplanque G.,
Loriot Y., Houede N., and Culine S. A comparison of
the outcomes after neoadjuvant (NC) or adjuvant
chemotherapy (AC) for muscle-invasive urothelial
bladder cancer (UC): A French contemporary
retrospective multicenter cohort. [2015] Journal of
Clinical Oncology (33) 7 suppl : 325. Impact factor :
20,982
157. Provencio Pulla M., Tabernero J., Moreno V., Trigo
Perez J.M., Lopez R., Kristeleit R., Awada A., Leary
A., Alexandre J., Delord J.P., Ferrari S., Santoro A.,
Bajetta E., Subbiah V., Weitman S., Manuel Villalobos
V., Raymond E., Sundlov A., Lardelli P., and Chawla
S.P. A multicenter phase II basket clinical trial of
lurbinectedin (PM01183) in selected advanced solid
tumors. [2015] Journal of Clinical Oncology (33) 15
suppl : TPS2604. Impact factor : 20,982
158. Ramalingam S.S., Rukazenkov Y., Thomas K., and
Soria J.C. A randomized, phase III study (FLAURA)
of AZD9291, a novel EGFR-TKI, versus gefitinib or
erlotinib in treatment-naive patients with advanced
non-small cell lung cancer and an EGFR-TKIsensitizing mutation . [2015] Journal of Clinical
Oncology (33) 15 suppl. Impact factor : 20,982
159. Ray-Coquard I.L., Domont J., Tresch-Bruneel E.,
Bompas E., Cassier P.A., Mir O., Piperno-Neumann
S., Italiano A., Chevreau C., Cupissol D., Bertucci F.,
Bay J.O., Collard O., Saada-Bouzid E., Isambert N.,
Delcambre C., Clisant S., Le Cesne A., Blay J.Y., and
Penel N. Paclitaxel Given Once Per Week With or
Without Bevacizumab in Patients With Advanced
Angiosarcoma: A Randomized Phase II Trial. [2015]
Journal of Clinical Oncology (33) 25 : 2797-2802.
Impact factor : 20,982
160. Ribas A., Robert C., Hodi F., Wolchok J.D., Joshua
A.M., Hwu W.J., Weber J.S., Zarour H.M., Kefford R.,
Loboda A., Albright A., Kang S.P., Ebbinghaus S.,
Yearley J., Murphy E., Nebozhyn M., Lunceford J.K.,
McClanahan T., Ayers M., and Daud A. Association
of response to programmed death receptor 1 (PD1) blockade with pembrolizumab (MK-3475) with an
interferon-inflammatory immune gene signature.
[2015] Journal of Clinical Oncology (33) 15 suppl :
3001. Impact factor : 20,982
161. Ribas A., Puzanov I., Dummer R., Schadendorf D.,
Hamid O., Robert C., Hodi F., Schachter J., Pavlick
A.C., Lewis K.D., Cranmer L.D., Blank C.U., O’Day
S.J., Ascierto P.A., Salama A.K., Margolin K.A., Loquai
C., Eigentler T.K., Gangadhar T.C., Carlino M.S.,
Agarwala S.S., Moschos S.J., Sosman J.A., Goldinger
S.M., Shapira-Frommer R., Gonzalez R., Kirkwood
J.M., Wolchok J.D., Eggermont A., Li X.N., Zhou W.,
Zernhelt A.M., Lis J., Ebbinghaus S., Kang S.P., and
Daud A. Pembrolizumab versus investigator-choice
chemotherapy for ipilimumab-refractory melanoma
(KEYNOTE-002): a randomised, controlled, phase
2 trial. [2015] Lancet Oncology (16) 8 : 908-918.
Impact factor : 26,509
1 62. Rini B., Goddard A., Knezevic D., and Escudier
B. Relapse models for clear cell renal carcinoma
reply - Authors’ reply. [2015] Lancet Oncology (16)
8 : e378. Impact factor : 26,509
163. Rini B., Goddard A., Knezevic D., Maddala T., Zhou M.,
Aydin H., Campbell S., Elson P., Koscielny S., Lopatin
M., Svedman C., Martini J.F., Williams J., Verkarre V.,
Radulescu C., Neuzillet Y., Hemmerle I., Timsit M.O.,
Tsiatis A.C., Bonham M., Lebret T., Mejean A., and
Escudier B. A 16-gene assay to predict recurrence
after surgery in localised renal cell carcinoma:
development and validation studies. [2015] Lancet
Oncology (16) 6 : 676-685. Impact factor : 26,509
164. Rizvi N.A., Mazieres J., Planchard D., Stinchcombe
T.E., Dy G.K., Antonia S.J., Horn L., Lena H., Minenza
E., Mennecier B., Otterson G.A., Campos L.T.,
Gandara D.R., Levy B.P., Nair S.G., Zalcman G., Wolf
20
J., Souquet P.J., Baldini E., Cappuzzo F., Chouaid
C., Dowlati A., Sanborn R., Lopez-Chavez A., Grohe
C., Huber R.M., Harbison C.T., Baudelet C., Lestini
B.J., and Ramalingam S.S. Activity and safety
of nivolumab, an anti-PD-1 immune checkpoint
inhibitor, for patients with advanced, refractory
squamous non-small-cell lung cancer (CheckMate
063): a phase 2, single-arm trial . [2015] Lancet
Oncology (16) 3 : 257-265. Impact factor : 26,509
165. Robert C., Karaszewska B., Schachter J., Rutkowski
P., Mackiewicz A., Stroiakovski D., Lichinitser M.,
Dummer R., Grange F., Mortier L., Chiarion-Sileni
V., Drucis K., Krajsova I., Hauschild A., Lorigan P.,
Wolter P., Long G.V., Flaherty K., Nathan P., Ribas A.,
Martin A.M., Sun P., Crist W., Legos J., Rubin S.D.,
Little S.M., and Schadendorf D. Improved Overall
Survival in Melanoma with Combined Dabrafenib
and Trametinib. [2015] New England Journal of
Medicine (372) 1 : 30-39. Impact factor : 59,558
166. Robert C., Long G.V., Brady B., Dutriaux C., Maio
M., Mortier L., Hassel J.C., Rutkowski P., McNeil C.,
Kalinka-Warzocha E., Savage K.J., Hernberg M.M.,
Lebbe C., Charles J., Mihalcioiu C., Chiarion-Sileni
V., Mauch C., Cognetti F., Arance A., Schmidt H.,
Schadendorf D., Gogas H., Lundgren-Eriksson L.,
Horak C., Sharkey B., Waxman I.M., Atkinson V., and
Ascierto P.A. Nivolumab in Previously Untreated
Melanoma without BRAF Mutation. [2015] New
England Journal of Medicine (372) 4 : 320-330.
Impact factor : 59,558
167. Robert C., Joshua A.M., Kefford R., Joseph R.W.,
Wolchok J.D., Hodi F., Hamid O., Weber J.S.,
Gangadhar T.C., Dronca R.S., Patnaik A., Zarour
H.M., Hwu W.J., Hersey P., Daud A., Giannotti
M., Li X.N., Ebbinghaus S., Kang S.P., and Ribas
A. Association of immune-related thyroid disorders
with pembrolizumab (pembro, MK-3475) in
patients (pts) with advanced melanoma treated in
KEYNOTE-001. [2015] Journal of Clinical Oncology
(33) 15 suppl : 9050. Impact factor : 20,982
168. Robert C., Schachter J., Long G.V., Arance A., Grob
J.J., Mortier L., Daud A., Carlino M.S., McNeil C.,
Lotem M., Larkin J., Lorigan P., Neyns B., Blank
C.U., Hamid O., Mateus C., Shapira-Frommer R.,
Kosh M., Zhou H., Ibrahim N., Ebbinghaus S., and
Ribas A. Pembrolizumab versus Ipilimumab in
Advanced Melanoma. [2015] New England Journal
of Medicine (372) 26 : 2521-2532. Impact factor :
59,558
169. Robert C., Sibaud V., Mateus C., Verschoore M.,
Charles C., Lanoy E., and Baran R. Nail toxicities
induced by systemic anticancer treatments. [2015]
Lancet Oncology (16) 4 : E181-E189. Impact factor :
26,509
170. Rodriguez-Galindo C., Friedrich P., Alcasabas P.,
Antillon F., Banavali S., Castillo L., Israels T., Jeha
S., Harif M., Sullivan M.J., Quah T.C., Patte C., Pui
C.H., Barr R., and Gross T. Toward the Cure of
All Children With Cancer Through Collaborative
Efforts: Pediatric Oncology As a Global Challenge.
[2015] Journal of Clinical Oncology (33) 27 : 30653073 . Impact factor : 20,982
171. Rondeau V., Krol A., Ferrer L., Pignon J.P., ProustLima C., Ducreux M., Bouche O., and Michiels
S. Predictive ability of tumor growth modeling for
overall survival in metastatic colorectal cancer .
[2015] Journal of Clinical Oncology (33) 15 suppl :
e14619. Impact factor : 20,982
172. Rosolen A., Perkins S.L., Pinkerton C.R., Guillerman
R.P., Sandlund J.T., Patte C., Reiter A., and Cairo
M.S. Revised international pediatric non-Hodgkin
lymphoma staging system . [2015] Journal of
Clinical Oncology (33) 18 : 2112-2118. Impact
factor : 20,982
173. Rouzier R., Gouy S., Selle F., Lambaudie E., Guyon
F., Fourchotte V., Pomel C., Colombo P.E., Kalbacher
E., Martin S., Fauvet R., Follana P., Lesoin A.,
Lecuru F., Menguy V., Ghazi Y., Chereau E., Zohar
S., Cottu P.H., and Joly F. Correlation of baseline
clinical characteristics and laparoscopic extent of
carcinomatosis of women with initially unresectable
ovarian, tubal or peritoneal adenocarcinoma, in
ANTHALYA study: A randomized, open-label, phase
II study assessing the efficacy and the safety of
bevacizumab in neoadjuvant . [2015] Journal of
Clinical Oncology (33) 15 suppl : 5538. Impact
factor : 20,982
174. Ryan C.J., Smith M.R., Fizazi K., Saad F., Mulders
P.F., Sternberg C.N., Miller K., Logothetis C.J., Shore
N.D., Small E.J., Carles J., Flaig T.W., Taplin M.E.,
Higano C.S., de Souza P., de Bono J.S., Griffin T.W.,
De Porre P., Yu M.K., Park Y.C., Li J., Kheoh T., Naini
V., Molina A., and Rathkopf D.E. Abiraterone acetate
plus prednisone versus placebo plus prednisone
in chemotherapy-naive men with metastatic
castration-resistant prostate cancer (COU-AA-302):
final overall survival analysis of a randomised,
double-blind, placebo-controlled phase 3 study.
[2015] Lancet Oncology (16) 2 : 152-160 . Impact
factor : 26,509
175. Saad F., Fizazi K., Jinga V., Efstathiou E., Fong P.C.,
Hart L.L., Jones R., McDermott R., Wirth M., Suzuki
21
K., MacLean D.B., Wang L., Akaza H., Nelson J., Scher
H.I., Dreicer R., Webb I.J., and de Wit R. Orteronel
plus prednisone in patients with chemotherapynaive metastatic castration-resistant prostate
cancer (ELM-PC 4): a double-blind, multicentre,
phase 3, randomised, placebo-controlled trial.
[2015] Lancet Oncology (16) 3 : 338-348. Impact
factor : 26,509
176. Salazar R., Verslype C., Baudin E., Libutti S.K., Yao
J.C., Buzzoni R., Antonuzzo L., Hubner R., GaricaCarbonero R., Custodio A.B., Wolin E.M., Turri S., Dey
D., Aimone P., Sulovski J., Mukherjee N., Herbst F.,
and Fazio N. Phase II studies of BEZ235 in patients
with advanced pancreatic neuroendocrine tumors
(pNET). [2015] Journal of Clinical Oncology (33) 15
suppl : 4102. Impact factor : 20,982
177. Saliba J., Saint-Martin C., Di Stefano A., Lenglet
G., Marty C., Keren B., Pasquier F., Della Valle V.,
Secardin L., Leroy G., Mahfoudhi E., Grosjean S.,
Droin N., Diop M.’., Dessen P., Charrier S., Palazzo
A., Merlevede J., Meniane J.C., Delaunay-Darivon C.,
Fuseau P., Isnard F., Casadevall N., Solary E., Debili
N., Bernard O.A., Raslova H., Najman A., Vainchenker
W., Bellanne-Chantelot C., and Plo I. Germline
duplication of ATG2B and GSKIP predisposes to
familial myeloid malignancies . [2015] Nature
Genetics (47) 10 : 1131-1140. Impact factor : 31,616
1 78. Sandlund J.T., Guillerman R.P., Perkins S.L.,
Pinkerton C.R., Rosolen A., Patte C., Reiter A., and
Cairo M.S. International pediatric non-Hodgkin
lymphoma response criteria. [2015] Journal of
Clinical Oncology (33) 18 : 2106-2111. Impact
factor : 20,982
1 79. Savas P.S., Salgado R., Caramia F., Denkert C.,
Loibl S., Sotiriou C., André F., Speed T.P., and Loi
S. Lack of correlation of neoantigens arising from
tumor somatic mutations with tumor infiltrating
lymphocytes (TILs) or survival in HER2-positive
breast cancer (HER2+BC). [2015] Journal of Clinical
Oncology (33) 15 suppl : 613. Impact factor : 20,982
1 80. Schadendorf D., Hodi F., Robert C., Weber J.S.,
Margolin K., Hamid O., Patt D., Chen T.T., Berman
D.M., and Wolchok J.D. Pooled Analysis of LongTerm Survival Data From Phase II and Phase III
Trials of Ipilimumab in Unresectable or Metastatic
Melanoma. [2015] Journal of Clinical Oncology (33)
17 : 1889-1894. Impact factor : 20,982
181. Schadendorf D., Dummer R., Hauschild A., Robert
C., Hamid O., Daud A., van den Eertwegh A.J.,
Cranmer L.D., O’Day S., Puzanov I., Schachter
J., Blank C.U., Salama A.K., Loquai C., Mehnert
J.M., Wang Y., Ebbinghaus S., Kang S.P., Zhou
W., and Ribas A. Patient-reported outcomes
(PROs) in KEYNOTE-002, a randomized study of
pembrolizumab vs chemotherapy in patients (pts)
with ipilimumab-refractory (IPI-R) metastatic
melanoma (MEL) . [2015] Journal of Clinical
Oncology (33) 15 suppl : 9040. Impact factor : 20,982
182. Schellens J.H., Tabernero J., Lassen U.N., Melero
I., Homicsko K., Argiles G., Perez Gracia J.L.,
Sorensen M., Coukos G., Angevin E., Joensuu
H., Van Brummelen E., Menke C.W., Nayak T.K.,
Romagnoli S., Reis B., Brossard S.S., Evers S.,
Saro Suarez J.M., and Verheul H.M. CEA-targeted
engineered IL2: Clinical confirmation of tumor
targeting and evidence of intra-tumoral immune
activation. [2015] Journal of Clinical Oncology (33)
15 suppl : 3016. Impact factor : 20,982
183. Scher H.I., Morris M.J., Stadler W.M., Higano C.S.,
Halabi S., Smith M.R., Basch E.M., Fizazi K., Ryan
C.J., Antonarakis E.S., Corn P.G., Liu G., De Bono
J.S., Schwartz L.H., Beer T.M., Kelly W.K., Hussain
M., Sartor A., Kantoff P.W., and Armstrong A.J. The
Prostate Cancer Working Group 3 (PCWG3)
consensus for trials in castration-resistant
prostate cancer (CRPC). [2015] Journal of Clinical
Oncology (33) 15 suppl : 5000. Impact factor :
20,982
184. Schlumberger M., Elisei R., Mueller S., Schoeffski
P., Brose M.S., Shah M.H., Licitra L.F., Jarzab B.,
Medvedev V., Kreissl M., Cohen E.E., Wirth L.J.,
Ali H.Y., Hessel C., Yaron Y., Ball D.W., Nelkin B.,
and Sherman S.I. Final overall survival analysis of
EXAM, an international, double-blind, randomized,
placebo-controlled phase III trial of cabozantinib
(Cabo) in medullary thyroid carcinoma (MTC)
patients with documented RECIST progression at
baseline. [2015] Journal of Clinical Oncology (33)
15 suppl : 6012. Impact factor : 20,982
1 85. Schlumberger M., Tahara M., and Wirth
L.J. Lenvatinib in Radioiodine-Refractory Thyroid
Cancer (Reply). [2015] New England Journal of
Medicine (372) 19 : 1868-1868. Impact factor :
59,558
186. Schlumberger M., Tahara M., Wirth L.J., Robinson B.,
Brose M.S., Elisei R., Habra M.A., Newbold K., Shah
M.H., Hoff A.O., Gianoukakis A.G., Kiyota N., Taylor
M.H., Kim S.B., Krzyzanowska M.K., Dutcus C.E., de
las Heras B., Zhu J., and Sherman S.I. Lenvatinib
versus Placebo in Radioiodine-Refractory Thyroid
Cancer. [2015] New England Journal of Medicine
(372) 7 : 621-630. Impact factor : 59,558
22
187. Schoeffski P., Maki R.G., Italiano A., Gelderblom
H., Grignani G., De Camargo V.P., Bauer S., Rha S.Y.,
Chawla S.P., Blay J.Y., Hohenberger P., D’Adamo D.R.,
Wang B., Chmielowski B., Le Cesne A., Demetri G.D.,
and Patel S. Randomized, open-label, multicenter,
phase III study of eribulin versus dacarbazine in
patients (pts) with leiomyosarcoma (LMS) and
adipocytic sarcoma (ADI). [2015] Journal of Clinical
Oncology (33) 15 suppl : LBA7005 . Impact factor :
20,982
188. Schwaederle M., Zhao M., Lee J.J., Eggermont A.M.,
Schilsky R.L., Mendelsohn J., Lazar V., and Kurzrock
R. Impact of Precision Medicine in Diverse Cancers:
A Meta-Analysis of Phase II Clinical Trials. [2015]
Journal of Clinical Oncology (33) 32 : 3817-3825.
Impact factor : 20,982
189.Schwaederle M.C., Zhao M.M., Lee J., Eggermont A.,
Schilsky R.L., Mendelsohn J., Lazar V., and Kurzrock
R. Personalized therapy in diverse cancers: Metaanalysis of 32,149 patients in phase II clinical trials.
[2015] Journal of Clinical Oncology (33) 15 suppl.
Impact factor : 20,982
190. Scotte F., Martelli N., Vainchtock A., and Borget
I. Incidence and costs of thromboembolic events
in cancer patients: A study on four major cancer
localizations. [2015] Journal of Clinical Oncology
(33) 15 suppl : e17795. Impact factor : 20,982
191. Segal N.H., Ou S.H.I., Balmanoukian A.S., Fury M.G.,
Massarelli E., Brahmer J.R., Weiss J., Schoffski P.,
Antonia S.J., Massard C., Zandberg D.P., Khleif S.,
Li X., Rebelatto M., Steele K., Robbins P.B., BlakeHaskins J.A., and Butler M.O. Safety and efficacy
of MEDI4736, an anti-PD-L1 antibody, in patients
from a squamous cell carcinoma of the head and
neck (SCCHN) expansion cohort. [2015] Journal
of Clinical Oncology (33) 15 suppl : 3011. Impact
factor : 20,982
1 92. Sequist L., V, Soria J.C., Goldman J., Wakelee
H., Gadgeel S., Varga A., Papadimitrakopoulou
V., Solomon B.J., Oxnard G.R., Dziadziuszko R.,
Aisner D.L., Doebele R.C., Galasso C., Garon E.B.,
Heist R.S., Logan J., Neal J.W., Mendenhall M.A.,
Nichols S., Piotrowska Z., Wozniak A.J., Raponi M.,
Karlovich C.A., Jaw-Tsai S., Isaacson J., Despain
D., Matheny S.L., Rolfe L., Allen A.R., and Camidge
D.R. Rociletinib in EGFR-Mutated Non-SmallCell Lung Cancer. [2015] New England Journal
of Medicine (372) 18 : 1700-1709. Impact factor :
59,558
193. Sequist L.V., Goldman J.W., Wakelee H.A., Camidge
D., Yu H.A., Varga A., Solomon B., Oxnard G.R., Ou
S.H.I., Papadimitrakopoulou V., Chao B.H., Liu S.V.,
Reckamp K.L., Spira A.I., Piotrowska Z., Despain D.,
Karlovich C.A., Yurasov S., and Soria J.C. Efficacy of
rociletinib (CO-1686) in plasma-genotyped T790Mpositive non-small cell lung cancer (NSCLC)
patients (pts). [2015] Journal of Clinical Oncology
(33) 15 suppl : 8001. Impact factor : 20,982
194. Shaw A.T., Bauer T.M., Felip E., Besse B., James L.P.,
Clancy J.S., Mugundu G., Martini J.F., Abbattista A.,
and Solomon B.J. Clinical activity and safety of PF06463922 from a dose escalation study in patients
with advanced ALK+ or ROS1+NSCLC . [2015]
Journal of Clinical Oncology (33) 15 suppl : 8018.
Impact factor : 20,982
195. Slamon D.J., Hurvitz S.A., Chen D., André F., Tseng
L.M., Jerusalem G.H.M., Wilks S., O’Regan R., Isaacs
C., Toi M., Burris H.A., He W., Riester M., Robinson
D., Taran T., and Gianni L. Predictive biomarkers
of everolimus efficacy in HER2+advanced breast
cancer: Combined exploratory analysis from
BOLERO-1 and BOLERO-3. [2015] Journal of Clinical
Oncology (33) 15 suppl : 512. Impact factor : 20,982
196. Slimano F., Rigaud C., Annereau M., Gaspar N., and
Lemare F. Aprepitant for paediatric chemotherapyinduced nausea and vomiting . [2015] Lancet
Oncology (16) 6 : e259. Impact factor : 26,509
197. Smith M.R., De Bono J.S., Sternberg C.N., Le Moulec
S., Oudard S., De Giorgi U., Krainer M., Bergman
A.M., Hoelzer W., de Wit R., Boegemann M., Saad
F., Cruciani G., Thiery-Vuillemin A., Feyerabend S.,
Miller K., Ramies D.A., Hessel C., Weitzman A., and
Fizazi K. Final analysis of COMET-1: Cabozantinib
(Cabo) versus prednisone (Pred) in metastatic
castration-resistant prostate cancer (mCRPC)
patients (pts) previously treated with docetaxel (D)
and abiraterone (A) and/or enzalutamide (E). [2015]
Journal of Clinical Oncology (33) 7 suppl : 139.
Impact factor : 20,982
198. Smith M.R., Brown J.E., Fizazi K., Klotz L., Marx G.M.,
Wang H., Warner D., and Lipton A. Bone metabolism
biomarkers in men with advanced prostate cancer
(PC) and bone metastases treated with denosumab
versus zoledronic acid (ZA) . [2015] Journal of
Clinical Oncology (33) 7 suppl : 267. Impact factor :
20,982
199. Soria J.C., Felip E., Cobo M., Lu S., Syrigos K., Lee
K.H., Goker E., Georgoulias V., Li W., Isla D., Guclu
S.Z., Morabito A., Min Y.J., Ardizzoni A., Gadgeel S.M.,
Wang B., Chand V.K., and Goss G.D. Afatinib versus
erlotinib as second-line treatment of patients with
advanced squamous cell carcinoma of the lung
23
(LUX-Lung 8): an open-label randomised controlled
phase 3 trial. [2015] Lancet Oncology (16) 8 : 897907. Impact factor : 26,509
200. Soria J.C., Wu Y.L., Nakagawa K., Kim S.W., Yang
J.J., Ahn M.J., Wang J., Yang J.C.-H., Lu Y., Atagi
S., Ponce S., Lee D.H., Liu Y., Yoh K., Zhou J.Y., Shi
X., Webster A., Jiang H., and Mok T.S. Gefitinib plus
chemotherapy versus placebo plus chemotherapy
in EGFR-mutation- positive non-small-cell lung
cancer after progression on first-line gefitinib
(IMPRESS): a phase 3 randomised trial . [2015]
Lancet Oncology (16) 8 : 990-998. Impact factor :
26,509
201. Sternberg C.N., Skoneczna I., Kerst J., Albers P.,
Fossa S.D., Agerbaek M., Dumez H., De Santis M.,
Theodore C., Leahy M.G., Chester J.D., Verbaeys A.,
Daugaard G., Wood L., Witjes J., de Wit R., Geoffrois
L., Sengelov L., Thalmann G., Charpentier D., Rolland
F., Mignot L., Sundar S., Symonds P., Graham J.,
Joly F., Marreaud S., Collette L., and Sylvester
R. Immediate versus deferred chemotherapy after
radical cystectomy in patients with pT3-pT4 or
N+M0 urothelial carcinoma of the bladder (EORTC
30994): an intergroup, open-label, randomised
phase 3 trial. [2015] Lancet Oncology (16) 1 : 7686. Impact factor : 26,509
202. Stratikopoulos E.E., Dendy M., Szabolcs M., Khaykin
A.J., Lefebvre C., Zhou M.M., and Parsons R. Kinase
and BET Inhibitors Together Clamp Inhibition
of PI3K Signaling and Overcome Resistance to
Therapy. [2015] Cancer Cell (27) 6 : 837-851. Impact
factor : 23,214
203. Strauss D.C., Callegaro D., Bonvalot S., Miceli R.,
Swallow C.J., Hohenberger P., van Coevorden F.,
Haas R.L., Rutkowski P., Pollock R.E., Fiore M.,
Hayes A.J., Fairweather M., Raut C.P., and Gronchi
A. Postoperative morbidity and mortality in a large
series of primary retroperitoneal sarcoma (RPS)
treated at 8 tertiary centers: A study from the
Transatlantic RPS Working Group. [2015] Journal
of Clinical Oncology (33) 15 suppl : 10557. Impact
factor : 20,982
204. Sullivan R., Alatise O.I., Anderson B.O., Audisio R.,
Autier P., Aggarwal A., Balch C., Brennan M.F., Dare
A., D’Cruz A., Eggermont A.M., Fleming K., Gueye
S.M., Hagander L., Herrera C.A., Holmer H., Ilbawi
A.M., Jarnheimer A., Ji J.f., Kingham T., Liberman
J., Leather A.J., Meara J.G., Mukhopadhyay S.,
Murthy S.S., Omar S., Parham G.P., Pramesh C.,
Riviello R., Rodin D., Santini L., Shrikhande S.V.,
Shrime M., Thomas R., Tsunoda A.T., van de Velde
C., Veronesi U., Vijaykumar D.K., Watters D., Wang
S., Wu Y.L., Zeiton M., and Purushotham A. Global
cancer surgery: delivering safe, aff ordable, and
timely cancer surgery. [2015] Lancet Oncology (16)
11 : 1193-1224. Impact factor : 26,509
205. Tabernero J., Bahleda R., Dienstmann R., Infante
J.R., Mita A., Italiano A., Calvo E., Moreno V., Adamo
B., Gazzah A., Zhong B., Platero S.J., Smit J.W.,
Stuyckens K., Chatterjee-Kishore M., Rodon J.,
Peddareddigari V., Luo F.R., and Soria J.C. Phase I
Dose-Escalation Study of JNJ-42756493, an Oral
Pan-Fibroblast Growth Factor Receptor Inhibitor,
in Patients With Advanced Solid Tumors . [2015]
Journal of Clinical Oncology (33) 30 : 3401-3408.
Impact factor : 20,982
2 06. Tahara M., Schlumberger M., Elisei R., Habra
M.A., Kiyota N., Dutcus C., Xu J., Zhu J., Hihara T.,
McGrath S., Matijevic M., Kadowaki T., Funahashi Y.,
and Sherman S.I. Pharmacodynamic biomarkers
of outcomes in the phase III study of lenvatinib
in I-131-refractory differentiated thyroid cancer
(SELECT). [2015] Journal of Clinical Oncology (33)
15 suppl : 6014. Impact factor : 20,982
207. Toullec C., Coindre J.M., Blay J.Y., Ranchere D.,
Meeus P., Stoeckle E., Bui B., Bonvalot S., Le Cesne
A., Terrier P., Duffaud F., Bertucci F., Cupissol D.,
Isambert N., Neumann S.P., Baumstarck K., and
Salas S. Sarcomas of the digestive tract (excluding
GISTs) (SDT): A study of 63 patients from the French
Sarcoma Group (GSF) database. [2015] Journal of
Clinical Oncology (33) 15 suppl : e21533. Impact
factor : 20,982
208. Tsao M.S., Shepherd F.A., Brambilla E., and Soria
J.C. Predictive versus prognostic value of lung
adenocarcinoma classification. [2015] Journal of
Clinical Oncology (33) 2 : 225-226. Impact factor :
20,982
209. Tsao M.S., Marguet S., Le Teuff G., Lantuejoul S.,
Shepherd F.A., Seymour L., Kratzke R., Graziano S.L.,
Popper H.H., Rosell R., Douillard J.Y., Le-Chevalier T.,
Pignon J.P., Soria J.C., and Brambilla E.M. Subtype
Classification of Lung Adenocarcinoma Predicts
Benefit From Adjuvant Chemotherapy in Patients
Undergoing Complete Resection. [2015] Journal
of Clinical Oncology (33) 30 : 3439-3446. Impact
factor : 20,982
2 10. Turner N.C., Ro J., André F., Loi S., Verma S.,
Iwata H., Harbeck N., Loibl S., Huang C., Zhang
B.K., Giorgetti C., Randolph S., Koehler M., and
Cristofanilli M. PALOMA3: A double-blind, phase
III trial of fulvestrant with or without palbociclib in
24
pre- and post-menopausal women with hormone
receptor-positive, HER2-negative metastatic breast
cancer that progressed on prior endocrine therapy.
[2015] Journal of Clinical Oncology (33) 15 suppl :
LBA502. Impact factor : 20,982
2 11. Turner N.C., Ro J., André F., Loi S., Verma S.,
Iwata H., Harbeck N., Loibl S., Bartlett C.H., Zhang
K., Giorgetti C., Randolph S., Koehler M., and
Cristofanilli M. Palbociclib in Hormone-ReceptorPositive Advanced Breast Cancer . [2015] New
England Journal of Medicine (373) 3 : 209-219.
Impact factor : 59,558
212. Vacchelli E., Ma Y., Baracco E.E., Sistigu A., Enot
D.P., Pietrocola F., Yang H., Adjemian S., Chaba K.,
Semeraro M., Signore M., De Ninno A., Lucarini V.,
Peschiaroli F., Businaro L., Gerardino A., Manic G.,
Ulas T., Guenther P., Schultze J.L., Kepp O., Stoll
G., Lefebvre C., Mulot C., Castoldi F., Rusakiewicz
S., Ladoire S., Apetoh L., Bravo-San Pedro J.M.,
Lucattelli M., Delarasse C., Boige V., Ducreux M.,
Delaloge S., Borg C., André F., Schiavoni G., Vitale I.,
Laurent-Puig P., Mattei F., Zitvogel L., and Kroemer
G. Chemotherapy-induced antitumor immunity
requires formyl peptide receptor 1. [2015] Science
(350) 6263 : 972-978. Impact factor : 34,661
213. Varga A., Piha-Paul S.A., Ott P.A., Mehnert J.M.,
Berton-Rigaud D., Johnson E.A., Cheng J.D., Yuan
S., Rubin E.H., and Matei D.E. Antitumor activity and
safety of pembrolizumab in patients (pts) with PDL1 positive advanced ovarian cancer: Interim results
from a phase Ib study. [2015] Journal of Clinical
Oncology (33) 15 suppl : 5510. Impact factor : 20,982
214. Vassal G., Blanc P., Copland C., and Pearson A. Will
the revised class waiver list make it? [2015] Lancet
Oncology (16) 9 : E425-E426. Impact factor : 26,509
215. Vassal G., Le Deley M.C., Tournigand C., Aparicio
T., Ray-Coquard I., Taillandier L., Escudier B., You
B., Goncalves A., Bohas C.L., Seitz J.F., Andre T.,
Merlio J.P., Arnould L., Ferretti G., Menu Y., Mortier
T., Lonchamp E., Oukhatar C.M.-A., and Moro-Sibilot
D. Activity of crizotinib in relapsed MET amplified
malignancies: Results of the French AcSe Program.
[2015] Journal of Clinical Oncology (33) 15 suppl :
2595. Impact factor : 20,982
2 16. Vassetzky Y., Gout I., and Kuznicki J. Research
reforms: Ukrainian science needs elixir of youth.
[2015] Nature (522) 7554 : 34. Impact factor : 38,138
2 17. Vetizou M., Pitt J.M., Daillere R., Lepage P.,
Waldschmitt N., Flament C., Rusakiewicz S., Routy
B., Roberti M.P., Duong C.P.M., Poirier-Colame
V., Roux A., Becharef S., Formenti S., Golden E.,
Cording S., Eberl G., Schlitzer A., Ginhoux F., Mani
S., Yamazaki T., Jacquelot N., Enot D.P., Berard
M., Nigou J., Opolon P., Eggermont A., Woerther
P.L., Chachaty E., Chaput N., Robert C., Mateus
C., Kroemer G., Raoult D., Boneca I.G., Carbonnel
F., Chamaillard M., and Zitvogel L. Anticancer
immunotherapy by CTLA-4 blockade relies on the
gut microbiota. [2015] Science (350) 6264 : 10791084. Impact factor : 34,661
218. Walter T., Tougeron D., Baudin E., Le Malicot K.,
Lecomte T., Guigay J., Hentic O., Manfredi S., Bonnet
I., Guimbaud R., Coriat R., Rougier P., Desauw C.,
Thirot-Bidault A., Dahan L., Roquin G., Aparicio
T., Lombard-Bohas C., Lepage C., and Cadiot
G. Characteristics, prognosis and treatments of 294
patients with poorly differentiated neuroendocrine
carcinoma: The FFCD-GTE national cohort. [2015]
Journal of Clinical Oncology (33) 15 suppl : 4095.
Impact factor : 20,982
2 19. Walterhouse D., Barkauskas D.A., Ferrari A.,
Koscielniak E., Stevens M., Martelli H., Seitz G.,
Rodeberg D.A., Shnorhavorian M., Dasgupta R.,
Breneman J.C., Anderson J.R., Hawkins D.S.,
and Minard-Colin V. Meta-analysis of effects of
demographic and treatment variables on outcome
for localized paratesticular rhabdomyosarcoma (PT
RMS) in North America and Europe. [2015] Journal
of Clinical Oncology (33) 15 suppl : 10044. Impact
factor : 20,982
220. Watters J.W., Dickson M.A., Schwartz G.K., Le Cesne
A., Bahleda R., Wagner A.J., Choy E., De Jonge
M.J., Light M., Jung J., Lee J.S., and Mace S. TP53
mutations emerge in circulating cell-free DNA
obtained from patients undergoing treatment with
the HDM2 antagonist SAR405838. [2015] Journal
of Clinical Oncology (33) 15 suppl : 2515. Impact
factor : 20,982
221. Weber J.S., Antonia S.J., Topalian S.L., Schadendorf
D., Larkin J.M., Sznol M., Liu H.Y., Waxman I., and
Robert C. Safety profile of nivolumab (NIVO) in
patients (pts) with advanced melanoma (MEL): A
pooled analysis. [2015] Journal of Clinical Oncology
(33) 15 suppl : 9018. Impact factor : 20,982
222. Wolchok J.D., Hamid O., Ribas A., Robert C., Kefford
R., Hwu W.J., Weber J.S., Joshua A.M., Gangadhar
T.C., Dronca R.S., Daud A., Patnaik A., Joseph R.W.,
Zarour H.M., Li X.N., Xue D., Ebbinghaus S., Kang
S.P., Perrone A.M., and Hodi F. Atypical patterns
of response in patients (pts) with metastatic
melanoma treated with pembrolizumab (MK-
25
3475) in KEYNOTE-001. [2015] Journal of Clinical
Oncology (33) 15 suppl : 3000. Impact factor : 20,982
2 23. Yatim F., Moutel G., Cristofalo P., Ferrua M., Di
Palma M., and Minvielle E. Analysis of home
care coordination activities in oncology: A mixed
methods study. [2015] Journal of Clinical Oncology
(33) 15 suppl : 6533. Impact factor : 20,982
224. Zalcman G., Mazieres J., Margery J., Greillier L.,
Audigier-Valette C., Moro-Sibilot D., Molinier O.,
Corre R., Monnet I., Gounant V., Janicot H., Gervais
R., Locher C., Milleron B., Quan T., Lebitasy M.P.,
Morin F., Creveuil C., Parienti J.J., and Scherpereel
A. Bevacizumab 15mg/kg plus cisplatin-pemetrexed
(CP) triplet versus CP doublet in Malignant Pleural
Mesothelioma (MPM): Results of the IFCTGFPC-0701 MAPS randomized phase 3 trial. [2015]
Journal of Clinical Oncology (33) 15 suppl : 7500.
Impact factor : 20,982
2 25. Zardavas D., Te Marvelde L., Milne R., Joensuu
H., Moynahan M.E., Hennessy B., Bieche I., Saal
L.H., Stal O., Iacopetta B., Jensen J.D., O’Toole S.,
Barbareschi M., Noguchi S., Lerma E., Wang Q.,
Piccart-Gebhart M.J., Sotiriou C., Michiels S., and
Loi S. Tumor PIK3CA genotype and prognosis: A
pooled analysis of 4,241 patients (pts) with earlystage breast cancer (BC). [2015] Journal of Clinical
Oncology (33) 15 suppl. Impact factor : 20,982
2 26. Zitvogel L., Galluzzi L., Kepp O., Smyth M.J.,
and Kroemer G. Type I interferons in anticancer
immunity. [2015] Nature Reviews Immunology (15)
7 : 405-414. Impact factor : 39,476
227. Zitvogel L. and Kroemer G. CANCER Antibodies
regulate antitumour immunity. [2015] Nature (521)
7550 : 35-37. Impact factor : 38,138
228. Zitvogel L. and Kroemer G. A p53-regulated immune
checkpoint relevant to cancer. [2015] Science (349)
6247 : 476-477. Impact factor : 34,661
26
/ Publications internationales
Gustave Roussy en 2015
À impact factor compris entre 10 et 20 (73 publications)
1.A l Nakouzi N., Le Moulec S., Albigès L., Wang C.,
Beuzeboc P., Gross-Goupil M., De La Motte Rouge T.,
Guillot A., Gajda D., Massard C., Gleave M., Fizazi K.,
and Loriot Y. CabazitaxelRemains Active in Patients
Progressing After Docetaxel Followed by Novel
Androgen Receptor Pathway Targeted Therapies.
[2015] European Urology (68) 2: 228-235. Impact
factor: 14,976
2. Albers P., Albrecht W., Algaba F., Bokemeyer C.,
Cohn-Cedermark G., Fizazi K., Horwich A., Laguna
M.P., Nicolai N., and Oldenburg J. Guidelines on
Testicular Cancer: 2015 Update. [2015] European
Urology (68) 6: 1054-1068. Impact factor: 14,976
3. Albigès L. and Escudier B. Sorafenib-Sunitinib
Sequence: The Jury Is Out. [2015] European Urology
(68) 5: 848-849. Impact factor: 14,976
4. Albigès L., Choueiri T., Escudier B., Galsky M.,
George D., Hofmann F., Lam T., Motzer R., Mulders
P., Porta C., Powles T., Sternberg C., and Bex A. A
Systematic Review of Sequencing and Combinations
of Systemic Therapy in Metastatic Renal Cancer.
[2015] European Urology (67) 1: 100-110. Impact
factor: 14,976
5. Albigès L., Loriot Y., Massard C., and Fizazi K. Longterm Efficacy and Safety Results: Can Enzalutamide
Challenge the Dogma of Androgen Deprivation
Therapy in Hormone-naive Prostate Cancer? [2015]
European Urology (68) 5: 802-804. Impact factor:
14,976
6. Aleksandrova K., Chuang S.C., Boeing H., Zuo H.,
Tell G.S., Pischon T., Jenab M., Bueno-de-Mesquita
B., Vollset S.E., Midttun O., Ueland P.M., Fedirko
V., Johansson M., Weiderpass E., Severi G., Racine
A., Boutron-Ruault M.C., Kaaks R., Kuehn T.,
Tjønneland A., Overvad K., Ramon Quiros J., Jakszyn
P., Sanchez M.J., Dorronsoro M., Chirlaque M.D.,
Ardanaz E., Khaw K.T., Wareham N.J., Travis R.C.,
Trichopoulou A., Lagiou P., Trichopoulos D., Palli D.,
Sieri S., Tumino R., Panico S., May A.M., Palmqvist
R., Ljuslinder I., Kong S.Y., Freisling H., Gunter
M.J., Lu Y., Cross A.J., Riboli E., and Vineis P. A
Prospective Study of the Immune System Activation
Biomarker Neopterin and Colorectal Cancer Risk.
[2015] Journal of the National Cancer Institute
(107) 4: UNSP djv010. Impact factor: 11,370
7. André F., Arnedos M., Goubar A., Ghouadni A., and
Delaloge S. Ki67-no evidence for its use in nodepositive breast cancer . [2015] Nature Reviews
Clinical Oncology (12) 5: 296-301. Impact factor:
18,786
8. Antony-Debre I., Manchev V.T., Balayn N., Bluteau
D., Tomowiak C., Legrand C., Langlois T., Bawa O.,
Tosca L., Tachdjian G., Leheup B., Debili N., Plo I.,
Mills J.A., French D.L., Weiss M.J., Solary E., Favier
R., Vainchenker W., and Raslova H. Level of RUNX1
activity is critical for leukemic predisposition but
not for thrombocytopenia. [2015] Blood (125) 6:
930-940. Impact factor: 11,841
9. Arnedos M., Vicier C., Loi S., Lefebvre C., Michiels
S., Bonnefoi H., and André F. Precision medicine for
metastatic breast cancer-limitations and solutions.
[2015] Nature Reviews Clinical Oncology (12) 12:
693-704. Impact factor: 18,786
10. Bodo S., Colas C., Buhard O., Collura A., Tinat J.,
Lavoine N., Guilloux A., Chalastanis A., Lafitte P.,
Coulet F., Buisine M.P., Ilencikova D., Ruiz-Ponte C.,
Kinzel M., Grandjouan S., Brems H.I., Lejeune S.,
Blanche H., Wang Q., Caron O., Cabaret O., Syrcek
M.L., Vidaud D., Parfait B., Verloes A., Knappe U.J.,
Soubrier F., Mortemousque I., Leis A., AuclairPerrossier J., Frebourg T., Flejou J.F., Entz-Werle N.,
Leclerc J., Malka D., Cohen-Haguenauer O., Goldberg
Y., Gerdes A.M., Fedhila F., Mathieu-Dramard M.,
Lin R.H., Wafaa B., Gauthier-Villars M., Bourdeaut
F., Sheridan E., Vasen H., Brugieres L., Wimmer K.,
Muleris M., and Duva A. Diagnosis of Constitutional
Mismatch Repair-Deficiency Syndrome Based on
Microsatellite Instability and Lymphocyte Tolerance
to Methylating Agents. [2015] Gastroenterology
(149) 4: 1017-1029. Impact factor: 18,187
11. Bosch A., Dumortier J., Maucort-Boulch D., Scoazec
J.Y., Wendum D., Conti F., Morard I., Rubbia-Brandt
L., Terris B., Radenne S., Abenavoli L., Chazouilleres
O., Calmus Y., Boillot O., Giostra E., and Corpechot
C. Preventive administration of UDCA after liver
transplantation for primary biliary cirrhosis is
associated with a lower risk of disease recurrence.
[2015] Journal of Hepatology (63) 6: 1449-1458.
Impact factor: 10,590
12. Bossi A. Re: The Impact of Definitive Local Therapy
for Lymph Node-positive Prostate Cancer: A
Population-based Study. [2015] European Urology
(68) 1: 161-161. Impact factor: 14,976
13. Bossi A., Wiegel T., and Roach M. Postprostatectomy
Radiotherapy for Patients with High-risk Features
on Definitive Pathology: A Plea for Evidence-based
Medicine. [2015] European Urology (68) 5: 775-776.
Impact factor: 14,976
14. Cabagnols X., Defour J., Ugo V., Ianotto J., Mossuz
P., Mondet J., Girodon F., Alexandre J., Mansier
O., Viallard J., Lippert E., Murati A., Mozziconacci
27
M., Saussoy P., Vekemans M., Knoops L., Pasquier
F., Ribrag V., Solary E., Plo I., Constantinescu S.,
Casadevall N., Vainchenker W., Marzac C., and
Bluteau O. Differential association of calreticulin
type 1 and type 2 mutations with myelofibrosis and
essential thrombocytemia: relevance for disease
evolution. [2015] Leukemia (29) 1: 249-252. Impact
factor: 12,104
15. Castel D., Philippe C., Calmon R., Le Dret L.,
Truffaux N., Boddaert N., Pages M., Taylor K.R.,
Saulnier P., Lacroix L., Mackay A., Jones C.,
Sainte-Rose C., Blauwblomme T., Andreiuolo F.,
Puget S., Grill J., Varlet P., and Debily M.A. Histone
H3F3A and HIST1H3B K27M mutations define two
subgroups of diffuse intrinsic pontine gliomas with
different prognosis and phenotypes. [2015] Acta
Neuropathologica (130) 6: 815-827. Impact factor:
11,360
16. Copie-Bergman C., Cuilliere-Dartigues P., Baia M.,
Briere J., Delarue R., Canioni D., Salles G., Parrens
M., Belhadj K., Fabiani B., Recher C., Petrella T.,
Ketterer N., Peyrade F., Haioun C., Nagel I., Siebert
R., Jardin F., Leroy K., Jais J.P., Tilly H., Molina
T.J., and Gaulard P. MYC-IG rearrangements are
negative predictors of survival in DLBCL patients
treated with immunochemotherapy: a GELA/LYSA
study . [26-11-2015] Blood (126) 22: 2466-2474.
Impact factor: 11,841
17. Dargaud Y., Scoazec J.Y., Wielders S.J., Trzeciak
C., Hackeng T.M., Négrier C., Hemker H.C.,
Lindhout T., and Castoldi E. Characterization of an
autosomal dominant bleeding disorder caused by
a thrombomodulin mutation. [2015] Blood (125) 9:
1497-1501. Impact factor: 11,841
18. de Batlle J., Ferrari P., Chajes V., Park J., Slimani N.,
McKenzie F., Overvad K., Roswall N., Tjønneland A.,
Boutron-Ruault M., Clavel-Chapelon F., Fagherazzi
G., Katzke V., Kaaks R., Bergmann M., Trichopoulou
A., Lagiou P., Trichopoulos D., Palli D., Sieri S.,
Panico S., Tumino R., Vineis P., Bueno-de-Mesquita
H., Peeters P., Hjartaker A., Engeset D., Weiderpass
E., Sanchez S., Travier N., Sanchez M., Amiano P.,
Chirlaque M., Barricarte Gurrea A., Khaw K., Key T.,
Bradbury K., Ericson U., Sonestedt E., Van Guelpen
B., Schneede J., Riboli E., and Romieu I. Dietary
Folate Intake and Breast Cancer Risk: European
Prospective Investigation Into Cancer and Nutrition.
[2015] Journal of the National Cancer Institute (107)
1: 367. Impact factor: 11,370
19. de la Fouchardiere A., Cabaret O., Petre J.,
Aydin S., Leroy A., de Potter P., Pissaloux D.,
Haddad V., Bressac-de Paillerets B., and Janin
N. Primary leptomeningeal melanoma is part of
the BAP1-related cancer syndrome. [2015] Acta
Neuropathologica (129) 6: 921-923. Impact factor:
11,360
20. Delfau-Larue M.H., Klapper W., Berger F., Jardin
F., Briere J., Salles G., Casasnovas O., Feugier P.,
Haioun C., Ribrag V., Thieblemont C., Unterhalt M.,
Dreyling M., Macintyre E., Pott C., Hermine O., and
Hoster E. High-dose cytarabine does not overcome
the adverse prognostic value of CDKN2A and TP53
deletions in mantle cell lymphoma. [2015] Blood
(126) 5: 604-611. Impact factor: 11,841
21. Dhedin N., Huynh A., Maury S., Tabrizi R., Beldjord
K., Asnafi V., Thomas X., Chevallier P., Nguyen S.,
Coiteux V., Bourhis J.H., Hichri Y., Escoffre-Barbe M.,
Reman O., Graux C., Chalandon Y., Blaise D., Schanz
U., Lheritier V., Cahn J.Y., Dombret H., and Ifrah
N. Role of allogeneic stem cell transplantation in
adult patients with Ph-negative acute lymphoblastic
leukemia. [2015] Blood (125) 16: 2486-2496. Impact
factor: 11,841
22. Dumortier J., Dharancy S., Cannesson A., Lassailly G.,
Rolland B., Pruvot F.R., Boillot O., Faure S., Guillaud
O., Rigole-Donnadieu H., Herrero A., Scoazec
J.Y., Mathurin P., and Pageaux G.P. Recurrent
Alcoholic Cirrhosis In Severe Alcoholic Relapse
After Liver Transplantation: A Frequent and
Serious Complication. [2015] American Journal of
Gastroenterology (110) 8: 1160-1166, quiz 1167.
Impact factor: 10,383
23. Fasanelli F., Baglietto L., Ponzi E., Guida F.,
Campanella G., Johansson M., Grankvist K.,
Johansson M., Assumma M.B., Naccarati A.,
Chadeau-Hyam M., Ala U., Faltus C., Kaaks R.,
Risch A., De Stavola B., Hodge A., Giles G.G.,
Southey M.C., Relton C.L., Haycock P.C., Lund E.,
Polidoro S., Sandanger T.M., Severi G., and Vineis
P. Hypomethylation of smoking-related genes
is associated with future lung cancer in four
prospective cohorts. [2015] Nature Communications
(6): 10192. Impact factor: 11,329
24. Fizazi K., Abrahamsson P.A., Ahlgren G., Bellmunt
J., Castellano D., Culine S., de Wit R., Gillessen S.,
Gschwend J.E., Hamdy F., James N., McDermott
R., Miller K., Wiegel T., Wirth M., and Tombal
B. Achievements and Perspectives in Prostate
Cancer Phase 3 Trials from Genitourinary Research
Groups in Europe: Introducing the Prostate Cancer
Consortium in Europe. [2015] European Urology
(67) 5: 904-912. Impact factor: 14,976
28
25. Fizazi K., Massard C., Smith M., Rader M., Brown J.,
Milecki P., Shore N., Oudard S., Karsh L., Carducci
M., Damiao R., Wang H., Ying W., and Goessl C. Bonerelated Parameters are the Main Prognostic Factors
for Overall Survival in Men with Bone Metastases
from Castration-resistant Prostate Cancer. [2015]
European Urology (68) 1: 42-50. Impact factor:
14,976
26. Fontes Jardim D.L., Schwaederle M., Wei C., Lee
J.J., Hong D.S., Eggermont A.M., Schilsky R.L.,
Mendelsohn J., Lazar V., and Kurzrock R. Impact
of a Biomarker-Based Strategy on Oncology Drug
Development: A Meta-analysis of Clinical Trials
Leading to FDA Approval. [2015] Journal of the
National Cancer Institute (107) 11: djv253. Impact
factor: 11,370
27. Galluzzi L., Pietrocola F., and Kroemer G. Molecular
Regulation of Circadian Rhythms by Polyamines.
[2015] Cell Metabolism (22) 5: 757-758. Impact
factor: 17,303
28. Garrouste-Org, Perrin M., Soufir L., Vesin A., Blot F.,
Maxime V., Beuret P., Troche G., Klouche K., Argaud
L., Azoulay E., and Timsit J.F. The Iatroref study:
medical errors are associated with symptoms of
depression in ICU staff but not burnout or safety
culture. [2015] Intensive Care Medicine (41) 2: 273284. Impact factor: 10,125
29. Gartrell B.A., Coleman R., Efstathiou E., Fizazi K.,
Logothetis C.J., Smith M.R., Sonpavde G., Sartor
O., and Saad F. Metastatic Prostate Cancer and the
Bone: Significance and Therapeutic Options. [2015]
European Urology (68) 5: 850-858. Impact factor:
14,976
30. Golan T., Messer A.R., Amitai-Lange A., Melamed
Z., Ohana R., Bell R.E., Kapitansky O., Lerman G.,
Greenberger S., Khaled M., Amar N., Albrengues
J., Gaggioli C., Gonen P., Tabach Y., Sprinzak D.,
Shalom-Feuerstein R., and Levy C. Interactions of
Melanoma Cells with Distal Keratinocytes Trigger
Metastasis via Notch Signaling Inhibition of MITF.
[2015] Molecular Cell (59) 4: 664-676. Impact factor:
13,958
31. Gravis G., Boher J.M., Fizazi K., Joly F., Priou F.,
Marino P., Latorzeff I., Delva R., Krakowski I.,
Laguerre B., Walz J., Rolland F., Theodore C.,
Deplanque G., Ferrero J.M., Pouessel D., Mourey L.,
Beuzeboc P., Zanetta S., Habibian M., Berdah J.F.,
Dauba J., Baciuchka M., Platini C., Linassier C.,
Labourey J.L., Machiels J.P., El Kouri C., Ravaud A.,
Suc E., Eymard J.C., Hasbini A., Bousquet G., Soulie
M., and Oudard S. Prognostic Factors for Survival in
Noncastrate Metastatic Prostate Cancer: Validation
of the Glass Model and Development of a Novel
Simplified Prognostic Model . [2015] European
Urology (68) 2: 196-204. Impact factor: 14,976
32. Guervilly J.H., Takedachi A., Naim V., Scaglione
S., Chawhan C., Lovera Y., Despras E., Kuraoka I.,
Kannouche P., Rosselli F., and Gaillard P.H. The
SLX4 Complex Is a SUMO E3 Ligase that Impacts on
Replication Stress Outcome and Genome Stability.
[2015] Molecular Cell (57) 1: 123-137. Impact factor:
13,958
33. Hangen E., Feraud O., Lachkar S., Mou H., Doti N.,
Fimia G.M., Ngoc-vy L., Zhu C., Godin I., Muller K.,
Chatzi A., Nuebel E., Ciccosanti F., Flamant S., Benit
P., Perfettini J.L., Sauvat A., Bennaceur-Griscelli
A., Roux K.S.-L., Gonin P., Tokatlidis K., Rustin P.,
Piacentini M., Ruvo M., Blomgren K., Kroemer G.,
and Modjtahedi N. Interaction between AIF and
CHCHD4 Regulates Respiratory Chain Biogenesis.
[2015] Molecular Cell (58) 6: 1001-1014. Impact
factor: 13,958
34. Hannani D., Vetizou M., Enot D., Rusakiewicz S.,
Chaput N., Klatzmann D., Desbois M., Jacquelot
N., Vimond N., Chouaib S., Mateus C., Allison J.P.,
Ribas A., Wolchok J.D., Yuan J., Wong P., Postow
M., Mackiewicz A., Mackiewicz J., Schadendorff
D., Jaeger D., Korman A.J., Bahjat K., Maio M.,
Calabro L., Teng M.W., Smyth M.J., Eggermont A.,
Robert C., Kroemer G., and Zitvogel L. Anticancer
immunotherapy by CTLA-4 blockade: obligatory
contribution of IL-2 receptors and negative
prognostic impact of soluble CD25 . [2015] Cell
Research (25) 2: 208-224. Impact factor: 14,812
35. Herold K.C., Majzoub J.A., Melmed S., Pendergrass
M., and Schlumberger M. Endocrinology researchreflecting on the past decade and looking to the
next. [2015] Nature Reviews Endocrinology (11) 11:
672-680. Impact factor: 15,432
36. Iacovelli R., Massari F., Albigès L., Loriot Y.,
Massard C., Fizazi K., and Escudier B. Evidence
and Clinical Relevance of Tumor Flare in Patients
Who Discontinue Tyrosine Kinase Inhibitors for
Treatment of Metastatic Renal Cell Carcinoma.
[2015] European Urology (68) 1: 154-160. Impact
factor: 14,976
37. Koontz B.F., Bossi A., Cozzarini C., Wiegel T., and
D’Amico A. A Systematic Review of Hypofractionation
for Primary Management of Prostate Cancer. [2015]
European Urology (68) 4: 683-691. Impact factor:
14,976
29
38. Kroemer G. Autophagy: a druggable process that
is deregulated in aging and human disease. [2015]
Journal of Clinical Investigation (125) 1: 1-4. Impact
factor: 12,575
39. Kvaskoff M., Mu F., Terry K.L., Harris H.R., Poole
E.M., Farland L., and Missmer S.A. Endometriosis:
a high-risk population for major chronic diseases?
[2015] Human Reproduction Update (21) 4: 500-516.
Impact factor: 11,194
40. Lawler M., Siu L.L., Rehm H.L., Chanock S.J.,
Alterovitz G., Burn J., Calvo F., Lacombe D., Teh B.T.,
North K.N., and Sawyers C.L. All the World’s a Stage:
Facilitating Discovery Science and Improved Cancer
Care through the Global Alliance for Genomics and
Health. [2015] Cancer Discovery (5) 11: 1133-1136.
Impact factor: 19,783
41. Lobry C. Restoring Ikaros’s wings to solve a
leukemia maze. [8-10-2015] Blood (126) 15: 17351736. Impact factor: 11,841
42. Madeo F., Zimmermann A., Maiuri M.C., and
Kroemer G. Essential role for autophagy in life span
extension. [2015] Journal of Clinical Investigation
(125) 1: 85-93. Impact factor: 12,575
43. Maiuri M.C. and Kroemer G. Essential Role for
Oxidative Phosphorylation in Cancer Progression.
[2015] Cell Metabolism (21) 1: 11-12. Impact factor:
17,303
44. Meldi K., Qin T., Buchi F., Droin N., Sotzen J., Micol
J.B., Selimoglu-Buet D., Masala E., Allione B., Gioia
D., Poloni A., Lunghi M., Solary E., Abdel-Wahab O.,
Santini V., and Figueroa M.E. Specific molecular
signatures predict decitabine response in chronic
myelomonocytic leukemia . [2015] Journal of
Clinical Investigation (125) 5: 1857-1872. Impact
factor: 12,575
45. Montgomery B., Kheoh T., Molina A., Li J., Bellmunt
J., Tran N., Loriot Y., Efstathiou E., Ryan C.J.,
Scher H.I., and de Bono J.S. Impact of Baseline
Corticosteroids on Survival and Steroid Androgens
in Metastatic Castration-resistant Prostate Cancer:
Exploratory Analysis from COU-AA-301 . [2015]
European Urology (67) 5: 866-873. Impact factor:
14,976
46. Morgans A.K., van Bommel A.C., Stowell C., Abrahm
J.L., Basch E., Bekelman J.E., Berry D.L., Bossi A.,
Davis I.D., de Reijke T.M., Denis L.J., Evans S.M.,
Fleshner N.E., George D.J., Kiefert J., Lin D.W.,
Matthew A.G., McDermott R., Payne H., Roos I.A.,
Schrag D., Steuber T., Tombal B., van Basten J.P., van
der Hoeven J.J., and Penson D.F. Development of a
Standardized Set of Patient-centered Outcomes for
Advanced Prostate Cancer: An International Effort
for a Unified Approach. [2015] European Urology
(68) 5: 891-898. Impact factor: 14,976
47. Mrizak D., Martin N., Barjon C., Jimenez-Pailhes
A.S., Mustapha R., Niki T., Guigay J., Pancre V.,
de Launoit Y., Busson P., Morales O., and Delhem
N. Effect of Nasopharyngeal Carcinoma-Derived
Exosomes on Human Regulatory T Cells . [2015]
Journal of the National Cancer Institute (107) 1:
363. Impact factor: 11,370
48. Nemazanyy I., Montagnac G., Russell R.C., Morzyglod
L., Burnol A.F., Guan K.L., Pende M., and Panasyuk
G. Class III PI3K regulates organismal glucose
homeostasis by providing negative feedback on
hepatic insulin signalling . [1-9-2015] Nature
Communications (6): 8283. Impact factor: 11,329
49. Ost P., Bossi A., Decaestecker K., De Meerleer G.,
Giannarini G., Karnes R., Roach M., III, and Briganti
A. Metastasis-directed Therapy of Regional and
Distant Recurrences After Curative Treatment
of Prostate Cancer: A Systematic Review of the
Literature. [2015] European Urology (67) 5: 852863. Impact factor: 14,976
50. Ozmadenci D., Féraud O., Markossian S., Kress E.,
Ducarouge B., Gibert B., Ge J., Durand I., Gadot N.,
Plateroti M., Bennaceur-Griscelli A., Scoazec J.Y.,
Gil J., Deng H., Bernet A., Mehlen P., and Lavial
F. Netrin-1 regulates somatic cell reprogramming
and pluripotency maintenance . [2015] Nature
Communications (6): 7398. Impact factor: 11,329
51. Paggetti J., Haderk F., Seiffert M., Janji B., Distler U.,
Ammerlaan W., Kim Y.J., Adam J., Lichter P., Solary
E., Berchem G., and Moussay E. Exosomes released
by chronic lymphocytic leukemia cells induce the
transition of stromal cells into cancer-associated
fibroblasts. [2015] Blood (126) 9: 1106-1117. Impact
factor: 11,841
52. Patard J.J. and Escudier B. Urological cancer:
towards rational post-nephrectomy follow-up
guidelines in RCC. [2015] Nature Reviews Clinical
Oncology (12) 3: 131-132. Impact factor: 18,786
53. Patten S.A., Margaritte-Jeannin P., Bernard J.C.,
Alix E., Labalme A., Besson A., Girard S.L., Fendri
K., Fraisse N., Biot B., Poizat C., Campan-Fournier
A., Abelin-Genevois K., Cunin V., Zaouter C., Liao
M., Lamy R., Lesca G., Menassa R., Marcaillou C.,
Letexier M., Sanlaville D., Berard J., Rouleau G.A.,
Clerget-Darpoux F., Drapeau P., Moldovan F., and
Edery P. Functional variants of POC5 identified in
30
patients with idiopathic scoliosis. [2015] Journal
of Clinical Investigation (125) 3: 1124-1128. Impact
factor: 12,575
54. Pietrocola F., Galluzzi L., Bravo-San Pedro J.M.,
Madeo F., and Kroemer G. Acetyl Coenzyme A: A
Central Metabolite and Second Messenger. [2015]
Cell Metabolism (21) 6: 805-821. Impact factor:
17,303
55. Poglio S., Cahu X., Uzan B., Besnard-Guerin C.,
Lapillonne H., Leblanc T., Baruchel A., LandmanParker J., Petit A., Baleydier F., Amsellem S., Baud
V., Ballerini P., and Pflumio F. Rapid childhood T-ALL
growth in xenograft models correlates with mature
phenotype and NF-kB pathway activation but not
with poor prognosis. [2015] Leukemia (29) 4: 977980. Impact factor: 12,104
56. Rahmi G., Lecomte T., Malka D., Maniere T., Le
Rhun M., Guimbaud R., Lapalus M.G., Le Sidaner
A., Moussata D., Caron O., Barbieux J.P., Gaudric
M., Coron E., Barange K., Ponchon T., Sautereau
D., Samaha E., Saurin J.C., Chaussade S., LaurentPuig P., Chatellier G., and Cellier C. Impact of
Chromoscopy on Adenoma Detection in Patients
With Lynch Syndrome: A Prospective, Multicenter,
Blinded, Tandem Colonoscopy Study . [2015]
American Journal of Gastroenterology (110) 2: 288298. Impact factor: 10,383
57. Rasmussen K.D., Jia G., Johansen J.V., Pedersen
M.T., Rapin N., Bagger F.O., Porse B.T., Bernard
O.A., Christensen J., and Helin K. Loss of
TET2 in hematopoietic cells leads to DNA
hypermethylation of active enhancers and induction
of leukemogenesis. [2015] Genes & Development
(29) 9: 910-922. Impact factor: 10,042
58. Repunte-Canonigo V., Shin W., Vendruscolo
L.F., Lefebvre C., van der Stap L., Kawamura T.,
Schlosburg J.E., Alvarez M., Koob G.F., Califano
A., and Sanna P.P. Identifying candidate drivers of
alcohol dependence-induced excessive drinking
by assembly and interrogation of brain-specific
regulatory networks. [2015] Genome Biology (16)
1: 68. Impact factor: 11,313
59. Saad F., De Bono J., Shore N., Fizazi K., Loriot
Y., Hirmand M., Franks B., Haas G.P., and Scher
H.I. Efficacy Outcomes by Baseline Prostatespecific Antigen Quartile in the AFFIRM Trial. [2015]
European Urology (67) 2: 223-230. Impact factor:
14,976
60. Saad F., Shore N., Van Poppel H., Rathkopf D.E.,
Smith M.R., de Bono J.S., Logothetis C.J., de Souza
P., Fizazi K., Mulders P.F., Mainwaring P., Hainsworth
J.D., Beer T.M., North S., Fradet Y., Griffin T.A., De
Porre P., Londhe A., Kheoh T., Small E.J., Scher H.I.,
Molina A., and Ryan C.J. Impact of Bone-targeted
Therapies in Chemotherapy-naive Metastatic
Castration-resistant Prostate Cancer Patients
Treated with Abiraterone Acetate: Post Hoc Analysis
of Study COU-AA-302. [2015] European Urology (68)
4: 570-577. Impact factor: 14,976
61. Sampson J.N., Wheeler W.A., Yeager M., Panagiotou
O., Wang Z., Berndt S.I., Lan Q., Abnet C.C.,
Amundadottir L.T., Figueroa J.D., Landi M.T.,
Mirabello L., Savage S.A., Taylor P.R., Vivo I.D.,
McGlynn K.A., Purdue M.P., Rajaraman P., Adami
H.O., Ahlbom A., Albanes D., Amary M.F., An S.J.,
Andersson U., Andriole G., Andrulis I.L., Angelucci
E., Ansell S.M., Arici C., Armstrong B.K., Arslan A.A.,
Austin M.A., Baris D., Barkauskas D.A., Bassig B.A.,
Becker N., Benavente Y., Benhamou S., Berg C., Van
Den Berg D., Bernstein L., Bertrand K.A., Birmann
B.M., Black A., Boeing H., Boffetta P., BoutronRuault M.C., Bracci P.M., Brinton L., Brooks-Wilson
A.R., Bueno-de-Mesquita H.B., Burdett L., Buring
J., Butler M.A., Cai Q., Cancel-Tassin G., Canzian F.,
Carrato A., Carreon T., Carta A., Chan J.K., Chang
E.T., Chang G.C., Chang I.S., Chang J., Chang-Claude
J., Chen C.J., Chen C.Y., Chen C., Chen C.H., Chen
C., Chen H., Chen K., Chen K.Y., Chen K.C., Chen
Y., Chen Y.H., Chen Y.S., Chen Y.M., Chien L.H.,
Chirlaque M.D., Choi J.E., Choi Y.Y., Chow W.H.,
Chung C.C., Clavel J., Clavel-Chapelon F., Cocco P.,
Colt J.S., Comperat E., Conde L., Connors J.M., Conti
D., Cortessis V.K., Cotterchio M., Cozen W., Crouch
S., Crous-Bou M., Cussenot O., Davis F.G., Ding T.,
Diver W.R., Dorronsoro M., Dossus L., Duell E.J.,
Ennas M.G., Erickson R.L., Feychting M., Flanagan
A.M., Foretova L., Fraumeni J.F., Freedman N.D.,
Beane Freeman L.E., Fuchs C., Gago-Dominguez M.,
Gallinger S., Gao Y.T., Gapstur S.M., Garcia-Closas
M., García-Closas R., Gascoyne R.D., Gastier-Foster
J., Gaudet M.M., Gaziano J.M., Giffen C., Giles G.G.,
Giovannucci E., Glimelius B., Goggins M., Gokgoz
N., Goldstein A.M., Gorlick R., Gross M., Grubb R.,
Gu J., Guan P., Gunter M., Guo H., Habermann T.M.,
Haiman C.A., Halai D., HAllmans G., Hassan M.,
Hattinger C., He Q., He X., Helzlsouer K., Henderson
B., Henriksson R., Hjalgrim H., Hoffman-Bolton J.,
Hohensee C., Holford T.R., Holly E.A., Hong Y.C.,
Hoover R.N., Horn-Ross P.L., Hosain G.M., Hosgood
H.D., Hsiao C.F., Hu N., Hu W., Hu Z., Huang M.S.,
Huerta J.M., Hung J.Y., Hutchinson A., Inskip P.D.,
Jackson R.D., Jacobs E.J., Jenab M., Jeon H.S., Ji
31
B.T., Jin G., Jin L., Johansen C., Johnson A., Jung
Y.J., Kaaks R., Kamineni A., Kane E., Kang C.H.,
Karagas M.R., Kelly R.S., Khaw K.T., Kim C., Kim
H.N., Kim J.H., Kim J.S., Kim Y.H., Kim Y.T., Kim
Y.C., Kitahara C.M., Klein A.P., Klein R.J., Kogevinas
M., Kohno T., Kolonel L.N., Kooperberg C., Kricker
A., Krogh V., Kunitoh H., Kurtz R.C., Kweon S.S.,
LaCroix A., Lawrence C., Lecanda F., Lee V.H., Li
D., Li H., Li J., Li Y.J., Li Y., Liao L.M., Liebow M.,
Lightfoot T., Lim W.Y., Lin C.C., Lin D., Lindstrom S.,
Linet M.S., Link B.K., Liu C., Liu J., Liu L., Ljungberg
B., Lloreta J., Lollo S.D., Lu D., Lund E., Malats N.,
Mannisto S., Marchand L.L., Marina N., Masala G.,
Mastrangelo G., Matsuo K., Maynadie M., McKay J.,
McKean-Cowdin R., Melbye M., Melin B.S., Michaud
D.S., Mitsudomi T., Monnereau A., Montalvan R.,
Moore L.E., Mortensen L.M., Nieters A., North K.E.,
Novak A.J., Oberg A.L., Offit K., Oh I.J., and Olson
S.H. Analysis of Heritability and Shared Heritability
Based on Genome-Wide Association Studies for
Thirteen Cancer Types . [2015] Journal of the
National Cancer Institute (107) 12: djv27. Impact
factor: 11,370
62. Savona M.R., Malcovati L., Komrokji R., Tiu R.V.,
Mughal T.I., Orazi A., Kiladjian J.J., Padron E.,
Solary E., Tibes R., Itzykson R., Cazzola M., Mesa R.,
Maciejewski J., Fenaux P., Garcia-Manero G., Gerds
A., Sanz G., Niemeyer C.M., Cervantes F., Germing
U., Cross N.C., and List A.F. An international
consortium proposal of uniform response criteria
for myelodysplastic/myeloproliferative neoplasms
(MDS/MPN) in adults. [2015] Blood (125) 12: 18571865. Impact factor: 11,841
63. Schmid C., Labopin M., Socie G., Daguindau E., Volin
L., Huynh A., Bourhis J.H., Milpied N., Cornelissen
J., Chevallier P., Maertens J., Jindra P., Blaise D.,
Lenhoff S., Ifrah N., Baron F., Ciceri F., Gorin C.,
Savani B., Giebel S., Polge E., Esteve J., Nagler A.,
and Mohty M. Outcome of patients with distinct
molecular genotypes and cytogenetically normal
AML after allogeneic transplantation. [22-10-2015]
Blood (126) 17: 2062-2069 . Impact factor: 11,841
64. Selimoglu-Buet D., Wagner-Ballon O., Saada V.,
Bardet V., Itzykson R., Bencheikh L., Morabito M., Met
E., Debord C., Benayoun E., Nloga A.M., Fenaux P.,
Braun T., Willekens C., Quesnel B., Ades L., Fontenay
M., Rameau P., Droin N., Koscielny S., and Solary
E. Characteristic repartition of monocyte subsets as
a diagnostic signature of chronic myelomonocytic
leukemia. [2015] Blood (125) 23: 3618-3626. Impact
factor: 11,841
65. Semeraro M., Rusakiewicz S., Minard-Colin V.,
Delahaye N.F., Enot D., Vely F., Marabelle A.,
Papoular B., Piperoglou C., Ponzoni M., Perri P.,
Tchirkov A., Matta J., Lapierre V., Shekarian T.,
Valsesia-Wittmann S., Commo F., Prada N., PoirierColame V., Bressac B., Cotteret S., Brugieres L.,
Farace F., Chaput N., Kroemer G., Valteau-Couanet
D., and Zitvogel L. Clinical impact of the NKp30/B7H6 axis in high-risk neuroblastoma patients. [2015]
Science Translational Medicine (7) 283: 283ra55.
Impact factor: 16,264
66. Sica V., Galluzzi L., Pedro J.M.B.-S., Izzo V., Maiuri
M.C., and Kroemer G. Organelle-Specific Initiation
of Autophagy. [2015] Molecular Cell (59) 4: 522-539.
Impact factor: 13,958
67. Sicre de Fontbrune F., Moignet A., Beaupain B.,
Suarez F., Galicier L., Socié G., Varet B., Coppo P.,
Michel M., Pautas C., Oksenhendler E., Lengline E.,
Terriou L., Moreau P., Chantepie S., Casadevall N.,
Michot J.M., Gardembas M., Michallet M., Croisille
L., Audrain M., Bellanné-Chantelot C., Donadieu J.,
and Lamy T. Severe chronic primary neutropenia in
adults: report on a series 108 patients. [2015] Blood
(126) 14: 1643-1650 . Impact factor: 11,841
68. Somers J., Wilson L.A., Kilday J.P., Horvilleur
E., Cannell I.G., Poeyry T.A., Cobbold L.C.,
Kondrashov A., Knight J.R., Puget S., Grill J.,
Grundy R.G., Bushell M., and Willis A.E. A common
polymorphism in the 5 ‘ UTR of ERCC5 creates
an upstream ORF that confers resistance to
platinum-based chemotherapy. [2015] Genes &
Development (29) 18: 1891-1896. Impact factor:
10,042
69. Thompson B.J., Bhansali R., Diebold L., Cook
D.E., Stolzenburg L., Casagrande A.S., Besson T.,
Leblond B., Desire L., Malinge S., and Crispino
J.D. DYRK1A controls the transition from
proliferation to quiescence during lymphoid
development by destabilizing Cyclin D3 . [1-62015] Journal of Experimental Medicine (212) 6:
953-970. Impact factor: 11,240
70. Vainchenker W. and Plo I. TET2 loss, a rescue of
JAK2V617F HSCs. [2015] Blood (125) 2: 212-213.
Impact factor: 11,841
71. Vera-Badillo F.E., Templeton A.J., Duran I., Ocana
A., de Gouveia P., Aneja P., Knox J.J., Tannock
I.F., Escudier B., and Amir E. Systemic Therapy
for Non-clear Cell Renal Cell Carcinomas: A
Systematic Review and Meta-analysis . [2015]
European Urology (67) 4: 740-749. Impact factor:
14,976
32
72. Zitvogel L. and Kroemer G. Subversion of anticancer
immunosurveillance by radiotherapy. [2015] Nature
Immunology (16) 10: 1005-1007. Impact factor:
19,381
73. Zitvogel L., Galluzzi L., Viaud S., Vetizou M., Daillere
R., Merad M., and Kroemer G. Cancer and the gut
microbiota: An unexpected link . [2015] Science
Translational Medicine (7) 271: 271ps1. Impact
factor: 16,264
33
/ Publications internationales (tous types)
Gustave Roussy en 2015
A impact factor compris entre 5 et 10 (458 publications)
1. Aapro M., Dielenseger P., Dranitsaris G., Jordan K.,
Molassiotis A., Roeland E., Schwartzberg L., and
Warr D. Patient-related factors in determining
the emetic risk potential for patients undergoing
chemotherapy: An evaluation of predictive models
for the development of a risk assessment tool .
[2015] European Journal of Cancer (51) suppl 3:
S234-S234. Impact factor: 6,163
2. Adam J., Boros A., Lacas B., Lacroix L., Pignon J.,
Caramella C., Planchard D., Levy A., Besse B., and
Le Pechoux C. Prognostic value of PDL1 expression
in stage III Non-Small Cell Lung Cancer (NSCLC)
treated by chemo-radiotherapy (CRT) . [2015]
European Journal of Cancer (51) Suppl 3: S604.
Impact factor: 6,163
3. Albigès L., Fay A.P., Xie W., Krajewski K., McDermott
D.F., Heng D.Y.C., Dariane C., DeVelasco G., Lester
R., Escudier B., and Choueiri T.K. Efficacy of targeted
therapies after PD-1/PD-L1 blockade in metastatic
renal cell carcinoma. [2015] European Journal of
Cancer (51) 17: 2580-2586. Impact factor: 6,163
4. Albigès L., Kube U., Eymard J.C., Schmidinger M.,
Bamias A., Kelkouli N., Mraz B., Florini S., Guderian
G., Cattaneo A., and Bergmann L. Everolimus for
patients with metastatic renal cell carcinoma
refractory to anti-VEGF therapy: Results of a pooled
analysis of non-interventional studies . [2015]
European Journal of Cancer (51) 16: 2368-2374.
Impact factor: 6,163
5. Aleksandrova K., Bamia C., Drogan D., Lagiou P.,
Trichopoulou A., Jenab M., Fedirko V., Romieu I.,
Bueno-de-Mesquita H.B., Pischon T., Tsilidis K.,
Overvad K., Tjønneland A., Bouton-Ruault M.C.,
Dossus L., Racine A., Kaaks R., Kuhn T., Tsironis C.,
Papatesta E.M., Saitakis G., Palli D., Panico S., Grioni
S., Tumino R., Vineis P., Peeters P.H., Weiderpass
E., Lukic M., Braaten T., Quiros J.R., Lujan-Barroso
L., Sanchez M.J., Chilarque M.D., Ardanas E.,
Dorronsoro M., Nilsson L.M., Sund M., Wallstrom
P., Ohlsson B., Bradbury K.E., Khaw K.T., Wareham
N., Stepien M., Duarte-Salles T., Assi N., Murphy N.,
Gunter M.J., Riboli E., Boeing H., and Trichopoulos
D. The association of coffee intake with liver cancer
risk is mediated by biomarkers of inflammation
and hepatocellular injury: data from the European
Prospective Investigation into Cancer and Nutrition.
[2015] American Journal of Clinical Nutrition (102)
6: 1498-1508. Impact factor: 6,703
6. Alentorn A., Dehais C., Ducray F., Carpentier C.,
Mokhtari K., Figarella-Branger D., Chinot O., CohenMoyal E., Ramirez C., Loiseau H., Elouahdani-Hamdi
S., Beauchesne P., Langlois O., Desenclos C.,
Guillamo J.S., Dam-Hieu P., Ghiringhelli F., Colin
P., Godard J., Parker F., Dhermain F., Carpentier
A.F., Frenel J.S., Menei P., Bauchet L., Faillot T.,
Fesneau M., Fontaine D., Motuo-Fotso M.J., Vauleon
E., Gaultier C., Le Guerinel C., Gueye E.M., Noel
G., Desse N., Durando X., Barrascout E., Wager
M., Ricard D., Carpiuc I., Delattre J.Y., and Idbaih
A. Allelic loss of 9p21 .3 is a prognostic factor
in 1p/19q codeleted anaplastic gliomas. [2015]
Neurology (85) 15: 1325-1331. Impact factor: 8,166
7. Allard M.A., Cunha A.S., Gayet B., Adam R., Goere
D., Bachellier P., Azoulay D., Ayav A., Navarro F.,
and Pessaux P. Early and Long-term Oncological
Outcomes After Laparoscopic Resection for
Colorectal Liver Metastases: A Propensity Scorebased Analysis. [2015] Annals of surgery (262) 5:
794-802. Impact factor: 8,569
8. Ameziane-El-Hassani R., Talbot M., Dos Santos
M.C.d.S., Al Ghuzlan A., Hartl D., Bidart J.M., De Deken
X., Miot F., Diallo I., De Vathaire F., Schlumberger
M., and Dupuy C. NADPH oxidase DUOX1 promotes
long-term persistence of oxidative stress after an
exposure to irradiation. [2015] Proceedings of the
National Academy of Sciences of the United States
of America (112) 16: 5051-5056. Impact factor: 9,423
9. Angileri F., Roy V., Morrow G., Scoazec J.Y., Gadot N.,
Orejuela D., and Tanguay R.M. Molecular changes
associated with chronic liver damage and neoplastic
lesions in a murine model of hereditary tyrosinemia
type 1 . [2015] Biochimica et Biophysica Acta Molecular Basis of Disease (1852) 12: 2603-2617.
Impact factor: 5,158
10. Angoulvant A., Stern J.B., Wittnebel S., Bourhis J.H.,
Gachot B., Vittecoq D., and Wyplosz B. Dyspnea and
Fever in an Allogeneic Stem Cell Recipient. [2015]
Clinical Infectious Diseases (60) 1: 100, 157-158.
Impact factor: 8,736
11. Antoun S., Bayar A., Ileana E., Laplanche A., Fizazi K.,
Di Palma M., Escudier B., Albigès L., Massard C., and
Loriot Y. High subcutaneous adipose tissue predicts
the prognosis in metastatic castration-resistant
prostate cancer patients in post chemotherapy
setting. [2015] European Journal of Cancer (51) 17:
2570-2577. Impact factor: 6,163
12. Aranda F., Buqué A., Bloy N., Castoldi F., Eggermont
A., Cremer I., Fridman W.H., Fucikova J., Galon J.,
Spisek R., Tartour E., Zitvogel L., Kroemer G., and
Galluzzi L. Trial Watch: Adoptive cell transfer for
oncological indications. [2015] Oncoimmunology (4)
11: e1046673. Impact factor: 7,644
34
13. Arca M., Fardet L., Galicier L., Riviere S., Marzac C.,
Aumont C., Lambotte O., and Coppo P. Prognostic
factors of early death in a cohort of 162 adult
haemophagocytic syndrome: impact of triggering
disease and early treatment with etoposide .
[2015] British Journal of Haematology (168) 1:
63-68. Impact factor: 5,401
14. Arnold D., Scheithauer W., Zurlo A., Salazar R.,
Ducreux M., Waddell T., Stein A., Tournigand C.,
Sobrero A., Van Cutsem E., and Cunningham
D. Immunomodulatory switch maintenance
therapy to improve overall survival in metastatic
colorectal carcinoma: The phase 3 IMPALA study.
[2015] Annals of Oncology (26) suppl 4: iv90-iv91.
Impact factor: 9,269
15. Attard G., Gurney H., Loriot Y., Borre M.,
Andresen C., Wu K., Taylor C., Amelsberg A.,
and Taplin M. Preliminary findings from PLATO:
A two-period, phase 4, randomized, doubleblind, placebo-controlled study of continued
enzalutamide treatment beyond progression
in men with chemotherapy-naive metastatic
castration-resistant prostate cancer (mCRPC).
[2015] European Journal of Cancer (51) suppl 3:
S487. Impact factor: 6,163
16. Attard G., de Bono J.S., Logothetis C.J., Fizazi
K., Mukherjee S.D., Joshuas A.M., Schrijvers D.,
van den Eertwegh A.J., Li W., Molina A., Griffin
T.W., Kheoh T., Ricci D.S., Zelinsky K., Rathkopf
D.E., Scher H.I., and Ryan C.J. Improvements
in Radiographic Progression-Free Survival
Stratified by ERG Gene Status in Metastatic
Castration-Resistant Prostate Cancer Patients
Treated with Abiraterone Acetate. [2015] Clinical
Cancer Research (21) 7: 1621-1627. Impact
factor: 8,738
17. Aumont C., Driss F., Lazure T., Picard V., Creidy R.,
De Botton S., Saada V., Lambotte O., Bilhou-Nabera
C., Tertian G., and Michot J.M. Myelodysplastic
syndrome with clonal cytogenetic abnormalities
followed by fatal erythroid leukemia after 14
years of exposure to hydroxyurea for sickle cell
anemia. [2015] American Journal of Hematology
(90) 7: E131-E132. Impact factor: 5
18. Autebert J., Coudert B., Champ J., Saias L., Guneri
E.T., Lebofsky R., Bidard F.C., Pierga J.Y., Farace
F., Descroix S., Malaquin L., and Viovy J.L. High
purity microfluidic sorting and analysis of
circulating tumor cells: towards routine mutation
detection. [2015] Lab on A Chip (15) 9: 2090-2101.
Impact factor: 5,586
19. Auzolle C., Dubreuil O., Pozet A., Coriat R., Dhooge
M., Ducreux M., Mons M., Brieau B., Baumgaertner
I., Gornet J., Lievre A., Locher C., Mary F., Bonnetain
F., and Landi B. Efficacy and toxicity of secondline chemotherapy in patients with advanced
oesophageal squamous cell carcinoma progressing
after a first line of 5-fluorouracil and platinumbased therapy: An AGEO retrospective multicentric
study. [2015] European Journal of Cancer (51) suppl
3: S438-S438. Impact factor: 6,163
20. Ayadi M., Bouygues A., Ouaret D., Ferrand N., Chouaib
S., Thiery J.P., Muchardt C., Sabbah M., and Larsen
A.K. Chronic chemotherapeutic stress promotes
evolution of stemness and WNT/beta-catenin
signaling in colorectal cancer cells: implications
for clinical use of WNT-signaling inhibitors. [2015]
Oncotarget (6) 21: 18518-18533. Impact factor:
5,008
21. Babitzki G., Hidalgo M., Massard C., Martinez Garcia
M., Le Tourneau C., Boni V., Albanell Mestres J., Taus
Garcia A., Alt M., Sablin M., Gerber P., Krieter O.,
Lahr A., Palme S., Rossomanno S., Harring S.V., Wild
N., Zajac M., and Lechner K. Biomarkers related to
Vanucizumab single agent therapy in serial plasma,
tumor tissue and skin wound-healing biopsies
of patients with advanced solid tumors . [2015]
European Journal of Cancer (51) suppl 3: S88-S89.
Impact factor: 6,163
22. Bach A.S., Derocq D., Laurent-Matha V., Montcourrier
P., Sebti S., Orsetti B., Theillet C., Gongora C., Pattingre
S., Ibing E., Roger P., Linares L.K., Reinheckel T.,
Meurice G., Kaiser F.J., Gespach C., and LiaudetCoopman E. Nuclear cathepsin D enhances TRPS1
transcriptional repressor function to regulate cell
cycle progression and transformation in human
breast cancer cells. [2015] Oncotarget (6) 29: 2808428103. Impact factor: 5,008
23. Badirou I., Pan J., Souquere S., Legrand C., Pierron
G., Wang A., Eckly A., Roy A., Gachet C., Vainchenker
W., Chang Y., and Leon C. Distinct localizations and
roles of non-muscle myosin II during proplatelet
formation and platelet release . [2015] Journal
of Thrombosis and Haemostasis (13) 5: 851-859.
Impact factor: 5,565
24. Bahleda R., Hollebecque A., Varga A., Gazzah A.,
Massard C., Deutsch E., Amellal N., Farace F., OuldKaci M., Roux F., Marzin K., and Soria J.C. Phase
I study of afatinib combined with nintedanib in
patients with advanced solid tumours. [2015] British
Journal of Cancer (113) 10: 1413-1420. Impact
factor: 5,569
35
25. Baldeck N., Janel-Bintz R., Wagner J., Tissier A.,
Fuchs R.P., Burkovics P., Haracska L., Despras E.,
Bichara M., Chatton B., and Cordonnier A.M. FF483484 motif of human Pol eta mediates its interaction
with the POLD2 subunit of Pol delta and contributes
to DNA damage tolerance . [2015] Nucleic acids
research (43) 4: 2116-2125. Impact factor: 9,202
26. Bamia C., Lagiou P., Jenab M., Trichopoulou A.,
Fedirko V., Aleksandrova K., Pischon T., Overvad
K., Olsen A., Tjønneland A., Boutron-Ruault M.C.,
Fagherazzi G., Racine A., Kuhn T., Boeing H., Floegel
A., Benetou V., Palli D., Grioni S., Panico S., Tumino R.,
Vineis P., Bueno-de-Mesquita H.B., Dik V.K., BhooPathy N., Uiterwaal C.S.P.M., Weiderpass E., Lund
E., Quirós J.R., Zamora-Ros R., Molina-Montes E.,
Chirlaque M.D., Ardanaz E., Dorronsoro M., Lindkvist
B., Wallström P., Nilsson L.M., Sund M., Khaw K.T.,
Wareham N., Bradbury K.E., Travis R.C., Ferrari P.,
Duarte-Salles T., Stepien M., Gunter M., Murphy
N., Riboli E., and Trichopoulos D. Coffee, tea and
decaffeinated coffee in relation to hepatocellular
carcinoma in a European population: Multicentre,
prospective cohort study . [2015] International
Journal of Cancer (136) 8: 1899-1908. Impact factor:
5,531
27. Bamia C., Lagiou P., Jenab M., Aleksandrova K.,
Fedirko V., Trichopoulos D., Overvad K., Tjønneland
A., Olsen A., Clavel-Chapelon F., Boutron-Ruault
M.C., Kvaskoff M., Katzke V.A., Kühn T., Boeing H.,
Nöthlings U., Palli D., Sieri S., Panico S., Tumino
R., Naccarati A., Bueno-de-Mesquita H.B., Peeters
P.H.M., Weiderpass E., Skeie G., Quirós J.R., Agudo
A., Chirlaque M.D., Sanchez M.J., Ardanaz E.,
Dorronsoro M., Ericson U., Nilsson L.M., Wennberg
M., Khaw K.T., Wareham N., Key T.J., Travis R.C.,
Ferrari P., Stepien M., Duarte-Salles T., Norat T.,
Murphy N., Riboli E., and Trichopoulou A. Fruit and
vegetable consumption in relation to hepatocellular
carcinoma in a multi-centre, European cohort study.
[2015] British Journal of Cancer (112) 7: 1273-1282.
Impact factor: 5,569
28. Bang Y., Doi T., De Braud F., Piha-Paul S., Hollebecque
A., Razak A., Lin C., Ott P., He A., Yuan S., Koshiji
M., Lam B., and Aggarwal R. Safety and efficacy of
pembrolizumab (MK-3475) in patients (pts) with
advanced biliary tract cancer: Interim results of
KEYNOTE-028. [2015] European Journal of Cancer
(51) suppl 3: S112-S112. Impact factor: 6,163
29. Bardet V., Wagner-Ballon O., Guy J., Morvan C.,
Debord C., Trimoreau F., Benayoun E., Chapuis N.,
Freynet N., Rossi C., Mathis S., Gourin M.P., Toma A.,
Béné M.C., Feuillard J., and Guérin E. Multicentric
study underlining the interest of adding CD5,
CD7 and CD56 expression assessment to the
flow cytometric Ogata score in myelodysplastic
syndromes and myelodysplastic/myeloproliferative
neoplasms. [2015] Haematologica (100) 4: 472-478.
Impact factor: 6,671
30. Barrdahl M., Canzian F., Lindström S., Shui I.,
Black A., Hoover R.N., Ziegler R.G., Buring J.E.,
Chanock S.J., Diver W., Gapstur S.M., Gaudet M.M.,
Giles G.G., Haiman C., Henderson B.E., Hankinson
S., Hunter D.J., Joshi A.D., Kraft P., Lee I.M., Le
Marchand L., Milne R.L., Southey M.C., Willett W.,
Gunter M., Panico S., Sund M., Weiderpass E.,
Sánchez M.-J., Overvad K., Dossus L., Peeters P.H.,
Khaw K.T., Trichopoulos D., Kaaks R., and Campa
D. Association of breast cancer risk loci with breast
cancer survival. [2015] International Journal of
Cancer (137) 12: 2837-2845. Impact factor: 5,531
31. Bastide N.M., Chenni F., Audebert M., Santarelli
R.L., Tache S., Naud N., Baradat M., Jouanin I.,
Surya R., Hobbs D.A., Kuhnle G.G., Raymond-Letron
I., Gueraud F., Corpet D.E., and Pierre F.H. A Central
Role for Heme Iron in Colon Carcinogenesis
Associated with Red Meat Intake. [2015] Cancer
Research (75) 5: 870-879. Impact factor: 8,556
32. Beelen R., Hoek G., Raaschou-Nielsen O., Stafoggia
M., Andersen Z.J., Weinmayr G., Hoffmann B.,
Wolf K., Samoli E., Fischer P.H., Nieuwenhuijsen
M.J., Xun W.W., Katsouyanni K., Dimakopoulou
K., Marcon A., Vartiainen E., Lanki T., Yli-Tuomi
T., Oftedal B., Schwarze P.E., Nafstad P., De Faire
U., Pedersen N.L., Otstenson C.G., Fratiglioni L.,
Penell J., Korek M., Pershagen G., Eriksen K.T.,
Overvad K., Sorensen M., Eeftens M., Peeters
P.H., Meliefste K., Wang M., Bueno-de-Mesquita
H., Sugiri D., Kramer U., Heinrich J., de Hoogh K.,
Key T., Peters A., Hampel R., Concin H., Nagel G.,
Jaensch A., Ineichen A., Tsai M.Y., Schaffner E.,
Probst-Hensch N.M., Schindler C., Ragettli M.S.,
Vilier A., Clavel-Chapelon F., Declercq C., Ricceri
F., Sacerdote C., Galassi C., Migliore E., Ranzi A.,
Cesaroni G., Badaloni C., Forastiere F., Katsoulis
M., Trichopoulou A., Keuken M., Jedynska A.,
Kooter I.M., Kukkonen J., Sokhi R.S., Vineis P.,
and Brunekreef B. Natural-Cause Mortality and
Long-Term Exposure to Particle Components: An
Analysis of 19 European Cohorts within the MultiCenter ESCAPE Project . [2015] Environmental
Health Perspectives (123) 6: 525-533. Impact
factor: 8,443
36
33. Bellera C., Penel N., Ouali M., Bonvalot S., Casali
P., Nielsen O., Delannes M., Litiere S., Bonnetain
F., Dabakuyo T., Benjamin R., Blay J., Bui B., Collin
F., Delaney T., Duffaud F., Filleron T., Fiore M.,
Gelderblom H., George S., Grimer R., Grosclaude
P., Gronchi A., Haas R., Hohenberger P., Issels R.,
Italiano A., Jooste V., Krarup-Hansen A., Le Pechoux
C., Mussi C., Oberlin O., Patel S., Piperno-Neumann
S., Raut C., Ray-coquard I., Rutkowski P., Schuetze
S., Sleijfer S., Stoeckle E., Van Glabbeke M., Woll
P., Gourgou-Bourgade S., and Mathoulin-Pelissier
S. Guidelines for time-to-event end point definitions
in sarcomas and gastrointestinal stromal tumors
(GIST) trials: results of the DATECAN initiative
(Definition for the Assessment of Time-to-event
Endpoints in CANcer trials) . [2015] Annals of
Oncology (26) 5: 865-872. Impact factor: 9,269
34. Bellini A., Bernard V., Leroy Q., Frio T.R., Pierron
G., Combaret V., Lapouble E., Clement N., Rubie
H., Thebaud E., Chastagner P., Defachelles A.S.,
Bergeron C., Buchbinder N., Taque S., Auvrignon A.,
Valteau-Couanet D., Michon J., Janoueix-Lerosey I.,
Delattre O., and Schleiermacher G. Deep Sequencing
Reveals Occurrence of Subclonal ALK Mutations in
Neuroblastoma at Diagnosis. [2015] Clinical Cancer
Research (21) 21: 4913-4921. Impact factor: 8,738
35. Ben Arush M., Minard-Colin V., Mosseri V., Defachelles
A., Bergeron C., Algret N., Fasola S., André N.,
Thebaud E., Corradini N., Bernier V., Martelli H.,
Ranchere D., and Orbach D. Does aggressive local
treatment have an impact on survival in children
with metastatic rhabdomyosarcoma? [2015]
European Journal of Cancer (51) 2: 193-201. Impact
factor: 6,163
36. Benhamou Y., Boelle P.Y., Baudin B., Ederhy S.,
Gras J., Galicier L., Azoulay E., Provot F., Maury
E., Pene F., Mira J., Wynckel A., Presne C., Poullin
P., Halimi J., Delmas Y., Kanouni T., Seguin A.,
Mousson C., Servais A., Bordessoule D., Perez P.,
Hamidou M., Cohen A., Veyradier A., and Coppo
P. Cardiac troponin-I on diagnosis predicts early
death and refractoriness in acquired thrombotic
thrombocytopenic purpura . Experience of the
French Thrombotic Microangiopathies Reference
Center. [2015] Journal of Thrombosis and
Haemostasis (13) 2: 293-302. Impact factor: 5,565
37. Benhamou Y., Baudel J.L., Wynckel A., Galicier L.,
Azoulay E., Provor F., Pene F., Mira J.P., Presne
C., Poullin P., Halimi J.M., Riviere E., Kanouni T.,
Seguin A., Mousson C., Servais A., Bordessoule D.,
Perez P., Hamidou M., Chauveau D., Veyradier A.,
and Coppo P. Are platelet transfusions harmful in
acquired thrombotic thrombocytopenic purpura
at the acute phase? experience of the French
thrombotic microangiopathies reference center.
[2015] American Journal of Hematology (90) 6:
E127-E129. Impact factor: 5
38. Benusiglio P.R., Couve S., Gilbert-Dussardier B.,
Deveaux S., Le Jeune H., Da Costa M., Fromont G.,
Memeteau F., Yacoub M., Coupier I., Leroux D., Mejean
A., Escudier B., Giraud S., Gimenez-Roqueplo A.P.,
Blondel C., Frouin E., Teh B.T., Ferlicot S., Bressacde Paillerets B., Richard S., and Gad S. A germline
mutation in PBRM1 predisposes to renal cell
carcinoma. [2015] Journal of Medical Genetics (52) 6:
426-430. Impact factor: 5,650
39. Benusiglio P.R., Colas C., Rouleau E., Uhrhammer
N., Romero P., Remenieras A., Moretta J., Wang Q.,
De Pauw A., Buecher B., Stoppa-Lyonnet D., MouretFourme E., Nogues C., Di Maria M., Tlemsani C.,
Warcoin M., Grandjouan S., Malka D., Caron O.,
and Blayau M. Hereditary diffuse gastric cancer
syndrome: improved performances of the 2015
testing criteria for the identification of probands
with a CDH1 germline mutation. [2015] Journal of
Medical Genetics (52) 8: 563-565. Impact factor: 5,650
40. Benyoucef A., Calvo J., Renou L., Arcangeli M.L., van
den Heuvel A., Amsellem S., Mehrpour M., Larghero
J., Soler E., Naguibneva I., and Pflumio F. The SCL/
TAL1 Transcription Factor Represses the Stress
Protein DDiT4/REDD1 in Human Hematopoietic
Stem/Progenitor Cells . [2015] Stem Cells (33) 7:
2268-2279. Impact factor: 5,902
41. Bergthold G., Bandopadhayay P., Hoshida Y.,
Ramkissoon S., Ramkissoon L., Rich B., Maire C.L.,
Paolella B.R., Schumacher S.E., Tabak B., FerrerLuna R., Ozek M., Sav A., Santagata S., Wen P.Y.,
Goumnerova L.C., Ligon A.H., Stiles C., Segal R., Golub
T., Grill J., Ligon K.L., Chan J.A., Kieran M.W., and
Beroukhim R. Expression profiles of 151 pediatric
low-grade gliomas reveal molecular differences
associated with location and histological subtype.
[2015] Neuro-Oncology (17) 11: 1486-1496. Impact
factor: 7,371
42. Bernardini M., Thevenet H., Berthold C., Fischer A.,
Petitguillaume A., Desbree A., Smadja C., Weinmann
P., and Ghazzar N. Reconstruction, volumetry and
dosimetry optimisation for 99mTc-SPECT and
90Y-PET images: towards reliable DVH for SIRT
treatments . [2015] European Journal of Nuclear
Medicine and Molecular Imaging (42) suppl 1:
S139-S139. Impact factor: 5,537
37
43. Bertrand J.R., Pioche-Durieu C., Ayala J., Petit T.,
Girard H.A., Malvy C.P., Le Cam E., Treussart F.,
and Arnault J.C. Plasma hydrogenated cationic
detonation nanodiamonds efficiently deliver to
human cells in culture functional siRNA targeting
the Ewing sarcoma junction oncogene . [2015]
Biomaterials (45): 93-98. Impact factor: 8,387
44. Besevic J., Gunter M.J., Fortner R.T., Tsilidis K.K.,
Weiderpass E., Charlotte Onland-Moret N., Dossus
L., Tjønneland A., Hansen L., Overvad K., Mesrine
S., Baglietto L., Clavel-Chapelon F., Kaaks R.,
Aleksandrova K., Boeing H., Trichopoulou A., Lagiou
P., Bamia C., Masala G., Agnoli C., Tumino R., Ricceri
F., Panico S., Bueno-de-Mesquita H.a., Peeters P.H.,
Jareid M., Ramon Quiros J., Duell E.J., Sanchez M.J.,
Larranaga N., Chirlaque M.D., Barricarte A., Dias
J.A., Sonestedt E., Idahl A., Lundin E., Wareham
N.J., Khaw K.T., Travis R.C., Rinaldi S., Romieu I.,
Riboli E., and Merritt M.A. Reproductive factors and
epithelial ovarian cancer survival in the EPIC cohort
study. [1-12-2015] British Journal of Cancer (113)
11: 1622-1631. Impact factor: 5,569
45. Besse B., Johnson M., Jaenne P., Garassino M.,
Eberhardt W., Peters S., Toh C., Kurata T., Li Z.,
Kowanetz M., Mocci S., Sandler A., and Rizvi N. Phase
II, single-arm trial (BIRCH) of atezolizumab as firstline or subsequent therapy for locally advanced or
metastatic PD-L1-selected non-small cell lung
cancer (NSCLC). [2015] European Journal of Cancer
(51) suppl 3: S717-S718. Impact factor: 6,163
46. Besse B., Girard N., Gazzah A., Hierro C., Felip E., De
Braud F., Camboni G., Dubois F., Leger C., Legrand
F., Robert R., Therasse P., and Soria J. Activity and
safety profile of lucitanib in patients with advanced
thymic epithelial tumours. [2015] European Journal
of Cancer (51) suppl 3: S607-S607. Impact factor:
6,163
47. Besse B., Le Moulec S., Mazieres J., Senellart
H., Barlesi F., Chouaid C., Dansin E., Berard H.,
Falchero L., Gervais R., Robinet G., Ruppert A.M.,
Schott R., Lena H., Clement-Duchene C., Quantin
X., Souquet P.J., Tredaniel J., Moro-Sibilot D., Perol
M., Madroszyk A.C., and Soria J.C. Bevacizumab
in Patients with Nonsquamous Non-Small Cell
Lung Cancer and Asymptomatic, Untreated Brain
Metastases (BRAIN): A Nonrandomized, Phase II
Study. [2015] Clinical Cancer Research (21) 8: 18961903. Impact factor: 8,738
48. Beuschlein F., Weigel J., Saeger W., Kroiss M., Wild V.,
Daffara F., Libe R., Ardito A., Al Ghuzlan A., Quinkler
M., Osswald A., Ronchi C.L., de Krijger R., Feelders
R.A., Waldmann J., Willenberg H.S., Deutschbein T.,
Stell A., Reincke M., Papotti M., Baudin E., Tissier
F., Haak H.R., Loli P., Terzolo M., Allolio B., Mueller
H.H., and Fassnacht M. Major Prognostic Role of
Ki67 in Localized Adrenocortical Carcinoma After
Complete Resection . [2015] Journal of Clinical
Endocrinology & Metabolism (100) 3: 841-849.
Impact factor: 5,531
49. Beuselinck B., Jean-Baptiste J., Couchy G., Job
S., De Reynies A., Wolter P., Theodore C., Gravis
G., Rousseau B., Albigès L., Joniau S., Verkarre V.,
Lerut E., Patard J., Schoffski P., Mejean A., Elaidi
R., Oudard S., and Zucman-Rossi J. RANK/OPG
ratio of expression in primary clear-cell renal cell
carcinoma is associated with bone metastasis and
prognosis in patients treated with anti-VEGFR-TKIs.
[2015] British Journal of Cancer (113) 9: 1313-1322.
Impact factor: 5,569
50. Bezu L., Gomes-de-Silva L.C., Dewitte H., Breckpot
K., Fucikova J., Spisek R., Galluzzi L., Kepp O.,
and Kroemer G. Combinatorial strategies for
the induction of immunogenic cell death. [2015]
Frontiers in Immunology (6): 187. Impact factor:
5,695
51. Bhoo-Pathy N., Peeters P.H., Uiterwaal C.S., Buenode-Mesquita H., Bulgiba A.M., Bech B.H., Overvad
K., Tjønneland A., Olsen A., Clavel-Chapelon F.,
Fagherazzi G., Perquier F., Teucher B., Kaaks R.,
Schuetze M., Boeing H., Lagiou P., Orfanos P.,
Trichopoulou A., Agnoli C., Mattiello A., Palli D.,
Tumino R., Sacerdote C., van Duijnhoven F.J., Braaten
T., Lund E., Skeie G., Redondo M.L., Buckland G.,
Sanchez Perez M.J., Chirlaque M.D., Ardanaz E.,
Amiano P., Wirfalt E., Wallstrom P., Johansson I.,
Nilsson L.M., Khaw K.T., Wareham N., Allen N.E.,
Key T.J., Rinaldi S., Romieu I., Gallo V., Riboli E., and
van Gils C.H. Coffee and tea consumption and risk
of pre- and postmenopausal breast cancer in the
European Prospective Investigation into Cancer and
Nutrition (EPIC) cohort study. [2015] Breast Cancer
Research (17): 15. Impact factor: 5,211
52. Bidard F.C., Stoppa-Lyonnet D., Nogues C., Caron O.,
Delaloge S., Dugast C., Lasset C., Berger F., Asselain
B., Lantz O., Stern M.H., and Pierga J.Y. TP53
mutants in circulating tumor DNA and follow-up
of BRCA1 mutation carriers: The CirCA01 study.
[2015] Cancer Research (75) 9 suppl: OT1-2-04.
Impact factor: 8,556
53. Bisio A., Latorre E., Andreotti V., Bressac-de Paillerets
B., Harland M., Scarra G.B., Ghiorzo P., Spitale R.C.,
Provenzani A., and Inga A. The 5 ‘-untranslated region
38
of p16(INK4a) melanoma tumor suppressor acts as
a cellular IRES, controlling mRNA translation under
hypoxia through YBX1 binding. [2015] Oncotarget
(6) 37: 39980-39994. Impact factor: 5,008
54. Biya J., Caramella C., Lindsay C.R., Planchard D.,
and Besse B. A Long-Term Spinal Intramedullary
Response to Ceritinib in ALK Rearranged NonSmall-Cell Lung Cancer. [2015] Journal of Thoracic
Oncology (10) 6: E44-E45. Impact factor: 5,040
55. Blanc L., Papoin J., Debnath G., Vidal M., Amson
R., Telerman A., An X., and Mohandas N. Abnormal
erythroid maturation leads to microcytic anemia
in the TSAP6/Steap3 null mouse model. [2015]
American Journal of Hematology (90) 3: 235-241.
Impact factor: 5
56. Blay J., Bertuzzi A., Bielack S., Bjerkehagen B.,
Bonvalot S., Boukovinas I., Bruzzi P., Dei Tos A., Dileo
P., Eriksson M., Fedenko A., Ferrari A., Ferrari S.,
Gelderblom H., Grimer R., Gronchi A., Haas R., Hall
K., Hohenberger P., Issels R., Joensuu H., Judson I.,
Le Cesne A., Litiere S., Martin-Broto J., Merimsky
O., Montemurro M., Morosi C., Picci P., Ray-coquard
I., Reichardt P., Rutkowski P., Schlemmer M.,
Stacchiotti S., Torri V., Trama A., Van Coevorden F.,
Van der Graaf W., Vanel D., Wardelmann E., and
Casali P. Gastrointestinal Stromal Tumours: ESMO
Clinical Practice Guidelines for diagnosis, treatment
and follow-up (vol 25, pg iii21, 2014). [2015] Annals
of Oncology (26) suppl 5: V174-V175. Impact factor:
9,269
57. Blay J., Bertuzzi A., Bielack S., Bjerkehagen B.,
Bonvalot S., Boukovinas I., Bruzzi P., Dei Tos A., Dileo
P., Eriksson M., Fedenko A., Ferrari A., Ferrari S.,
Gelderblom H., Grimer R., Gronchi A., Haas R., Hall
K., Hohenberger P., Issels R., Joensuu H., Judson I.,
Le Cesne A., Litiere S., Martin-Broto J., Merimsky
O., Montemurro M., Morosi C., Picci P., Ray-coquard
I., Reichardt P., Rutkowski P., Schlemmer M.,
Stacchiotti S., Torri V., Trama A., Van Coevorden F.,
Van der Graaf W., Vanel D., Wardelmann E., and
Casali P. Bone Sarcomas: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up
(vol 25, pg iii113, 2014). [2015] Annals of Oncology
(26) suppl 5: V176-V177. Impact factor: 9,269
58. Blay J., Bertuzzi A., Bielack S., Bjerkehagen B.,
Bonvalot S., Boukovinas I., Bruzzi P., Dei Tos A., Dileo
P., Eriksson M., Fedenko A., Ferrari A., Ferrari S.,
Gelderblom H., Grimer R., Gronchi A., Haas R., Hall
K., Hohenberger P., Issels R., Joensuu H., Judson I.,
Le Cesne A., Litiere S., Martin-Broto J., Merimsky
O., Montemurro M., Morosi C., Picci P., Ray-coquard
I., Reichardt P., Rutkowski P., Schlemmer M.,
Stacchiotti S., Torri V., Trama A., Van Coevorden F.,
Van der Graaf W., Vanel D., Wardelmann E., and
Casali P. Soft Tissue and Visceral Sarcomas: ESMO
Clinical Practice Guidelines for diagnosis, treatment
and follow-up (vol 25, pg iii102, 2014). [2015] Annals
of Oncology (26) suppl 5: V175-V176. Impact factor:
9,269
59. Blein S., Bardel C., Danjean V., McGuffog L., Healey
S., Barrowdale D., Lee A., Dennis J., Kuchenbaecker
K.B., Soucy P., Terry M.B., Chung W.K., Goldgar D.E.,
Buys S.S., Janavicius R., Tihomirova L., Tung N.,
Dorfling C.M., van Rensburg E.J., Neuhausen S.L.,
Ding Y.C., Gerdes A.M., Ejlertsen B., Nielsen F.C.,
Hansen T.V.O., Osorio A., Benitez J., Conejero R.A.,
Segota E., Weitzel J.N., Thelander M., Peterlongo P.,
Radice P., Pensotti V., Dolcetti R., Bonanni B., Peissel
B., Zaffaroni D., Scuvera G., Manoukian S., Varesco
L., Capone G.L., Papi L., Ottini L., Yannoukakos
D., Konstantopoulou I., Garber J., Hamann U.,
Donaldson A., Brady A., Brewer C., Foo C., Evans
D.G., Frost D., Eccles D., Douglas F., Cook J., Adlard
J., Barwell J., Walker L., Izatt L., Side L.E., Kennedy
M.J., Tischkowitz M., Rogers M.T., Porteous M.E.,
Morrison P.J., Platte R., Eeles R., Davidson R.,
Hodgson S., Cole T., Godwin A.K., Isaacs C., Claes K.,
De Leeneer K., Meindl A., Gehrig A., Wappenschmidt
B., Sutter C., Engel C., Niederacher D., Steinemann
D., Plendl H., Kast K., Rhiem K., Ditsch N., Arnold
N., Varon-Mateeva R., Schmutzler R.K., PreislerAdams S., Markov N.B., Wang-Gohrke S., de Pauw
A., Lefol C., Lasset C., Leroux D., Rouleau E.,
Damiola F., Dreyfus H., Barjhoux L., Golmard L.,
Uhrhammer N., Bonadona V., Sornin V., Bignon Y.J.,
Carter J., Van Le L., Piedmonte M., DiSilvestro P.A.,
de la Hoya M., Caldes T., Nevanlinna H., Aittomäki K.,
Jager A., van den Ouweland A.M.W., Kets C.M., Aalfs
C.M., van Leeuwen F.E., Hogervorst F.B.L., MeijersHeijboer H.E.J., Oosterwijk J.C., van Roozendaal
K.E.P., Rookus M.A., Devilee P., van der Luijt R.B.,
Olah E., Diez O., Teulé A., Lazaro C., Blanco I., Del
Valle J., Jakubowska A., Sukiennicki G., Gronwald
J., Lubinski J., Durda K., Jaworska-Bieniek K.,
Agnarsson B.A., Maugard C., Amadori A., Montagna
M., Teixeira M.R., Spurdle A.B., Foulkes W., Olswold
C., Lindor N.M., Pankratz V.S., Szabo C.I., Lincoln A.,
Jacobs L., Corines M., Robson M., Vijai J., Berger A.,
Fink-Retter A., Singer C.F., Rappaport C., Kaulich
D.G., Pfeiler G., Tea M.K., Greene M.H., Mai P.L.,
Rennert G., Imyanitov E.N., Mulligan A.M., Glendon
G., Andrulis I.L., Tchatchou S., Toland A.E., Pedersen
I.S., Thomassen M., Kruse T.A., Jensen U.B., Caligo
39
M.A., Friedman E., Zidan J., Laitman Y., Lindblom A.,
Melin B., Arver B., Loman N., Rosenquist R., Olopade
O.I., Nussbaum R.L., Ramus S.J., Nathanson K.L.,
Domchek S.M., Rebbeck T.R., Arun B.K., Mitchell G.,
Karlan B.Y., Lester J., Orsulic S., Stoppa-Lyonnet D.,
Thomas G., Simard J., Couch F.J., Offit K., Easton
D.F., Chenevix-Trench G., Antoniou A.C., Mazoyer S.,
Phelan C.M., Sinilnikova O.M., Cox D.G., Angelakos
M., Maskiell J., Dite G., Tsimiklis H., Rudaitis V.,
Griškevicius L., Eglitis D.J., Krilova A., Stengrevics
A., Ding C., Steele L., Barroso A., Alonso R., Pita G.,
Viel A., della Puppa L., Barile M., Tommasi S., Pilato
B., Lambo R., Martayan A., Tibiletti M.G., Ellis S.,
Fineberg E., Miedzybrodzka Z., Gregory H., Jeffers L.,
Ong F.R., Hoffman J., James M., Paterson J., Taylor
A., Murray A., McCann E., Barton D., Drummond S.,
Kivuva E., Searle A., Goodman S., Hill K., Murday
V., Bradshaw N., Snadden L., Longmuir M., Watt
C., Gibson S., Haque E., Tobias E., and Duncan
A. An original phylogenetic approach identified
mitochondrial haplogroup T1a1 as inversely
associated with breast cancer risk in BRCA2
mutation carriers. [2015] Breast Cancer Research
(17) 1: 61. Impact factor: 5,211
60. Bloy N., Sauvat A., Chaba K., Buque A., Humeau
J., Bravo-San Pedro J.M., Bui J., Kepp O., Kroemer
G., and Senovilla L. Morphometric analysis of
immunoselection against hyperploid cancer cells.
[1-12-2015] Oncotarget (6) 38: 41204-41215. Impact
factor: 5,008
61. Bloy N., Buque A., Aranda F., Castoldi F., Eggermont
A., Cremer I., Sautes-Fridman C., Fucikova J., Galon
J., Spisek R., Tartour E., Zitvogel L., Kroemer G., and
Galluzzi L. Trial watch: Naked and vectored DNAbased anticancer vaccines. [2015] Oncoimmunology
(4) 5: e1026531. Impact factor: 7,644
62. Blumenschein G., Smit E., Planchard D., Kim D.,
Cadranel J., De Pas T., Dunphy F., Udud K., Ahn
M., Hanna N., Kim J., Mazieres J., Kim S., Baas P.,
Rappold E., Redhu S., Puski A., Wu F., and Jaenne
P. A randomized phase II study of the MEK1/MEK2
inhibitor trametinib (GSK1120212) compared with
docetaxel in KRAS-mutant advanced non-smallcell lung cancer (NSCLC). [2015] Annals of Oncology
(26) 5: 894-901. Impact factor: 9,269
63. Bluthgen M., V, Caramella C., Faivre L., Rosellini S.,
Facchinetti F., Haspinger E., Ferte C., Ammari S.,
Michiels S., Soria J., and Besse B. Prognostic value
of texture analysis in advanced non-small cell lung
cancer (NSCLC). [2015] European Journal of Cancer
(51) suppl 3: S645-S646. Impact factor: 6,163
64. Bodo S., Svrcek M., Sourrouille I., CuillieresDartigues P., Ledent T., Dumont S., Dinard L., Lafitte
P., Capel C., Collura A., Buhard O., Wanherdrick K.,
Chalastanis A., Penard-Lacronique V., Fabiani B.,
Flejou J.F., Brousse N., Beaugerie L., Duval A., and
Muleris M. Azathioprine induction of tumors with
microsatellite instability: Risk evaluation using a
mouse model. [2015] Oncotarget (6) 28: 2496924977. Impact factor: 5,008
65. Body J.J., Bone H.G., De Boer R.H., Stopeck A., Van
Poznak C., Damiao R., Fizazi K., Henry D.H., Ibrahim
T., Lipton A., Saad F., Shore N., Takano T., Shaywitz
A.J., Wang H., Bracco O.L., Braun A., and Kostenuik
P.J. Hypocalcaemia in patients with metastatic bone
disease treated with denosumab. [2015] European
Journal of Cancer (51) 13: 1812-1821. Impact factor:
6,163
66. Bollard J., Massoma P., Vercherat C., Blanc M.,
Lepinasse F., Gadot N., Couderc C., Poncet G.,
Walter T., Joly M.O., Hervieu V., Scoazec J.Y., and
Roche C. The axon guidance molecule Semaphorin
3F is a negative regulator of tumor progression and
proliferation in ileal neuroendocrine tumors. [2015]
Oncotarget (6) 34: 36731-36745. Impact factor:
5,008
67. Bompas E., Le Cesne A., Tresch-Bruneel E., Lebellec
L., Laurence V., Collard O., Saada-Bouzid E., Isambert
N., Blay J., Amela E., Salas S., Chevreau C., Bertucci
F., Italiano A., Clisant S., and Penel N. Sorafenib
in patients with locally advanced and metastatic
chordomas: a phase II trial of the French Sarcoma
Group (GSF/GETO). [2015] Annals of Oncology (26)
10: 2168-2173. Impact factor: 9,269
68. Bonham M., Koscielny S., Lopatin M., Svedman C.,
Verkarre V., Radulescu C., Neuzillet Y., Hemmerle
I., Olivier T.M., Martini J.F., Williams J., Tsiatis A.,
Knezevic D., Lebret T., Goddard A., Mejean A., and
Escudier B. A 16 Gene Signature for Assessing
Risk of Recurrence in Renal Cancer: Performance
Beyond Conventional Pathologic Factors and Impact
of Tumor Heterogeneity. [2015] Modern Pathology
(28) S2: 209A-209A. Impact factor: 5,485
69. Bonnefoi H., Jacot W., Saghatchian M., Moldovan
C., Venat-Bouvet L., Zaman K., Matos E., Petit T.,
Bodmer A., Quenel-Tueux N., Chakiba C., Vuylsteke
P., Jerusalem G., Brain E., Tredan O., Messina C.,
Slaets L., and Cameron D. Neoadjuvant treatment
with docetaxel plus lapatinib, trastuzumab, or both
followed by an anthracycline-based chemotherapy
in HER2-positive breast cancer: results of the
randomised phase II EORTC 10054 study. [2015]
40
Annals of Oncology (26) 2: 325-332. Impact factor:
9,269
70. Bonnet F., Affret A., Boutron-Ruault M.C., Balkau B.,
Clavel-Chapelon F., and Fagherazzi G. Association
Between Handedness and Type 2 Diabetes: The E3N
Study. [2015] Diabetes Care (38) 12: e199. Impact
factor: 8,934
71. Bonneterre J., Bosq J., Alleaume C., Gilles E.,
Jamme P., and Zukiwski A. Triple negative breast
cancer, the impact of isotype-specific progesterone
receptor antibodies on the diagnosis results. [2015]
Cancer Research (75) 9 suppl: P5-02-13. Impact
factor: 8,556
72. Bonora M., Wieckowski M., Chinopoulos C., Kepp
O., Kroemer G., Galluzzi L., and Pinton P. Molecular
mechanisms of cell death: central implication
of ATP synthase in mitochondrial permeability
transition. [2015] Oncogene (34) 12: 1475-1486.
Impact factor: 7,923
73. Boros A., Lacroix L., Lacas B., Adam J., Pignon J.,
Caramella C., Planchard D., Levy A., Montpreville V.,
Deutsch E., Besse B., and Le Pechoux C. Chemoradiation (CRT) and mutation profile in stage III
Non Small Cell Lung Cancer (NSCLC): An analysis
of the prognostic value. [2015] European Journal
of Cancer (51) suppl 3: S595-S595. Impact factor:
6,163
74. Bouchahda M., Ducreux M., Denis S., Abdoulaye
K., Mohamed H., Celine L., Christian F., Rosine
G., Pasquale I., Sameh A., Carlos C., Salvatore T.,
Stephanie T., Thierry D., Denis C., Philippe R., Valerie
B., Francois M., Rene A., and Francis L. Early tumor
shrinkage as a predictor for long-term outcome in
patients (pts) with unresectable liver metastases
from wt-KRAS colorectal cancer (LM-CRC) treated
with hepatic artery infusion (HAI) of Irinotecan,
5-Fluorouracil and Oxaliplatin plus intravenous
Cetuximab (IV-Cet) after failure of one to three
systemic protocols (European phase II clinical trial
NCT00852228). [2015] European Journal of Cancer
(51) suppl 3: S348-S348. Impact factor: 6,163
75. Bouda C., Traore F., Atteby J., Raquin M., Guedenon
K., Pondy A., Moreira C., Harif M., and Patte C. A
multicenter study of the Groupe Franco Africain
d’Oncologie Pediatrique for the treatment of
children with Burkitt lymphoma in sub-Saharan
countries. [2015] British Journal of Haematology
(171) suppl 1: 79-79. Impact factor: 5,401
76. Boudra M.T., Bolin C., Chiker S., Fouquin A., Zaremba
T., Vaslin L., Biard D., Cordelières F.P., Mégnin-
Chanet F., Favaudon V., Fernet M., Pennaneach V., and
Hall J. PARP-2 depletion results in lower radiation
cell survival but cell line-specific differences
in poly(ADP-ribose) levels . [2015] Cellular and
Molecular Life Sciences (72) 8: 1585-1597. Impact
factor: 5,694
77. Bouillet T., Bigard X., Brami C., Chouahnia K., Copel
L., Dauchy S., Delcarnbre C., Descotes J., Joly F.,
Lepeu G., Marre A., Scotte F., Spano J., Vanleinmens
L., and Zelek L. Role of physical activity and sport
in oncology Scientific commission of the National
Federation Sport and Cancer CAMI. [2015] Critical
Reviews in Oncology Hematology (94) 1: 74-86.
Impact factor: 5,039
78. Bousquet J., Anto J.M., Berkouk K., Gergen P.,
Antunes J.P., Augé P., Camuzat T., Bringer J., Mercier
J., Best N., Bourret R., Akdis M., Arshad S.H.,
Bedbrook A., Berr C., Bush A., Cavalli G., Charles
M.A., Clavel-Chapelon F., Gillman M., Gold D.R.,
Goldberg M., Holloway J.W., Iozzo P., Jacquemin
S., Jeandel C., Kauffmann F., Keil T., Koppelman
G.H., Krauss-Etschmann S., Kuh D., Lehmann S.,
Carlsen K.C., Maier D., Méchali M., Melén E., Moatti
J.P., Momas I., Nérin P., Postma D.S., Ritchie K.,
Robine J.M., Samolinski B., Siroux V., Slagboom
P.E., Smit H.A., Sunyer J., Valenta R., Van de Perre
P., Verdier J.M., Vrijheid M., Wickman M., Yiallouros
P., and Zins M. Developmental determinants in noncommunicable chronic diseases and ageing. [2015]
Thorax (70) 6: 595-597. Impact factor: 8,121
79. Boussemart L., Malka-Mahieu H., Girault I., Allard
D., Hemmingson O., Kamsu-Kom N., Agoussi S.,
Eggermont A., Desaubry L., Robert C., and Vagner
S. eIF4F is a key and targetable convergence nexus
of multiple mechanisms of resistance to anti-BRAF
and anti-MEK cancer therapies. [2015] Clinical
Cancer Research (21) suppl 4: A23. Impact factor:
8,738
80. Boutros C., Mazouni C., Lerebours F., Stevens
D., Lei X., Gonzalez-Angulo A., and Delaloge S. A
preoperative nomogram to predict the risk of
synchronous distant metastases at diagnosis of
primary breast cancer. [2015] British Journal of
Cancer (112) 6: 992-997. Impact factor: 5,569
81. Bouzigon E., Nadif R., Thompson E., Concas M.,
Kuldanek S., Du G., Brossard M., Lavielle N.,
Sarnowski C., Vaysse A., Dessen P., van der Valk
R., Duijts L., Henderson A., Jaddoe V., de Jongste
J., Casula S., Biino G., Dizier M., Pin I., Matran R.,
Lathrop M., Pirastu M., Demenais F., and Ober C. A
common variant in RAB27A gene is associated with
41
fractional exhaled nitric oxide levels in adults .
[2015] Clinical and Experimental Allergy (45) 4:
797-806. Impact factor: 5,587
82. Bracarda S., Iacovelli R., Boni L., Rizzo M., Derosa
L., Rossi M., Galli L., Procopio G., Sisani M., Longo
F., Santoni M., Morelli F., Di Lorenzo G., Altavilla A.,
Porta C., Camerini A., Escudier B., Martignetti A.,
Ricotta R., Gasparro D., Sabbatini R., Ceresoli G.L.,
Mosca A., Santini D., Caserta C., Cavanna L., Massari
F., Sava T., Boni C., Verzoni E., Cartenì G., and
Hamzaj A. Sunitinib administered on 2/1 schedule in
patients with metastatic renal cell carcinoma: The
RAINBOW analysis. [2015] Annals of Oncology (26)
10: 2107-2113. Impact factor: 9,269
83. Braun R.J., Sommer C., Leibiger C., Gentier R.J.,
Dumit V.I., Paduch K., Eisenberg T., Habernig L.,
Trausinger G., Magnes C., Pieber T., Sinner F.,
Dengjel J., van Leeuwen F.W., Kroemer G., and Madeo
F. Accumulation of Basic Amino Acids at Mitochondria
Dictates the Cytotoxicity of Aberrant Ubiquitin. [2015]
Cell Reports (10) 9: 1557-1571. Impact factor: 7,870
84. Bravo-San Pedro J.M., Wei Y., Sica V., Maiuri M.C.,
Zou Z., Kroemer G., and Levine B. BAX and BAK1
are dispensable for ABT-737-induced dissociation
of the BCL2-BECN1 complex and autophagy. [2015]
Autophagy (11) 3: 452-459. Impact factor: 9,108
85. Brugieres L. Treatment and prognosis of childhood
and adolescent anaplastic large cell lymphoma .
[2015] British Journal of Haematology (171) suppl 1:
19-19. Impact factor: 5,401
86. Buckland G., Travier N., Huerta J., Bueno-deMesquita H., Siersema P., Skeie G., Weiderpass E.,
Engeset D., Ericson U., Ohlsson B., Agudo A., Romieu
I., Ferrari P., Freisling H., Colorado-Yohar S., Li K.,
Kaaks R., Pala V., Cross A., Riboli E., Trichopoulou A.,
Lagiou P., Bamia C., Boutron-Ruault M., Fagherazzi
G., Dartois L., May A., Peeters P., Panico S., Johansson
M., Wallner B., Palli D., Key T., Khaw K., Ardanaz E.,
Overvad K., Tjønneland A., Dorronsoro M., Sanchez
M., Quiros J., Naccarati A., Tumino R., Boeing H., and
Gonzalez C. Healthy lifestyle index and risk of gastric
adenocarcinoma in the EPIC cohort study. [2015]
International Journal of Cancer (137) 3: 598-606.
Impact factor: 5,531
87. Buque A., Bloy N., Aranda F., Castoldi F., Eggermont
A., Cremer I., Fridman W.H., Fucikova J., Galon J.,
Marabelle A., Spisek R., Tartour E., Zitvogel L., Kroemer
G., and Galluzzi L. Trial Watch: Immunomodulatory
monoclonal antibodies for oncological indications.
[2015] Oncoimmunology (4) 4: e1008814. Impact
factor: 7,644
88. Cadeau C., Fournier A., Mesrine S., ClavelChapelon F., Fagherazzi G., and Boutron-Ruault
M.C. Interaction between current vitamin D
supplementation and menopausal hormone
therapy use on breast cancer risk: evidence from
the E3N cohort. [2015] American Journal of Clinical
Nutrition (102) 4: 966-973. Impact factor: 6,703
89. Callea M., Albigès L., Gupta M., Cheng S.C.,
Genega E.M., Fay A.P., Song J., Carvo I., Bhatt R.S.,
Atkins M.B., Hodi F.S., Choueiri T.K., McDermott
D.F., Freeman G.J., and Signoretti S. Differential
expression of PD-L1 between primary and
metastatic sites in clear cell Renal Cell Carcinoma.
[2015] Cancer Immunology Research (3) 10: 11581164. Impact factor: 6,665
90. Campa D., Barrdahl M., Gaudet M.M., Black A.,
Chanock S.J., Diver W., Gapstur S.M., Haiman C.,
Hankinson S., Hazra A., Henderson B., Hoover R.N.,
Hunter D.J., Joshi A.D., Kraft P., Le Marchand L.,
Lindstrom S., Willett W., Travis R.C., Amiano P.,
Siddiq A., Trichopoulos D., Sund M., Tjønneland A.,
Weiderpass E., Peeters P.H., Panico S., Dossus L.,
Ziegler R.G., Canzian F., and Kaaks R. Genetic risk
variants associated with in situ breast cancer .
[2015] Breast Cancer Research (17) 1: 82. Impact
factor: 5,211
91. Cao K., I, Lebas N., Gerber S., Levy C., Le Scodan
R., Bourgier C., Pierga J., Gobillion A., Savignoni A.,
and Kirova Y. Phase II randomized study of wholebrain radiation therapy with or without concurrent
temozolomide for brain metastases from breast
cancer. [2015] Annals of Oncology (26) 1: 89-94.
Impact factor: 9,269
92. Caplin M., Baudin E., Ferolla P., Filosso P.,
Garcia-Yuste M., Lim E., Oberg K., Pelosi G.,
Perren A., Rossi R., and Travis W. Pulmonary
neuroendocrine (carcinoid) tumors: European
Neuroendocrine Tumor Society expert consensus
and recommendations for best practice for typical
and atypical pulmonary carcinoids. [2015] Annals of
Oncology (26) 8: 1604-1620. Impact factor: 9,269
93. Caramella C., Bluthgen M., V, Rosellini S., Leduc C.,
Facchinetti F., Haspinger E., Ferte C., Michiels S.,
Soria J., and Besse B. Prognostic value of texture
analysis and correlation with molecular profile in
EGFR mutated/ALK rearranged advanced nonsmall cell lung cancer (NSCLC). [2015] European
Journal of Cancer (51) suppl 3: S647-S648. Impact
factor: 6,163
94. Carré A., Louzada R.A., Fortunato R.S., AmezianeEl-Hassani R., Morand S., Ogryzko V., de Carvalho
42
D.P., Grasberger H., Leto T.L., and Dupuy C. When
an Intramolecular Disulfide Bridge Governs the
Interaction of DUOX2 with Its Partner DUOXA2 .
[2015] Antioxidants & Redox Signaling (23) 9: 724733. Impact factor: 7,093
95. Cella D., Ivanescu C., Holmstrom S., Bui C., Spalding
J., and Fizazi K. Impact of enzalutamide on quality
of life in men with metastatic castration-resistant
prostate cancer after chemotherapy: additional
analyses from the AFFIRM randomized clinical
trial. [2015] Annals of Oncology (26) 1: 179-185.
Impact factor: 9,269
96. Chaput N. and Marabelle A. Foxp3+ cells are running
the show in patients with surgically resected
nonsmall cell lung cancer . [2015] European
Respiratory Journal (46) 6: 1541-1543. Impact
factor: 8,332
97. Chatre L., Biard D.S., Sarasin A., and Ricchetti
M. Reversal of mitochondrial defects with CSBdependent serine protease inhibitors in patient
cells of the progeroid Cockayne syndrome. [2015]
Proceedings of the National Academy of Sciences of
the United States of America (112) 22: E2910-E2919.
Impact factor: 9,423
98. Chester C., Marabelle A., Houot R., and Kohrt
H.E. Dual antibody therapy to harness the innate
anti-tumor immune response to enhance antibody
targeting of tumors. [2015] Current Opinion in
Immunology (33): 1-8. Impact factor: 7,126
99. Cho B., Dy G., Govindan R., Kim D., Pennell N.,
Zalcman G., Besse B., Nogai H., Rajagopalan P.,
Ocker M., and Barlesi F. Phase Ib/II study of the pancyclin-dependent kinase (CDK) inhibitor roniciclib
(BAY 1000394) in combination with chemotherapy as
first-line therapy in subjects with extensive disease
small cell lung cancer (ED-SCLC). [2015] European
Journal of Cancer (51) suppl 3: S634-S634. Impact
factor: 6,163
100. Choueiri T., Escudier B., Powles T., Mainwaring P.,
Rini B., Donskov F., Hammers H., Hutson T., Roth
B., Peltola K., Lee J., Heng D., Schmidinger M.,
Borgman-Hagey A., Hessel C., Scheffold C., Schwab
G., Tannir N., and Motzer R. Cabozantinib versus
everolimus in patients with advanced renal cell
carcinoma: Results of the randomized phase 3
METEOR trial. [2015] European Journal of Cancer
(51) suppl 3: S708-S709. Impact factor: 6,163
1 01. Civaschi E., Klersy C., Melazzini F., Pujol-Moix
N., Santoro C., Cattaneo M., Lavenu-Bombled C.,
Bury L., Minuz P., Nurden P., Cid A.R., Cuker A.,
Latger-Cannard V., Favier R., Nichele I., and Noris
P. Analysis of 65 pregnancies in 34 women with
five different forms of inherited platelet function
disorders. [2015] British Journal of Haematology
(170) 4: 559-563. Impact factor: 5,401
102. Colombo C., Miceli R., Le Péchoux C., Palassini E.,
Honoré C., Stacchiotti S., Mir O., Casali P., Dômont
J., Fiore M., Le Cesne A., Gronchi A., and Bonvalot
S. Sporadic extra abdominal wall desmoid-type
fibromatosis: Surgical resection can be safely
limited to a minority of patients. [2015] European
Journal of Cancer (51) 2: 186-192. Impact factor:
6,163
103. Commo F., Fert C., Soria J., Friend S., Andre F., and
Guinney J. Impact of centralization on aCGH-based
genomic profiles for precision medicine in oncology.
[2015] Annals of Oncology (26) 3: 582-588 . Impact
factor: 9,269
104. Cornelis G., Vernochet C., Carradec Q., Souquere
S., Mulot B., Catzeflis F., Nilsson M.A., Menzies
B.R., Renfree M.B., Pierron G., Zeller U., Heidmann
O., Dupressoir A., and Heidmann T. Retroviral
envelope gene captures and syncytin exaptation
for placentation in marsupials. [2015] Proceedings
of the National Academy of Sciences of the United
States of America (112) 5: E487-E496. Impact
factor: 9,423
105. Cornely O.A., Gachot B., Akan H., Bassetti M., Uzun
O., Kibbler C., Marchetti O., de Burghgraeve P.,
Ramadan S., Pylkkanen L., Ameye L., Paesmans
M., and Donnelly P.J. Epidemiology and Outcome
of Fungemia in a Cancer Cohort of the Infectious
Diseases Group (IDG) of the European Organization
for Research and Treatment of Cancer (EORTC
65031). [2015] Clinical Infectious Diseases (61) 3:
324-331. Impact factor: 8,736
106. Cortier M., Boina-Ali R., Racoeur C., Paul C., Solary
E., Jeannin J.F., and Bettaieb A. H89 enhances the
sensitivity of cancer cells to glyceryl trinitrate
through a purinergic receptor-dependent pathway.
[2015] Oncotarget (6) 9: 6877-6886. Impact factor:
5,008
107. Cosson A., Chapiro E., Lambert J., Cung H., Algrin
C., Damm F., Gabillaud C., Davi F., Merle-Beral H.,
Choquet S., Uzunov M., Morel V., Leblond V., Maloum
K., Lepretre S., Feugier P., Lesty C., Lejeune J., Sutton
L., Susin S., and Nguyen-Khac F. The Gain of the Short
Arm of Chromosome 2 (2P) in Chronic Lymphocytic
Leukemia (Cll) Results in Xpo1 Overexpression and
Drug Resistance. [2015] Haematologica (100) suppl
1: 222-222. Impact factor: 6,671
43
108. Cottu P., Rouge T., Pautier P., Provansal M., Floquet
A., Selle F., Mouret-Reynier M., Fabbro M., Kalbacher
E., Piprot C., Follana P., Lesoin A., Medioni J.,
Menguy V., Ghazi Y., Bidard F., Dubot C., and Joly
F. Circulating tumor cells kinetics in ovarian
carcinoma: correlation with baseline characteristics
and CA-125 levels in the randomized ANTHALYA
trial evaluating bevacizumab in the neoadjuvant
setting. [2015] European Journal of Cancer (51)
suppl 3: S555-S555. Impact factor: 6,163
109. Cottu P.H., Duhoux F., Lemonnier J., Bonnefoi H.,
Salomon A.V., Asselain B., and Delaloge S. NEOPAL:
A randomized phase II study comparing RCB
response to neoadjuvant chemotherapy or letrozolepalbociclib in PAM50 defined postmenopausal
luminal breast cancer. [2015] Cancer Research (75)
9 suppl: OT3-2-06. Impact factor: 8,556
110. Cousin S., Hollebecque A., Isambert N., Italiano A.,
Kotecki N., Postel-Vinay S., Gobbo J., Toulmonde M.,
and Penel N. Dose-seeking phase I trials (DSPT)
of approved molecularly targeted therapies (MTT):
Exhaustiveness and readability of published clinical
reports. [2015] European Journal of Cancer (51)
suppl 3: S62-S63. Impact factor: 6,163
111. Croce S., Ribeiro A., Brulard C., Noel J.C., Amant F.,
Stoeckle E., Devouassoux-Shisheborah M., Floquet
A., Arnould L., Guyon F., Mishellany F., Garbay D.,
Cuppens T., Zikan M., Leroux A., Frouin E., Duvillard
P., Terrier P., Farre I., Valo I., MacGrogan G.M., and
Chibon F. Uterine smooth muscle tumor analysis
by comparative genomic hybridization: a useful
diagnostic tool in challenging lesions . [2015]
Modern Pathology (28) 7: 1001-1010. Impact factor:
5,485
1 12. d’Assignies M., Laplanche A., Fekih M., Pezant
E., Bouvet N., Lacas B., Ezenfis J., Bourron A.,
Warembourg D., Dauchy S., Delaloge S., and Amiel
P. BEAUTY, a large randomised controlled trial of
beauty care for early stage breast cancer patients
receiving adjuvant chemotherapy: Impact on body
image-related quality of life . [2015] European
Journal of Cancer (51) suppl 3: S222-S223. Impact
factor: 6,163
113. Damm-Welk C., Yamashita Y., Bench A., Turner S.,
Lamant L., Verge V., Tosato E., Schieferstein J., and
Mussolin L. Quality control of standardized methods
for NPM-ALK RT-PCR and anti-ALK-AntibodyMeasurement for anaplastic large cell lymphoma
- a report of the EICNHL Reference Laboratory
Group. [2015] British Journal of Haematology (171)
suppl 1: 56-56. Impact factor: 5,401
114. Danjou A.M., Fervers B., Boutron-Ruault M.C., Philip
T., Clavel-Chapelon F., and Dossus L. Estimated
dietary dioxin exposure and breast cancer risk
among women from the French E3N prospective
cohort. [2015] Breast Cancer Research (17): 39.
Impact factor: 5,211
115. Das A.M., Eggermont A.M., and ten Hagen T.L. A
ring barrier-based migration assay to assess cell
migration in vitro. [2015] Nature Protocols (10) 6:
904-915. Impact factor: 9,646
116. Daskalogianni C., Pyndiah S., Apcher S., Mazars A.,
Manoury B., Ammari N., Nylander K., Voisset C.,
Blondel M., and Fåhraeus R. Epstein-Barr virusencoded EBNA1 and ZEBRA: Targets for therapeutic
strategies against EBV-carrying cancers. [2015]
Journal of Pathology (235) 2: 334-341. Impact
factor: 7,585
117. de Baere T., Tselikas L., and Callstrom M. Reply
to Dr. Macbeth Letter. [2015] Journal of Thoracic
Oncology (10) 12: e121-e122. Impact factor: 5,040
118. de Baère T., Aupérin A., Deschamps F., Chevallier
P., Gaubert Y., Boige V., Fonck M., Escudier B.,
and Palussière J. Reply to the letter to the editor
‘Ablative therapies for lung metastases: a need to
acknowledge the efficacy and toxicity of stereotactic
ablative body radiotherapy’ by Siva et al. [2015]
Annals of Oncology (26) 10: 2196-2197. Impact
factor: 9,269
119. de Baère T., Aupérin A., Deschamps F., Chevallier
P., Gaubert Y., Boige V., Fonck M., Escudier B., and
Palussière J. Radiofrequency ablation is a valid
treatment option for lung metastases: experience
in 566 patients with 1037 metastases. [2015] Annals
of Oncology (26) 5: 987-991. Impact factor: 9,269
1 20. De Baère T., Tselikas L., Woodrum D., Abtin F.,
Littrup P., Deschamps F., Suh R., Aoun H.D., and
Callstrom M. Evaluating Cryoablation of Metastatic
Lung Tumors in Patients-Safety and Efficacy The
ECLIPSE Trial-Interim Analysis at 1 Year. [2015]
Journal of Thoracic Oncology (10) 10: 1468-1474.
Impact factor: 5,040
121. de Botton S. Targeting isocitrate dehydrogenase
(IDH)1 and IDH2 mutations Clinical results in
advanced hematologic malignancies. [2015] Annals
of Oncology (26) suppl 2: ii15-ii15. Impact factor:
9,269
122. de Botton S., Pollyea D., Stein E., DiNardo C., Fathi
A., Roboz G., Collins R., Swords R., Flinn I., Altman
J., Tallman M., Kantarjian H., Colby K., Fan B.,
Goldwasser M., Prahl M., Agresta S., and Stone
44
R. Clinical Safety and Activity of Ag-120, A First-InClass, Potent Inhibitor of the Idh1 Mutant Protein,
in A Phase 1 Study of Patients with Advanced
Idh1-Mutant Hematologic Malignancies . [2015]
Haematologica (100) suppl 1: 214-215. Impact
factor: 6,671
123. de Corbiere P., Ritzel K., Cazabat L., Ropers J.,
Schott M., Libe R., Koschker A.C., Leboulleux S.,
Deutschbein T., Do C.C., Hahner S., Drui D., Miehle
K., Caron P., Waldmann J., Chabre O., Quinkler
M., Touraine P., Villares Fragoso M.C., Bertherat
J., Bertagna X., Fassnacht M., and Raffin-Sanson
M.L. Pregnancy in Women Previously Treated for
an Adrenocortical Carcinoma. [2015] Journal of
Clinical Endocrinology and Metabolism (100) 12:
4604-4611. Impact factor: 5,531
124. de Leval L., Parrens M., Le B.F., Jais J.P., Fataccioli
V., Martin A., Lamant L., Delarue R., Berger F.,
Arbion F., Bossard C., Copin M.C., Canioni D.,
Charlotte F., Damaj G., Dartigues P., Fabiani B.,
Ledoux-Pilon A., Montagne K., Molina T., Patey M.,
Tas P., Peoch M., Petit B., Petrella T., Picquenot J.M.,
Rousset T., Rousselet M.C., Soubeyran I., Thiebault
S., Tournilhac O., Xerri L., Gisselbrecht C., Haioun C.,
Delsol G., and Gaulard P. Angioimmunoblastic T-cell
lymphoma is the most common T-cell lymphoma in
two distinct French information data sets. [2015]
Haematologica (100) 9: e361-e364. Impact factor:
6,671
1 25. De Mestier L., Gaujoux S., Cros J., Hentic O.,
Vullierme M.P., Couvelard A., Cadiot G., Sauvanet
A., Ruszniewski P., Richard S., and Hammel
P. Long-term Prognosis of Resected Pancreatic
Neuroendocrine Tumors in von Hippel-Lindau
Disease Is Favorable and Not Influenced by Small
Tumors Left in Place. [2015] Annals of surgery (262)
2: 384-388. Impact factor: 8,569
126. De Vathaire F., Haddy N., Allodji R.S., Hawkins M.,
Guibout C., El-Fayech C., Teinturier C., Oberlin O.,
Pacquement H., Diop F., Kalhouche A., Benadjaoud
M., Winter D., Jackson A., Bezin Mai-Quynh G.,
Benabdennebi A., Llanas D., Veres C., Munzer M.,
Nguyen T.D., Bondiau P.Y., Berchery D., Laprie A.,
Deutsch E., Lefkopoulos D., Schlumberger M.,
Diallo I., and Rubino C. Thyroid Radiation Dose and
Other Risk Factors of Thyroid Carcinoma Following
Childhood Cancer . [2015] Journal of Clinical
Endocrinology and Metabolism (100) 11: 4282-4290.
Impact factor: 5,531
127. De Weger V., Varga A., De Jonge M., Langenberg
M., Mergui-Roelvink M., Massard C., Van der
Vlist A., Devriese L., Goodstal S., Zheng W., Tuffal
G., Semiond D., Mace S., Watters J., Demers B.,
Schellens J., and Deutsch E. A phase I study of the
HDM2 antagonist SAR405838 combined with the
MEK inhibitor pimasertib in patients with advanced
solid tumors. [2015] European Journal of Cancer
(51) suppl 3: S55-S55. Impact factor: 6,163
128. Deandreis D., Terroir M., Al Ghuzlan A., Berdelou A.,
Lacroix L., Bidault F., Troalen F., Hartl D., Lumbroso J.,
Baudin E., Schlumberger M., and Leboulleux S. (18)
Fluorocholine PET/CT in parathyroid carcinoma:
a new tool for disease staging? [2015] European
Journal of Nuclear Medicine and Molecular Imaging
(42) 12: 1941-1942. Impact factor: 5,537
129. Defferrari R., Mazzocco K., Ambros I., Ambros P.,
Bedwell C., Beiske K., Benard J., Berbegall A.P.,
Bown N., Combaret V., Couturier J., Erminio G.,
Gambini C., Garaventa A., Gross N., Haupt R., Kohler
J., Jeison M., Lunec J., Marques B., Martinsson T.,
Noguera R., Parodi S., Schleiermacher G., Tweddle
D.A., Valent A., Van Roy N., Vicha A., Villamon E., and
Tonini G.P. Influence of segmental chromosome
abnormalities on survival in children over the age of
12 months with unresectable localised peripheral
neuroblastic tumours without MYCN amplification.
[2015] British Journal of Cancer (112) 2: 290-295.
Impact factor: 5,569
130. Dercle L., Ammari S., Texier M., Lanoy E., Champiat
S., Deandreis D., Terroir M., Marabelle A., and
Schlumberger M. Prolonged overall survival in
metastatic melanoma with low tumor burden at
anti-PD1 initiation: CT-scan, 18-FDG-PET and
blood samples. [2015] European Journal of Nuclear
Medicine and Molecular Imaging (42) suppl 1:
S154-S154. Impact factor: 5,537
131. Dercle L., Ammari S., Rozenblum L., Deandreis
D., Terroir M., Schlumberger M., and Bidault
F. Diagnostic accuracy of F18-FDG-PET/CT for
the detection of perineural spread in head and
neck cancer. [2015] European Journal of Nuclear
Medicine and Molecular Imaging (42) suppl 1:
S256-S256. Impact factor: 5,537
132. Dercle L., Chisin R., Ammari S., Gillebert Q., Ouali
M., Jaudet C., Delord J.P., Dierickx L., Zerdoud S.,
Schlumberger M., and Courbon F. Nonsurgical giant
cell tumour of the tendon sheath or of the diffuse
type: Are MRI or F-18-FDG PET/CT able to provide
an accurate prediction of long-term outcome?
[2015] European Journal of Nuclear Medicine and
Molecular Imaging (42) 3: 397-408. Impact factor:
5,537
45
1 33. Deroose J.P., Grunhagen D.J., de Wilt J.H.,
Eggermont A.M., and Verhoef C. Treatment
modifications in tumour necrosis factor-alpha
(TNF)-based isolated limb perfusion in patients
with advanced extremity soft tissue sarcomas.
[2015] European Journal of Cancer (51) 3: 367-373.
Impact factor: 6,163
1 34. Derosa L., Guida A., Albigès L., Massard C.,
Loriot Y., Galli L., Fizazi K., and Escudier B. New
prognostic factors for second-line targeted
therapy (TT) in metastatic renal cell carcinoma
(mRCC). [2015] European Journal of Cancer (51)
suppl 3: S478-S479. Impact factor: 6,163
135. Desaubry L., Zhao Q., Basmadjian C., Thuaud F.,
Ribeiro N., Nebigil C., Eggermont A., Robert C.,
and Vagner S. Development of Novel Anticancer
Agents That Target Prohibitins and the Translation
Initiation Factor Eif4A. [2015] Annals of Oncology
(26) suppl 2: P5.02. Impact factor: 9,269
1 36. Desterke C., Martinaud C., Guerton B., Pieri
L., Bogani C., Clay D., Torossian F., Lataillade
J.J., Hasselbach H.C., Gisslinger H., Demory
J.L., Dupriez B., Boucheix C., Rubinstein E.,
Amsellem S., Vannucchi A.M., and Le BousseKerdiles M.-C. Tetraspanin CD9 participates in
dysmegakaryopoiesis and stromal interactions in
primary myelofibrosis. [2015] Haematologica (100)
6: 757-767. Impact factor: 6,671
137. Deutsch E., Le Pechoux C., Faivre L., Rivera S., Tao
Y., Pignon J., Angokai M., Bahleda R., Deandreis
D., Angevin E., Hennequin C., Besse B., Levy A.,
and Soria J.-C. Phase I trial of everolimus in
combination with thoracic radiotherapy in nonsmall-cell lung cancer. [2015] Annals of Oncology
(26) 6: 1223-1229. Impact factor: 9,269
138. Di Stefano A.L., Fucci A., Frattini V., Labussiere
M., Mokhtari K., Zoppoli P., Marie Y., Bruno A.,
Boisselier B., Giry M., Savatovsky J., Touat M.,
Belaid H., Kamoun A., Idbaih A., Houillier C., Luo
F.R., Soria J.C., Tabernero J., Eoli M., Paterra
R., Yip S., Petrecca K., Chan J.A., Finocchiaro G.,
Lasorella A., Sanson M., and Iavarone A. Detection,
Characterization, and Inhibition of FGFR-TACC
Fusions in IDH Wild-type Glioma . [15-7-2015]
Clinical Cancer Research (21) 14: 3307-3317.
Impact factor: 8,738
139. Diakite M.L.Y., Rollin J., Jary D., Berthier J., MourtonGilles C., Sauvaire D., Philippe C., Delapierre G.,
and Gidrol X. Point-of-care diagnostics for ricin
exposure. [2015] Lab on A Chip (15) 10: 2308-2317.
Impact factor: 5,586
140. Dianat N., Le Viet B., Gobbo E., Auger N., Bieche
I., Bennaceur-Griscelli A., and Griscelli F. Midkine
Lacking Its Last 40 Amino Acids Acts on Endothelial
and Neuroblastoma Tumor Cells and Inhibits
Tumor Development . [2015] Molecular Cancer
Therapeutics (14) 1: 213-224. Impact factor: 5,579
1 41. Dieci M., V, Mathieu M., Guarneri V., Conte P.,
Delaloge S., Andre F., and Goubar A. Prognostic and
predictive value of tumor-infiltrating lymphocytes
in two phase III randomized adjuvant breast cancer
trials. [2015] Annals of Oncology (26) 8: 1698-1704.
Impact factor: 9,269
142. DiNardo C., Stein E., Altman J., Collins R., DeAngelo
D., Fathi A., Flinn I., Frankel A., Levine R., Medeiros
B., Patel M., Pollyea D., Roboz G., Stone R., Swords
R., Tallman M., Almon C., Fan B., Goldwasser M.,
Yen K., Attar E., and de Botton S. Ag-221, An Oral,
Selective, First-In-Class, Potent Inhibitor of the
Idh2 Mutant Enzyme, Induced Durable Responses in
A Phase 1 Study of Idh2 Mutation-Positive Advanced
Hematologic Malignancies. [2015] Haematologica
(100) suppl 1: 216-217. Impact factor: 6,671
1 43. Dossus L. and Benusiglio P.R. Lobular breast
cancer: incidence and genetic and non-genetic risk
factors. [2015] Breast Cancer Research (17) 1: 37.
Impact factor: 5,211
144. Doussau A., Thiebaut R., Geoerger B., Schoffski
P., Floquet A., Le Deley M., Mathoulin-Pelissier S.,
Rizzo E., Fumoleau P., Le Tourneau C., and Paoletti
X. A new approach to integrate toxicity grade and
repeated treatment cycles in the analysis and
reporting of phase I dose-finding trials. [2015]
Annals of Oncology (26) 2: 422-428. Impact factor:
9,269
145. Dreanic J., Dhooge M., Barret M., Brezault C., Mir
O., Chaussade S., and Coriat R. Anti-epidermal or
anti-vascular endothelial growth factor as first-line
metastatic colorectal cancer in modified Glasgow
prognostic score 2 ‘ patients. [2015] Journal of
Cachexia Sarcopenia and Muscle (6) 3: 231-236.
Impact factor: 7,883
146. Duarte-Salles T., Fedirko V., Stepien M., Aleksandrova
K., Bamia C., Lagiou P., Laursen A.S.D., Hansen L.,
Overvad K., Tjønneland A., Boutron-Ruault M.C.,
Fagherazzi G., His M., Boeing H., Katzke V., Kuehn
T., Trichopoulou A., Valanou E., Kritikou M., Masala
G., Panico S., Sieri S., Ricceri F., Tumino R., Buenode-Mesquita H., Peeters P.H., Hjartaker A., Skeie G.,
Weiderpass E., Ardanaz E., Bonet C., Chirlaque M.D.,
Dorronsoro M., Quiros J., Johansson I., Ohlsson B.,
Sjoberg K., Wennberg M., Khaw K.T., Travis R.C.,
46
Wareham N., Ferrari P., Freisling H., Romieu I.,
Cross A.J., Gunter M., Lu Y., and Jenab M. Dietary
fat, fat subtypes and hepatocellular carcinoma in a
large European cohort. [2015] International Journal
of Cancer (137) 11: 2715-2728. Impact factor: 5,531
147. Duchemann B., Friboulet L., and Besse B. Therapeutic
management of ALK(+) nonsmall cell lung cancer
patients. [2015] European Respiratory Journal (46)
1: 230-242. Impact factor: 8,332
148. Ducreux M., Bennouna J., Adenis A., Conroy T., Lievre
A., Portales F., McGovern D., Li L., and Romano
A. Efficacy and safety of nab-paclitaxel (nab-P) in
patients (pts) with previously treated metastatic
colorectal cancer (mCRC): The phase II COLO-001
trial. [2015] European Journal of Cancer (51) suppl
3: S376-S376. Impact factor: 6,163
149. Ducreux M., Falcone A., Punt C., Majdi A., O’Connor
J., and Cervantes A. A prospective, observational
trial to assess the safety and efficacy of regorafenib
in patients with metastatic colorectal cancer
(mCRC) in routine clinical practice (CORRELATE).
[2015] Annals of Oncology (26) suppl 4: P 311.
Impact factor: 9,269
150. Ducreux M., Cuhna A., Caramella C., Hollebecque A.,
Burtin P., Goere D., Seufferlein T., Haustermans K.,
Van Laethem J., Conroy T., and Arnold D. Cancer of
the pancreas: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. [2015] Annals
of Oncology (26) suppl 5: V56-V68. Impact factor:
9,269
151. Duell E.J., Bonet C., Munoz X., Lujan-Barroso L.,
Weiderpass E., Boutron-Ruault M.C., Racine A.,
Severi G., Canzian F., Rizzato C., Boeing H., Overvad
K., Tjønneland A., Argueelles M., Sanchez-Cantalejo
E., Chamosa S., Maria Huerta J., Barricarte A.,
Khaw K.T., Wareham N., Travis R.C., Trichopoulou
A., Trichopoulos D., Yiannakouris N., Palli D., Agnoli
C., Tumino R., Naccarati A., Panico S., Bueno-deMesquita H., Siersema P.D., Peeters P.H., Ohlsson
B., Lindkvist B., Johansson I., Ye W., Johansson
M., Fenger C., Riboli E., Sala N., and Gonzalez
C.A. Variation at ABO histo-blood group and FUT
loci and diffuse and intestinal gastric cancer risk in
a European population. [2015] International Journal
of Cancer (136) 4: 880-893. Impact factor: 5,531
152. Duffaud F., Sleijfer S., Litière S., Ray-coquard I., Le
Cesne A., Papai Z., Judson I., Schöffski P., Chawla
S.P., Dewji R., Marreaud S., Verweij J., and van
der Graaf W.T. Hypertension (HTN) as a potential
biomarker of efficacy in pazopanib-treated
patients with advanced non-adipocytic soft tissue
sarcoma. A retrospective study based on European
Organisation for Research and Treatment of Cancer
(EORTC) 62043 and 62072 trial. [2015] European
Journal of Cancer (51) 17: 2615-2623. Impact factor:
6,163
153. Duployez N., Antony-Debre I., Bucci M., Geffroy S.,
Boissel N., Berthon C., Dhedin N., Leblanc T., Rea D.,
Heller P., Favier R., Latger-Cannard V., Mozziconacci
M., Nelken B., Raslova H., and Preudhomme
C. Additional Molecular Aberrations Leading to
Leukemic Transformation in Patients with Familial
Platelet Disorder. [2015] Haematologica (100) suppl
1: 208-208. Impact factor: 6,671
154. Duran G.E., Wang Y.C., Francisco E.B., Rose J.C.,
Martinez F.J., Coller J., Brassard D., Vrignaud P., and
Sikic B.I. Mechanisms of resistance to cabazitaxel.
[2015] Molecular Cancer Therapeutics (14) 1: 193201. Impact factor: 5,579
155. Dyakonova E.S., Koval V.V., Lomzov A.A., Ishchenko
A.A., and Fedorova O.S. The role of His-83 of
yeast apurinic/apyrimidinic endonuclease Apn1
in catalytic incision of abasic sites in DNA. [2015]
Biochimica et Biophysica Acta - General Subjects
(1850) 6: 1297-1309. Impact factor: 5,083
156. Eberhardt W., De Ruysscher D., Weder W., Le Pechoux
C., De Leyn P., Hoffmann H., Westeel V., Stahel
R., Felip E., and Peters S. 2nd ESMO Consensus
Conference in Lung Cancer: locally advanced stage
III non-small-cell lung cancer. [2015] Annals of
Oncology (26) 8: 1573-1588. Impact factor: 9,269
157. Edmands W.M., Ferrari P., Rothwell J.A., Rinaldi
S., Slimani N., Barupal D.K., Biessy C., Jenab M.,
Clavel-Chapelon F., Fagherazzi G., Boutron-Ruault
M.C., Katzke V.A., Kuehn T., Boeing H., Trichopoulou
A., Lagiou P., Trichopoulos D., Palli D., Grioni S.,
Tumino R., Vineis P., Mattiello A., Romieu I., and
Scalbert A. Polyphenol metabolome in human urine
and its association with intake of polyphenol-rich
foods across European countries. [2015] American
Journal of Clinical Nutrition (102) 4: 905-913.
Impact factor: 6,703
158. Ekelund U., Ward H.A., Norat T., Luan J., May A.M.,
Weiderpass E., Sharp S.J., Overvad K., Ostergaard
J.N., Tjønneland A., Johnsen N.F., Mesrine S.,
Foamier A., Fagherazzi G., Trichopoulou A., Lagiou
P., Trichopoulos D., Li K., Kaaks R., Ferrari P., Licaj
I., Jenab M., Bergmann M., Boeing H., Palli D.,
Sieri S., Panico S., Tumino R., Vineis P., Peeters
P.H., Monnikhof E., Bueno-de-Mesquita H., Ramon
Quiros J., Agudo A., Sanchez M.J., Maria Huerta J.,
Ardanaz E., Arriola L., Hedblad B., Wirfalt E., Sand
47
M., Johansson M., Key T.J., Travis R.C., Khaw K.T.,
Brage S., Wareham N.J., and Riboli E. Physical
activity and all-cause mortality across levels of
overall and abdominal adiposity in European men
and women: the European Prospective Investigation
into Cancer and Nutrition Study (EPIC) . [2015]
American Journal of Clinical Nutrition (101) 3: 613621. Impact factor: 6,703
159. El-Daher M.T., Hangen E., Bruyere J., Poizat G., AlRamahi I., Pardo R., Bourg N., Souquere S., Mayet
C., Pierron G., Leveque-Fort S., Botas J., Humbert
S., and Saudou F. Huntingtin proteolysis releases
non-polyQ fragments that cause toxicity through
dynamin 1 dysregulation. [2015] Embo Journal (34)
17: 2255-2271. Impact factor: 9,643
160. El Kababri M., Cherkaoui S., Hessissen L., Madani A.,
Khattab M., Quessar A., Barsaoui S., Cherif N., Raquin
M., Raphael M., Patte C., and Harif M. Childhood
Burkitt lymphoma in North Africa: a study of the
French-African Pediatric Oncology Group (GFAOP).
[2015] British Journal of Haematology (171) suppl
1: 2-2. Impact factor: 5,401
161. Elias D., Faron M., Iuga B.S., Honore C., Dumont
F., Bourgain J.L., Dartigues P., Ducreux M., and
Goere D. Prognostic Similarities and Differences in
Optimally Resected Liver Metastases and Peritoneal
Metastases From Colorectal Cancers. [2015] Annals
of surgery (261) 1: 157-163 . Impact factor: 8,569
1 62. Engeset D., Braaten T., Teucher B., Kuhn T.,
Bueno-de-Mesquita H., Leenders M., Agudo A.,
Bergmann M.M., Valanou E., Naska A., Trichopoulou
A., Key T.J., Crowe F.L., Overvad K., Sonestedt E.,
Mattiello A., Peeters P.H., Wennberg M., Jansson
J.H., Boutron-Ruault M.C., Dossus L., Dartois L.,
Li K., Barricarte A., Ward H., Riboli E., Agnoli C.,
Maria Huerta J., Sanchez M.J., Tumino R., Altzibar
J.M., Vineis P., Masala G., Ferrari P., Muller D.C.,
Johansson M., Luisa Redondo M., Tjønneland A.,
Olsen A., Olsen K.S., Brustad M., Skeie G., and Lund
E. Fish consumption and mortality in the European
Prospective Investigation into Cancer and Nutrition
cohort. [2015] European Journal of Epidemiology
(30) 1: 57-70. Impact factor: 7,105
163. Erokhin M., Vassetzky Y., Georgiev P., and Chetverina
D. Eukaryotic enhancers: common features,
regulation, and participation in diseases. [2015]
Cellular and Molecular Life Sciences (72) 12: 23612375. Impact factor: 5,694
1 64. Facchinetti F., Kalai K., Lueza B., Lacroix L.,
Pignon J., Valent A., Adam J., Auger N., and Besse
B. Prognostic value of ALK gene copy number in
advanced Non Small Cell Lung Cancer (NSCLC)
patients. [2015] European Journal of Cancer (51)
suppl 3: S646-S647. Impact factor: 6,163
1 65. Fages A., Duarte-Salles T., Stepien M., Ferrari
P., Fedirko V., Pontoizeau C., Trichopoulou A.,
Aleksandrova K., Tjønneland A., Olsen A., ClavelChapelon F., Boutron-Ruault M.C., Severi G.,
Kaaks R., Kuhn T., Floegel A., Boeing H., Lagiou P.,
Bamia C., Trichopoulos D., Palli D., Pala V., Panico
S., Tumino R., Vineis P., Bueno-de-Mesquita H.,
Peeters P.H., Weiderpass E., Agudo A., MolinaMontes E., Maria Huerta J., Ardanaz E., Dorronsoro
M., Sjoberg K., Ohlsson B., Khaw K.T., Wareham N.,
Travis R.C., Schmidt J.A., Cross A., Gunter M., Riboli
E., Scalbert A., Romieu I., Elena-Herrmann B., and
Jenab M. Metabolomic profiles of hepatocellular
carcinoma in a European prospective cohort. [2015]
Bmc Medicine (13): 242. Impact factor: 8,005
166. Fagherazzi G., Gusto G., Clavel-Chapelon F., Balkau
B., and Bonnet F. ABO and Rhesus blood groups and
risk of type 2 diabetes: evidence from the large E3N
cohort study. [2015] Diabetologia (58) 3: 519-522.
Impact factor: 7,206
1 67. Fanidi A., Relton C., Ueland P.M., Midttun O.,
Vollset S.E., Travis R.C., Trichopoulou A., Lagiou P.,
Trichopoulos D., Bueno-de-Mesquita H., Ros M.,
Boeing H., Tumino R., Panico S., Palli D., Sieri S.,
Vineis P., Sanchez M.J., Maria Huerta J., Barricarte
Gurrea A., Lujan-Barroso L., Ramon Quiros J.,
Tjønneland A., Halkjaer J., Boutron-Ruault M.C.,
Clavel-Chapelon F., Cadeau C., Weiderpass E.,
Johansson M., Riboli E., Brennan P., and Johansson
M. A prospective study of one-carbon metabolism
biomarkers and cancer of the head and neck and
esophagus. [2015] International Journal of Cancer
(136) 4: 915-927. Impact factor: 5,531
168. Faron M., Pignon J.P., Malka D., Bourredjem A.,
Douillard J.Y., Adenis A., Elias D., Bouche O., and
Ducreux M. Is primary tumour resection associated
with survival improvement in patients with
colorectal cancer and unresectable synchronous
metastases? A pooled analysis of individual data
from four randomised trials . [2015] European
Journal of Cancer (51) 2: 166-176. Impact factor:
6,163
169. Favier R. and Raslova H. Progress in understanding
the diagnosis and molecular genetics of
macrothrombocytopenias. [2015] British Journal of
Haematology (170) 5: 626-639. Impact factor: 5,401
170. Ferrari A., De Salvo G., Brennan B., van Noesel
M., De Paoli A., Casanova M., Francotte N., Kelsey
48
A., Alaggio R., Oberlin O., Carli M., Ben-Arush M.,
Bergeron C., Merks J., Jenney M., Stevens M.,
Bisogno G., and Orbach D. Synovial sarcoma in
children and adolescents: the European Pediatric
Soft Tissue Sarcoma Study Group prospective trial
(EpSSG NRSTS 2005). [2015] Annals of Oncology
(26) 3: 567-572. Impact factor: 9,269
171.Fizazi K., Greco F., Pavlidis N., Daugaard G., Oien
K., and Pentheroudakis G. Cancers of unknown
primary site: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. [2015] Annals
of Oncology (26) suppl 5: V133-V138. Impact factor:
9,269
1 72. Fizazi K., Jenkins C., and Tannock I.F. Should
docetaxel be standard of care for patients with
metastatic hormone-sensitive prostate cancer? Pro
and contra. [2015] Annals of Oncology (26) 8: 16601667. Impact factor: 9,269
173. Flores C., Tomasic G., Poirier-Colame V., Lanoy
E., Cherif-Rebai K., Robert C., Zitvogel L., and
Eggermont A. Mx1 incomplete loss in primary
ulcerated melanoma: An observation that may
help explain IFN alpha sensitivity of ulcerated
melanoma? [2015] European Journal of Cancer (51)
suppl 3: S685-S685. Impact factor: 6,163
174. Fonseca-Nunes A., Agudo A., Aranda N., Arija V.,
Cross A.J., Molina E., Jose Sanchez M., Bueno-deMesquita H., Siersema P., Weiderpass E., Krogh
V., Mattiello A., Tumino R., Saieva C., Naccarati
A., Ohlsson B., Sjoberg K., Boutron-Ruault M.C.,
Cadeau C., Fagherazzi G., Boeing H., Steffen A.,
Kuehn T., Katzke V., Tjønneland A., Olsen A., Khaw
K.T., Wareham N., Key T., Lu Y., Riboli E., Peeters
P.H., Gavrila D., Dorronsoro M., Ramon Quiros J.,
Barricarte A., Jenab M., Zamora-Ros R., Freisling H.,
Trichopoulou A., Lagiou P., Bamia C., and Jakszyn
P. Body iron status and gastric cancer risk in the
EURGAST study. [2015] International Journal of
Cancer (137) 12: 2904-2914. Impact factor: 5,531
1 75. Fortner R.T., Ose J., Merritt M.A., Schock H.,
Tjønneland A., Hansen L., Overvad K., Dossus
L., Clavel-Chapelon F., Baglietto L., Boeing H.,
Trichopoulou A., Benetou V., Lagiou P., Agnoli C.,
Mattiello A., Masala G., Tumino R., Sacerdote C.,
Bueno-de-Mesquita H., Onland-Moret N., Peeters
P.H., Weiderpass E., Gram I.T., Duell E.J., Larranaga
N., Ardanaz E., Sanchez M.J., Chirlaque M.D.,
Braendstedt J., Idahl A., Lundin E., Khaw K.T.,
Wareham N., Travis R.C., Rinaldi S., Romieu I.,
Gunter M.J., Riboli E., and Kaaks R. Reproductive
and hormone-related risk factors for epithelial
ovarian cancer by histologic pathways, invasiveness
and histologic subtypes: Results from the EPIC
cohort. [2015] International Journal of Cancer (137)
5: 1196-1208. Impact factor: 5,531
176. Fouchardiere Fontaniere C., Paule B., Burtin P.,
Wallet J., Tougeron D., Dourthe L., Etienne P., Mineur
L., Becuwe C., Maes P., Dauba J., Michel P., Wendling
J., Linot B., Hollebecque A., Clisant S., Morere J.,
Andre T., Phelip J., and Adenis A. Survival benefit,
safety, and prognostic factors for outcome with
Regorafenib (RE) in patients (pts) with pretreated
metastatic colorectal cancer (mCRC). Main analyses
of the REBECCA study. [2015] European Journal
of Cancer (51) suppl 3: S360-S360. Impact factor:
6,163
177. Fourquet J., Vilotte F., Sunyach M., LePechoux C.,
Ranchere-Vince D., Bonvalot S., Coindre J., Terrier
P., Meeus P., Kao W., Biau J., Helfre S., Martin E.,
Vogin G., Penel N., Stoeckle E., and Sargos P. Time
interval (TI) between surgery and start of adjuvant
radiotherapy (RT): A retrospective analysis of
1150 cases from the French Sarcoma Group .
[2015] European Journal of Cancer (51) suppl 3:
S688-S689. Impact factor: 6,163
178. Frazer J., Li K.J., Galardy P., Perkins S.L., Auperin
A., Anderson J.R., Pinkerton R., Buxton A., Gross
T.G., Weinstein H., Harrison L., Shiramizu B., Barth
M., Goldman S., Patte C., and Cairo M.S. Excellent
outcomes in children and adolescents with
central nervous system-positive (CNS+) Burkitt
lymphoma/leukemia (BL) or other mature B-NHL
using intrathecal and systemic chemotherapy
without CNS irradiation: results from FAB/LMB96
and ANHL01P1 studies . [2015] British Journal
of Haematology (171) suppl 1: 6-7. Impact factor:
5,401
1 79. Fucikova J., Moserova I., Urbanova L., Bezu L.,
Kepp O., Cremer I., Salek C., Strnad P., Kroemer G.,
Galluzzi L., and Spisek R. Prognostic and predictive
value of DAMPs and DAMP-associated processes in
cancer. [2015] Frontiers in Immunology (6) JUL: 402.
Impact factor: 5,695
180. Gadgeel S., Soria J., Goldman J., Wakelee H., Camidge
D., Yu H., Varga A., Solomon B., Oxnard G., Ou S.,
Papadimitrakopoulou V., Liu S., V, Reckamp K., Spira
A., Piotrowska Z., Despain D., Karlovich C., Yurasov
S., and Sequist L., V Efficacy of rociletinib (co-1686)
in EGFR-mutant non-small cell lung cancer (NSCLC)
patients (pts) assessed with a plasma EGFR test .
[2015] European Journal of Cancer (51) suppl 3:
S628-S628. Impact factor: 6,163
49
181. Galluzzi L., Bravo-San Pedro J., Vitale I., Aaronson S.,
Abrams J., Adam D., Alnemri E., Altucci L., Andrews
D., Annicchiarico-Petruzzelli M., Baehrecke E.,
Bazan N., Bertrand M., Bianchi K., Blagosklonny M.,
V, Blomgren K., Borner C., Bredesen D., Brenner C.,
Campanella M., Candi E., Cecconi F., Chan F., Chandel
N., Cheng E., Chipuk J., Cidlowski J., Ciechanover A.,
Dawson T., Dawson V., De laurenzi V., De Maria R.,
Debatin K.M., Di Daniele N., Dixit V., Dynlacht B., ElDeiry W., Fimia G., Flavell R., Fulda S., Garrido C.,
Gougeon M.L., Green D., Gronemeyer H., Hajnoczky
G., Hardwick J., Hengartner M., Ichijo H., Joseph B.,
Jost P., Kaufmann T., Kepp O., Klionsky D., Knight R.,
Kumar S., Lemasters J., Levine B., Linkermann A.,
Lipton S., Lockshin R., Lopez-Otin C., Lugli E., Madeo
F., Malorni W., Marine J.C., Martin S., Martinou
J.C., Medema J., Meier P., Melino S., Mizushima
N., Moll U., Munoz-Pinedo C., Nunez G., Oberst A.,
Panaretakis T., Penninger J., Peter M., Piacentini
M., Pinton P., Prehn J., Puthalakath H., Rabinovich
G., Ravichandran K., Rizzuto R., Rodrigues C.,
Rubinsztein D., Rudel T., Shi Y., Simon H.U., Stockwell
B., Szabadkai G., Tait S., Tang H., Tavernarakis N.,
Tsujimoto Y., Berghe T., V, Vandenabeele P., Villunger
A., Wagner E., Walczak H., White E., Wood W., Yuan
J., Zakeri Z., Zhivotovsky B., Melino G., and Kroemer
G. Essential versus accessory aspects of cell death:
recommendations of the NCCD 2015. [2015] Cell
Death and Differentiation (22) 1: 58-73. Impact
factor: 8,278
1 82. Galluzzi L., Bravo-San Pedro J., and Kroemer
G. Ferroptosis in p53-dependent oncosuppression
and organismal homeostasis. [2015] Cell Death and
Differentiation (22) 8: 1237-1238. Impact factor:
8,278
183. Galluzzi L. and Kroemer G. Defective autophagy gets
to the brain. [2015] Oncotarget (6) 37: 39396-39397.
Impact factor: 5,008
184. Galluzzi L., Pietrocola F., Bravo-San Pedro J.M.,
Amaravadi R.K., Baehrecke E.H., Cecconi F., Codogno
P., Debnath J., Gewirtz D.A., Karantza V., Kimmelman
A., Kumar S., Levine B., Maiuri M.C., Martin S.J.,
Penninger J., Piacentini M., Rubinsztein D.C., Simon
H.U., Simonsen A., Thorburn A.M., Velasco G., Ryan
K.M., and Kroemer G. Autophagy in malignant
transformation and cancer progression . [2015]
Embo Journal (34) 7: 856-880. Impact factor: 9,643
185. Galluzzi L., Pedro J.M.B.-S., and Kroemer G. Necrosis:
Linking the Inflammasome to Inflammation. [2015]
Cell Reports (11) 10: 1501-1502. Impact factor:
7,870
186. Garg A.D., Galluzzi L., Apetoh L., Baert T., Birge
R.B., Bravo-San Pedro J.M., Breckpot K., Brough D.,
Chaurio R., Cirone M., Coosemans A., Coulie P.G., De
Ruysscher D., Dini L., de Witte P., Dudek-Peric A.M.,
Faggioni A., Fucikova J., Gaipl U.S., Golab J., Gougeon
M.L., Hamblin M.R., Hemminki A., Herrmann M.,
Hodge J.W., Kepp O., Kroemer G., Krysko D.V.,
Land W.G., Madeo F., Manfredi A.A., Mattarollo S.R.,
Maueroder C., Merendino N., Multhoff G., Pabst T.,
Ricci J.E., Riganti C., Romano E., Rufo N., Smyth
M.J., Sonnemann J., Spisek R., Stagg J., Vacchelli
E., Vandenabeele P., Vandenberk L., Van den Eynde
B.J., Van Gool S., Velotti F., Zitvogel L., and Agostinis
P. Molecular and Translational Classifications of
DAMPs in Immunogenic Cell Death. [2015] Frontiers
in Immunology (6): 588. Impact factor: 5,695
1 87. Gattolliat C.H., Uguen A., Pesson M., Trillet K.,
Simon B., Doucet L., Robaszkiewicz M., and Corcos
L. MicroRNA and targeted mRNA expression
profiling analysis in human colorectal adenomas
and adenocarcinomas. [2015] European Journal of
Cancer (51) 3: 409-420. Impact factor: 6,163
188. Gautschi O., Milia J., Cabarrou B., Bluthgen M.V.,
Besse B., Smit E.F., Wolf J., Peters S., Frueh M.,
Koeberle D., Oulkhouir Y., Schuler M., CurioniFontecedro A., Huret B., Kerjouan M., Michels S.,
Pall G., Rothschild S., Schmid-Bindert G., Scheffler
M., Veillon R., Wannesson L., Diebold J., Zalcman
G., Filleron T., and Mazieres J. Targeted Therapy for
Patients with BRAF-Mutant Lung Cancer Results
from the European EURAF Cohort. [2015] Journal
of Thoracic Oncology (10) 10: 1451-1457. Impact
factor: 5,040
1 89. Gelderblom H., Blay J., D’Adamo D., Hudgens
S., Kontoudis I., Le Cesne A., and Schoffski
P. Randomized, open-label, multicenter, phase 3
study of eribulin versus dacarbazine in patients with
leiomyosarcoma and adipocytic sarcoma: Healthrelated quality of life results. [2015] European
Journal of Cancer (51) suppl 3: S702-S702. Impact
factor: 6,163
190. Gilles E., Bosq J., Alleaume C., Zukiwski A., Hutt E.,
and Bonneterre J. Activated form of the estrogen
receptor alpha (ER) in breast cancer (BC) and its
correlation with prognosis. [2015] Cancer Research
(75) 9 suppl: P6-08-19. Impact factor: 8,556
1 91. Gillessen S., Omlin A., Attard G., de Bono J.,
Efstathiou E., Fizazi K., Halabi S., Nelson P.,
Sartor O., Smith M., Soule H., Akaza H., Beer T.,
Beltran H., Chinnaiyan A., Daugaard G., Davis I., De
Santis M., Drake C., Eeles R., Fanti S., Gleave M.,
50
Heidenreich A., Hussain M., James N., Lecouvet F.,
Logothetis C., Mastris K., Nilsson S., Oh W., Olmos
D., Padhani A., Parker C., Rubin M., Schalken J.,
Scher H., I, Sella A., Shore N., Small E., Sternberg
C., Suzuki H., Sweeney C., Tannock I., and Tombal
B. Management of patients with advanced prostate
cancer: recommendations of the St Gallen Advanced
Prostate Cancer Consensus Conference (APCCC)
2015. [2015] Annals of Oncology (26) 8: 1589-1604.
Impact factor: 9,269
192. Girard E., Ditzler S., Lee D., Richards A., Yagle K.,
Park J., Eslamy H., Bobilev D., Vrignaud P., and
Olson J. Efficacy of cabazitaxel in mouse models of
pediatric brain tumors. [2015] Neuro-Oncology (17)
1: 107-115. Impact factor: 7,371
193.Giraudmaillet T., Mokrane F., Zadro C., Rousseau H.,
and Dercle L. Is CMR reproducible enough to replace
Gated Blood Pool SPECT for the follow-up of RVEF?
[2015] European Journal of Nuclear Medicine and
Molecular Imaging (42) suppl 1: S532-S532. Impact
factor: 5,537
194. Girault A., Ferrua M., Lalloue B., Sicotte C., Fourcade
A., Yatim F., Hebert G., Di Palma M., and Minvielle
E. Internet-based technologies to improve cancer
care coordination: Current use and attitudes among
cancer patients. [2015] European Journal of Cancer
(51) 4: 551-557. Impact factor: 6,163
195. Gizzi M., Pautier P., Lhomme C., and Leary A. Novel
membrane-based targets - Therapeutic potential
in gynecological cancers. [2015] Critical Reviews
in Oncology Hematology (93) 3: 293-303. Impact
factor: 5,039
196. Goldszmid R.S., Dzutsev A., Viaud S., Zitvogel L.,
Restifo N.P., and Trinchieri G. Microbiota Modulation
of Myeloid Cells in Cancer Therapy. [2015] Cancer
Immunology Research (3) 2: 103-109. Impact factor:
6,665
197. Gontier H.O., Lesueur L.L., Mir L.M., and Andre
F.M. In Vitro Electrotransfer of Small and Large
Plasmids in Mesenchymal Stem Cells: Calcium,
Temperature and PH Impact . [2015] Molecular
Therapy (23) suppl 1: S145-S145. Impact factor:
6,938
198. Gourgou-Bourgade S., Cameron D., Poortmans P.,
Asselain B., Azria D., Cardoso F., A’Hern R., Bliss
J., Bogaerts J., Bonnefoi H., Brain E., Cardoso M.,
Chibaudel B., Coleman R., Cufer T., Dal Lago L.,
Dalenc F., De Azambuja E., Debled M., Delaloge S.,
Filleron T., Gligorov J., Gutowski M., Jacot W., Kirkove
C., MacGrogan G., Michiels S., Negreiros I., Offersen
B., V, Llorca F., Pruneri G., Roche H., Russell N.,
Schmitt F., Servent V., Thuerlimann B., Untch M., van
der Hage J., van Tienhoven G., Wildiers H., Yarnold
J., Bonnetain F., Mathoulin-Pelissier S., Bellera
C., and Dabakuyo-Yonli T. Guidelines for time-toevent end point definitions in breast cancer trials:
results of the DATECAN initiative (Definition for the
Assessment of Time-to-event Endpoints in CANcer
trials). [2015] Annals of Oncology (26) 5: 873-879.
Impact factor: 9,269
199. Grasso C.S., Tang Y., Truffaux N., Berlow N.E., Liu L.,
Debily M.A., Quist M.J., Davis L., Huang E.C., Woo P.J.,
Ponnuswami A., Chen S., Johung T., Sun W., Kogiso
M., Du Y., Lin Q., Huang Y., Hutt-Cabezas M., Warren
K.E., Le Dret L., Meltzer P.S., Mao H., Quezado M.,
van Vuurden D.G., Abraham J., Fouladi M., Svalina
M.N., Wang N., Hawkins C., Raabe E., Hulleman E.,
Spellman P.T., Li X.N., Keller C., Pal R., Grill J., and
Monje M. Functionally-Defined Therapeutic Targets
in Diffuse Intrinsic Pontine Glioma. [2015] NeuroOncology (17) suppl 3: 3-3. Impact factor: 7,371
200. Grieve K., Palazzo L., Dalimier E., Vielh P., and Fabre
M. A feasibility study of full-field optical coherence
tomography for rapid evaluation of EUS-guided
microbiopsy specimens. [2015] Gastrointestinal
Endoscopy (81) 2: 342-350. Impact factor: 6,217
201. Grill J. Translating preclinical hopes into clinical
reality for children with ependymoma . [2015]
Neuro-Oncology (17) 12: 1545-1546. Impact factor:
7,371
202. Grob J., Amonkar M., Karaszewska B., Schachter J.,
Dummer R., Mackiewicz A., Stroiakovski D., Drucis
K., Grange F., Chiarion-Sileni V., Rutkowski P.,
Lichinitser M., Levchenko E., Wolter P., Hauschild A.,
Long G., V, Sun P., McDowell D., Mookerjee B., and
Robert C. COMBI-v: health-related quality of life
(HRQoL) impact of the combination of dabrafenib
and trametinib (D plus T) vs vemurafenib (V) in
patients with BRAF V600 metastatic melanoma
(MM) . [2015] European Journal of Cancer (51)
suppl 3: S682-S683. Impact factor: 6,163
2 03. Guerin M., Sfumato P., Boher J., Salem N.,
Dermeche S., Thomassin J., Fizazi K., Joly F.,
Oudard S., Habibian M., Culine S., Walz J., and
Gravis G. Clinical outcome of initially metastatic
hormone sensitive prostate cancer (HSPC) in real
life population from a single center: Comparison
with initially metastatic HSPC patients included in
the GETUG-AFU 15 trial. [2015] European Journal
of Cancer (51) suppl 3: S494-S495. Impact factor:
6,163
51
204. Guida A., Matias M., Albigès L., Derosa L., Loriot Y.,
Massard C., Fizazi K., and Escudier B. Efficacy and
safety of axitinib as third line therapy in metastatic
renal cell carcinoma (mRCC): Retrospective
analysis. [2015] European Journal of Cancer (51)
suppl 3: S521-S521. Impact factor: 6,163
205. Guigay J., Fayette J., Dillies A., Sire C., Kerger J.,
Tennevet I., Machiels J., Zanetta S., Pointreau Y.,
Bozec Le Moal L., Henry S., Schilf A., and Bourhis
J. Cetuximab, docetaxel, and cisplatin as first-line
treatment in patients with recurrent or metastatic
head and neck squamous cell carcinoma: a
multicenter, phase II GORTEC study. [2015] Annals
of Oncology (26) 9: 1941-1947. Impact factor: 9,269
206. Guo M., Sherman S., Wirth L., Schlumberger M.,
Dutcus C., Robinson B., Tahara M., and Latimer
N. Overall survival gain with lenvatinib vs. placebo
in radioactive iodine refractory differentiated
thyroid cancer (RR-DTC): An updated analysis.
[2015] European Journal of Cancer (51) suppl 3:
S559-S559. Impact factor: 6,163
207. Gupta S., Argilés G., Munster P.N., Hollebecque A.,
Dajani O., Cheng J.D., Wang R., Swift A., Tosolini
A., and Piha-Paul S.A. A Phase I Trial of Combined
Ridaforolimus and MK-2206 in Patients with
Advanced Malignancies . [2015] Clinical Cancer
Research (21) 23: 5235-5244. Impact factor: 8,738
208. Gurunathan G., Yu Z., Coulombe Y., Masson J.Y.,
and Richard S. Arginine methylation of hnRNPUL1
regulates interaction with NBS1 and recruitment to
sites of DNA damage. [2015] Scientific Reports (5):
10475. Impact factor: 5,228
209. Harbeck N., Cristofanilli M., Ro J., Andre F., Loi S.,
Verma S., Iwata H., Loibl S., Bartlett C., Zhang K.,
Iyer S., Thiele A., Theall K., Koehler M., and Turner
N. A double blind phase 3 trial of fulvestrant with
placebo or palbociclib in pre- and post-menopausal
women with hormone receptor-positive (HR+ve),
HER2-negative (HER2-ve) metastatic breast cancer
(MBC) that progressed on prior endocrine therapy
(PALOMA 3): Detailed analysis of patient-reported
outcomes. [2015] European Journal of Cancer (51)
suppl 3: S270-S271. Impact factor: 6,163
210. Hartl D.M. Reply to letter: «Optimization of staging
of the neck with prophylactic central and lateral
neck dissection for papillary thyroid carcinoma».
[2015] Annals of surgery (261) 1: e30. Impact factor:
8,569
211. Hasmim M., Messai Y., Ziani L., Thiery J., Bouhris
J.H., Noman M.Z., and Chouaib S. Critical role
of tumor microenvironment in shaping NK cell
functions: implication of hypoxic stress . [2015]
Frontiers in Immunology (6): 482. Impact factor:
5,695
212. Haspinger E., Rosellini S., Ammari S., Dercle L.,
Bluthgen M., V, Besse B., Caramella C., Massard
C., Lacroix L., de Baere T., Deschamps F., Michiels
S., Soria J., and Ferte C. Radiomics to identify
HER2 amplification or mutation in metastatic
patients with solid tumors prospectively enrolled in
MOSCATO-01. [2015] European Journal of Cancer
(51) suppl 3: S101-S101. Impact factor: 6,163
213. Hebbar M., Heurgue-Berlot A., Boige V., Le Malicot K.,
Bernard-Chabert B., Marcus C., Dharancy S., Sergent
G., Perarnau J., Ehrhard F., Ollivier-Hourmand I.,
Vergniol J., Michel P., Edeline J., Rinaldi Y., Seitz J.,
Lepage C., and de Baere T. Randomized phase 2/3
trial of transcatheter arterial chemoembolization
(TACE) plus sunitinib or placebo in patients with
hepatocellular carcinoma (HCC) (PRODIGE 16/
SATURNE study): Results of the Phase II part. [2015]
European Journal of Cancer (51) suppl 3: S434-S434.
Impact factor: 6,163
214. Hebert G., Netzer F., Ferrua M., Ducreux M., Lemare
F., and Minvielle E. Evaluating iatrogenic prescribing:
Development of an oncology-focused trigger tool.
[2015] European Journal of Cancer (51) 3: 427-435.
Impact factor: 6,163
215. Helissey C., Poterie A., Massard C., Hollebecque
A., Paoletti X., Lanoy E., Soria J., and Postel-Vinay
S. Impact of the re-definition of dose-limiting toxicities
(DLTs) according to recent recommendations on the
DLT rate in phase 1 trials of molecularly targeted
agents. [2015] European Journal of Cancer (51)
suppl 3: S70-S70. Impact factor: 6,163
216. Hersh E.M., Del Vecchio M., Brown M.P., Kefford
R., Loquai C., Testori A., Bhatia S., Gutzmer R.,
Conry R., Haydon A., Robert C., Ernst S., Homsi J.,
Grob J.J., Kendra K., Agarwala S.S., Li M., Clawson
A., Brachmann C., Karnoub M., Elias I., Renschler
M.F., and Hauschild A. A randomized, controlled
phase III trial of nab -Paclitaxel versus dacarbazine
in chemotherapy-naïve patients with metastatic
melanoma. [2015] Annals of Oncology (26) 11: 22672274. Impact factor: 9,269
217. Hescot S., Seck A., Guerin M., Cockenpot F., Huby T.,
Broutin S., Young J., Paci A., Baudin E., and Lombes
M. Lipoprotein-Free Mitotane Exerts High Cytotoxic
Activity in Adrenocortical Carcinoma. [2015] Journal
of Clinical Endocrinology and Metabolism (100) 8:
2890-2898. Impact factor: 5,531
52
218. Hjorth L., Haupt R., Skinner R., Grabow D., Byrne
J., Karner S., Levitt G., Michel G., Van Der Pal
H., Bardi E., Beck J.D., de V.F., Essig S., Frey E.,
Garwicz S., Hawkins M., Jakab Z., Jankovic M.,
Kazanowska B., Kepak T., Kremer L., Lackner H.,
Sugden E., Terenziani M., Zaletel L.Z., and Kaatsch
P. Survivorship after childhood cancer: PanCare: A
European Network to promote optimal long-term
care. [2015] European Journal of Cancer (51) 10:
1203-1211. Impact factor: 6,163
219. Hollebecque A., Malka D., Ferte C., Ducreux M.,
and Boige V. Systemic treatment of advanced
hepatocellular carcinoma: From disillusions to new
horizons. [2015] European Journal of Cancer (51) 3:
327-339. Impact factor: 6,163
220. Houot R., Schultz L.M., Marabelle A., and Kohrt
H. T-cell-based Immunotherapy: Adoptive Cell
Transfer and Checkpoint Inhibition. [2015] Cancer
Immunology Research (3) 10: 1115-1122. Impact
factor: 6,665
2 21. Hsu C., Lee S., Ejadi S., Even C., Cohen R., Le
Tourneau C., Mehnert J., Algazi A., Van Brummelen
E., Yuan S., Thanigaimani P., Cheng J., and Hansen
A. Antitumor activity and safety of pembrolizumab
in patients with PD-L1-positive nasopharyngeal
carcinoma: Interim results from a phase 1b study.
[2015] European Journal of Cancer (51) suppl 3:
S558-S558. Impact factor: 6,163
222. Hughes D.J., Fedirko V., Jenab M., Schomburg L.,
Meplan C., Freisling H., Bueno-de-Mesquita H.,
Hybsier S., Becker N.P., Czuban M., Tjønneland A.,
Outzen M., Boutron-Ruault M.C., Racine A., Bastide
N., Kuehn T., Kaaks R., Trichopoulos D., Trichopoulou
A., Lagiou P., Panico S., Peeters P.H., Weiderpass E.,
Skeie G., Dagrun E., Chirlaque M.D., Sanchez M.J.,
Ardanaz E., Ljuslinder I., Wennberg M., Bradbury
K.E., Vineis P., Naccarati A., Palli D., Boeing H.,
Overvad K., Dorronsoro M., Jakszyn P., Cross A.J.,
Quiros J.R., Stepien M., Kong S.Y., Duarte-Salles
T., Riboli E., and Hesketh J.E. Selenium status
is associated with colorectal cancer risk in the
European prospective investigation of cancer and
nutrition cohort. [2015] International Journal of
Cancer (136) 5: 1149-1161. Impact factor: 5,531
223. Hurvitz S.A., André F., Jiang Z., Shao Z., Neciosup
S.P., Mano M.S., Tseng L.M., Zhang Q., Shen K.,
Liu D., Dreosti L.M., Feng J., Burris H.A., Toi M.,
Buyse M.E., Cabaribere D., Lindsay M.A., Kunz T.,
Rao S., Pacaud L.B., Taran T., and Slamon D. Phase
3, randomized, double-blind, placebo-controlled
multicenter trial of daily everolimus plus weekly
trastuzumab and paclitaxel as first-line therapy
in women with HER2+ advanced breast cancer:
BOLERO-1. [2015] Cancer Research (75) 9 suppl:
S6-01. Impact factor: 8,556
224. Isakoff S.J., Bendell J.C., Cervantes A., Soria J.C.,
Molife L., Sanabria-Bohorquez S.M., Punnoose
E.A., Jia S., Patel P., and Saura C. Phase Ib doseescalation study of an Akt inhibitor ipatasertib (Ipat)
in combination with docetaxel (Doc) or paclitaxel
(Pac) in patients (pts) with metastatic breast cancer
(MBC). [2015] Cancer Research (75) 9 suppl: P6-1202. Impact factor: 8,556
225. Isambert N., Delord J.P., Soria J.C., Hollebecque A.,
Gomez-Roca C., Purcea D., Rouits E., Belli R., and
Fumoleau P. Debio0932, a second-generation oral
heat shock protein (HSP) inhibitor, in patients with
advanced cancer-results of a first-in-man doseescalation study with a fixed-dose extension phase.
[2015] Annals of Oncology (26) 5: 1005-1011. Impact
factor: 9,269
226. Italiano A., Keilhack H., Toulmonde M., Coindre J.,
Michot J., Massard C., Ottesen L., Reyderman L.,
Blakemore S., Kraljevic S., Thomson B., McDonald
A., Ho P., and Ribrag V. A phase 1 study of EPZ-6438
(E7438), an Enhancer of Zeste-Homolog 2 (EZH2)
inhibitor: Preliminary activity in INI1-negative
tumors. [2015] European Journal of Cancer (51)
suppl 3: S54-S55. Impact factor: 6,163
227. Izzedine H., Derosa L., Le Teuff G., Albigès L., and
Escudier B. Hypertension and angiotensin system
inhibitors: impact on outcome in sunitinib-treated
patients for metastatic renal cell carcinoma. [2015]
Annals of Oncology (26) 6: 1128-1133. Impact factor:
9,269
228. Jacquemin B., Siroux V., Sanchez M., Carsin A.E.,
Schikowski T., Adam M., Bellisario V., Buschka A.,
Bono R., Brunekreef B., Cai Y., Cirach M., ClavelChapelon F., Declercq C., de Marco R., de Nazelle A.,
Ducret-Stich R.E., Ferretti V.V., Gerbase M.W., Hardy
R., Heinrich J., Janson C., Jarvis D., Al Kanaani Z.,
Keidel D., Kuh D., Le Moual N., Nieuwenhuijsen
M.J., Marcon A., Modig L., Pin I., Rochat T., Schindler
C., Sugiri D., Stempfelet M., Temam S., Tsai M.Y.,
Varraso R., Vienneau D., Vierkötter A., Hansell
A.L., Krämer U., Probst-Hensch N.M., Sunyer J.,
Künzli N., and Kauffmann F. Ambient Air Pollution
and Adult Asthma Incidence in Six European
Cohorts (ESCAPE). [2015] Environmental Health
Perspectives (123) 6: 613-621. Impact factor: 8,443
229. Jacquemin G., Margiotta D., Kasahara A., Bassoy
E.Y., Walch M., Thiery J., Lieberman J., and
53
Martinvalet D. Granzyme B-induced mitochondrial
ROS are required for apoptosis. [2015] Cell Death
and Differentiation (22) 5: 862-874. Impact factor:
8,278
230. Jaenne P., Ahn M., Kim D., Kim S., Planchard D.,
Ramalingam S., Frewer P., Cantarini M., Ghiorghiu
S., and Yang J. A Phase I Study of Azd9291 in
Patients with Egfr-Tki-Resistant Advanced Nsclc
- Updated Progression Free Survival and Duration
of Response Data. [2015] Annals of Oncology (26)
suppl 1: LBA3. Impact factor: 9,269
231. Jeurnink S.M., Ros M.M., Leenders M., van Duijnhoven
F.J., Siersema P.D., Jansen E.H., van Gils C.H.,
Bakker M.F., Overvad K., Roswall N., Tjønneland A.,
Boutron-Ruault M.C., Racine A., Cadeau C., Grote V.,
Kaaks R., Aleksandrova K., Boeing H., Trichopoulou
A., Benetou V., Valanou E., Palli D., Krogh V., Vineis
P., Tumino R., Mattiello A., Weiderpass E., Skeie
G., Huerta Castano J.M., Duell E.J., Barricarte A.,
Molina-Montes E., Argueelles M., Dorronsoro M.,
Johansen D., Lindkvist B., Sund M., Crowe F.L., Khaw
K.T., Jenab M., Fedirko V., Riboli E., and Bueno-deMesquita H. Plasma carotenoids, vitamin C, retinol
and tocopherols levels and pancreatic cancer risk
within the European Prospective Investigation into
Cancer and Nutrition: A nested case-control study
Plasma micronutrients and pancreatic cancer risk.
[2015] International Journal of Cancer (136) 6:
E665-E676. Impact factor: 5,531
2 32. Jiang X., Pissaloux D., De La Fouchardiere C.,
Desseigne F., Wang Q., Fondrevelle M., Cassier P.,
Seigne C., Perol D., Ray-coquard I., Le Cesne A.,
Penel N., Tredan O., and Blay J. The sum of gains and
losses of genes encoding for protein tyrosine kinase
targets predicts response to multi-kinase inhibitor
treatment. [2015] European Journal of Cancer (51)
suppl 3: S30. Impact factor: 6,163
2 33. Jiang X., Pissaloux D., De La Fouchardiere C.,
Desseigne F., Wang Q., Attignon V., Fondrevelle M.E.,
de la Fouchardiere A., Perol M., Cassier P., Seigne
C., Perol D., Ray-Coquard I., Meeus P., Fayette J.,
Flechon A., Le Cesne A., Penel N., Tredan O., and Blay
J.Y. The sum of gains and losses of genes encoding
the protein tyrosine kinase targets predicts
response to multi-kinase inhibitor treatment:
Characterization, validation, and prognostic value.
[2015] Oncotarget (6) 28: 26388-26399. Impact
factor: 5,008
234. Jobard E., Blanc E., Negrier S., Escudier B., Gravis
G., Chevreau C., Elena-Herrmann B., and Tredan O. A
serum metabolomic fingerprint of bevacizumab and
temsirolimus combination as first-line treatment
of metastatic renal cell carcinoma. [2015] British
Journal of Cancer (113) 8: 1148-1157. Impact factor:
5,569
235. Joly F., Pautier P., Vergote I., Melichar B., Kutarska
E., Hall G., Lisayankaya A., Reed N., Oaknin A.,
Ostapenko V., Zvirbule Z., Chetaille E., Shoaib M.,
Green A., and Heutte N. Impact of frailty on outcome
of elderly patients treated with hormone therapy
for advanced/recurrent endometrial cancer (EC).
[2015] European Journal of Cancer (51) suppl 3:
S541-S541. Impact factor: 6,163
236. Jordheim L.P., Ribrag V., Ghesquieres H., Pallardy S.,
Delarue R., Tilly H., Haioun C., Jardin F., Demangel
D., Salles G.A., and Dumontet C. Single nucleotide
polymorphisms in ABCB1 and CBR1 can predict
toxicity to R-CHOP type regimens in patients
with diffuse non-Hodgkin lymphoma . [2015]
Haematologica (100) 5: e204-e206. Impact factor:
6,671
237. Jourdain A., Auperin A., Minard-Colin V., Aladjidi N.,
Zsiros J., Coze C., Gandemer V., Bertrand Y., Leverger
G., Bergeron C., Michon J., and Patte C. Outcome of
and prognostic factors for relapse in children and
adolescents with mature B-cell lymphoma and
leukemia treated in three consecutive prospective
«Lymphomes Malins B» protocols . A Societe
Francaise des Cancers de l’Enfant study. [2015]
Haematologica (100) 6: 810-817. Impact factor:
6,671
238. Jovelet C., Seck A., Mir O., Simasotchi C., Broutin S.,
Goffinet F., Bidart J., Paci A., and Gil S. Variation in
transplacental transfer of tyrosine kinase inhibitors
in the human perfused cotyledon model . [2015]
Annals of Oncology (26) 7: 1500-1504. Impact factor:
9,269
2 39. Kapetanakis N.I., Uzan C., Jimenez-Pailhes
A.S., Gouy S., Bentivegna E., Morice P., Caron O.,
Gourzones-Dmitriev C., Le Teuff G., and Busson
P. Plasma miR-200b in ovarian carcinoma patients:
distinct pattern of pre/post-treatment variation
compared to CA-125 and potential for prediction of
progression-free survival. [2015] Oncotarget (6) 34:
36815-36824. Impact factor: 5,008
240. Kasper B., Baumgarten C., Bonvalot S., Haas R.,
Haller F., Hohenberger P., Moreau G., Van der
Graaf W., and Gronchi A. Management of sporadic
desmoid-type fibromatosis: A European consensus
approach based on patients’ and professionals’
expertise - A Sarcoma Patients EuroNet and
European Organisation for Research and Treatment
54
of Cancer/Soft Tissue and Bone Sarcoma Group
initiative. [2015] European Journal of Cancer (51)
2: 127-136. Impact factor: 6,163
241. Kawaguchi T., Tanigawa A., Naganuma T., Ohkawa
Y., Souquere S., Pierron G., and Hirose T. SWI/
SNF chromatin-remodeling complexes function in
noncoding RNA-dependent assembly of nuclear
bodies. [2015] Proceedings of the National Academy
of Sciences of the United States of America (112)
14: 4304-4309. Impact factor: 9,423
242. Kempf E., Lemoine N., Tergemina-Clain G., Turpin A.,
Postel-Vinay S., Lanoy E., Soria J., and Hollebecque
A. Risk factors of screen-failures in phase 1 clinical
trials. [2015] European Journal of Cancer (51) suppl
3: S61-S61. Impact factor: 6,163
243. Kempf E., Planchard D., Le Chevalier T., and Soria
J.C. 10-year long-term survival of a metastatic
EGFR-mutated nonsmall cell lung cancer patient.
[2015] European Respiratory Journal (46) 1: 280282. Impact factor: 8,332
244. Kentish-Barnes N., Chaize M., Seegers V., Legriel
S., Cariou A., Jaber S., Lefrant J.Y., Floccard B.,
Renault A., Vinatier I., Mathonnet A., Reuter D.,
Guisset O., Cohen-Solal Z., Cracco C., Seguin A.,
Durand-Gasselin J., Eon B., Thirion M., Rigaud J.P.,
Philippon-Jouve B., Argaud L., Chouquer R., Adda M.,
Dedrie C., Georges H., Lebas E., Rolin N., Bollaert
P.E., Lecuyer L., Viquesnel G., Leone M., ChalumeauLemoine L., Garrouste M., Schlemmer B., Chevret S.,
Falissard B., and Azoulay E. Complicated grief after
death of a relative in the intensive care unit. [2015]
European Respiratory Journal (45) 5: 1341-1352.
Impact factor: 8,332
245. Kepp O., Semeraro M., Bravo-San Pedro J.M., Bloy N.,
Buque A., Huang X., Zhou H., Senovilla L., Kroemer
G., and Galluzzi L. eIF2 alpha phosphorylation as
a biomarker of immunogenic cell death . [2015]
Seminars in Cancer Biology (33): 86-92. Impact
factor: 9,955
2 46. Khayati F., Pérez-Cano L., Maouche K., Sadoux
A., Boutalbi Z., Podgorniak M.P., Maskos U.,
Setterblad N., Janin A., Calvo F., Lebbé C., Menashi
S., Fernandez-Recio J., and Mourah S. EMMPRIN/
CD147 is a novel coreceptor of VEGFR-2 mediating
its activation by VEGF. [2015] Oncotarget (6): 97669780. Impact factor: 5,008
247. Kim E., Rich J., Karoutas A., Tarlykov P., Cochet
E., Malysheva D., Mamchaoui K., Ogryzko V., and
Pirozhkova I. ZNF555 protein binds to transcriptional
activator site of 4qA allele and ANT1: potential
implication in Facioscapulohumeral dystrophy .
[2015] Nucleic acids research (43) 17: 8227-8242.
Impact factor: 9,202
2 48. Kramar A., Negrier S., Sylvester R., Joniau S.,
Mulders P., Powles T., Bex A., Bonnetain F., Bossi
A., Bracarda S., Bukowski R., Catto J., Choueiri
T.K., Crabb S., Eisen T., El Demery M., Fitzpatrick
J., Flamand V., Goebell P.J., Gravis G., Houede N.,
Jacqmin D., Kaplan R., Malavaud B., Massard C.,
Melichar B., Mourey L., Nathan P., Pasquier D.,
Porta C., Pouessel D., Quinn D., Ravaud A., Rolland
F., Schmidinger M., Tombal B., Tosi D., Vauleon
E., Volpe A., Wolter P., Escudier B., and Filleron
T. Guidelines for the definition of time-to-event end
points in renal cell cancer clinical trials: results
of the DATECAN project(aEuro). [2015] Annals of
Oncology (26) 12: 2392-2398. Impact factor: 9,269
2 49. Kramar A., Paule B., Burtin P., Tougeron D.,
Desseigne F., Dourthe L., Wallet J., Etienne P.,
Mineur L., Becuwe C., Maes P., Dauba J., Michel
P., Hollebecque A., Linot B., Morere J., De La
Fouchardiere C., Phelip J., Andre T., and Adenis
A. Prognostic score (REGOSCORE) for survival after
Regorafenib (RE) treatment for patients (pts) with
pretreated metastatic colorectal cancer (mCRC) .
[2015] European Journal of Cancer (51) suppl 3:
S358-S358. Impact factor: 6,163
250. Kroemer G., Pedro J., and Galluzzi L. Novel function
of cytoplasmic p53 at the interface between
mitochondria and the endoplasmic reticulum .
[2015] Cell Death & Disease (6) 3: e1698. Impact
factor: 5,378
2 51. Kroemer G. and Galluzzi L. Immunotherapy
of hematological cancers: PD-1 blockade for
the treatment of Hodgkin’s lymphoma . [2015]
Oncoimmunology (4) 6: e1008853. Impact factor:
7,644
2 52. Kroemer G. and Galluzzi L. Combinatorial
immunotherapy with checkpoint blockers solves the
problem of metastatic melanoma-An exclamation
sign with a question mark. [2015] Oncoimmunology
(4) 7: e1058037. Impact factor: 7,644
253. Kroemer G., Galluzzi L., Zitvogel L., and Fridman
W.H. Colorectal cancer: the first neoplasia
found to be under immunosurveillance and the
last one to respond to immunotherapy? [2015]
Oncoimmunology (4) 7: e1058597. Impact factor:
7,644
254. Kushwaha R., Jagadish N., Kustagi M., Tomishima
M.J., Mendiratta G., Bansal M., Kim H.R., Sumazin
55
P., Alvarez M.J., Lefebvre C., Villagrasa-Gonzalez P.,
Viale A., Korkola J.E., Houldsworth J., Feldman D.R.,
Bosl G.J., Califano A., and Chaganti R.S. Interrogation
of a context-specific transcription factor network
identifies novel regulators of pluripotency. [2015]
Stem Cells (33) 2: 367-377. Impact factor: 5,902
255. Kvaskoff M., Pandeya N., Green A.C., Perry S., Baxter
C., Davis M.B., Mortimore R., Westacott L., Wood D.,
Triscott J., Williamson R., and Whiteman D.C. Solar
elastosis and cutaneous melanoma: A site-specific
analysis. [2015] International Journal of Cancer
(136) 12: 2900-2911. Impact factor: 5,531
256. Ladoire S., Penault-Llorca F., Senovilla L., Dalban
C., Enot D., Locher C., Prada N., Poirier-Colame
V., Chaba K., Arnould L., Ghiringhelli F., Fumoleau
P., Spielmann M., Delaloge S., Poillot M.L., Arveux
P., Goubar A., André F., Zitvogel L., and Kroemer
G. Combined evaluation of LC3B puncta and HMGB1
expression predicts residual risk of relapse after
adjuvant chemotherapy in breast cancer. [2015]
Autophagy (11) 10: 1878-1890. Impact factor: 9,108
257. Lae M., La Rosa P., Mandel J., Hupe P., Terrier P.,
and Couturier J. Whole-Genome Profiling Helps To
Prognostically Classify Phyllodes Tumors of the
Breast. [2015] Modern Pathology (28) S2: 53A-53A.
Impact factor: 5,485
258. Laplane L., Beke A., Vainchenker W., and Solary
E. Induced Pluripotent Stem Cells As New Model
Systems In Oncology. [2015] Stem Cells (33) 10:
2887-2892. Impact factor: 5,902
259. Laplane L., Beke A., Vainchenker W., and Solary
E. Concise Review: Induced Pluripotent Stem Cells
as New Model Systems in Oncology. [2015] Stem
Cells (33) 10: 2887-2892. Impact factor: 5,902
260. Laurent-Puig P., Pekin D., Normand C., Kotsopoulos
S.K., Nizard P., Perez-Toralla K., Rowell R., Olson J.,
Srinivasan P., Le Corre D., Hor T., El Harrak Z., Li X.,
Link D.R., Bouche O., Emile J.F., Landi B., Boige V.,
Hutchison J., and Taly V. Clinical Relevance of KRASMutated Subclones Detected with Picodroplet
Digital PCR in Advanced Colorectal Cancer Treated
with Anti-EGFR Therapy . [2015] Clinical Cancer
Research (21) 5: 1087-1097 . Impact factor: 8,738
261. Lavoine N., Denizeau P., Colas C., Entz-Werle N.,
Couillault G., Leverger G., Bourdeaut F., Macintyre
E., Patte C., and Brugieres L. Lymphoma associated
with a constitutional mismatch repair deficiency
syndrome: clinical description in a French cohort.
[2015] British Journal of Haematology (171) suppl
1: 32-32. Impact factor: 5,401
262. Lavoine N., Colas C., Muleris M., Bodo S., Duval A.,
Entz-Werle N., Coulet F., Cabaret O., Andreiuolo F.,
Charpy C., Sebille G., Wang Q., Lejeune S., Buisine
M., Leroux D., Couillault G., Leverger G., Fricker
J., Guimbaud R., Mathieu-Dramard M., Jedraszak
G., Cohen-Hagenauer O., Guerrini-Rousseau L.,
Bourdeaut F., Grill J., Caron O., Baert-Dusermont
S., Tinat J., Bougeard G., Frebourg T., and Brugieres
L. Constitutional mismatch repair deficiency
syndrome: clinical description in a French cohort.
[2015] Journal of Medical Genetics (52) 11: 770-778.
Impact factor: 5,650
263. Lavoine N., Le Deley M.C., Woessmann W., Pillon
M., Williams D., Horibe K., Wrobel G., Attarbaschi
A., Bezhuisen A., Uyttebroeck A., Mellgren K., and
Brugieres L. Second and subsequent relapses of
ALCL: EICNHL experience. [2015] British Journal
of Haematology (171) suppl 1: 55-55. Impact factor:
5,401
2 64. Lazar V., Rubin E., Depil S., Pawitan Y., Martini
J.F., Gomez-Navarro J., Yver A., Kan Z., Dry J.R.,
Kehren J., Validire P., Rodon J., Vielh P., Ducreux
M., Galbraith S., Lehnert M., Onn A., Berger R.,
Pierotti M.A., Porgador A., Pramesh C., Ye D.w.,
Carvalho A.L., Batist G., Le Chevalier T., Morice
P., Besse B., Vassal G., Mortlock A., Hansson J.,
Berindan-Neagoe I., Dann R., Haspel J., Irimie
A., Laderman S., Nechushtan H., Al Omari A.S.,
Haywood T., Bresson C., Soo K.C., Osman I., Mata H.,
Lee J.J., Jhaveri K., Meurice G., Palmer G., Lacroix
L., Koscielny S., Eterovic K.A., Blay J.Y., Buller R.,
Eggermont A., Schilsky R.L., Mendelsohn J., Soria
J.C., Rothenberg M., Scoazec J.Y., Hong W.K., and
Kurzrock R. A simplified interventional mapping
system (SIMS) for the selection of combinations of
targeted treatments in non-small cell lung cancer.
[2015] Oncotarget (6) 16: 14139-14152. Impact
factor: 5,008
2 65. Lazarovici J., Dartigues P., Brice P., Oberic L.,
Gaillard I., Hunault-Berger M., Broussais-Guillaumot
F., Gyan E., Bologna S., Nicolas-Virelizier E., Touati
M., Casasnovas O., Delarue R., Orsini-Piocelle
F., Stamatoullas A., Gabarre J., Fornecker L.M.,
Gastinne T., Peyrade F., Roland V., Bachy E., Andre
M., Mounier N., and Ferme C. Nodular lymphocyte
predominant Hodgkin lymphoma: a Lymphoma
Study Association retrospective study . [2015]
Haematologica (100) 12: 1579-1586. Impact factor:
6,671
266. Le Cesne A., Ray-Coquard I., Duffaud F., Chevreau
C., Penel N., Binh B.N., Piperno-Neumann S.,
56
Delcambre C., Rios M., Chaigneau L., Le Maignan
C., Guillemet C., Bertucci F., Bompas E., Linassier
C., Olivier T., Kurtz J.E., Even C., Cousin P., and
Blay J.Y. Trabectedin in patients with advanced soft
tissue sarcoma: A retrospective national analysis
of the French Sarcoma Group . [2015] European
Journal of Cancer (51) 6: 742-750. Impact factor:
6,163
267. Le Gall M., Crepin R., Neiveyans M., Auclair C.,
Fan Y., Zhou Y., Marks J.D., Pelegrin A., and Poul
M.A. Neutralization of KIT oncogenic signaling in
leukemia with antibodies targeting KIT membrane
proximal domain 5 . [2015] Molecular Cancer
Therapeutics (14) 11: 2595-2605. Impact factor:
5,579
268. Leary A., Evans A., Johnston S.R., A’Hern R., Bliss
J.M., Sahoo R., Detre S., Haynes B.P., Hills M.,
Harper-Wynne C., Bundred N., Coombes G., Smith I.,
and Dowsett M. Antiproliferative Effect of Lapatinib
in HER2-Positive and HER2-Negative/HER3High Breast Cancer: Results of the Presurgical
Randomized MAPLE Trial (CRUK E/06/039). [2015]
Clinical Cancer Research (21) 13: 2932-2940. Impact
factor: 8,738
269. Leenders M., Siersema P.D., Overvad K., Tjønneland
A., Olsen A., Boutron-Ruault M.C., Bastide N.,
Fagherazzi G., Katzke V., Kuehn T., Boeing H.,
Aleksandrova K., Trichopoulou A., Lagiou P., Klinaki
E., Masala G., Grioni S., De Magistris M.S., Tumino
R., Ricceri F., Peeters P.H., Lund E., Skeie G.,
Weiderpass E., Ramon Quiros J., Agudo A., Sanchez
M.J., Dorronsoro M., Navarro C., Ardanaz E., Ohlsson
B., Jirstroem K., Van Guelpen B., Wennberg M., Khaw
K.T., Wareham N., Key T.J., Romieu I.,Huybrechts
I., Cross A.J., Murphy N., Riboli E., and Buenode-Mesquita H. Subtypes of fruit and vegetables,
variety in consumption and risk of colon and rectal
cancer in the European Prospective Investigation
into Cancer and Nutrition . [2015] International
Journal of Cancer (137) 11: 2705-2714. Impact
factor: 5,531
2 70. Lepoutre-Lussey C., Caramella C., Bidault F.,
Deandreis D., Berdelou A., Al Ghuzlan A., Hartl
D., Borget I., Gimenez-Roqueplo A., Dumont F.,
Deschamps F., Nascimento C., Lumbroso J.,
Guillaud-Bataille M., Schlumberger M., Baudin E.,
and Leboulleux S. Screening in asymptomatic SDHx
mutation carriers: added value of F-18-FDG PET/
CT at initial diagnosis and 1-year follow-up. [2015]
European Journal of Nuclear Medicine and Molecular
Imaging (42) 6: 868-876. Impact factor: 5,537
271. Li H., Yang B., Huang J., Lin Y., Xiang T., Wan J., Li H.,
Chouaib S., and Ren G. Cyclooxygenase-2 in tumorassociated macrophages promotes breast cancer
cell survival by triggering a positive-feedback loop
between macrophages and cancer cells. [2015]
Oncotarget (6) 30: 29637-29650. Impact factor:
5,008
272. Li J., Drubay D., Michiels S., and Gautheret D. Mining
the coding and non-coding genome for cancer
drivers. [2015] Cancer Letters (369) 2: 307-315.
Impact factor: 5,992
273. Li K., Hüsing A., Fortner R.T., Tjønneland A., Hansen
L., Dossus L., Chang-Claude J., Bergmann M.,
Steffen A., Bamia C., Trichopoulos D., Trichopoulou
A., Palli D., Mattiello A., Agnoli C., Tumino R., OnlandMoret N.C., Peeters P.H., Bueno-de-Mesquita H.B.,
Gram I.T., Weiderpass E., Sanchez-Cantalejo E.,
Chirlaque M.D., Duell E.J., Ardanaz E., Idahl A.,
Lundin E., Khaw K.T., Travis R.C., Merritt M.A.,
Gunter M.J., Riboli E., Ferrari P., Terry K., Cramer
D., and Kaaks R. An epidemiologic risk prediction
model for ovarian cancer in Europe: the EPIC study.
[2015] British Journal of Cancer (112) 7: 1257-1265.
Impact factor: 5,569
274. Libe R., Borget I., Ronchi C., Zaggia B., Kroiss M.,
Kerkhofs T., Bertherat J., Volante M., Quinkler
M., Chabre O., Bala M., Tabarin A., Beuschlein
F., Vezzosi D., Deutschbein T., Borson-chazot F.,
Hermsen I., Stell A., Fottner C., Leboulleux S.,
Hahner S., Mannelli M., Berruti A., Haak H., Terzolo
M., Fassnacht M., and Baudin E. Prognostic factors
in stage III-IV adrenocortical carcinomas (ACC): an
European Network for the Study of Adrenal Tumor
(ENSAT) study. [2015] Annals of Oncology (26) 10:
2119-2125. Impact factor: 9,269
2 75. Lievre A., Merlin J., Laurent-Puig P., Artru P.,
Seronde A., Gicquel C., Sabourin J., and Ducreux
M. Flash RAS study: RAS testing assessment in
patients with metastatic colorectal cancer in 2014.
[2015] European Journal of Cancer (51) suppl 3:
S85-S85. Impact factor: 6,163
276. Loi M., Dunant A., Cascales-Garcia A., SlockerEscarpa A., Deutsch E., Arriagada R., and Rivera
S. Response to chemotherapy predicts outcome
after combined modality therapy for inflammatory
breast cancer. [2015] European Journal of Cancer
(51) suppl 3: S278-S279. Impact factor: 6,163
2 77. Loriot Y., Eymard J.C., Patrikidou A., Ileana E.,
Massard C., Albigès L., Di Palma M., Escudier B.,
and Fizazi K. Prior long response to androgen
deprivation predicts response to next-generation
57
androgen receptor axis targeted drugs in castration
resistant prostate cancer. [2015] European Journal
of Cancer (51) 14: 1946-1952. Impact factor: 6,163
278. Maiuri M. and Kroemer G. Autophagy in stress and
disease. [2015] Cell Death and Differentiation (22)
3: 365-366. Impact factor: 8,278
279. Malcolm T., Villarese P., Fairbairn C., Lamant L.,
Trinquand A., Hook C., Burke G., Brugieres L.,
Hughes K., Payet D., Merkel O., Schiefer A.I., Mian S.,
Wasik M., Turner M., Kenner L., Asnafi V., Macintyre
E., and Turner S.D. NPM-ALK mimics thymic
pre-T cell receptor (TCR) expansion but requires
transient TCR expression for thymic egress and
peripheral anaplastic large cell lymphoma (ALCL)
development. [2015] British Journal of Haematology
(171) suppl 1: 21-21. Impact factor: 5,401
280. Manfredi S., Walter T., Cadiot G., Baudin E., Coriat
R., Ruszniewski P., Lecomte T., Laurenty A., Goichot
B., Rohmer V., Roquin G., Cojocarasu O., Cardotbauters C., Legoux J., Borson-chazot F., Teissier
M., Goudet P., Lepage C., Laine F., and Lombardboas C. Gastric neuroendocrine tumors (NETs):
Data from the national French cohort of the Groupe
d’Etude des Tumeurs Endocrines (GTE), CARGAS
study. [2015] European Journal of Cancer (51) suppl
3: S409-S409. Impact factor: 6,163
281. Marabelle A. and Eggermont A. How should we use
anti-CTLA-4 antibodies? [2015] European Journal
of Cancer (51) 17: 2686-2688. Impact factor: 6,163
282. Mariot V., Roche S., Hourde C., Portilho D., Sacconi S.,
Puppo F., Duguez S., Rameau P., Caruso N., Delezoide
A.L., Desnuelle C., Bessieres B., Collardeau S.,
Feasson L., Maisonobe T., Magdinier F., Helmbacher
F., Butler-Browne G., Mouly V., and Dumonceaux
J. Correlation between low FAT1 expression and
early affected muscle in facioscapulohumeral
muscular dystrophy. [2015] Annals of Neurology
(78) 3: 387-400. Impact factor: 9,638
283. Massard C. Enriching phase I trials with molecular
alterations: Interim analysis of 708 patients enrolled
in the MOSCATO 01. [2015] Annals of Oncology (26)
suppl 2: ii4-ii4. Impact factor: 9,269
284. Massard C. Enriching Phase I Trials with Molecular
Alterations: Interim Analysis of 708 Patients
Enrolled in the Moscato 01 . [2015] Annals of
Oncology (26): O3.7. Impact factor: 9,269
2 85. McKenzie F., Ferrari P., Freisling H., Chajes V.,
Rinaldi S., de Batlle J., Dahm C.C., Overvad K.,
Baglietto L., Dartois L., Dossus L., Lagiou P.,
Trichopoulos D., Trichopoulou A., Krogh V., Panico
S., Tumino R., Rosso S., Bueno-de-Mesquita H.,
May A., Peeters P.H., Weiderpass E., Buckland G.,
Sanchez M.J., Navarro C., Ardanaz E., Andersson
A., Sund M., Ericson U., Wirfalt E., Key T.J., Travis
R.C., Gunter M., Riboli E., Vergnaud A.C., and
Romieu I. Healthy lifestyle and risk of breast cancer
among postmenopausal women in the European
Prospective Investigation into Cancer and Nutrition
cohort study. [2015] International Journal of Cancer
(136) 11: 2640-2648. Impact factor: 5,531
286. Menis J., Girard N., Hasan B., and Besse B. PanEuropean survey on thymic malignancies:
A collaboration of the EORTC Lung Cancer
Group (LCG) with the RYTHMIC network. [2015]
European Journal of Cancer (51) suppl 3
suppl 3: S604-S604. Impact factor: 6,163
287. Merlin J.L., Lion M., Wong J., Bachelot T., André
F., Treilleux I., Loussouarn D., Bonneterre J., Rios
M., Dieras V., Jimenez M., Leroux A., and Campone
M. Alterations of intratumoral signalling in
breast cancer patients receiving pre-operative
trastuzumab alone or combined with everolimus.
[2015] Cancer Research (75) 9 suppl: P3-06-07.
Impact factor: 8,556
288. Merritt M.A., Riboli E., Murphy N., Kadi M., Tjønneland
A., Olsen A., Overvad K., Dossus L., Dartois L.,
Clavel-Chapelon F., Fortner R.T., Katzke V.A., Boeing
H., Trichopoulou A., Lagiou P., Trichopoulos D.,
Palli D., Sieri S., Tumino R., Sacerdote C., Panico
S., Bueno-de-Mesquita H., Peeters P.H., Lund E.,
Nakamura A., Weiderpass E., Quiros J., Agudo A.,
Molina-Montes E., Larranaga N., Dorronsoro M.,
Cirera L., Barricarte A., Olsson A., Butt S., Idahl
A., Lundin E., Wareham N.J., Key T.J., Brennan P.,
Ferrari P., Wark P.A., Norat T., Cross A.J., and Gunter
M.J. Reproductive factors and risk of mortality in
the European Prospective Investigation into Cancer
and Nutrition; a cohort study. [2015] Bmc Medicine
(13): 252. Impact factor: 8,005
289. Messai Y., Noman M.Z., Hasmim M., Escudier B., and
Chouaib S. HIF-2 alpha/ITPR1 axis: A new saboteur
of NK-mediated lysis. [2015] Oncoimmunology (4)
2: e985951. Impact factor: 7,644
290. Messaoudi K., Ashfaq A., Palazzo A., Bluteau O.,
Rameau P., Raslova H., Plo I., Vainchenker W., and
Debili N. Of men and mice: divergence effect of
HDAC6 on proplatelet formation. [2015] Journal of
Thrombosis and Haemostasis (13) suppl 2: 124-125.
Impact factor: 5,565
291. Michels J., Adam J., Goubar A., Obrist F., Damotte
D., Robin A., Alifano M., Vitale I., Olaussen K.A.,
58
Girard P., Cremer I., Castedo M., Soria J.C., and
Kroemer G. Negative prognostic value of high levels
of intracellular poly(ADP-ribose) in non-small cell
lung cancer. [2015] Annals of Oncology (26) 12:
2470-2477. Impact factor: 9,269
292. Michot J., Benajiba L., Baldini C., Faivre L., Danu A.,
Hollebecque A., Massard C., Varga A., Bahleda R.,
Gazzah A., Soria J., and Ribrag V. Outcome of Patients
with Relapsed/Refractory Lymphoma in A Large Cohort
Inside A Phase 1 Clinic Department. [2015] Annals of
Oncology (26) supplt 2: P1.07. Impact factor: 9,269
293. Michot J.M., Canioni D., Driss H., Alric L., Cacoub P.,
Suarez F., Sibon D., Thieblemont C., Dupuis J., Terrier
B., Feray C., Tilly H., Pol S., Leblond V., Settegrana C.,
Rabiega P., Barthe Y., Hendel-Chavez H., Nguyen-Khac
F., Merle-Béral H., Berger F., Molina T., Charlotte F.,
Carrat F., Davi F., Hermine O., and Besson C. Antiviral
therapy is associated with a better survival in patients
with hepatitis C virus and B-cell non-Hodgkin
lymphomas, ANRS HC-13 lympho-C study . [2015]
American Journal of Hematology (90) 3: 197-203.
Impact factor: 5
294. Michot J.M., Mazeron R., Danu A., Lazarovici J., Ghez
D., Antosikova A., Willekens C., Chamseddine A.N.,
Minard V., Dartigues P., Bosq J., Carde P., Koscielny
S., De Botton S., Ferme C., Girinsky T., and Ribrag
V. Concurrent Etoposide, Steroid, High-dose Ara-C
and Platinum chemotherapy with radiation therapy
in localised extranodal natural killer (NK)/T-cell
lymphoma, nasal type. [2015] European Journal of
Cancer (51) 16: 2386-2395. Impact factor: 6,163
295. Mir O., Dumont S., and Armand J. Pharmacokinetic
and pharmacodynamic end points with anti-VEGFR:
the more it hurts, the more it works? [2015] Annals of
Oncology (26) 7: 1277-1278. Impact factor: 9,269
296. Mir O., Poinsignon V., Arnedos M., Delaloge S., and Paci
A. Pharmacokinetic interaction involving fenofibrate
and everolimus. [2015] Annals of Oncology (26) 1: 248249. Impact factor: 9,269
297. Mirghani H., Amen F., Blanchard P., Moreau F., Guigay
J., Hartl D., and St Guily J. Treatment de-escalation in
HPV-positive oropharyngeal carcinoma: Ongoing trials,
critical issues and perspectives. [2015] International
Journal of Cancer (136) 7: 1494-1503. Impact factor:
5,531
298. Mirghani H., Amen F., Tao Y., Deutsch E., and Levy
A. Increased radiosensitivity of HPV-positive head
and neck cancers: Molecular basis and therapeutic
perspectives. [2015] Cancer treatment reviews (41) 10:
844-852. Impact factor: 7,983
299. Mirghani H., Casiraghi O., Amen F., He M., Ma X.J.,
Saulnier P., Lacroix L., Drusch F., Ben Lakdhar A.,
Saint Guily J.L., Badoual C., Scoazec J.Y., and Vielh
P. Diagnosis of HPV-driven head and neck cancer
with a single test in routine clinical practice. [2015]
Modern Pathology (28) 12: 1518-1527. Impact
factor: 5,485
300. Mondet J., Park J.H., Menard A., Marzac C., Carillo
S., Pourcelot E., Girodon F., Cabagnols X., Lode L.,
Socoro N., Chauvet M., Bulabois C.E., Cony-Makhoul
P., Corm S., Cahn J.Y., and Mossuz P. Endogenous
megakaryocytic colonies underline association
between megakaryocytes and calreticulin
mutations in essential thrombocythemia. [2015]
Haematologica (100) 5: e176-e178. Impact factor:
6,671
301. Mondini M., Nizard M., Thi T., Mauge L., Loi M.,
Clemenson C., Dugue D., Maroun P., Louvet E., Adam
J., Badoual C., Helley D., Dransart E., Johannes L.,
Vozenin M.C., Perfettini J.L., Tartour E., and Deutsch
E. Synergy of Radiotherapy and a Cancer Vaccine for
the Treatment of HPV-Associated Head and Neck
Cancer. [2015] Molecular Cancer Therapeutics (14)
6: 1336-1345. Impact factor: 5,579
3 02. Morice P., Bentivegna E., Fruscio R., Satoh T.,
Kajiyama H., Roussin S., Uzan C., Colombo N., and
Gouy S. Long-term follow-up of patients with an
isolated ovarian recurrence after conservative
treatment of epithelial ovarian cancer: Results of
an international multicenter study comprising 545
patients. [2015] European Journal of Cancer (51)
suppl 3: S533-S533. Impact factor: 6,163
3 03. Mughal T.I., Cross N.C., Padron E., Tiu R.V.,
Savona M., Malcovati L., Tibes R., Komrokji R.S.,
Kiladjian J.J., Garcia-Manero G., Orazi A., Mesa
R., Maciejewski J.P., Fenaux P., Itzykson R.,
Mufti G., Solary E., and List A.F. An International
MDS/MPN Working Group’s perspective and
recommendations on molecular pathogenesis,
diagnosis and clinical characterization of
myelodysplastic/myeloproliferative neoplasms .
[2015] Haematologica (100) 9: 1117-1130. Impact
factor: 6,671
304. Nanbakhsh A., Visentin G., Olive D., Janji B., Mussard
E., Dessen P., Meurice G., Zhang Y., Louache F.,
Bourhis J.H., and Chouaib S. miR-181a modulates
acute myeloid leukemia susceptibility to natural
killer cells. [2015] Oncoimmunology (4) 12: e996475.
Impact factor: 7,644
305. Nardacci R., Perfettini J.L., Grieco L., Thieffry D.,
Kroemer G., and Piacentini M. Syncytial apoptosis
59
signaling network induced by the HIV-1 envelope
glycoprotein complex: an overview. [2015] Cell
Death & Disease (6): e1846. Impact factor: 5,378
306. Nayak T., Massard C., Martinez Garcia M., Le Tourneau
C., Boni V., Garralda E., Taus A., Albanell J., Lahr
A., Krieter O., and Hidalgo M. Vanucizumab reduces
vessel permeability, perfusion and cellular density
of tumor lesions in cancer patients as measured by
DCE-MRI and DW-MRI. [2015] European Journal of
Cancer (51) suppl 3: S55-S56. Impact factor: 6,163
307. Neuzillet C., Seitz J., Fartoux L., Malka D., Lledo
G., Tijeras-Raballand A., De Gramont A., Ronot M.,
Bouattour M., Dreyer C., Granier M., Benner S., Amin
A., Bourget P., Hadengue A., Roldan N., Chibaudel B.,
Raymond E., and Faivre S. Sunitinib as second-line
treatment in patients with advanced intrahepatic
cholangiocarcinoma: Final results of the SUN-CK
phase II trial from GERCOR IRC. [2015] European
Journal of Cancer (51) suppl 3: S452-S452. Impact
factor: 6,163
308. Newbold K., Sherman S., Wirth L., Habra M., Rietschel
P., Song J., Schlumberger M., and Gianoukakis
A. The influence of time to objective response on
lenvatinib clinical outcomes in the phase 3 SELECT
trial. [2015] European Journal of Cancer (51) suppl
3: S577-S577. Impact factor: 6,163
309. Ngiow S.F., Young A., Jacquelot N., Yamazaki T., Enot
D., Zitvogel L., and Smyth M.J. A Threshold Level of
Intratumor CD8(+) T-cell PD1 Expression Dictates
Therapeutic Response to Anti-PD1. [2015] Cancer
Research (75) 18: 3800-3811. Impact factor: 8,556
310. Nimptsch K., Aleksandrova K., Boeing H., Janke J.,
Lee Y.A., Jenab M., Kong S.Y., Tsilidis K.K., Weiderpass
E., Bueno-de-Mesquita H., Siersema P.D., Jansen
E.H., Trichopoulou A., Tjønneland A., Olsen A., Wu C.,
Overvad K., Boutron-Ruault M.C., Racine A., Freisling
H., Katzke V., Kaaks R., Lagiou P., Trichopoulos D.,
Severi G., Naccarati A., Mattiello A., Palli D., Grioni
S., Tumino R., Peeters P.H., Ljuslinder I., Nystrom
H., Brandstedt J., Sanchez M.J., Gurrea A.B., Bonet
C.B., Chirlaque M.D., Dorronsoro M., Quiros J.R.,
Travis R.C., Khaw K.T., Wareham N., Riboli E., Gunter
M.J., and Pischon T. Plasma fetuin-A concentration,
genetic variation in the AHSG gene and risk of
colorectal cancer. [2015] International Journal of
Cancer (137) 4: 911-920. Impact factor: 5,531
311. Nimptsch K., Aleksandrova K., Boeing H., Janke J.,
Lee Y.A., Jenab M., Bueno-de-Mesquita H., Jansen
E.H., Tsilidis K.K., Trichopoulou A., Weiderpass E., Wu
C., Overvad K., Tjønneland A., Boutron-Ruault M.C.,
Dossus L., Racine A., Kaaks R., Canzian F., Lagiou
P., Trichopoulos D., Palli D., Agnoli C., Tumino R.,
Vineis P., Panico S., Johansson A., Van Guelpen B.,
Khaw K.T., Wareham N., Peeters P.H., Ramon Quiros
J., Vencesla Garcia A., Molina-Montes E., Dorronsoro
M., Chirlaque M.D., Barricarte Gurrea A., Key T.J.,
Duarte-Salles T., Stepien M., Gunter M.J., Riboli E.,
and Pischon T. Association of CRP genetic variants
with blood concentrations of C-reactive protein and
colorectal cancer risk. [2015] International Journal
of Cancer (136) 5: 1181-1192. Impact factor: 5,531
312. Niso-Santano M., Malik S.A., Pietrocola F., BravoSan Pedro J.M., Marino G., Cianfanelli V., BenYounes A., Troncoso R., Markaki M., Sica V., Izzo V.,
Chaba K., Bauvy C., Dupont N., Kepp O., Rockenfeller
P., Wolinski H., Madeo F., Lavandero S., Codogno P.,
Harper F., Pierron G., Tavernarakis N., Cecconi F.,
Maiuri M.C., Galluzzi L., and Kroemer G. Unsaturated
fatty acids induce non-canonical autophagy. [2015]
Embo Journal (34) 8: 1025-1041. Impact factor:
9,643
3 13. Niso-Santano M., Bravo-San Pedro J.M., Maiuri
M.C., Tavernarakis N., Cecconi F., Madeo F., Codogno
P., Galluzzi L., and Kroemer G. Novel inducers of
BECN1-independent autophagy: cis-unsaturated
fatty acids . [2015] Autophagy (11) 3: 575-577.
Impact factor: 9,108
3 14. Noel N., Dutasta F., Costedoat-Chalumeau N.,
Bienvenu B., Mariette X., Geffray L., Sene D., Chaidi
R.B., Michot J.M., Fain O., Darnige L., Ankri A.,
Cacoub P., Piette J.C., and Saadoun D. Safety and
efficacy of oral direct inhibitors of thrombin and
factor Xa in antiphospholipid syndrome. [2015]
Autoimmunity Reviews (14) 8: 680-685. Impact
factor: 8,490
3 15. Noerenberg D., Frick M., Couronne L., Lenze
D., Baldus C., Bastard C., Okosun J., Fitzgibbon
J., Doerken B., Schmitt C., Zenz T., Hummel M.,
Bernard O., and Damm F. NfkbieMutations Occur
in 15% of Gcb Dlbcl and in Various Other Lymphoid
Malignancies. [2015] Haematologica (100) suppl 1:
549-549. Impact factor: 6,671
3 16. Noman M.Z., Janji B., Hu S., Wu J.C., Martelli
F., Bronte V., and Chouaib S. Tumor-Promoting
Effects of Myeloid-Derived Suppressor Cells Are
Potentiated by Hypoxia-Induced Expression of miR210. [2015] Cancer Research (75) 18: 3771-3787.
Impact factor: 8,556
317. Nunes M., Vrignaud P., Vacher S., Richon S., Lièvre
A., Cacheux W., Weiswald L.B., Massonnet G.,
Chateau-Joubert S., Nicolas A., Dib C., Zhang W.,
Watters J., Bergstrom D., Roman-Roman S., Bièche
60
I., and Dangles-Marie V. Evaluating patient-derived
colorectal cancer xenografts as preclinical models
by comparison with patient clinical data . [2015]
Cancer Research (75) 8: 1560-1566. Impact factor:
8,556
3 18. Obba S., Hizir Z., Boyer L., Selimoglu-Buet D.,
Pfeifer A., Michel G., Hamouda M.A., Gonçalvés
D., Cerezo M., Marchetti S., Rocchi S., Droin N.,
Cluzeau T., Robert G., Luciano F., Robaye B., Foretz
M., Viollet B., Legros L., Solary E., Auberger P., and
Jacquel A. The PRKAA1/AMPKa1 pathway triggers
autophagy during CSF1-induced human monocyte
differentiation and is a potential target in CMML .
[2015] Autophagy (11) 7: 1114-1129. Impact factor:
9,108
319. Oberthuer A., Juraeva D., Hero B., Volland R., Sterz
C., Schmidt R., Faldum A., Kahlert Y., Engesser A.,
Asgharzadeh S., Seeger R., Ohira M., Nakagawara
A., Scaruffi P., Tonini G.P., Janoueix-Lerosey I.,
Delattre O., Schleiermacher G., Vandesompele J.,
Speleman F., Noguera R., Piqueras M., Benard J.,
Valent A., Avigad S., Yaniv I., Grundy R.G., Ortmann
M., Shao C., Schwab M., Eils R., Simon T., Theissen
J., Berthold F., Westermann F., Brors B., and
Fischer M. Revised Risk Estimation and Treatment
Stratification of Low- and Intermediate-Risk
Neuroblastoma Patients by Integrating Clinical
and Molecular Prognostic Markers. [2015] Clinical
Cancer Research (21) 8: 1904-1915. Impact factor:
8,738
320. Ophuis C., Verhoef C., Rutkowski P., Voit C., Cook M.,
Van Leeuwen P., Testori A., Hoekstra H., Gruenhagen
D., Eggermont A., and Van Akkooi A. The interval
between primary melanoma excision and sentinel
node biopsy (SNB) does not affect survival;
regardless of SNB status - an EORTC Melanoma
Group study. [2015] European Journal of Cancer
(51) suppl 3: S711-S711. Impact factor: 6,163
321. Ose J., Fortner R., Schock H., Peeters P., OnlandMoret N., Bueno-de-Mesquita H., Weiderpass E.,
Gram I., Overvad K., Tjønneland A., Dossus L.,
Fournier A., Baglietto L., Trichopoulou A., Benetou
V., Trichopoulos D., Boeing H., Masala G., Krogh
V., Matiello A., Tumino R., Popovic M., ObonSantacana M., Larranaga N., Ardanaz E., Sanchez
M.J., Menendez V., Chirlaque M.D., Travis R., Khaw
K.T., Braendstedt J., Idahl A., Lundin E., Rinaldi S.,
Kuhn E., Romieu I., Gunter M., Merritt M., Riboli E.,
and Kaaks R. Insulin-like growth factor I and risk
of epithelial invasive ovarian cancer by tumour
characteristics: results from the EPIC cohort .
[2015] British Journal of Cancer (112) 1: 162-166.
Impact factor: 5,569
322. Ose J., Fortner R.T., Rinaldi S., Schock H., Overvad
K., Tjønneland A., Hansen L., Dossus L., Fournier
A., Baglietto L., Romieu I., Kuhn E., Boeing H.,
Trichopoulou A., Lagiou P., Trichopoulos D., Palli
D., Masala G., Sieri S., Tumino R., Sacerdote C.,
Mattiello A., Ramon Quiros J., Obon-Santacana
M., Larranaga N., Chirlaque M.D., Sanchez M.J.,
Barricarte A., Peeters P.H., Bueno-de-Mesquita H.,
Onland-Moret N., Braendstedt J., Lundin E., Idahl A.,
Weiderpass E., Gram I.T., Lund E., Kaw K.T., Travis
R.C., Merritt M.A., Gunther M.J., Riboli E., and Kaaks
R. Endogenous androgens and risk of epithelial
invasive ovarian cancer by tumor characteristics
in the European Prospective Investigation into
Cancer and Nutrition. [2015] International Journal
of Cancer (136) 2: 399-410. Impact factor: 5,531
323. Ou D., Levy A., Blanchard P., Leijenaar R., Robert
C., Nguyen F., Lambin P., Deutsch E., and Tao
Y. Radiomics feature quantification in patients with
locally advanced head and neck carcinomas treated
with chemoradiotherapy. [2015] European Journal
of Cancer (51) suppl 3: S582-S582. Impact factor:
6,163
3 24. Oudard S., Benhamouda N., Escudier B., Ravel
P., Kothari D., Mehmud F., Levionnois E., Sevin E.,
Negrier S., Barthelemy P., Berdah J., Ravaud A.,
Sternberg C., Bono P., Porta C., De Giorgi U., Parikh
O., Hawkins R., Highley M., Tartour E., Decker T., and
Wilkie J. Decrease of pro-angiogenic monocytes
predicts clinical response to anti-angiogenic
treatment in patients with metastatic renal cell
carcinoma (mRCC) . [2015] European Journal of
Cancer (51) suppl 3: S89-S90. Impact factor: 6,163
325. Oza A., Selle F., Davidenko I., Korach J., Mendiola
C., Gocze P., Pautier P., Chmielowska E., Bamias A.,
DeCensi A., Zvirbule Z., Gonzalez-Martin A., Hegg R.,
Joly F., Zamagni C., Gadducci A., Deurloo R., Revil C.,
Robb S., and Colombo N. Safety and efficacy in ROSiA,
a single-arm study of extended duration front-line (FL)
bevacizumab (BEV)-containing therapy in 1021 women
with ovarian cancer (OC). [2015] European Journal of
Cancer (51) suppl 3: S532-S532. Impact factor: 6,163
326. Pailler E., Auger N., Lindsay C., Vielh P., Islas-MorrisHernandez A., Borget I., Ngo-Camus M., Planchard
D., Soria J., Besse B., and Farace F. High level of
chromosomal instability in circulating tumor cells of
ROS1-rearranged non- small- cell lung cancer. [2015]
Annals of Oncology (26) 7: 1408-1415. Impact factor:
9,269
61
327. Pam A., Vernerey D., Baron B., Chauffert B., Louvet
C., Wagener J., Levi F., Hans S., Trouilloud I., Jan J.,
Van Laethem J., Taieb J., Haustermans K., Dahan L.,
Dureux M., Lutz M., Bellera C., Gourgou S., Anota A.,
and Bonnetain F. Impact of the definition of time to
event endpoint on randomized clinical trials results
in oncology (datecan-2): an analysis of 9 pancreatic
cancer trials. [2015] European Journal of Cancer
(51) suppl 3: S462-S462. Impact factor: 6,163
3 28. Paoletti X., Ezzalfani M., and Le Tourneau
C. Statistical controversies in clinical research:
requiem for the 3+3 design for phase I trials. [2015]
Annals of Oncology (26) 9: 1808-1812. Impact factor:
9,269
329. Patrier-Sallebert S., Bougeard G., Baert-Desurmont
S., Lamy A., Flaman J.M., Mansuy L., Bronner M.,
Lasset C., Brugieres L., Golfier F., and Frebourg
T. Transmission of germline TP53 mutations from
male carriers to female partners. [2015] Journal
of Medical Genetics (52) 3: 145-146. Impact factor:
5,650
330. Patte C. Diagnosis and treatment of mature B-cell
lymphoma in children: challenging cases. [2015]
British Journal of Haematology (171) suppl 1: 1717. Impact factor: 5,401
331. Pautier P., Selle F., Devouassoux-Shisheboran M.,
Treilleux I., Floquet A., Croce S., Ferron G., MeryLamarche E., Pomel C., Penault-Llorca F., Leblanc
E., Lefeuvre-Plesse C., Henno S., Joly F., Nadeau C.,
Dubois-Gordeeff A., Chiannilkulchai N., Genestie C.,
Vacher-Lavenu M., and Ray-coquard I. The French
National Network dedicated to Ovarian Malignant
Rare Tumors (TMRO): How this organization
changed management over the time for rare
cancers. [2015] European Journal of Cancer (51)
suppl 3: S533-S533. Impact factor: 6,163
332. Peeters M., Oliner K.S., Price T.J., Cervantes A.,
Sobrero A.F., Ducreux M., Hotko Y., Andre T., Chan
E., Lordick F., Punt C.J., Strickland A.H., Wilson
G., Ciuleanu T.E., Roman L., Van C.E., He P., Yu H.,
Koukakis R., Terwey J.H., Jung A.S., Sidhu R., and
Patterson S.D. Analysis of KRAS/NRAS Mutations
in a Phase III Study of Panitumumab with FOLFIRI
Compared with FOLFIRI Alone as Second-line
Treatment for Metastatic Colorectal Cancer. [1512-2015] Clinical Cancer Research (21) 24: 54695479. Impact factor: 8,738
3 33. Penel N., Coindre J., Le Cesne A., Italiano A.,
Neuville A., Bonvalot S., Terrier P., Ray-coquard I.,
Ranchere-Vince D., Robin Y., Isambert N., Chevreau
C., Duffaud F., Bertucci F., Rios M., Toulmonde M.,
Le Pechoux C., Guillement C., Courreges J., and
Blay J. Management of Desmoid Tumours (DT):
A nationwide survey after labeling of 2 expert
networks (RRePS and NetSarc). [2015] European
Journal of Cancer (51) suppl 3: S688-S688. Impact
factor: 6,163
3 34. Peterlin P., Renneville A., Ben Abdelali R.,
Nibourel O., Thomas X., Pautas C., De Botton S.,
Raffoux E., Cayuela J.M., Boissel N., Terre C.,
Celli-Lebras K., Castaigne S., Preudhomme C.,
Gardin C., and Dombret H. Impact of additional
genetic alterations on the outcome of patients
with NPM1-mutated cytogenetically normal acute
myeloid leukemia. [2015] Haematologica (100) 5:
e196-e199. Impact factor: 6,671
335. Petrylak D., Eigl B., Senkus E., Loriot Y., Twardowski
P., Castellano D., Blais N., Sridhar S., Sternberg
C., Retz M., Blumenstein B., Jacobs C., Stewart
P., and Bellmunt J. Baseline circulating tumor
cells (CTC) and serum heat shock protein 27
(Hsp27) levels are increased in advanced bladder
cancer (BC) patients with poor prognostic factors:
Results from the randomized phase 2 Borealis-1
(TM) trial of first-line gemcitabine/cisplatin plus
apatorsen or placebo. [2015] European Journal
of Cancer (51) suppl 3: S525-S525. Impact factor:
6,163
336. Peyvandi S., Buart S., Samah B., Vetizou M., Zhang
Y., Durrieu L., Polrot M., Chouaib S., Benihoud K.,
Louache F., and Karray S. Fas Ligand Deficiency
Impairs Tumor Immunity by Promoting an
Accumulation of Monocytic Myeloid-Derived
Suppressor Cells. [2015] Cancer Research (75)
20: 4292-4301. Impact factor: 8,556
337. Piessen G., Lefevre J.H., Cabau M., Duhamel A.,
Behal H., Perniceni T., Mabrut J.Y., Regimbeau
J.M., Bonvalot S., Tiberio G.A.M., Mathonnet M.,
Regenet N., Guillaud A., Glehen O., Mariani P.,
Denost Q., Maggiori L., Benhaim L., Manceau G.,
Mutter D., Bail J.P., Meunier B., Porcheron J.,
Mariette C., and Brigand C. Laparoscopic Versus
Open Surgery for Gastric Gastrointestinal Stromal
Tumors: What Is the Impact on Postoperative
Outcome and Oncologic Results? [2015] Annals
of surgery (262) 5: 831-840. Impact factor: 8,569
338. Pietrocola F., Lachkar S., Enot D., Niso-Santano M.,
Bravo-San Pedro J., Sica V., Izzo V., Maiuri M., Madeo
F., Marino G., and Kroemer G. Spermidine induces
autophagy by inhibiting the acetyltransferase
EP300. [2015] Cell Death and Differentiation (22)
3: 509-516. Impact factor: 8,278
62
339. Piha-Paul S., Munster P., Hollebecque A., Argiles G.,
Dajani O., Cheng J., Wang R., Swift A., Tosolini A.,
and Gupta S. Results of a phase 1 trial combining
ridaforolimus and MK-0752 in patients with
advanced solid tumours. [2015] European Journal
of Cancer (51) 14: 1865-1873. Impact factor: 6,163
3 40. Planchard D. AZD9291 a novel EGFR-TKI that
overcomes T790M-mediated resistance in NSCLC.
[2015] Annals of Oncology (26) suppl 2: ii14-ii14.
Impact factor: 9,269
341. Planchard D., Loriot Y., Andre F., Gobert A., Auger
N., Lacroix L., and Soria J. EGFR-independent
mechanisms of acquired resistance to AZD9291
in EGFR T790M-positive NSCLC patients. [2015]
Annals of Oncology (26) 10: 2073-2078. Impact
factor: 9,269
342. Planchard D., Faivre L., Sullivan I., Kahn-charpy
V., Lacroix L., Auger N., Adam J., De Montpreville
V., Dorfmuller P., Le Pechoux C., Le Chevalier T.,
Gazzah A., Remon J., Bescher G., Soria J., Pignon
J., and Besse B. Molecular Tumor Board (MTB) in
non-small cell lung cancers (NSCLC) to optimize
targeted therapies: 4 years’ experience at Gustave
Roussy. [2015] European Journal of Cancer (51)
suppl 3: S624-S624. Impact factor: 6,163
343. Planchard D. and Besse B. Lung cancer in neversmokers. [2015] European Respiratory Journal (45)
5: 1214-1217. Impact factor: 8,332
344. Poggi M., Baccini V., Favier M., Canault M., Mezzapesa
A., Ghalloussi D., Chelghoum N., Mohand-Oumoussa
B., Falaise C., Peiretti F., Morange P., Saut N.,
Ghysdael J., Nurden A., Guidez F., Bernot D.,
Nurden P., Raslova H., Tregouet D.A., and Alessi
M.C. Mutation in Ets Variant Gene 6 associates with
autosomal dominant thrombocytopenia and raised
levels of circulating CD34(+) cells. [2015] Journal
of Thrombosis and Haemostasis (13) suppl 2: 5-5.
Impact factor: 5,565
345. Pol J., Vacchelli E., Aranda F., Castoldi F., Eggermont
A., Cremer I., Sautes-Fridman C., Fucikova J., Galon
J., Spisek R., Tartour E., Zitvogel L., Kroemer G., and
Galluzzi L. Trial Watch: Immunogenic cell death
inducers for anticancer chemotherapy . [2015]
Oncoimmunology (4) 4: e1008866. Impact factor:
7,644
346. Pol J., Bloy N., Buque A., Eggermont A., Cremer I.,
Sautes-Fridman C., Galon J., Tartour E., Zitvogel L.,
Kroemer G., and Galluzzi L. Trial Watch: Peptidebased anticancer vaccines. [2015] Oncoimmunology
(4) 4: e974411. Impact factor: 7,644
3 47. Postel-Vinay S. and Soria J. Phase I trials in
oncology: a new era has started. [2015] Annals of
Oncology (26) 1: 7-9. Impact factor: 9,269
348. Pujals A., Favre L., Pioche-Durieu C., Robert A.,
Meurice G., Le Gentil M., Chelouah S., Martin-Garcia
N., Le Cam E., Guettier C., Raphaël M., Vassilev
L.T., Gaulard P., Codogno P., Lipinski M., and Wiels
J. Constitutive autophagy contributes to resistance
to TP53-mediated apoptosis in Epstein-Barr viruspositive latency III B-cell lymphoproliferations .
[2015] Autophagy (11) 12: 2275-2287. Impact factor:
9,108
349. Quinquenel A., Willekens C., Dupuis J., Royer B.,
Ysebaert L., De Guibert S., Michallet A.S., Feugier
P., Guieze R., Levy V., and Delmer A. Bendamustine
and rituximab combination in the management
of chronic lymphocytic leukemia-associated
autoimmune hemolytic anemia: a multicentric
retrospective study of the French CLL intergroup
(GCFLLC/MW and GOELAMS) . [2015] American
Journal of Hematology (90) 3: 204-207. Impact
factor: 5
3 50. Racine A., Carbonnel F., Chan S., Hart A., de
Mesquita B., Oldenburg B., VanSchaik F., Tjønneland
A., Olsen A., Dahm C., Key T., Luben R., Kaw K.,
Riboli E., Grip O., Lindgren S., HAllmans G., Karling
P., Clavel-Chapelon F., Bergman M., Boeing H.,
Buijsse B., Kaaks R., Katzke V., Palli D., Masala G.,
Jantchou P., and Ruault M. Dietary patterns and risk
of Inflammatory Bowel Disease in Europe: Results
from the EPIC study. [2015] Journal of Crohns &
Colitis (9) suppl 1: S26-S26. Impact factor: 6,585
351. Ragot T., Azan A., and Mir L.M. Metallic Particles
Generated During Electric Pulses Enhance
Adenovirus-Mediated Gene Transfer . [2015]
Molecular Therapy (23) suppl 1: S143-S143. Impact
factor: 6,938
352. Rambow F., Job B., Petit V., Gesbert F., Delmas
V., Meurice G., Dessen P., Cornell R., Sarasin A.,
and Larue L. Tumor cell lineage-specific analysis
reveals new signatures for understanding
melanoma biology. [2015] Journal of Investigative
Dermatology (135) suppl 2: S21-S21. Impact factor:
6,915
353. Rambow F., Job B., Petit V., Gesbert F., Delmas
V., Seberg H., Meurice G., Van Otterloo E., Dessen
P., Robert C., Gautheret D., Cornell R.A., Sarasin
A., and Larue L. New Functional Signatures for
Understanding Melanoma Biology from Tumor Cell
Lineage-Specific Analysis. [2015] Cell Reports (13)
4: 840-853. Impact factor: 7,870
63
3 54. Raut C., Miceli R., Strauss D., Swallow C.,
Hohenberger P., Van Coevorden F., Rutkowski P.,
Fiore M., Callegaro D., Casali P., Haas R., Hayes
A., Honore C., Cannell A., Jakob J., Szacht M.,
Fairweather M., Pollock R., Bonvalot S., and Gronchi
A. External validation of a nomogram predicting
disease-free (DFS) and overall survival (OS) in
patients (pts) with primary retroperitoneal sarcoma
(pRPS). [2015] European Journal of Cancer (51)
suppl 3: S689-S690. Impact factor: 6,163
355. Ravaud A., Oudard S., De Fromont M., Chevreau
C., Gravis G., Zanetta S., Theodore C., Jimenez M.,
Sevin E., Laguerre B., Rolland F., Ouali M., Culine
S., and Escudier B. First-line treatment with
sunitinib for type 1 and type 2 locally advanced or
metastatic papillary renal cell carcinoma: a phase
II study (SUPAP) by the French Genitourinary Group
(GETUG). [2015] Annals of Oncology (26) 6: 11231128. Impact factor: 9,269
3 56. Remon J., Gorham J., Besse B., and Sculier
J.P. Circulating free DNA, new dynamic marker
in nonsmall cell lung cancer patients? [2015]
European Respiratory Journal (46): 1548-1550 .
Impact factor: 8,332
3 57. Remon J., Gazzah A., Besse B., and Soria
J.C. Crizotinib Improves Osteoarthritis Symptoms
in a ROS1-Fusion Advanced Non-Small Cell Lung
Cancer Patient. [2015] Journal of Thoracic Oncology
(10) 8: e72-e73. Impact factor: 5,040
358. Ribas A., Wolchok J., Robert C., Kefford R., Hamid O.,
Daud A., Hwu W.J., Weber J., Joshua A., Gangadhar
T., Patnaik A., Hersey P., Dronca R., Zarour H.,
Gergich K., Lindia J., Giannotti M., Li X., Ebbinghaus
S., Kang S., and Hodi F. Updated Clinical Efficacy of
the Anti-Pd-1 Monoclonal Antibody Pembrolizumab
(Mk-3475) in 411 Patients with Melanoma. [2015]
European Journal of Cancer (51): E24-E24. Impact
factor: 6,163
359. Ricceri F., Fasanelli F., Giraudo M.T., Sieri S., Tumino
R., Mattiello A., Vagliano L., Masala G., Ramon Quiros
J., Travier N., Sanchez M.J., Larranaga N., Chirlaque
M.D., Ardanaz E., Tjønneland A., Olsen A., Overvad
K., Chang-Claude J., Kaaks R., Boeing H., ClavelChapelon F., Kvaskoff M., Dossus L., Trichopoulou
A., Benetou V., Adarakis G., Bueno-de-Mesquita H.,
Peeters P.H., Sund M., Andersson A., Borgquist S.,
Butt S., Weiderpass E., Skeie G., Khaw K.T., Travis
R.C., Rinaldi S., Romieu I., Gunter M., Kadi M., Riboli
E., Vineis P., and Sacerdote C. Risk of second primary
malignancies in women with breast cancer: Results
from the European prospective investigation into
cancer and nutrition (EPIC). [2015] International
Journal of Cancer (137) 4: 940-948. Impact factor:
5,531
360. Rivoirard R., Langrand-Escure J., Vallard A., Mery
B., Guy J., Espenel S., Trone J., Ben Mrad M., Diao
P., Guillot A., Escudier B., Negrier S., Chargari C.,
and Magne N. Safety assessment of radiotherapy
associated to targeted therapies in metastatic
renal-cell carcinoma . [2015] European Journal
of Cancer (51) suppl 3: S117-S117. Impact factor:
6,163
3 61. Robb W.B., Dahan L., Mornex F., Maillard E.,
Thomas P.A., Meunier B., Boige V., Pezet D., Le
Brun-Ly V., Bosset J.F., Mabrut J.Y., Triboulet J.P.,
Bedenne L., Seitz J.F., and Mariette C. Impact of
Neoadjuvant Chemoradiation on Lymph Node
Status in Esophageal Cancer Post hoc Analysis of
a Randomized Controlled Trial. [2015] Annals of
surgery (261) 5: 902-908 . Impact factor: 8,569
362. Robert C., Karaszewska B., Schachter J., Rutkowski
P., Mackiewicz A., Stroyakovskiy D., Lichinitser
M., Dummer R., Grange F., Mortier L., ChiarionSileni V., Drucis K., Krajsova I., Hauschild A.,
Mookerjee B., Legos J., and Schadendorf D. Two
year estimate of overall survival in COMBI-v, a
randomized, open-label, phase III study comparing
the combination of dabrafenib (D) and trametinib
(T) with vemurafenib (Vem) as first-line therapy in
patients (pts) with unresectable or metastatic BRAF
V600E/K mutation-positive cutaneous melanoma.
[2015] European Journal of Cancer (51) suppl 3:
S663-S664. Impact factor: 6,163
3 63. Rockenfeller P., Koska M., Pietrocola F.,
Minois N., Knittelfelder O., Sica V., Franz J.,
Carmona-Gutierrez D., Kroemer G., and Madeo
F. Phosphatidylethanolamine positively regulates
autophagy and longevity. [2015] Cell Death and
Differentiation (22) 3: 499-508. Impact factor: 8,278
364. Rodon J., Soria J., Berger R., Batist G., Tsimberidou
A., Bresson C., Lee J., Rubin E., Onn A., Schilsky
R.L., Miller W.H., Eggermont A.M., Mendelsohn J.,
Lazar V., and Kurzrock R. Challenges in initiating
and conducting personalized cancer therapy
trials: perspectives from WINTHER, a Worldwide
Innovative Network (WIN) Consortium trial. [2015]
Annals of Oncology (26) 8: 1791-1798. Impact factor:
9,269
365. Rohrmann S., Linseisen J., Overvad K., Wurtz A.M.L.,
Roswall N., Tjønneland A., Boutron-Ruault M.C.,
Racine A., Bastide N., Palli D., Agnoli C., Panico S.,
Tumino R., Sacerdote C., Weikert S., Steffen A., Kuehn
64
T., Li K., Khaw K.T., Wareham N.J., Bradbury K.E.,
Peppa E., Trichopoulou A., Trichopoulos D., Buenode-Mesquita H., Peeters P.H., Hjartaker A., Skeie G.,
Weiderpass E., Jakszyn P., Dorronsoro M., Barricarte
A., Santiuste de Pablos C., Molina-Montes E., Alonso
de la Torre R., Ericson U., Sonestedt E., Johansson
M., Ljungberg B., Freisling H., Romieu I., Cross A.J.,
Vergnaud A.C., Riboli E., and Boeing H. Meat and fish
consumption and the risk of renal cell carcinoma
in the European prospective investigation into
cancer and nutrition. [2015] International Journal
of Cancer (136) 5: E423-E431. Impact factor: 5,531
366. Romaguera D., Ward H., Wark P.A., Vergnaud A.C.,
Peeters P.H., van Gils C.H., Ferrari P., Fedirko V.,
Jenab M., Boutron-Ruault M.C., Dossus L., Dartois
L., Hansen C.P., Dahm C.C., Buckland G., Sanchez
M.J., Dorronsoro M., Navarro C., Barricarte A., Key
T.J., Trichopoulou A., Tsironis C., Lagiou P., Masala
G., Pala V., Tumino R., Vineis P., Panico S., Bueno-deMesquita H., Siersema P.D., Ohlsson B., Jirstrom K.,
Wennberg M., Nilsson L.M., Weiderpass E., Kuehn
T., Katzke V., Khaw K.T., Wareham N.J., Tjønneland
A., Boeing H., Quiros J.R., Gunter M.J., Riboli E.,
and Norat T. Pre-diagnostic concordance with the
WCRF/AICR guidelines and survival in European
colorectal cancer patients: a cohort study. [2015]
Bmc Medicine (13): 107. Impact factor: 8,005
367. Romieu I., Scoccianti C., Chajes V., de Batlle J.,
Biessy C., Dossus L., Baglietto L., Clavel-Chapelon
F., Overvad K., Olsen A., Tjønneland A., Kaaks R.,
Lukanova A., Boeing H., Trichopoulou A., Lagiou
P., Trichopoulos D., Palli D., Sieri S., Tumino R.,
Vineis P., Panico S., Bueno-de-Mesquita H., van Gils
C.H., Peeters P.H., Lund E., Skeie G., Weiderpass
E., Quiros Garcia J.R., Chirlaque M.D., Ardanaz E.,
Sanchez M.J., Duell E.J., Amiano P., Borgquist S.,
Wirfalt E., Hallmans G., Johansson I., Nilsson L.M.,
Khaw K.T., Wareham N., Key T.J., Travis R.C., Murphy
N., Wark P.A., Ferrari P., and Riboli E. Alcohol intake
and breast cancer in the European prospective
investigation into cancer and nutrition . [2015]
International Journal of Cancer (137) 8: 1921-1930.
Impact factor: 5,531
3 68. Rosenberg J., Petrylak D., Abidoye O., Van der
Heijden M., Hofman-Censits J., Necchi A., O’Donnell
P., Balmanoukian A., Loriot Y., Retz M., PerezGracia J., Dawson N., Balar A., Galsky M., Fleming
M., Powles T., Cui N., Mariathasan S., Fine G., and
Dreicer R. Atezolizumab in patients (pts) with
locally-advanced or metastatic urothelial carcinoma
(mUC): Results from a pivotal multicenter phase
II study (IMvigor 210) . [2015] European Journal
of Cancer (51) suppl 3: S720-S720. Impact factor:
6,163
3 69. Rouge T., Pautier P., Alexandre J., Ray-coquard
I., Cottu P., Rodrigues M., Follana P., Floquet A.,
Lortholary A., Heudel P., Combe P., Joly F., Suau D.,
Maribas D., Licour M., De La Porte I., Varoqueaux
N., and Pujade-Lauraine E. First real life data on
Olaparib in BRCA1/2 mutated Platinum-Sensitive
Relapsed (PSR) Epithelial Ovarian Cancer (EOC)
in France: Analysis of 52 patients (pts) enrolled in
the French Temporary Authorization for Use (ATU).
[2015] European Journal of Cancer (51) suppl 3:
S548-S549. Impact factor: 6,163
3 70. Rouzier R., Uzan C., Rousseau A., Guillot E.,
Zilberman S., Meyer C., Estevez P., Dupre P.F., Kere
D., Doridot V., D’halluin G., Fritel X., Pouget N.,
Mazouni C., Simon T., and Coutant C. Prospective
evaluation of the reliability of the combined use
of two models to predict non-sentinel lymph node
status in breast cancer patients with metastatic
sentinel lymph nodes: The MSKCC nomogram and
the Tenon score - PHRC-NOTEGS study . [2015]
Cancer Research (75) 9 suppl: P2-01-1. Impact
factor: 8,556
371. Rudolph A., Milne R.L., Truong T., Knight J.A., Seibold
P., Flesch-Janys D., Behrens S., Eilber U., Bolla M.K.,
Wang Q., Dennis J., Dunning A.M., Shah M., Munday
H.R., Darabi H., Eriksson M., Brand J.S., Olson J.,
Vachon C.M., Hallberg E., Castelao J.E., Carracedo
A., Torres M., Li J., Humphreys K., Cordina-Duverger
E., Menegaux F., Flyger H., Nordestgaard B.G.,
Nielsen S.F., Yesilyurt B.T., Floris G., Leunen K.,
Engelhardt E.G., Broeks A., Rutgers E.J., Glendon G.,
Mulligan A.M., Cross S., Reed M., Gonzalez-Neira A.,
Arias Perez J.I., Provenzano E., Apicella C., Southey
M.C., Spurdle A., Häberle L., Beckmann M.W., Ekici
A.B., Dieffenbach A.K., Arndt V., Stegmaier C.,
McLean C., Baglietto L., Chanock S.J., Lissowska J.,
Sherman M.E., Brüning T., Hamann U., Ko Y.D., Orr
N., Schoemaker M., Ashworth A., Kosma V.M., Kataja
V., Hartikainen J.M., Mannermaa A., Swerdlow A.,
Giles G.G., Brenner H., Fasching P.A., ChenevixTrench G., Hopper J., Benitez J., Cox A., Andrulis I.L.,
Lambrechts D., Gago-Dominguez M., Couch F., Czene
K., Bojesen S.E., Easton D.F., Schmidt M.K., Guénel
P., Hall P., Pharoah P.D., Garcia-Closas M., and
Chang-Claude J. Investigation of gene-environment
interactions between 47 newly identified breast
cancer susceptibility loci and environmental risk
factors . [2015] International Journal of Cancer
(136) 6: E685-E696. Impact factor: 5,531
65
372. Ruf S., Brugieres L., Pillon M., Zimmermann M.,
Attarbaschi A., Mellgren K., Williams D., Uyttebroeck
A., Wrobel G., Reiter A., and Woessmann W. Riskadapted therapy for patients with relapsed or
refractory ALCL - final report of the prospective
ALCL-relapse trial of the EICNHL. [2015] British
Journal of Haematology (171) suppl 1: 45-45. Impact
factor: 5,401
373. Saade E., Pirozhkova I., Aimbetov R., Lipinski M., and
Ogryzko V. Molecular turnover, the H3.3 dilemma and
organismal aging (hypothesis). [2015] Aging Cell (14)
3: 322-333. Impact factor: 5,760
3 74. Sabino D., Gogendeau D., Gambarotto D., Nano
M., Pennetier C., Dingli F., Arras G., Loew D., and
Basto R. Moesin is a major regulator of centrosome
behavior in epithelial cells with extra centrosomes.
[2015] Current Biology (25) 7: 879-889. Impact factor:
8,983
375. Salas S., Brulard C., Terrier P., Ranchere-Vince D.,
Neuville A., Guillou L., Lae M., Leroux A., Verola O.,
Jean-Emmanuel K., Bonvalot S., Blay J.Y., Le Cesne
A., Aurias A., Coindre J.M., and Chibon F. Gene
Expression Profiling of Desmoid Tumors by cDNA
Microarrays and Correlation with Progression-Free
Survival. [2015] Clinical Cancer Research (21) 18:
4194-4200. Impact factor: 8,738
376. Sauvat A., Wang Y., Segura F., Spaggiari S., Mueller
K., Zhou H., Galluzzi L., Kepp O., and Kroemer
G. Quantification of cellular viability by automated
microscopy and flow cytometry. [2015] Oncotarget
(6) 11: 9467-9475. Impact factor: 5,008
377. Scagliotti G., V, Bondarenko I., Blackhall F., Barlesi F.,
Hsia T., Jassem J., Milanowski J., Popat S., SanchezTorres J., Novello S., Benner R., Green S., Molpus K.,
Soria J., and Shepherd F. Randomized, phase III trial
of figitumumab in combination with erlotinib versus
erlotinib alone in patients with nonadenocarcinoma
nonsmall-cell lung cancer. [2015] Annals of Oncology
(26) 3: 497-504. Impact factor: 9,269
3 78. Schadendorf D., Amonkar M.M., Stroyakovskiy
D., Levchenko E., Gogas H., de Braud F., Grob
J.J., Bondarenko I., Garbe C., Lebbe C., Larkin J.,
Chiarion-Sileni V., Millward M., Arance A., Mandala
M., Flaherty K.T., Nathan P., Ribas A., Robert C.,
Casey M., DeMarini D.J., Irani J.G., Aktan G., and
Long G.V. Health-related quality of life impact in
a randomised phase III study of the combination
of dabrafenib and trametinib versus dabrafenib
monotherapy in patients with BRAF V600 metastatic
melanoma. [2015] European Journal of Cancer (51)
7: 833-840. Impact factor: 6,163
3 79. Schneider D.T., Orbach D., Cecchetto G.,
Stachowicz-Stencel T., Brummel B., Brecht I.B.,
Bisogno G., Ferrari A., Reguerre Y., Godzinski
J., Bien E., Calaminus G., Goebel U., and Patte
C. Ovarian Sertoli Leydig cell tumours in children
and adolescents: An analysis of the European
Cooperative Study Group on Pediatric Rare Tumors
(EXPeRT). [2015] European Journal of Cancer (51)
4: 543-550. Impact factor: 6,163
380. Schöffski P., Besse B., Gauler T., de Jonge M.J.A.,
Scambia G., Santoro A., Davite C., Jannuzzo M.G.,
Petroccione A., and Delord J.P. Efficacy and safety
of biweekly i.v. administrations of the Aurora
kinase inhibitor danusertib hydrochloride in
independent cohorts of patients with advanced or
metastatic breast, ovarian, colorectal, pancreatic,
small-cell and non-small-cell lung cancer: A
multi-tumour,multi-institutional phase II study.
[2015] Annals of Oncology (26) 3: 598-607. Impact
factor: 9,269
381. Schuler M., Yang J., Park K., Chand V., Wang B.,
and Planchard D. Afatinib (A) Plus Paclitaxel
(P) Following Progression on A Monotherapy in
Patients (Pts) with Metastatic Non-Small-Cell Lung
Cancer (Nsclc) Who Previously Benefited from
Erlotinib (E)/Gefitinib (G): A Global Randomised
Phase Iii Triallux-Lung 5 (Ll5). [2015] Annals of
Oncology (26) suppl 1: 107PD. Impact factor: 9,269
382. Schwaederlé M., Lazar V., Validire P., Hansson J.,
Lacroix L., Soria J.C., Pawitan Y., and Kurzrock
R. VEGF-A Expression Correlates with TP53
Mutations in Non-Small Cell Lung Cancer:
Implications for Antiangiogenesis Therapy. [2015]
Cancer Research (75) 7: 1187-1190. Impact factor:
8,556
383. Scotte F., Borget I., Martelli N., and Vainchtock
A. The cost of thromboembolic events in
hospitalized patients: A study on four major cancer
localizations. [2015] European Journal of Cancer
(51) suppl 3: S178-S178. Impact factor: 6,163
3 84. Scourzic L., Mouly E., and Bernard O.A. TET
proteins and the control of cytosine demethylation
in cancer. [2015] Genome Medicine (7) 1: 9. Impact
factor: 5,7
385. Seah S., Low I.C., Hirpara J.L., Sachaphibulkij K.,
Kroemer G., Brenner C., and Pervaiz S. Activation
of surrogate death receptor signaling triggers
peroxynitrite-dependent execution of cisplatinresistant cancer cells. [2015] Cell Death & Disease
(6): e1926. Impact factor: 5,378
66
386. Selle F., Gouy S., Lambaudie E., Guyon F., Fourchotte
V., Pomel C., Colombo P., Kalbacher E., MartinFrancoise S., Fauvet R., Follana P., Lesoin A., Lecuru
F., Menguy V., Ghazi Y., Chereau E., Zohar S., Cottu
P., Joly F., and Rouzier R. Safety of bevacizumabcontaining neoadjuvant therapy followed by interval
debulking surgery in advanced ovarian cancer: Data
from the ANTHALYA trial. [2015] European Journal
of Cancer (51) suppl 3: S553-S553. Impact factor:
6,163
387. Selmi A., de Saint-Jean M., Jallas A.C., Garin E.,
Hogarty M.D., Benard J., Puisieux A., Marabelle
A., and Valsesia-Wittmann S. TWIST1 is a direct
transcriptional target of MYCN and MYC in
neuroblastoma. [2015] Cancer Letters (357) 1: 412418. Impact factor: 5,992
3 88. Semeraro M., Rusakiewicz S., Zitvogel L.,
and Kroemer G. Natural killer cell mediated
immunosurveillance of pediatric neuroblastoma .
[2015] Oncoimmunology (4) 11: e1042202. Impact
factor: 7,644
389. Sen A., Tsilidis K.K., Allen N.E., Rinaldi S., Appleby
P.N., Almquist M., Schmidt J.A., Dahm C.C., Overvad
K., Tjønneland A., Rostgaard-Hansen A.L., ClavelChapelon F., Baglietto L., Boutron-Ruault M.C.,
Kuehn T., Katze V.A., Boeing H., Trichopoulou A.,
Tsironis C., Lagiou P., Palli D., Pala V., Panico S.,
Tumino R., Vineis P., Bueno-de-Mesquita H., Peeters
P.H., Hjartaker A., Lund E., Weiderpass E., Ramon
Quiros J., Agudo A., Sanchez M.J., Arriola L., Gavrila
D., Barricarte Gurrea A., Tosovic A., Hennings J.,
Sandstrom M., Romieu I., Ferrari P., Zamora-Ros
R., Khaw K.T., Wareham N.J., Riboli E., Gunter M.,
and Franceschi S. Baseline and lifetime alcohol
consumption and risk of differentiated thyroid
carcinoma in the EPIC study. [2015] British Journal
of Cancer (113) 5: 840-847. Impact factor: 5,569
3 90. Sharma P., Escudier B., McDermott D., George
S., Hammers H., Srinivas S., Tykodi S., Sosman J.,
Procopio G., Plimack E., Castellano D., Gurney H.,
Donskov F., Bono P., Wagstaff J., Gauler T., Ueda T.,
Xu L., Waxman I., and Motzer R. CheckMate 025: a
randomized, open-label, phase III study of nivolumab
(NIVO) versus everolimus (EVE) in advanced renal
cell carcinoma (RCC) . [2015] European Journal
of Cancer (51) suppl 3: S708-S708. Impact factor:
6,163
391. Shou Y., Robinson D.M., Amakye D.D., Rose K.L., Cho
Y.J., Ligon K.L., Sharp T., Haider A.S., Bandaru R.,
Ando Y., Geoerger B., Doz F., Ashley D.M., Hargrave
D.R., Casanova M., Tawbi H.A., Rodon J., Thomas
A.L., Mita A.C., MacDonald T.J., and Kieran M.W. A
Five-Gene Hedgehog Signature Developed as a
Patient Preselection Tool for Hedgehog Inhibitor
Therapy in Medulloblastoma. [2015] Clinical Cancer
Research (21) 3: 585-593. Impact factor: 8,738
392. Sicard A., Ducreux S., Rabeyrin M., Couzi L., McGregor
B., Badet L., Scoazec J.Y., Bachelet T., Lepreux S.,
Visentin J., Merville P., Fremeaux-Bacchi V., Morelon
E., Taupin J.L., Dubois V., and Thaunat O. Detection
of C3d-binding donor-specific anti-HLA antibodies
at diagnosis of humoral rejection predicts renal
graft loss. [2015] Journal of the American Society
of Nephrology (26) 2: 457-467. Impact factor: 8,491
393. Skarbek C., Lesueur L.L., Chapuis H., Deroussent
A., Pioche-Durieu C., Daville A., Caron J., Rivard
M., Martens T., Bertrand J.R., Le Cam E., Vassal G.,
Couvreur P., Desmaele D., and Paci A. Preactivated
Oxazaphosphorines Designed for lsophosphoramide
Mustard Delivery as Bulk Form or Nanoassemblies:
Synthesis and Proof of Concept. [2015] Journal of
Medicinal Chemistry (58) 2: 705-717. Impact factor:
5,589
394. Sluijs I., Holmes M.V., van der Schouw Y.T., Beulens J.W.,
Asselbergs F.W., Huerta J.M., Palmer T.M., Arriola L.,
Balkau B., Barricarte A., Boeing H., Clavel-Chapelon
F., Fagherazzi G., Franks P.W., Gavrila D., Kaaks R.,
Khaw K.T., Kühn T., Molina-Montes E., Mortensen L.M.,
Nilsson P.M., Overvad K., Palli D., Panico S., Quirós
J.R., Rolandsson O., Sacerdote C., Sala N., Schmidt
J.A., Scott R.A., Sieri S., Slimani N., Spijkerman A.M.,
Tjønneland A., Travis Dphil R.C., Tumino R., van d.A.,
Sharp S.J., Forouhi N.G., Langenberg C., Riboli E.,
and Wareham N.J. A Mendelian randomization study
of circulating uric acid and type 2 diabetes. [2015]
Diabetes (64) 8: 3028-3036. Impact factor: 8,784
395. Smith M.R., Coleman R.E., Klotz L., Pittman K., Milecki
P., Ng S., Chi K.N., Balakumaran A., Wei R., Wang H.,
Braun A., and Fizazi K. Denosumab for the Prevention
of Skeletal Complications in Metastatic CastrationResistant Prostate Cancer: Comparison of SkeletalRelated Events and Symptomatic Skeletal Events.
[2015] Annals of Oncology (26) 2: 368-374. Impact
factor: 9,269
396. Sobrero A., Price T., Cervantes A., Ducreux M., Andre
T., Lordick F., Punt C., Hechmati G., Demonty G.,
Koukakis R., and Peeters M. Quality of life (QoL)
during second-line treatment with FOLFIRI plus /panitumumab (pmab) in patients (pts) with RAS wildtype (WT) metastatic colorectal carcinoma (mCRC).
[2015] European Journal of Cancer (51) suppl 3:
S369-S370. Impact factor: 6,163
67
397. Solomon B., Wakelee H., Sequist L., V, Gadgeel
S., Soria J., Goldman J., Yu H., Camidge D.,
Papadimitrakopoulou V., Matheny S., Despain D.,
and Besse B. Rociletinib treatment and outcomes
in non-small cell lung cancer (NSCLC) patients with
negative central testing for T790M. [2015] European
Journal of Cancer (51) suppl 3: S636-S636. Impact
factor: 6,163
398. Soria J.C., Flotten O., Horn L., Felip E., Gandhi L.,
Hui R., Hellmann M., Leighl N., Zhang J., Kondic A.,
Rangwala R., Lubiniecki G., and Garon E. Efficacy
and Safety of Pembrolizumab (Pembro; MK-3475)
for Patients (Pts) With Previously Treated Advanced
Non-Small Cell Lung Cancer (NSCLC) Enrolled in
KEYNOTE-001. [2015] European Journal of Cancer
(51) suppl 3: S726-S727. Impact factor: 6,163
399. Soria J.C., Goldman J., Wakelee H., Gadgeel S.,
Camidge D., Solomon B., Yu H., Oxnard G., Ou S.,
Papadimitrakopoulou V., Perol M., Reckamp K.,
Varga A., Dziadziuszko R., Chouaid C., Cortot A.,
Do P., Moro-sibilot D., Poudenx M., and Sequist L.,
V Dose optimization of rociletinib for EGFR mutated
NSCLC: Benefit/risk analysis from the TIGER-X
trial. [2015] European Journal of Cancer (51) suppl
3: S637-S637. Impact factor: 6,163
400. Soria J.C. and Buyse M. ‘Statistical controversies
in clinical research’: a new series in Annals of
Oncology. [2015] Annals of Oncology (26) 8: 15321532. Impact factor: 9,269
401. Soria J.C., Sequist L.V., Goldman J., Wakelee H.A.,
Neal J., Camidge R., Gadgeel S., Papadimitrakopoulou
V., Dziadziuszko R., Piotrowska Z., Varga A., and
Solomon B.J. O10.3 Rociletinib: an oral, irreversible,
highly selective small molecule inhibitor of mutant
EGFR including T790M. [2015] Annals of Oncology
(26) suppl 2: ii14-ii14. Impact factor: 9,269
402. Soria J.C., Boni V., Gazzah A., Holgado E., Even C.,
Ould-Kaci M., Nazabadioko S., Xue W., and Calvo
E. O3.5A A Phase Ib dose escalation study of afatinib
in combination with standard-dose cetuximab
in patients with advanced solid tumours. [2015]
Annals of Oncology (26) suppl 2: ii4. Impact factor:
9,269
403. Soria J.C., Marabelle A., Brahmer J.R., and Gettinger
S. Immune Checkpoint Modulation for Non-Small
Cell Lung Cancer. [2015] Clinical Cancer Research
(21) 10: 2256-2262. Impact factor: 8,738
404. Stahel R., Bogaerts J., Ciardiello F., De Ruysscher
D., Dubsky P., Ducreux M., Finn S., Laurent-Puig
P., Peters S., Piccart M., Smit E., Sotiriou C., Tejpar
S., Van Cutsem E., and Tabernero J. Optimising
translational oncology in clinical practice: Strategies
to accelerate progress in drug development. [2015]
Cancer treatment reviews (41) 2: 129-135. Impact
factor: 7,983
4 05. Steffen A., Huerta J.M., Weiderpass E., Buenode-Mesquita H., May A.M., Siersema P.D., Kaaks
R., Neamat-Allah J., Pala V., Panico S., Saieva C.,
Tumino R., Naccarati A., Dorronsoro M., SanchezCantalejo E., Ardanaz E., Ramon Quiros J., Ohlsson
B., Johansson M., Wallner B., Overvad K., Halkjaer
J., Tjønneland A., Fagherazzi G., Racine A., ClavelChapelon F., Key T.J., Khaw K.T., Wareham N., Lagiou
P., Bamia C., Trichopoulou A., Ferrari P., Freisling
H., Lu Y., Riboli E., Cross A.J., Gonzalez C.A., and
Boeing H. General and abdominal obesity and risk
of esophageal and gastric adenocarcinoma in the
European Prospective Investigation into Cancer and
Nutrition. [2015] International Journal of Cancer
(137) 3: 646-657. Impact factor: 5,531
406. Stelloo E., Bosse T., Nout R.A., MacKay H.J., Church
D.N., Nijman H.W., Leary A., Edmondson R.J., Powell
M.E., Crosbie E.J., Kitchener H.C., Mileshkin L., Pollock
P.M., Smit V.T., and Creutzberg C.L. Refining prognosis
and identifying targetable pathways for high-risk
endometrial cancer; a TransPORTEC initiative. [2015]
Modern Pathology (28) 6: 836-844. Impact factor: 5,485
407. Stoll G., Bindea G., Mlecnik B., Galon J., Zitvogel L.,
and Kroemer G. Meta-analysis of organ-specific
differences in the structure of the immune infiltrate in
major malignancies. [2015] Oncotarget (6) 14: 1189411909. Impact factor: 5,008
408. Stone J., Thompson D.J., Silva I.d.S., Scott C., Tamimi
R.M., Lindstrom S., Kraft P., Hazra A., Li J., Eriksson
L., Czene K., Hall P., Jensen M., Cunningham J., Olson
J.E., Purrington K., Couch F.J., Brown J., Leyland
J., Warren R.M., Luben R.N., Khaw K.T., Smith P.,
Wareham N.J., Jud S.M., Heusinger K., Beckmann
M.W., Douglas J.A., Shah K.P., Chan H.P., Helvie M.A.,
Le Marchand L., Kolonel L.N., Woolcott C., Maskarinec
G., Haiman C., Giles G.G., Baglietto L., Krishnan K.,
Southey M.C., Apicella C., Andrulis I.L., Knight J.A.,
Ursin G., Alnaes G.I., Kristensen V.N., Borresen-Dale
A.L., Gram I.T., Bolla M.K., Wang Q., Michailidou K.,
Dennis J., Simard J., Pharoah P., Dunning A.M., Easton
D.F., Fasching P.A., Pankratz V., Hopper J.L., and
Vachon C.M. Novel Associations between Common
Breast Cancer Susceptibility Variants and RiskPredicting Mammographic Density Measures. [2015]
Cancer Research (75) 12: 2457-2467. Impact factor:
8,556
68
4 09. Sullivan I., Baudin E., Guigay J., Scoazec J.,
Leboulleux S., Berdelou A., Ducreux M., Malka D.,
Caramella C., Besse B., and Planchard D. Tumor
control of advanced pulmonary carcinoid tumors
with somatostatin analogs: Experience at Gustave
Roussy. [2015] European Journal of Cancer (51)
suppl 3: S622-S623. Impact factor: 6,163
4 10. Susman S., Barnoud R., Bibeau F., Borrini
F., Pocard M., and Sabourin J.C. The Lauren
Classification Highlights the Role of EpithelialMesenchymal Transition in Gastric Carcinogenesis:
An Immunohistochemistry Study of p-Stat3 and
Adhesion Molecule Expression . [2015] Modern
Pathology (28) S2: 194A-194A. Impact factor: 5,485
411. Tabernero J., Homicsko K., Schellens J., Hoekstra O.,
Van der Veen L., Melero I., Argiles G., Mau-Sorensen
M., Angevin E., Joensuu H., Van Brummelen
E., Menke-van der Houven van Oordt, Nayak T.,
Romagnoli S., Reis B., Brossard S.S., Evers S., Saro
J., Verheul H., and Lassen U. Clinical evidence
of intra-tumoral immune activation and tumor
targeting with RG7813, a CEA-targeted engineered
IL-2 immunocytokine. [2015] European Journal
of Cancer (51) suppl 3: S104-S105. Impact factor:
6,163
412. Tejera-Vaquerizo A., Nagore E., Puig S., Robert C.,
Saiag P., Martín-Cuevas P., Gallego E., HerreraAcosta E., Aguilera J., Malvehy J., Carrera C.,
Cavalcanti A., Rull R., Vilalta-Solsona A., Lannoy E.,
Boutros C., Benannoune N., Tomasic G., Aegerte P.,
Vidal-Sicart S., Palou J., Alos L., Requena C., Traves
V., Pla Á., Bolumar I., Soriano V., Guillén C., and
Herrera-Ceballos E. Effect of time to sentinel-node
biopsy on the prognosis of cutaneous melanoma.
[2015] European Journal of Cancer (51) 13: 17801793. Impact factor: 6,163
4 13. Terroir M., Borget I., Bidault F., Deandreis D.,
Al Ghuzlan A., Hartl D., Ricard M., Berdelou A.,
Dercle L., Lumbroso J., Baudin E., Schlumberger
M., and Leboulleux S. The intensity of 18FDG
uptake is not a surrogate marker of morphological
tumor progression in patients with metastatic
differentiated thyroid cancer . [2015] European
Journal of Nuclear Medicine and Molecular Imaging
(42) suppl 1: S37-S37. Impact factor: 5,537
414. Terry S., El-Sayed I.Y., Destouches D., Maille P.,
Nicolaiew N., Ploussard G., Semprez F., Pimpie
C., Beltran H., Londono-Vallejo A., Allory Y., de la
Taille A., Salomon D.S., and Vacherot F. CRIPTO
o v e re x p re s s i o n p ro m o t e s m e s e n c h y m a l
differentiation in prostate carcinoma cells through
parallel regulation of AKT and FGFR activities .
[2015] Oncotarget (6) 14: 11994-12008. Impact
factor: 5,008
415. Thuringer D., Berthenet K., Cronier L., Jego G.,
Solary E., and Garrido C. Oncogenic extracellular
HSP70 disrupts the gap-junctional coupling
between capillary cells. [2015] Oncotarget (6) 12:
10267-10283. Impact factor: 5,008
416. Thuringer D., Berthenet K., Cronier L., Solary E., and
Garrido C. Primary tumor- and metastasis-derived
colon cancer cells differently modulate connexin
expression and function in human capillary
endothelial cells. [2015] Oncotarget (6) 30: 2880028815. Impact factor: 5,008
417. Tikk K., Sookthai D., Fortner R.T., Johnson T., Rinaldi
S., Romieu I., Tjønneland A., Olsen A., Overvad
K., Clavel-Chapelon F., Baglietto L., Boeing H.,
Trichopoulou A., Lagiou P., Trichopoulos D., Masala
G., Krogh V., Tumino R., Ricceri F., Mattiello A.,
Agudo A., Menendez V., Sanchez M.J., Amiano P.,
Chirlaque M.D., Barricarte A., Bueno-de-Mesquita
H.B., Monninkhof E.M., Onland-Moret N., Andresson
A., Sund M., Weiderpass E., Khaw K.T., Key T.J.,
Travis R.C., Merritt M.A., Riboli E., Dossus L., and
Kaaks R. Circulating prolactin and in situ breast
cancer risk in the European EPIC cohort: a casecontrol study. [2015] Breast Cancer Research (17)
1: 49. Impact factor: 5,211
4 18. Toffano-Nioche C., Gautheret D., and Leclerc
F. Revisiting the structure/function relationships of
H/ACA(-like) RNAs: a unified model for Euryarchaea
and Crenarchaea. [2015] Nucleic acids research
(43) 16: 7744-7761. Impact factor: 9,202
4 19. Touat M., Dhermain F., Andre F., and Sanson
M. Adapting the drivers to the road: a new strategy
for cancer evolution? [2015] Annals of Oncology (26)
5: 827-829. Impact factor: 9,269
420. Touat M., Ileana E., Postel-Vinay S., André F., and
Soria J.C. Targeting FGFR Signaling in Cancer .
[2015] Clinical Cancer Research (21) 12: 2684-2694.
Impact factor: 8,738
4 21. Toulmonde M., Le Cesne A., Piperno-Neumann
S., Penel N., Chevreau C., Duffaud F., Bellera C.,
and Italiano A. Aplidin in patients with advanced
dedifferentiated liposarcomas: a French Sarcoma
Group Single-Arm Phase II study. [2015] Annals of
Oncology (26) 7: 1465-1470. Impact factor: 9,269
422. Touzart A., Garnier N., Trinquand A., Cieslak A.,
Landman-Parker J., Aladjidi N., Minard-Colin V.,
Callens C., Molina T., Asnafi V., Bertrand Y., and
69
Macintyre E. Analysis of new pronostic molecular
markers in French pediatric T-LBL treated
according to the EuroLB02 trial . [2015] British
Journal of Haematology (171) suppl 1: 45-45.
Impact factor: 5,401
423. Treilleux I., Arnedos M., Cropet C., Wang Q., Ferrero
J., Abadie-Lacourtoisie S., Levy C., Legouffe E.,
Lortholary A., Pujade-Lauraine E., Bourcier A.,
Eymard J., Spaeth D., and Bachelot T. Translational
studies within the TAMRAD randomized GINECO
trial: evidence for mTORC1 activation marker as a
predictive factor for everolimus efficacy in advanced
breast cancer. [2015] Annals of Oncology (26) 1:
120-125. Impact factor: 9,269
424. Trinquand A., Malcom T., Villarese P., Fairbairn C.,
Lamant L., Hook E., Burke A., Brugieres L., Hughes
K., Payet D., Merkel O., Schiefer A., Mian S., Wasik
M., Turner M., Kenner L., Asnafi V., Macintyre E.,
and Turner S. Npm-Alk Mimics Thymic Pre-T Cell
Receptor (Tcr) Expansion But Requires Transient
Tcr Expression for Thymic Egress and Peripheral
Anaplastic Large Cell Lymphoma Development .
[2015] Haematologica (100) suppl 1: 166-166.
Impact factor: 6,671
425. Truffaux N., Philippe C., Paulsson J., Andreiuolo
F., Guerrini-Rousseau L., Cornilleau G., Le Dret L.,
Richon C., Lacroix L., Puget S., Geoerger B., Vassal
G., Oestman A., and Grill J. Preclinical evaluation
of dasatinib alone and in combination with
cabozantinib for the treatment of diffuse intrinsic
pontine glioma. [2015] Neuro-Oncology (17) 7: 953964. Impact factor: 7,371
426. Tselikas L., Souillard-Scemama R., Naggara O.,
Mellerio C., Varlet P., Dezamis E., Domont J.,
Dhermain F., Devaux B., Chrétien F., Meder J.F.,
Pallud J., and Oppenheim C. Imaging of gliomas at
1.5 and 3 Tesla - A comparative study. [2015] NeuroOncology (17) 6: 895-900. Impact factor: 7,371
427. Turpin A., Tergemina-Clain G., Kempf E., PostelVinay S., Massard C., Soria J., and Loriot Y. Inclusion
of patients with urothelial bladder cancer in phase 1
trials: What is the impact? [2015] European Journal
of Cancer (51) suppl 3: S523-S523. Impact factor:
6,163
428. Tursz T. and Bernards R. Hurdles on the road to
personalized medicine. [2015] Molecular Oncology
(9) 5: 935-939. Impact factor: 5,367
429. Vacchelli E., Sistigu A., Yamazaki T., Vitale I., Zitvogel
L., and Kroemer G. Autocrine signaling of type 1
interferons in successful anticancer chemotherapy.
[2015] Oncoimmunology (4) 8: e988042. Impact
factor: 7,644
430. Vacchelli E., Pol J., Bloy N., Eggermont A., Cremer
I., Fridman W.H., Galon J., Marabelle A., Kohrt
H., Zitvogel L., Kroemer G., and Galluzzi L. Trial
watch: Tumor-targeting monoclonal antibodies for
oncological indications. [2015] Oncoimmunology (4)
1: e985940. Impact factor: 7,644
431. Vacchelli E., Semeraro M., Enot D.P., Chaba K., Colame
V.P., Dartigues P., Perier A., Villa I., Rusakiewicz
S., Gronnier C., Goere D., Mariette C., Zitvogel L.,
and Kroemer G. Negative prognostic impact of
regulatory T cell infiltration in surgically resected
esophageal cancer post-radiochemotherapy. [2015]
Oncotarget (6) 25: 20840-20850. Impact factor:
5,008
432. Valdagni R., Van Poppel H., Aitchison M., Albers P.,
Berthold D., Bossi A., Brausi M., Denis L., DrudgeCoates L., De Santis M., Feick G., Harrison C.,
Haustermans K., Hollywood D., Hoyer M., Hummel
H., Mason M., Mirone V., Mueller S.C., Parker C.,
Saghatchian M., Sternberg C.N., Tombal B., van
Muilekom E., Watson M., Wesselmann S., Wiegel
T., Magnani T., and Costa A. Prostate Cancer
Unit Initiative in Europe: A position paper by the
European School of Oncology . [2015] Critical
Reviews in Oncology Hematology (95) 2: 133-143.
Impact factor: 5,039
433. van den Berg H., Paulussen M., Le Teuff G., Judson
I., Gelderblom H., Dirksen U., Brennan B., Whelan
J., Ladenstein R.L., Marec-Berard P., Kruseova J.,
Hjorth L., Kuehne T., Brichard B., Wheatley K., Craft
A., Juergens H., Gaspar N., and Le Deley M.C. Impact
of gender on efficacy and acute toxicity of alkylating
agent -based chemotherapy in Ewing sarcoma:
Secondary analysis of the Euro-Ewing99-R1 trial.
[2015] European Journal of Cancer (51) 16: 24532464. Impact factor: 6,163
434. van der Post R.S., Vogelaar I.P., Carneiro F., Guilford
P., Huntsman D., Hoogerbrugge N., Caldas C.,
Schreiber K.E.C., Hardwick R.H., Ausems M.G.,
Bardram L., Benusiglio P.R., Bisseling T.M., Blair
V., Bleiker E., Boussioutas A., Cats A., Coit D.,
DeGregorio L., Figueiredo J., Ford J.M., Heijkoop
E., Hermens R., Humar B., Kaurah P., Keller G.,
Lai J., Ligtenberg M.J., O’Donovan M., Oliveira C.,
Pinheiro H., Ragunath K., Rasenberg E., Richardson
S., Roviello F., Schackert H., Seruca R., Taylor A.,
ter Huurne A., Tischkowitz M., Joe S.T., van Dijck
B., van Grieken N.C., van Hillegersberg R., van
Sandick J.W., Vehof R., van Krieken J., and Fitzgerald
70
R.C. Hereditary diffuse gastric cancer: updated
clinical guidelines with an emphasis on germline
CDH1 mutation carriers. [2015] Journal of Medical
Genetics (52) 6: 361-374. Impact factor: 5,650
435. van Nielen M., Feskens E.J., Mensink M., Sluijs I.,
Molina E., Amiano P., Ardanaz E., Balkau B., Beulens
J.W., Boeing H., Clavel-Chapelon F., Fagherazzi G.,
Franks P.W., Halkjaer J., Huerta J.M., Katzke V.,
Key T.J., Khaw K.T., Krogh V., Kühn T., Menéndez
V.V., Nilsson P., Overvad K., Palli D., Panico S.,
Rolandsson O., Romieu I., Sacerdote C., Sánchez
M.J., Schulze M.B., Spijkerman A.M., Tjønneland
A., Tumino R., van d.A., Würtz A.M., Zamora-Ros R.,
Langenberg C., Sharp S.J., Forouhi N.G., Riboli E.,
and Wareham N.J. Erratum.Dietary Protein Intake
and Incidence of Type 2 Diabetes in Europe: The
EPIC-InterAct Case-Cohort Study. Diabetes Care
2014;37:1854-1862. [2015] Diabetes Care (38) 10:
1992. Impact factor: 8,934
4 36. Van C.E., Prenen H., D’Haens G., Bennouna J.,
Carrato A., Ducreux M., Bouche O., Sobrero A., Latini
L., Staines H., Oum’Hamed Z., Dressler H., Studeny
M., and Capdevila J. A phase I/II, open-label,
randomised study of nintedanib plus mFOLFOX6
versus bevacizumab plus mFOLFOX6 in first-line
metastatic colorectal cancer patients. [2015] Annals
of Oncology (26) 10: 2085-2091. Impact factor: 9,269
437. Vansteenkiste J.F., Canon J.L., de Braud F., Grossi
F., De Pas T., Gray J.E., Su W.C., Felip E., Yoshioka
H., Gridelli C., Dy G.K., Thongprasert S., Reck M.,
Aimone P., Vidam G.A., Roussou P., Wang Y.A., Di
Tomaso E., and Soria J.C. Safety and Efficacy of
Buparlisib (BKM120) in Patients with PI3K PathwayActivated Non-Small Cell Lung Cancer Results from
the Phase II BASALT-1 Study. [2015] Journal of
Thoracic Oncology (10) 9: 1319-1327. Impact factor:
5,040
438. Varga A., Camidge D., Sequist L., V, Wakelee H., Ou
S., Goldman J., Papadimitrakopoulou V., Gadgeel
S., Mekhail T., Oxnard G., Socinski M., Solomon B.,
Yu H., Matheny S., Despain D., and Soria J. Activity
of rociletinib in EGFR mutant NSCLC patients with
a history of CNS involvement . [2015] European
Journal of Cancer (51) suppl 3: S598-S598. Impact
factor: 6,163
4 39. Vassal G., Moro-sibilot D., Le Deley M., Hooglabouret N., Nowak F., Jimenez M., Tournigand C.,
Houot R., Malka D., Aparicio T., Escudier B., Raycoquard I., Godbert Y., Taillandier L., Bieche I.,
Lantuejoul S., Ferretti G., Menu Y., Blay J., and Buzyn
A. Biomarker-driven access to crizotinib in ALK,
MET or ROS1 positive (+) malignancies in adults
and children: The French national AcSe Program.
[2015] European Journal of Cancer (51) suppl 3:
S715-S715. Impact factor: 6,163
440. Vassal G., Rousseau R., Blanc P., Moreno L., Bode
G., Schwoch S., Schrappe M., Skolnik J., Bergman
L., Bradley-Garelik M.B., Saha V., Pearson A., and
Zwierzina H. Creating a unique, multi-stakeholder
Paediatric Oncology Platform to improve drug
development for children and adolescents with
cancer. [2015] European Journal of Cancer (51) 2:
218-224. Impact factor: 6,163
441. Velot L., Molina A., Rodrigues-Ferreira S., Nehlig
A., Bouchet B.P., Morel M., Leconte L., Serre L.,
Arnal I., Braguer D., Savina A., Honore S., and
Nahmias C. Negative regulation of EB1 turnover
at microtubule plus ends by interaction with
microtubule-associated protein ATIP3 . [22-122015] Oncotarget (6) 41: 43557-43570. Impact
factor: 5,008
4 42. Vences-Catalán F., Rajapaksa R., Srivastava
M.K., Marabelle A., Kuo C.C., Levy R., and Levy
S. Tetraspanin CD81 promotes tumor growth
and metastasis by modulating the functions of T
regulatory and myeloid-derived suppressor cells.
[2015] Cancer Research (75) 21: 4517-4526. Impact
factor: 8,556
4 43. Versluis M., de Jong R., Plat A., Bosse T., Smit
V., Mackay H., Powell M., Leary A., Mileshkin
L., Kitchener H., Crosbie E., Edmondson R.,
Creutzberg C., Hollema H., Daemen T., de Bock G.,
and Nijman H. Prediction model for regional or
distant recurrence in endometrial cancer based
on classical pathological and immunological
parameters. [2015] British Journal of Cancer (113)
5: 786-793. Impact factor: 5,569
444. Viaud S., Daillere R., Boneca I., Lepage P., Langella P.,
Chamaillard M., Pittet M., Ghiringhelli F., Trinchieri
G., Goldszmid R., and Zitvogel L. Gut microbiome
and anticancer immune response: really hot Sh*t!
[2015] Cell Death and Differentiation (22) 2: 199214. Impact factor: 8,278
445. Vignot S., Lefebvre C., Frampton G.M., Meurice G.,
Yelensky R., Palmer G., Capron F., Lazar V., Hannoun
L., Miller V.A., André F., Stephens P.J., Soria J.C., and
Spano J.P. Comparative analysis of primary tumour
and matched metastases in colorectal cancer
patients: Evaluation of concordance between
genomic and transcriptional profiles . [2015]
European Journal of Cancer (51) 7: 791-799. Impact
factor: 6,163
71
446. von Tresckow B., Morschhauser F., Ribrag V., Topp
M.S., Chien C., Seetharam S., Aquino R., Kotoulek
S., de Boer C.J., and Engert A. An Open-Label,
Multicenter, Phase I/II Study of JNJ-40346527,
a CSF-1R Inhibitor, in Patients with Relapsed or
Refractory Hodgkin Lymphoma . [2015] Clinical
Cancer Research (21) 8: 1843-1850. Impact factor:
8,738
447. Walter T., van Brakel B., Vercherat C., Hervieu V.,
Forestier J., Chayvialle J.A., Molin Y., Lombard-Bohas
C., Joly M.O., and Scoazec J.Y. O6-MethylguanineDNA methyltransferase status in neuroendocrine
tumours: prognostic relevance and association
with response to alkylating agents. [2015] British
Journal of Cancer (112) 3: 523-531. Impact factor:
5,569
448. Wang L., Liu S., Zhao Y., Liu D., Liu Y., Chen C., Karray
S., Shi S., and Jin Y. Osteoblast-induced osteoclast
apoptosis by fas ligand/FAS pathway is required for
maintenance of bone mass. [2015] Cell Death and
Differentiation (22) 10: 1654-1664. Impact factor:
8,278
449. Wanquet A., Prebet T., Berthon C., Sebert M., Roux
C., Kulasekararaj A., Micol J.B., Esterni B., Itzykson
R., Thepot S., Recher C., Delaunay J., Dreyfus F.,
Mufti G., Fenaux P., and Vey N Azacitidine treatment
for patients with myelodysplastic syndrome
and acute myeloid leukemia with chromosome
3q abnormalities . [2015] American Journal of
Hematology (90) 10: 859-863. Impact factor: 5
450. Wolff R.F., Ryder S., Bossi A., Briganti A., Crook J.,
Henry A., Karnes J., Potters L., de Reijke T., Stone
N., Burckhardt M., Duffy S., Worthy G., and Kleijnen
J. A systematic review of randomised controlled
trials of radiotherapy for localised prostate cancer.
[2015] European Journal of Cancer (51) 16: 23452367. Impact factor: 6,163
451. Wozniak M.B., Brennan P., Brenner D.R., Overvad
K., Olsen A., Tjønneland A., Boutron-Ruault M.C.,
Clavel-Chapelon F., Fagherazzi G., Katzke V., Kuehn
T., Boeing H., Bergmann M.M., Steffen A., Naska
A., Trichopoulou A., Trichopoulos D., Saieva C.,
Grioni S., Panico S., Tumino R., Vineis P., Bueno-deMesquita H., Peeters P.H., Hjartaker A., Weiderpass
E., Arriola L., Molina-Montes E., Duell E.J., Santiuste
C., Alonso de la Torre R., Barricarte Gurrea A.,
Stocks T., Johansson M., Ljungberg B., Wareham
N., Khaw K.T., Travis R.C., Cross A.J., Murphy N.,
Riboli E., and Scelo G. Alcohol consumption and the
risk of renal cancers in the European prospective
investigation into cancer and nutrition (EPIC) .
[2015] International Journal of Cancer (137) 8:
1953-1966. Impact factor: 5,531
4 52. Xhaard C., De Vathaire F., Clero E., Maillard S.,
Ren Y., Borson-Chazot F., Sassolas G., Schvartz
C., Colonna M., Lacour B., Danzon A., Velten M.,
Marrer E., Bailly L., Barjoan E.M., Schlumberger M.,
Orgiazzi J., Adjadj E., and Rubino C. Anthropometric
Risk Factors for Differentiated Thyroid Cancer in
Young Men and Women From Eastern France: A
Case-Control Study. [2015] American Journal of
Epidemiology (182) 3: 202-214. Impact factor: 5,036
4 53. Yamamoto-Ibusuki M., Arnedos M., and André
F. Targeted therapies for ER+/HER2-metastatic
breast cancer . [2015] Bmc Medicine (13): 137.
Impact factor: 8,005
454. Yamamoto Y., Loriot Y., Beraldi E., Zhang F., Wyatt
A.W., Nakouzi N.A., Mo F., Zhou T., Kim Y., Monia
B.P., MacLeod A.R., Fazli L., Wang Y., Collins C.C.,
Zoubeidi A., and Gleave M. Generation 2.5 antisense
oligonucleotides targeting the androgen receptor
and its splice variants suppress enzalutamideresistant prostate cancer cell growth. [2015]
Clinical Cancer Research (21) 7: 1675-1687. Impact
factor: 8,738
4 55. Yang H., Yamazaki T., Pietrocola F., Zhou H.,
Zitvogel L., Ma Y., and Kroemer G. STAT3 Inhibition
Enhances the Therapeutic Efficacy of Immunogenic
Chemotherapy by Stimulating Type 1 Interferon
Production by Cancer Cells. [2015] Cancer Research
(75) 18: 3812-3822. Impact factor: 8,556
456. Zalcman G., Rizvi N., Lena H., Wolf J., Mazieres J.,
Antonia S., Minenza E., Planchard D., Lestini B., and
Ramalingam S. Phase 2 Study of Nivolumab (AntiProgrammed Death-1 [Pd-1]) in Patients (Pts) with
Advanced, Refractory Squamous (Sq) Non-Small
Cell Lung Cancer (Nsclc). [2015] Annals of Oncology
(26) suppl 1: 104PD. Impact factor: 9,269
4 57. Zhou H., Forveille S., Sauvat A., Sica V., Izzo V.,
Durand S., Mueller K., Liu P., Zitvogel L., Rekdal O.,
Kepp O., and Kroemer G. The oncolytic peptide LTX315 kills cancer cells through Bax/Bak-regulated
mitochondrial membrane permeabilization. [2015]
Oncotarget (6) 29: 26599-26614. Impact factor: 5,008
458. Zubrilov I., Sagi-Assif O., Izraely S., Meshel T., BenMenahem S., Ginat R., Pasmanik-Chor M., Nahmias
C., Couraud P.O., Hoon D.S., and Witz I.P. Vemurafenib
resistance selects for highly malignant brain and
lung-metastasizing melanoma cells. [2015] Cancer
Letters (361) 1: 86-96. Impact factor: 5,992
/ GUSTAVE ROUSSY
114, rue édouard-Vaillant
94805 Villejuif Cedex - France
www.gustaveroussy.fr